
<html lang="en"     class="pb-page"  data-request-id="11c14971-c029-4447-aa1f-e9500a0ec156"  
><head data-pb-dropzone="head"><meta name="pbContext" content=";requestedJournal:journal:jmcmar;journal:journal:jmcmar;page:string:Article/Chapter View;ctype:string:Journal Content;issue:issue:10.1021/jmcmar.2012.55.issue-24;wgroup:string:ACHS website Group;article:article:10.1021/jm301389h;website:website:acspubs;pageGroup:string:Publication Pages;subPage:string:Full Text"/></meta>




        <link rel="schema.DC" href="http://purl.org/DC/elements/1.0/" /></link><meta name="dc.Title" content="Potent, Selective, and Orally Bioavailable Inhibitors of the Mammalian Target of Rapamycin Kinase Domain Exhibiting Single Agent Antiproliferative Activity" /></meta><meta name="dc.Creator" content="Michael F. T.  Koehler" /></meta><meta name="dc.Creator" content="Philippe  Bergeron" /></meta><meta name="dc.Creator" content="Elizabeth  Blackwood" /></meta><meta name="dc.Creator" content="Krista K.  Bowman" /></meta><meta name="dc.Creator" content="Yung-Hsiang  Chen" /></meta><meta name="dc.Creator" content="Gauri  Deshmukh" /></meta><meta name="dc.Creator" content="Xiao  Ding" /></meta><meta name="dc.Creator" content="Jennifer  Epler" /></meta><meta name="dc.Creator" content="Kevin  Lau" /></meta><meta name="dc.Creator" content="Leslie  Lee" /></meta><meta name="dc.Creator" content="Lichuan  Liu" /></meta><meta name="dc.Creator" content="Cuong  Ly" /></meta><meta name="dc.Creator" content="Shiva  Malek" /></meta><meta name="dc.Creator" content="Jim  Nonomiya" /></meta><meta name="dc.Creator" content="Jason  Oeh" /></meta><meta name="dc.Creator" content="Daniel F.  Ortwine" /></meta><meta name="dc.Creator" content="Deepak  Sampath" /></meta><meta name="dc.Creator" content="Steve  Sideris" /></meta><meta name="dc.Creator" content="Lan  Trinh" /></meta><meta name="dc.Creator" content="Tom  Truong" /></meta><meta name="dc.Creator" content="Jiansheng  Wu" /></meta><meta name="dc.Creator" content="Zhonghua  Pei" /></meta><meta name="dc.Creator" content="Joseph P.  Lyssikatos" /></meta><meta name="dc.Description" content="Selective inhibitors of mammalian target of rapamycin (mTOR) kinase based upon saturated heterocycles fused to a pyrimidine core were designed and synthesized. Each series produced compounds with K..." /></meta><meta name="Description" content="Selective inhibitors of mammalian target of rapamycin (mTOR) kinase based upon saturated heterocycles fused to a pyrimidine core were designed and synthesized. Each series produced compounds with K..." /></meta><meta name="dc.Publisher" content="American Chemical Society" /></meta><meta name="dc.Date" scheme="WTN8601" content="December 12, 2012" /></meta><meta name="dc.Type" content="research-article" /></meta><meta name="dc.Format" content="text/HTML" /></meta><meta name="dc.Identifier" scheme="doi" content="10.1021/jm301389h" /></meta><meta name="dc.Language" content="EN" /></meta><meta name="dc.Coverage" content="world" /></meta><meta name="dc.Rights" content="© 2012 American Chemical Society" /></meta>
        
        

        
            <link rel="meta" type="application/atom+xml" href="https://doi.org/10.1021%2Fjm301389h" /></link>
            <link rel="meta" type="application/rdf+json" href="https://doi.org/10.1021%2Fjm301389h" /></link>
            <link rel="meta" type="application/unixref+xml" href="https://doi.org/10.1021%2Fjm301389h" /></link>
        
    
    

<title>Potent, Selective, and Orally Bioavailable Inhibitors of the Mammalian Target of Rapamycin Kinase Domain Exhibiting Single Agent Antiproliferative Activity | Journal of Medicinal Chemistry</title>












<meta charset="UTF-8">




<meta name="robots" content="noarchive"/></meta>
<meta name="pb-robots-disabled">









        <meta property="og:url" content="https://pubs.acs.org/doi/full/10.1021/jm301389h" /></meta><meta property="og:title" content="Potent, Selective, and Orally Bioavailable Inhibitors of the Mammalian Target of Rapamycin Kinase Domain Exhibiting Single Agent Antiproliferative Activity" /></meta><meta property="og:image" content="https://pubs.acs.org/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-24/jm301389h/production/images/large/jm-2012-01389h_0015.jpeg" /></meta><meta property="og:description" content="Selective inhibitors of mammalian target of rapamycin (mTOR) kinase based upon saturated heterocycles fused to a pyrimidine core were designed and synthesized. Each series produced compounds with Ki &lt; 10 nM for the mTOR kinase and &gt;500-fold selectivity over closely related PI3 kinases. This potency translated into strong pathway inhibition, as measured by phosphorylation of mTOR substrate proteins and antiproliferative activity in cell lines with a constitutively active PI3K pathway. Two compounds exhibiting suitable mouse PK were profiled in in vivo tumor models and were shown to suppress mTORC1 and mTORC2 signaling for over 12 h when dosed orally. Both compounds were additionally shown to suppress tumor growth in vivo in a PC3 prostate cancer model over a 14 day study." /></meta><meta property="og:type" content="Article" /></meta><meta property="og:site_name" content="ACS Publications" /></meta><meta name="twitter:card" content="summary_large_image" /></meta><meta name="twitter:site" content="@ACSPublications" /></meta>
    


    <meta name="viewport" content="width=device-width,initial-scale=1,maximum-scale=10, user-scalable=0"/></meta>















    

    <meta name="dc.identifier" content="10.1021/jm301389h"/></meta>



<meta name="format-detection" content="telephone=no">













<link rel="stylesheet" type="text/css" href="/wro/kfa7~product.css">


    <link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-roboto/font-roboto.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/css/build-f32cfd249ff7cb4cf9c7.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-lato/font-lato.css"/></link>




<meta http-equiv="X-UA-Compatible" content="IE=edge">
<meta http-equiv="content-type" content="text/html; charset=UTF-8">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/achs-1625058702970.css">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/acs-1622125181777.css">
<script type="text/javascript" src="/templates/jsp/js/jquery-3.1.1.min.js"></script>
<script type="text/javascript" src="/pb-assets/javascript/eloqua-1619549134767.js"></script>
<script async="" type="text/javascript" src="https://www.googletagservices.com/tag/js/gpt.js" rel="preconnect"></script>

<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"5200035e6e4d5180","startTime":1570117212010}'></script>






    








    
        
            <script type="text/javascript">
                (function (i, s, o, g, r, a, m) {
                    i['GoogleAnalyticsObject'] = r;
                    i[r] = i[r] || function () {
                        (i[r].q = i[r].q || []).push(arguments)
                    }, i[r].l = 1 * new Date();
                    a = s.createElement(o), m = s.getElementsByTagName(o)[0];
                    a.async = 1;
                    a.src = g;
                    m.parentNode.insertBefore(a, m)
                })(window, document, 'script', '//www.google-analytics.com/analytics.js', 'ga');
                ga('create', 'UA-7663985-4'
                    
                    
                    , 'auto'
                    
                    );
                
                
                ga('send', 'pageview');
            </script>
            
        
    















    
    
            
                
                

                <link rel="canonical" href="https://pubs.acs.org/doi/10.1021/jm301389h">
            
        




























    
    

    
    
    
    
    <script src="//unpkg.com/@theidentityselector/thiss-ds"></script>

    <script type="text/javascript">

        var SeamlessAccessService = {
            spUrl: "/action/ssostart",
            returnURL: window.location.href,
            my_context: 'seamlessaccess.org',
            timeout: 5000,

            getWAYFLessUrl: function (entityId) {
                return this.spUrl + "?idp=" + encodeURIComponent(entityId)
                    + "&redirectUri=" + encodeURIComponent(this.returnURL);
            },
            retrieveEntity: function (ms) {
                var self = this;
                var persistService = new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                if(ms == undefined || ms === ''){
                    ms = this.timeout;
                }

                return new Promise(function (resolve, reject) {
                    persistService.entities(self.my_context)
                        .then(function (res) {
                            // get the results
                            var results = res.data;
                            return resolve(results);
                        }, function (err) {
                            // failed
                            reject('retrieve entity error: ' + err);
                        });
                        // Set up the timeout
                        setTimeout(function() {
                            reject('Promise timed out ' + ms + ' ms');
                        }, ms);
                });
            },
            updateEntity: function (entitydata) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                var jsonObj = {};
                try {
                    //try to parse it, if it is a json string
                    jsonObj = JSON.parse(entitydata.val());
                } catch (e) {
                    jsonObj = entitydata;
                }
                return new Promise(function (resolve, reject) {
                    persistService.update(self.my_context, jsonObj)
                        .then(function (res) {
                            // Process the results
                            var ssoInstitutions = res.data;
                            return resolve(ssoInstitutions);
                        }, function (err) {
                            // failed
                            console.log('failed to update the local storage duo to: ' + err);
                            reject(err);
                        });
                })
            },
            removeEntity: function (entityId) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                return new Promise(function (resolve) {
                    persistService.remove(self.my_context, entityId)
                        .then(function (res) {
                            return resolve(res);
                        }, function (err) {
                            // failed
                            console.log('failed to remove from local storage duo to: ' + err);
                        });
                })
            },
            getAccessibleEntityStatus: function (doi, entityId) {
                return new Promise(function (resolve) {
                    $.ajax({
                        type: 'POST',
                        url: '/action/seamlessAccess',
                        accept: {
                            text: "application/json"
                        },
                        data: {doi: doi, entityid: entityId}

                    }).done(function (status) {
                        return resolve(status);
                    });
                });
            },
            getEntitiesWithAllInfo: function (doi) {
                let self = this,
                    arrayOfPromises = [];
                return new Promise(function (resolve, reject) {
                    self.retrieveEntity().then(function (res) {
                        let allSsoInstitutions = res;
                        for (i = 0; i < allSsoInstitutions.length; i++) {
                            let ssoInstitution = allSsoInstitutions[i];
                            arrayOfPromises.push(new Promise(function (resolve) {
                                self.getAccessibleEntityStatus(doi, ssoInstitution.entity.entityID)
                                    .then(function (entityStatus) {
                                        resolve({
                                            entityID: ssoInstitution.entity.entityID,
                                            entityTitle: ssoInstitution.entity.title,
                                            entityStatusObj: entityStatus,
                                            entitySsoUrl: self.getWAYFLessUrl(ssoInstitution.entity.entityID)
                                        });
                                    }, function (err) {
                                        console.log('failed to get the entity status: ' + err);
                                    });
                            }));
                        }
                        Promise.all(arrayOfPromises)
                            .then(function (finalResponse) {
                                resolve(finalResponse);
                            });

                    }).catch(function (err) {
                        reject(err);
                    })
                });
            }
        };

        window.addEventListener('load', function () {
            document.querySelectorAll(".sso-institution").forEach(function (institution) {
                var entityId = institution.getAttribute('data-entityid');
                var entityName = institution.getAttribute('data-name');
                var entitydata = {
                    entityID: entityId,
                    title: entityName
                };
                institution.addEventListener("click", function (e) {
                    e.preventDefault();
                    var self = this;
                    SeamlessAccessService.updateEntity(entitydata).then(function (res) {
                        console.log(res);
                        window.location.href = self.href;
                    }).catch(function (err){
                        window.location.href = self.href;
                    });
                });
            });
        });

    </script>




























    






    <meta name="google-site-verification" content="uBHpu2M2kL7VihPCSRXWyBSxooDf7L_BGgfHA3cjSfY" /></meta>


<link rel="prefetch" href="https://tpc.googlesyndication.com/safeframe/1-0-29/html/container.html"></head>
<body class="pb-ui">


























<script type="text/javascript">

    if(false) {
        document.getElementById("skipNavigationLink").onclick =function skipElement () {
            var element = document.getElementById('');
            if(element == null || element == undefined) {
                element = document.getElementsByClassName('').item(0);
            }
            element.setAttribute('tabindex','0');
            element.focus();

        }

    }

</script>











    <div id="pb-page-content" data-ng-non-bindable>
        <div data-pb-dropzone="main" data-pb-dropzone-name="Main">










        <div data-widget-def="UX3HTMLWidget" data-widget-id="ed6ae788-7707-48f4-b02c-3187c75e10db" class="hide">
        



        
        

        </div>
    




        
        




        
        



        <div class="pb-ad">
            <script type="text/javascript">
	var dartInstitutionType = 'none';
	var dartMember = 'false';
</script>
        </div>
    





        
        <script type="text/javascript">
$(document).ready(function() {
	setTimeout(function() {
		// var journalTitle = 'medicinal_chemistry';
		var taxonomyKeywords = $('.article_header-taxonomy');
		var articleKeyword = $('meta[name="keywords"]');
		var articleTitle = $('meta[name="dc.Title"]');
		var articleDescription = $('meta[name="dc.Description"]');
		var abstractKeyword = $('p.articleBody_abstractText:contains("Keywords: ")');
		var searchTerms = [];

		if (taxonomyKeywords.length > 0) {
			$(taxonomyKeywords).children(".rlist--inline").children("li").each(function() {
				searchTerms.push($(this).text());
			});
		}
		else if (articleKeyword.length > 0) { 
			searchTerms = searchTerms.concat(articleKeyword.prop('content').split(', '));
		}
		else if (abstractKeyword.length > 0) {
			searchTerms = searchTerms.concat(abstractKeyword.text().split("Keywords: ")[1].split('; '));
		}
		else if (articleDescription.length > 0) {
			$(articleDescription).each(function() {
				articleDescriptionKeywords = $(this).prop('content');
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/.,/g,"");
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/\s{2,}/g," ");
				searchTerms = searchTerms.concat(articleDescriptionKeywords.split(' '));
			});
		}

		if (articleTitle.length > 0) {
			searchTerms = searchTerms.concat(articleTitle.prop('content').split(' '));
		}

		googletag.cmd.push(function() {
			var mappingLeader = googletag.sizeMapping().
			addSize([320, 400], [320, 50]).
			addSize([320, 700], [320, 50]).
			addSize([750, 200], [728, 90]). 
			addSize([980, 690], [728, 90]).
			addSize([1024, 768], [728, 90]).
			build();
			//leaderboard
			googletag.defineSlot('/8868/journal/medicinal_chemistry/article', [728, 90], 'dfp-journal-article-leaderboard').defineSizeMapping(mappingLeader).setTargeting('location', 'leaderboard1').setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//recommend
			googletag.defineSlot("/8868/journal/medicinal_chemistry/article", [1, 1], "dfp-journal-article-recommend").setTargeting("ntvPlacement", ["1100167"]).setTargeting("location", "recommend").setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//googletag.pubads().enableSingleRequest();
			googletag.pubads().collapseEmptyDivs();
			googletag.pubads().setTargeting('inst',dartInstitutionType).setTargeting('memb',dartMember);
			googletag.pubads().addEventListener("slotRenderEnded", function(event) {
				if((event.isEmpty === false) && (event.slot.getSlotElementId() != "dfp-journal-article-recommend")) {
					$("#" + event.slot.getSlotElementId()).parents(".advertisement").slideDown();
				}
			});
			googletag.enableServices();
		});
	}, 1000);
});
</script>





        
        <script src="https://common.ccdc.cam.ac.uk/ccdc-widget/1.0.0.76/Widget.min.js"></script>




        
        <header class="header header_article_inactive">



        
        <div class="header_topbar hidden-sm hidden-xs">



        
        <div class="container"><div class="row"><div class="col-lg-3 col-md-4 col-sm-5 header_topbar_left">









        <div data-widget-def="UX3HTMLWidget" data-widget-id="0be92cec-36a8-4b4d-9a08-a28c790ce306" class="header_mainmenu">
        



        
        <ul>
	<li>
		<a href="http://www.acs.org">ACS</a>
	</li>
	<li class="header_mainmenu_current">
		<a href="/">ACS Publications</a>
	</li>
	<li>
		<a href="https://cen.acs.org">C&EN</a>
	</li>
	<li>
		<a href="https://www.cas.org">CAS</a>
	</li>
</ul>

        </div>
    
</div><div class="col-lg-9 col-md-8 col-sm-7 header_topbar_right">



        
        <div class="institution"><span class="institution-info-wrapper"><span class="institution__intro">Access provided by</span><span class="institution__name">Hong Kong University of Science and Technology Library</span></span></div>




        
        <div class="user-login-bar"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" name="heartBeatReloadInterval" value="1740000" class="heartBeatReloadInterval"/></input><input type="hidden" name="logoutUrl" value="https://pubs.acs.org/action/doLogout?logoutRedirectUrl=https%3A%2F%2Fsso.acs.org%2Fidp%2Fglogout%3Fappid%3Datypon-live%26returnURL%3Dhttps%253A%252F%252Fpubs.acs.org%252F" class="logoutUrl"/></input><img src="https://sso.acs.org/idp/heartbeat?appid=atypon-lives&amp;max_auth_age=2592000" alt="Blank image" class="ssoHeartBeatImg"/></img><span class="user-login-bar__value"><a href="https://pubs.acs.org/action/ssoRequestForLoginPage" class="user-login-bar__Login">Log In</a></span><input type="hidden" name="isUserLoggedIn" value="false" class="user-login-bar_is-loggedin"/></input><input type="hidden" name="isPaired" value="false" class="pair-device-is-paired"/></input><input type="hidden" name="isStronglyAuthenticated" value="false" class="isStronglyAuthenticated"/></input></div>
</div></div></div>
</div>




        
        <div class="header_content">



        
        <div class="container"><div class="row"><div class="header_content_main">



        
        <div class="header_content_row">



        
        <div class="header_content_left pull-left">



        
        <a href="/" title="ACS Publications. Most Trusted. Most Cited. Most Read"><img id="" alt="ACS Publications. Most Trusted. Most Cited. Most Read" src="/pb-assets/ux3/pubs-logo-481x82-1523435513963.png"/></img></a>




        
        <div class="pj-badge"></div><a href="/journal/jmcmar" title="journal logo" class="header_article-logo"><img src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo"></a><div class="header_article-separator"></div>
</div><div class="header_content_center">



        
        <div class="header_contnav">
    <div class="header_contnav-row">
         <a href="#" title="Previous" class="header_contnav-pre">
                <i class="icon-angle-left"></i>
        </a>
       <div class="header_contnav-title">
            <span>
                <a href="#" title=""></a>
            </span>
        </div>
         <a href="#" title="Next" class="header_contnav-next">
                <i class="icon-angle-right"></i>
            </a>
    </div>
</div>
</div><div class="header_content_right pull-right">



        
        <div class="header_qv-link"><a href="#" title="Quick View" data-slide-target=".article_qv-xs-container" class="w-slide__btn slide-active icon-quickview">Quick View</a></div>




        
        <div class="header_article-share">



        
        <script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="527d28d6-3414-4cb2-9560-99e677e62c0d" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone1" title="ShareDropzone1"></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone2" title="ShareDropzone2"></div><div data-db-target-of="527d28d6-3414-4cb2-9560-99e677e62c0d" id="527d28d6-3414-4cb2-9560-99e677e62c0d_Pop" class="share__block dropBlock__holder fixed"><div class="pb-dropzone" data-pb-dropzone="shareBlock" title="shareBlock"></div><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>WeChat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li><li><a role="link" class="addthis_button_email"><i aria-hidden="true" class="at-icon-wrapper icon-envelope-o"></i>Email</a></li></ul></div></div>
</div>




        
        <div class="header_article-separator"></div>




        
        <div class="quick-search"><a href="#" aria-label="quick search" class="quick-search_icon icon-search"></a><div class="quick-search_content"><form action="/action/checkIsValidDoi" name="defaultQuickSearch" method="get" title="Quick Search" autocomplete="off" class="quick-search_default"><input type="search" name="AllField" placeholder="Search text, DOI, authors, etc." aria-label="Search text, DOI, authors, etc." data-auto-complete-max-words="7" data-auto-complete-max-chars="32" data-contributors-conf="3" data-topics-conf="3" data-publication-titles-conf="3" data-history-items-conf="3" value="" required="true" class="quick-search_all-field autocomplete"/></input><button type="submit" title="Search" class="icon-search"></button><div role="radiogroup" aria-labelledby="journal filter" class="quick-search_journal-filter"><label for="thisJournalRadio" tabindex="0" aria-checked="true" role="radio" class="radio--primary"><input id="thisJournalRadio" type="radio" value="jmcmar" name="SeriesKey" checked="checked" class="all-content"/></input><span>J. Med. Chem.</span></label><label for="allPubRadio" tabindex="0" aria-checked="false" role="radio" class="radio--primary"><input id="allPubRadio" type="radio" value="" name="SeriesKey" class="all-content"/></input><span>All Publications/Website</span></label></div></form><p>OR SEARCH CITATIONS</p><form action="/action/quickLink" name="citationQuickSearch" method="get" title="Quick Search" class="quick-search_citation"><input type="hidden" name="quickLink" value="true"/></input><select name="quickLinkJournal" class="quick-search_journals-select"><option value="jmcmar">Journal of Medicinal Chemistry</option><option value="achre4">Accounts of Chemical Research</option><option value="amrcda">Accounts of Materials Research</option><option value="aastgj">ACS Agricultural Science & Technology</option><option value="aabmcb">ACS Applied Bio Materials</option><option value="aaembp">ACS Applied Electronic Materials</option><option value="aaemcq">ACS Applied Energy Materials</option><option value="aamick">ACS Applied Materials & Interfaces</option><option value="aanmf6">ACS Applied Nano Materials</option><option value="aapmcd">ACS Applied Polymer Materials</option><option value="abmcb8">ACS Bio & Med Chem Au</option><option value="abseba">ACS Biomaterials Science & Engineering</option><option value="accacs">ACS Catalysis</option><option value="acscii">ACS Central Science</option><option value="acbcct">ACS Chemical Biology</option><option value="achsc5">ACS Chemical Health & Safety</option><option value="acncdm">ACS Chemical Neuroscience</option><option value="acsccc">ACS Combinatorial Science</option><option value="aesccq">ACS Earth and Space Chemistry</option><option value="aelccp">ACS Energy Letters</option><option value="aeacb3">ACS Engineering Au</option><option value="aeacc4">ACS Environmental Au</option><option value="aeecco">ACS ES&T Engineering</option><option value="aewcaa">ACS ES&T Water</option><option value="afsthl">ACS Food Science & Technology</option><option value="aidcbc">ACS Infectious Diseases</option><option value="amlccd">ACS Macro Letters</option><option value="amacgu">ACS Materials Au</option><option value="amlcef">ACS Materials Letters</option><option value="amachv">ACS Measurement Science Au</option><option value="amclct">ACS Medicinal Chemistry Letters</option><option value="ancac3">ACS Nano</option><option value="anaccx">ACS Nanoscience Au</option><option value="acsodf">ACS Omega</option><option value="aoiab5">ACS Organic & Inorganic Au</option><option value="aptsfn">ACS Pharmacology & Translational Science</option><option value="apchd5">ACS Photonics</option><option value="apcach">ACS Physical Chemistry Au</option><option value="apaccd">ACS Polymers Au</option><option value="ascefj">ACS Sensors</option><option value="ascecg">ACS Sustainable Chemistry & Engineering</option><option value="asbcd6">ACS Synthetic Biology</option><option value="ancham">Analytical Chemistry</option><option value="bichaw">Biochemistry</option><option value="bcches">Bioconjugate Chemistry</option><option value="bomaf6">Biomacromolecules</option><option value="bipret">Biotechnology Progress</option><option value="cgeabj">C&EN Global Enterprise</option><option value="cenear">Chemical & Engineering News Archive</option><option value="chlseg">Chemical Health & Safety</option><option value="chlseg0">Chemical Health & Safety</option><option value="crtoec">Chemical Research in Toxicology</option><option value="chreay">Chemical Reviews</option><option value="cmatex">Chemistry of Materials</option><option value="cgdefu">Crystal Growth & Design</option><option value="enfuem">Energy & Fuels</option><option value="esthag">Environmental Science & Technology</option><option value="estlcu">Environmental Science & Technology Letters</option><option value="iepra6.2">I&EC Product Research and Development</option><option value="iechad">Industrial & Engineering Chemistry</option><option value="iecac0">Industrial & Engineering Chemistry Analytical Edition</option><option value="iecjc0">Industrial & Engineering Chemistry Chemical & Engineering Data Series</option><option value="iecfa7">Industrial & Engineering Chemistry Fundamentals</option><option value="iepdaw">Industrial & Engineering Chemistry Process Design and Development</option><option value="iepra6">Industrial & Engineering Chemistry Product Research and Development</option><option value="iecred">Industrial & Engineering Chemistry Research</option><option value="iecnav">Industrial and Engineering Chemistry, News Edition</option><option value="inocaj">Inorganic Chemistry</option><option value="jaaucr">JACS Au</option><option value="jacsat">Journal of the American Chemical Society</option><option value="jafcau">Journal of Agricultural and Food Chemistry</option><option value="jceaax">Journal of Chemical & Engineering Data</option><option value="jci001">Journal of Chemical Documentation</option><option value="jceda8">Journal of Chemical Education</option><option value="jchsc2">Journal of Chemical Health & Safety</option><option value="jchsc20">Journal of Chemical Health & Safety</option><option value="jcics1">Journal of Chemical Information and Computer Sciences</option><option value="jcisd8">Journal of Chemical Information and Modeling</option><option value="jctcce">Journal of Chemical Theory and Computation</option><option value="jcchff">Journal of Combinatorial Chemistry</option><option value="iechad.1">Journal of Industrial & Engineering Chemistry</option><option value="jmcmar.1">Journal of Medicinal and Pharmaceutical Chemistry</option><option value="jnprdf">Journal of Natural Products</option><option value="joceah">The Journal of Organic Chemistry</option><option value="jpchax">The Journal of Physical Chemistry</option><option value="jpchax.2">The Journal of Physical Chemistry</option><option value="jpcafh">The Journal of Physical Chemistry A</option><option value="jpcbfk">The Journal of Physical Chemistry B</option><option value="jpccck">The Journal of Physical Chemistry C</option><option value="jpclcd">The Journal of Physical Chemistry Letters</option><option value="jprobs">Journal of Proteome Research</option><option value="jamsef">Journal of the American Society for Mass Spectrometry</option><option value="jamsef1">Journal of the American Society for Mass Spectrometry</option><option value="jamsef0">Journal of the American Society for Mass Spectrometry</option><option value="langd5">Langmuir</option><option value="mamobx">Macromolecules</option><option value="mpohbp">Molecular Pharmaceutics</option><option value="nalefd">Nano Letters</option><option value="neaca9">News Edition, American Chemical Society</option><option value="orlef7">Organic Letters</option><option value="oprdfk">Organic Process Research & Development</option><option value="orgnd7">Organometallics</option><option value="iepra6.1">Product R&D</option><option value="scimts">SciMeetings</option><option value="jpchax.1">The Journal of Physical and Colloid Chemistry</option></select><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkVolume" autoComplete="false" placeholder="Vol" required="required" class="quick-search_volume-input"/></input><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkPage" autoComplete="false" placeholder="Page" required="required" class="quick-search_page-input"/></input><button type="submit" title="Search" class="icon-search"></button></form></div></div>




        
        <div class="header_my-activity">



        
        <a href="#"><i class="icon-id-badge" aria-hidden=”true”></i><span>My Activity</span></a>
<div class="header_my-activity-content">
    <div class="header_my-activity-single">
        <i aria-hidden="true" aria-label="close" class="icon-close"></i>
        <div class="" data-name="recentlyViewedDropzone">



        
        <div class="show-recently"><div class="show-recently-header">Recently Viewed</div><h6 class="show-recently-empty">You have not visited any articles yet, Please visit some articles to see contents here. </h6></div>
</div>
    </div>
</div>
</div>




        
        <div class="header_publications">



        
        <a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>Publications</span></a>

</div>




        
        <div class="header_burger-menu">



        
        <a href="#?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuIcon&amp;utm_campaign=Pubs_Refere" class="header_burger-menu_button" title="menu button" aria-label="menu button"><i class="icon-navicon"></i><i
        class="icon-close"></i></a>
<div class="header_burger-menu_content">
    <ul class="hidden-lg">
        <li><a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>publications</span></a></li>
        <li class="myActivityMobile"><a href="#" class="openTabletActivity"><i class="icon-id-badge" aria-hidden=”true”></i><span>my Activity</span></a>
            <ul>
                <li><a href="javascript:void(0)" class="recentlyViewed--open">Recently Viewed</a></li>
            </ul>
        </li>
    </ul>
    <ul>
        <li><a href="#">user resources</a>
            <ul>
                <li><a href="/page/remoteaccess"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Access Options');">Access Options</a></li>
                <li><a href="https://publish.acs.org/publish/"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Authors & Reviewers');">Authors &
                        Reviewers</a></li>
                <li><a href="http://www.acs.org/content/acs/en/membership-and-networks/acs/benefits/professional/publications-benefits.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS Members');">ACS Members</a></li>
                <li><a href="https://preferences.acspubs.org/journals"
                        onclick="ga('send', 'event', 'Home_MainMenu', 'Click', 'eAlert');">eAlerts</a></li>
                <li><a href="/page/follow.html?widget=follow-pane-mobile"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'RSS & Mobile');">RSS & Mobile</a></li>
            </ul>
        </li>
		<li><a href="#">for organizations</a>
			<ul>
			    <li><a href="https://solutions.acs.org/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Products & Services');">Products & Services</a></li>
				<li><a href="https://solutions.acs.org/access-options/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Get Access');">Get Access</a></li>
				<li><a href="https://solutions.acs.org/resources/manage-my-account/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Manage My Account');">Manage My Account</a></li>
			</ul>
		</li>
        <li><a href="#">support</a>
            <ul>
                <li><a href="/page/demo/index.html">Website Demos & Tutorials</a></li>
                <li><a href="https://acs.service-now.com/acs"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Support FAQs');">Support FAQs </a></li>
                <li><a href="#"
                        onClick="SnapEngage.startLink();return false; ga('send', 'event', 'Top Nav', 'Menu', 'Live Chat with Agent');"
                        class="help help-chat">Live Chat with Agent</a></li>
                <li><a href="https://acsmediakit.org/digital/acs-pubs/?utm_source=Nav&amp;utm_medium=Pubs&amp;utm_campaign=CEN"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Advertisers');">For Advertisers</a></li>
                <li><a href="https://solutions.acs.org/help/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Librarians & Account Managers');">For
                        Librarians & Account Managers</a></li>
            </ul>
        </li>
        <li class="hidden-sm hidden-xs"><a href="#">pairing</a>
            <ul>
                <li><a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a></li>
                <li><a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Pair this device');">Pair this device</a></li>
                <li><a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
                </li>
            </ul>
        </li>
        <li class="hidden-lg hidden-md">
            <a class="header_burger-menu_my-profile-link" href="/action/showPreferences">My Profile</a>
            <a class="header_burger-menu_login-link" href="/action/ssoRequestForLoginPage">Login</a>
            <a class="header_burger-menu_logout-link" href="#">Logout</a>
            <a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a>
            <a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode">Pair this
                device</a>
            <a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
        </li>
        <li><a href="#">about us</a>
            <ul>
                <li><a href="/page/about-us.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Overview');">Overview</a></li>
                <li><a href="http://acsopenscience.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS & Open Access');">ACS & Open Access</a>
                </li>
                <li><a href="/#partners" onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Partners');">Partners</a></li>
                <li><a href="http://acsoncampus.acs.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Events');">Events</a></li>
            </ul>
        </li>
    </ul>
</div>
<div class="activity-container-tablet"><i aria-hidden="true" class="icon-close"></i></div>


<script type="text/javascript">
  (function() {
    var se = document.createElement('script'); se.type = 'text/javascript'; se.async = true;
    se.src = 'https://storage.googleapis.com/code.snapengage.com/js/921a4ec7-cecf-43a6-afa5-6cd1346520b1.js';
    var done = false;
    se.onload = se.onreadystatechange = function() {
      if (!done&&(!this.readyState||this.readyState==='loaded'||this.readyState==='complete')) {
        done = true;
        /* Place your SnapEngage JS API code below */
        /* SnapEngage.allowChatSound(true); Example JS API: Enable sounds for Visitors. */
      }
    };
    var s = document.getElementsByTagName('script')[0]; s.parentNode.insertBefore(se, s);
  })();
</script>

<style>
    #SnapABug_Button,
    #designstudio-button {
        display: none;
    }
</style>

</div>
</div>
</div>
</div></div></div>
</div>




        
        <div class="pub"><div aria-live="polite" aria-atomic="true" class="pub-modal"><div class="pub-modal_content loop-trap"><a href="#" aria-label="close" tabindex="0" class="pub-modal_close icon-close pull-right"></a><div class="pub-modal_row"><div class="pub-modal_left"><div class="pub-modal_left-content"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_types"><h6>CONTENT TYPES</h6><ul class="pub-modal_types-list"><li data-type="all" id="allID" class="pub-modal_types-active"><a href="#"><h4>All Types</h4></a></li></ul></div><div class="pub-modal_subjects hidden-sm hidden-xs"><h6>SUBJECTS</h6><ul class="pub-modal_subjects-list"></ul></div></div></div><div class="pub-modal_right"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications: All Types</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_right--inner"><div class="pub-content"></div></div></div></div></div><input type="hidden" name="pubModalData" value="{&quot;types&quot;:[{&quot;code&quot;:&quot;journals&quot;,&quot;label&quot;:&quot;Journals&quot;},{&quot;code&quot;:&quot;books&quot;,&quot;label&quot;:&quot;Books and Reference&quot;},{&quot;code&quot;:&quot;news&quot;,&quot;label&quot;:&quot;News&quot;}],&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;,&quot;label&quot;:&quot;Analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;,&quot;label&quot;:&quot;Applied&quot;},{&quot;code&quot;:&quot;cat_biological&quot;,&quot;label&quot;:&quot;Biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;,&quot;label&quot;:&quot;Materials Science &amp; Engineering&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;,&quot;label&quot;:&quot;Organic-Inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;,&quot;label&quot;:&quot;Physical&quot;}],&quot;publications&quot;:[{&quot;char&quot;:&quot;A&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achre4/2021/achre4.2021.54.issue-15/achre4.2021.54.issue-15/20210803/achre4.2021.54.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;achre4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Chemical Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achre4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amrcda/2021/amrcda.2021.2.issue-7/amrcda.2021.2.issue-7/20210723/amrcda.2021.2.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amrcda&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Materials Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amrcda&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aastgj/2021/aastgj.2021.1.issue-3/aastgj.2021.1.issue-3/20210621/aastgj.2021.1.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aastgj&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS Agricultural Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aastgj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aabmcb/2021/aabmcb.2021.4.issue-7/aabmcb.2021.4.issue-7/20210719/aabmcb.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aabmcb&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Bio Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aabmcb&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaembp/2021/aaembp.2021.3.issue-7/aaembp.2021.3.issue-7/20210727/aaembp.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaembp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Electronic Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaembp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaemcq/2021/aaemcq.2021.4.issue-7/aaemcq.2021.4.issue-7/20210726/aaemcq.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaemcq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Energy Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaemcq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aamick/2021/aamick.2021.13.issue-30/aamick.2021.13.issue-30/20210804/aamick.2021.13.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;aamick&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Materials &amp; Interfaces&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aamick&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aanmf6/2021/aanmf6.2021.4.issue-7/aanmf6.2021.4.issue-7/20210723/aanmf6.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aanmf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Nano Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aanmf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aapmcd/2021/aapmcd.2021.3.issue-7/aapmcd.2021.3.issue-7/20210709/aapmcd.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aapmcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Polymer Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aapmcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/abmcb8/largecover.png&quot;,&quot;code&quot;:&quot;abmcb8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;}],&quot;name&quot;:&quot;ACS Bio &amp; Med Chem Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abmcb8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/abseba/2021/abseba.2021.7.issue-7/abseba.2021.7.issue-7/20210712/abseba.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;abseba&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Biomaterials Science &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abseba&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/accacs/2021/accacs.2021.11.issue-14/accacs.2021.11.issue-14/20210716/accacs.2021.11.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;accacs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Catalysis&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/accacs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acscii/2021/acscii.2021.7.issue-7/acscii.2021.7.issue-7/20210728/acscii.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acscii&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Central Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acscii&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acbcct/2021/acbcct.2021.16.issue-7/acbcct.2021.16.issue-7/20210716/acbcct.2021.16.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acbcct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acbcct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achsc5/2021/achsc5.2021.28.issue-4/achsc5.2021.28.issue-4/20210726/achsc5.2021.28.issue-4.largecover.jpg&quot;,&quot;code&quot;:&quot;achsc5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Health &amp; Safety&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achsc5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acncdm/2021/acncdm.2021.12.issue-15/acncdm.2021.12.issue-15/20210804/acncdm.2021.12.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;acncdm&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Neuroscience&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acncdm&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsccc/2020/acsccc.2020.22.issue-12/acsccc.2020.22.issue-12/20201214/acsccc.2020.22.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;acsccc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Combinatorial Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsccc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aesccq/2021/aesccq.2021.5.issue-7/aesccq.2021.5.issue-7/20210715/aesccq.2021.5.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aesccq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Earth and Space Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aesccq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aelccp/2021/aelccp.2021.6.issue-7/aelccp.2021.6.issue-7/20210709/aelccp.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aelccp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Energy Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aelccp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacb3/largecover.png&quot;,&quot;code&quot;:&quot;aeacb3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Engineering Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacb3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacc4/largecover.png&quot;,&quot;code&quot;:&quot;aeacc4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Environmental Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacc4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aeecco/2021/aeecco.2021.1.issue-7/aeecco.2021.1.issue-7/20210709/aeecco.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aeecco&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS ES&amp;T Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeecco&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aewcaa/2021/aewcaa.2021.1.issue-7/aewcaa.2021.1.issue-7/20210709/aewcaa.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aewcaa&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS ES&amp;T Water&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aewcaa&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/afsthl/2021/afsthl.2021.1.issue-6/afsthl.2021.1.issue-6/20210716/afsthl.2021.1.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;afsthl&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Food Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/afsthl&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;styleguide&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;}],&quot;name&quot;:&quot;ACS Guide to Scholarly Communication&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/styleguide&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;infocus&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS In Focus&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/infocus&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aidcbc/2021/aidcbc.2021.7.issue-7/aidcbc.2021.7.issue-7/20210709/aidcbc.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aidcbc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Infectious Diseases&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aidcbc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlccd/2021/amlccd.2021.10.issue-7/amlccd.2021.10.issue-7/20210720/amlccd.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amlccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Macro Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amacgu/largecover.png&quot;,&quot;code&quot;:&quot;amacgu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Materials Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amacgu&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlcef/2021/amlcef.2021.3.issue-8/amlcef.2021.3.issue-8/20210802/amlcef.2021.3.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;amlcef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Materials Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlcef&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amachv/largecover.png&quot;,&quot;code&quot;:&quot;amachv&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;}],&quot;name&quot;:&quot;ACS Measurement Science Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amachv&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amclct/2021/amclct.2021.12.issue-7/amclct.2021.12.issue-7/20210708/amclct.2021.12.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amclct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Medicinal Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amclct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancac3/2021/ancac3.2021.15.issue-7/ancac3.2021.15.issue-7/20210727/ancac3.2021.15.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ancac3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Nano&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancac3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/anaccx/largecover.png&quot;,&quot;code&quot;:&quot;anaccx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Nanoscience Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/anaccx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsodf/2021/acsodf.2021.6.issue-30/acsodf.2021.6.issue-30/20210803/acsodf.2021.6.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;acsodf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Omega&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsodf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aoiab5/largecover.png&quot;,&quot;code&quot;:&quot;aoiab5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;}],&quot;name&quot;:&quot;ACS Organic &amp; Inorganic Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aoiab5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aptsfn/2021/aptsfn.2021.4.issue-3/aptsfn.2021.4.issue-3/20210611/aptsfn.2021.4.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aptsfn&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Pharmacology &amp; Translational Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aptsfn&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/apchd5/2021/apchd5.2021.8.issue-7/apchd5.2021.8.issue-7/20210721/apchd5.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;apchd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Photonics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apchd5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apcach/largecover.png&quot;,&quot;code&quot;:&quot;apcach&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;}],&quot;name&quot;:&quot;ACS Physical Chemistry Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apcach&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apaccd/largecover.png&quot;,&quot;code&quot;:&quot;apaccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Polymers Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apaccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/reagents/2017/acsreagents/acsreagents/20170228/acsreagents.largecover.png&quot;,&quot;code&quot;:&quot;reagents&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS Reagent Chemicals&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/reagents&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascefj/2021/ascefj.2021.6.issue-7/ascefj.2021.6.issue-7/20210723/ascefj.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ascefj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sensors&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascefj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascecg/2021/ascecg.2021.9.issue-30/ascecg.2021.9.issue-30/20210802/ascecg.2021.9.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;ascecg&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sustainable Chemistry &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascecg&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/symposium/2021/bk-2021-1379/bk-2021-1379/20210430-01/bk-2021-1379.largecover.jpg&quot;,&quot;code&quot;:&quot;symposium&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;ACS Symposium Series&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/symposium&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/asbcd6/2021/asbcd6.2021.10.issue-7/asbcd6.2021.10.issue-7/20210716/asbcd6.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;asbcd6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Synthetic Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/asbcd6&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;advances&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;Advances in Chemistry&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/advances&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancham/2021/ancham.2021.93.issue-30/ancham.2021.93.issue-30/20210803/ancham.2021.93.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;ancham&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Analytical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancham&quot;}]},{&quot;char&quot;:&quot;B&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bichaw/2021/bichaw.2021.60.issue-30/bichaw.2021.60.issue-30/20210803/bichaw.2021.60.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;bichaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biochemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bichaw&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bcches/2021/bcches.2021.32.issue-7/bcches.2021.32.issue-7/20210721/bcches.2021.32.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bcches&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Bioconjugate Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bcches&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bomaf6/2021/bomaf6.2021.22.issue-7/bomaf6.2021.22.issue-7/20210712/bomaf6.2021.22.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bomaf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biomacromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bomaf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/bipret/largecover.jpg&quot;,&quot;code&quot;:&quot;bipret&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;Biotechnology Progress&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bipret&quot;}]},{&quot;char&quot;:&quot;C&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgeabj/2021/cgeabj.2021.99.issue-28/cgeabj.2021.99.issue-28/20210802/cgeabj.2021.99.issue-28.largecover.jpg&quot;,&quot;code&quot;:&quot;cgeabj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;C&amp;EN Global Enterprise&quot;,&quot;type&quot;:&quot;news&quot;,&quot;url&quot;:&quot;/journal/cgeabj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/crtoec/2021/crtoec.2021.34.issue-7/crtoec.2021.34.issue-7/20210719/crtoec.2021.34.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;crtoec&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Research in Toxicology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/crtoec&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/chreay/2021/chreay.2021.121.issue-14/chreay.2021.121.issue-14/20210728/chreay.2021.121.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;chreay&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;articletoc&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Reviews&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/chreay&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cmatex/2021/cmatex.2021.33.issue-14/cmatex.2021.33.issue-14/20210727/cmatex.2021.33.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;cmatex&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemistry of Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cmatex&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgdefu/2021/cgdefu.2021.21.issue-8/cgdefu.2021.21.issue-8/20210804/cgdefu.2021.21.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;cgdefu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Crystal Growth &amp; Design&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cgdefu&quot;}]},{&quot;char&quot;:&quot;E&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/enfuem/2021/enfuem.2021.35.issue-14/enfuem.2021.35.issue-14/20210715/enfuem.2021.35.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;enfuem&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Energy &amp; Fuels&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/enfuem&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/esthag/2021/esthag.2021.55.issue-15/esthag.2021.55.issue-15/20210803/esthag.2021.55.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;esthag&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/esthag&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/estlcu/2021/estlcu.2021.8.issue-7/estlcu.2021.8.issue-7/20210713/estlcu.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;estlcu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/estlcu&quot;}]},{&quot;char&quot;:&quot;I&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.2&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;I&amp;EC Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.2&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecac0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Analytical Edition&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecac0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecjc0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Chemical &amp; Engineering Data Series&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecjc0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecfa7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Fundamentals&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecfa7&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepdaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Process Design and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepdaw&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/iecred/2021/iecred.2021.60.issue-30/iecred.2021.60.issue-30/20210804/iecred.2021.60.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;iecred&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecred&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/inocaj/2021/inocaj.2021.60.issue-15/inocaj.2021.60.issue-15/20210802/inocaj.2021.60.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;inocaj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Inorganic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/inocaj&quot;}]},{&quot;char&quot;:&quot;J&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jaaucr/2021/jaaucr.2021.1.issue-7/jaaucr.2021.1.issue-7/20210726/jaaucr.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jaaucr&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;JACS Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jaaucr&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jafcau/2021/jafcau.2021.69.issue-30/jafcau.2021.69.issue-30/20210804/jafcau.2021.69.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;jafcau&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Agricultural and Food Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jafcau&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceaax/2021/jceaax.2021.66.issue-7/jceaax.2021.66.issue-7/20210708/jceaax.2021.66.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceaax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical &amp; Engineering Data&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceaax&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jci001&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Documentation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jci001&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceda8/2021/jceda8.2021.98.issue-7/jceda8.2021.98.issue-7/20210713/jceda8.2021.98.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceda8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;divched&quot;}],&quot;name&quot;:&quot;Journal of Chemical Education&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceda8&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jcics1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Computer Sciences&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcics1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jcisd8/2021/jcisd8.2021.61.issue-7/jcisd8.2021.61.issue-7/20210726/jcisd8.2021.61.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jcisd8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Modeling&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcisd8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jctcce/2021/jctcce.2021.17.issue-7/jctcce.2021.17.issue-7/20210713/jctcce.2021.17.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jctcce&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Theory and Computation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jctcce&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad.1&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jmcmar.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal and Pharmaceutical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar.1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-14/jmcmar.2021.64.issue-14/20210722/jmcmar.2021.64.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;jmcmar&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jnprdf/2021/jnprdf.2021.84.issue-7/jnprdf.2021.84.issue-7/20210723/jnprdf.2021.84.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jnprdf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Natural Products&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jnprdf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/joceah/2021/joceah.2021.86.issue-14/joceah.2021.86.issue-14/20210716/joceah.2021.86.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;joceah&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Organic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/joceah&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jpchax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpchax&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcafh/2021/jpcafh.2021.125.issue-29/jpcafh.2021.125.issue-29/20210729/jpcafh.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcafh&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry A&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcafh&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcbfk/2021/jpcbfk.2021.125.issue-29/jpcbfk.2021.125.issue-29/20210729/jpcbfk.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcbfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry B&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcbfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpccck/2021/jpccck.2021.125.issue-29/jpccck.2021.125.issue-29/20210729/jpccck.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpccck&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry C&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpccck&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpclcd/2021/jpclcd.2021.12.issue-29/jpclcd.2021.12.issue-29/20210729/jpclcd.2021.12.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpclcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpclcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jprobs/2021/jprobs.2021.20.issue-7/jprobs.2021.20.issue-7/20210702/jprobs.2021.20.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jprobs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Proteome Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jprobs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jacsat/2021/jacsat.2021.143.issue-30/jacsat.2021.143.issue-30/20210804/jacsat.2021.143.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;jacsat&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Chemical Society&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jacsat&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jamsef/2021/jamsef.2021.32.issue-8/jamsef.2021.32.issue-8/20210804/jamsef.2021.32.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;jamsef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Society for Mass Spectrometry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jamsef&quot;}]},{&quot;char&quot;:&quot;L&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/langd5/2021/langd5.2021.37.issue-30/langd5.2021.37.issue-30/20210803/langd5.2021.37.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;langd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Langmuir&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/langd5&quot;}]},{&quot;char&quot;:&quot;M&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mamobx/2021/mamobx.2021.54.issue-14/mamobx.2021.54.issue-14/20210727/mamobx.2021.54.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;mamobx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Macromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mamobx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mpohbp/2021/mpohbp.2021.18.issue-8/mpohbp.2021.18.issue-8/20210802/mpohbp.2021.18.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;mpohbp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Molecular Pharmaceutics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mpohbp&quot;}]},{&quot;char&quot;:&quot;N&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/nalefd/2021/nalefd.2021.21.issue-14/nalefd.2021.21.issue-14/20210728/nalefd.2021.21.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;nalefd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Nano Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/nalefd&quot;}]},{&quot;char&quot;:&quot;O&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orlef7/2021/orlef7.2021.23.issue-14/orlef7.2021.23.issue-14/20210716/orlef7.2021.23.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orlef7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orlef7&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/oprdfk/2021/oprdfk.2021.25.issue-7/oprdfk.2021.25.issue-7/20210716/oprdfk.2021.25.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;oprdfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Process Research &amp; Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/oprdfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orgnd7/2021/orgnd7.2021.40.issue-14/orgnd7.2021.40.issue-14/20210726/orgnd7.2021.40.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orgnd7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organometallics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orgnd7&quot;}]},{&quot;char&quot;:&quot;P&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Product R&amp;D&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.1&quot;}]}]}"/></input></div></div>
</header>




        
        <main data-widget-id="28284a6d-730d-4a56-93ad-909787c5ac1b" id="" class="content article"><article data-figures="https://pubs.acs.org/action/ajaxShowFigures?doi=10.1021%2Fjm301389h&amp;ajax=true" data-references="https://pubs.acs.org/action/ajaxShowEnhancedAbstract?doi=10.1021%2Fjm301389h&amp;ajax=true" data-enable-mathjax="true"><div class="figure-viewer"><div class="figure-viewer_row"><div class="figure-viewer_col loop-trap"><div aria-live="polite" aria-atomic="true" class="figure-viewer_modal"><a href="#" title="Close" aria-label="close" tabindex="0" class="figure-viewer_close icon-close"></a><h2 class="figure-viewer_label"><span class="figure-viewer_current"></span></h2><div class="figure-viewer_image"><a href="#" title="Next" class="figure-viewer_next icon-angle-right"></a><a href="#" title="Previous" class="figure-viewer_prev icon-angle-left"></a><div class="figure-viewer_image-content"><img src="" alt="Figure 1" class="fv-img"/></img><img src="/pb-assets/ux3/loading-1525090748317.gif" alt="Loading Img" class="loading-img"/></img></div></div><div class="figure-viewer_links"><a href="#" title="Download Hi-Res Image" target="_blank" class="figure-viewer_hi-res-link"><i class="icon-file-image-o"></i><span>Download Hi-Res Image</span></a><span class="fv-separator"></span><a href="#" title="Download to MS-PowerPoint" class="figure-viewer_ms-p-link"><i class="icon-file-powerpoint-o"></i><span>Download to MS-PowerPoint</span></a><span class="cit-this-container"><a href="/action/showCitFormats?doi=10.1021/jm301389h&amp;href=/doi/10.1021/jm301389h" title="Cite This" class="figure-viewer-cite-this-link"><i class="icon-check-circle"></i><span><strong>Cite This:</strong></span></a><span class="article_header-cite-this figure-viewer-cite-this"><span class="cit-fg-title"><i>J. Med. Chem.</i></span><span class="cit-fg-year"> 2012</span><span class="cit-fg-volume">, 55</span><span class="cit-fg-issue">, 24</span><span class="cit-fg-pageRange">, 10958-10971</span></span></span></div></div></div></div></div><div class="article_fullPage"><div class="article_header"><div class="articleHeaderDropzone5" data-pb-dropzone="articleHeaderDropzone5"><div class="advertisement">
	<div class="advertisement-link">
		<a href="http://acsmediakit.org">ADVERTISEMENT</a>
	</div>
	<div id="dfp-journal-article-leaderboard">
		<script type="text/javascript">
			$(document).ready(function() {
				setTimeout(function() {
					googletag.cmd.push(function() { googletag.display("dfp-journal-article-leaderboard"); });
				}, 1400);
			});
		</script>
	</div>
</div></div><div class="container container_scaled-down"><div class="row"><div class="col-xs-12.clearfix"><div class="article_header-left pull-left"><div class="article_header-dropzone-1"><div class="articleHeaderDropzone1" data-pb-dropzone="articleHeaderDropzone1"><div class="content-navigation clearfix"><a href="/toc/jmcmar/55/24" title="Return to Issue" id="returnToIssues" class="content-navigation__btn--return"><span>RETURN TO ISSUE</span></a><a href="/doi/10.1021/jm301328h" title="Previous" id="prevID" class="content-navigation__btn--pre"><i class="icon-angle-left"></i><span>PREV</span></a><span class="content-navigation__contentType">Article</span><a href="/doi/10.1021/jm301404a" title="Next" id="nextID" class="content-navigation__btn--next"><span>NEXT</span><i class="icon-angle-right"></i></a></div></div></div><div class="headerLogo_e-alertsMobile_container"><div class="article_header-logo hidden-lg"><div class="pj-badge"></div><a href="/journal/jmcmar" title="Journal Logo"><img src="/specs/ux3/releasedAssets/images/loader.gif" data-src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo" /></img></a></div><div class="e-alertsMobile_container hidden-md hidden-lg"></div></div><h1 class="article_header-title"><span class="hlFld-Title">Potent, Selective, and Orally Bioavailable Inhibitors of the Mammalian Target of Rapamycin Kinase Domain Exhibiting Single Agent Antiproliferative Activity</span></h1><ul class="loa non-jats-loa"><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Michael+F.+T.++Koehler">Michael F. T. Koehler</a></span><span class="author-xref-symbol "><sup>*</sup></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Philippe++Bergeron">Philippe Bergeron</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Elizabeth++Blackwood">Elizabeth Blackwood</a></span><span class="author-xref-symbol author-aff-symbol"><sup>‡</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Krista+K.++Bowman">Krista K. Bowman</a></span><span class="author-xref-symbol author-aff-symbol"><sup>§</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Yung-Hsiang++Chen">Yung-Hsiang Chen</a></span><span class="author-xref-symbol author-aff-symbol"><sup>#</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Gauri++Deshmukh">Gauri Deshmukh</a></span><span class="author-xref-symbol author-aff-symbol"><sup>#</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Xiao++Ding">Xiao Ding</a></span><span class="author-xref-symbol author-aff-symbol"><sup>#</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Jennifer++Epler">Jennifer Epler</a></span><span class="author-xref-symbol author-aff-symbol"><sup>‡</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Kevin++Lau">Kevin Lau</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Leslie++Lee">Leslie Lee</a></span><span class="author-xref-symbol author-aff-symbol"><sup>‡</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Lichuan++Liu">Lichuan Liu</a></span><span class="author-xref-symbol author-aff-symbol"><sup>#</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Cuong++Ly">Cuong Ly</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Shiva++Malek">Shiva Malek</a></span><span class="author-xref-symbol author-aff-symbol"><sup>‡</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Jim++Nonomiya">Jim Nonomiya</a></span><span class="author-xref-symbol author-aff-symbol"><sup>∥</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Jason++Oeh">Jason Oeh</a></span><span class="author-xref-symbol author-aff-symbol"><sup>‡</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Daniel+F.++Ortwine">Daniel F. Ortwine</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Deepak++Sampath">Deepak Sampath</a></span><span class="author-xref-symbol author-aff-symbol"><sup>‡</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Steve++Sideris">Steve Sideris</a></span><span class="author-xref-symbol author-aff-symbol"><sup>∥</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Lan++Trinh">Lan Trinh</a></span><span class="author-xref-symbol author-aff-symbol"><sup>∥</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Tom++Truong">Tom Truong</a></span><span class="author-xref-symbol author-aff-symbol"><sup>‡</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Jiansheng++Wu">Jiansheng Wu</a></span><span class="author-xref-symbol author-aff-symbol"><sup>∇</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Zhonghua++Pei">Zhonghua Pei</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, and </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Joseph+P.++Lyssikatos">Joseph P. Lyssikatos</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator"></span></ul><div class="affiliations"><div class="view-affs"><span class="title">View Author Information</span><i class="caret-icon icon-angle-down"></i></div><div class="all-aff-infos hlFld-Affiliation"><div class="aff-info" id="aff1"><span class="aff-text"><sup>†</sup>Department of Discovery Chemistry, <sup>‡</sup>Department of Translational Oncology, <sup>§</sup>Department of Structural Biology, <sup>∥</sup>Department of Small Molecule Biochemical Pharmacology, <sup>#</sup>Department of Drug Metabolism and Pharmacokinetics, and <sup>∇</sup>Department of Protein Chemistry, Genentech, Inc., 1 DNA Way, South San Francisco, California 94080, United States</span></div><div class="corresp-info"><strong>*</strong>Phone: 650-225-1000. Fax: 650-467-8922. E-mail: <a href="/cdn-cgi/l/email-protection#9ff2f4f0faf7f3faeddff8faf1fab1fcf0f2"><span class="__cf_email__" data-cfemail="93fef8fcf6fbfff6e1d3f4f6fdf6bdf0fcfe">[email protected]</span></a></div></div></div><div class="article_header-meta clearfix"><div class="article_header-meta-left pull-left"><input type="hidden" name="journalCodeForjhpLink" value="jmcmar" /></input><input type="hidden" name="journalNameForjhpLink" value="Journal of Medicinal Chemistry" /></input><div class="article_header-cite-this"><a href="/action/showCitFormats?doi=10.1021%2Fjm301389h&amp;href=/doi/10.1021%2Fjm301389h" title="Cite This"><i class="icon-check-circle"></i><strong>Cite this: </strong></a><span class="cit-title"><i>J. Med. Chem.</i></span> <span class="cit-year-info"><span>2012</span></span><span class="cit-volume">, 55</span><span class="cit-issue">, 24</span><span class="cit-pageRange">, 10958–10971</span></div><div class="article_header-epubdate"><span class="pub-date epub-date">Publication Date</span><span class="web-text"> (Web)</span><span class="date-separator">:</span><span class="pub-date-value">November 30, 2012</span><div class="article_header-history base dropBlock"><a href="#" data-db-target-for="article_header-history" title="History" target="_self" class="" aria-expanded="false"><i class="icon-angle-down"></i><i class="icon-angle-up"></i></a><div data-db-target-of="article_header-history" class="dropBlock__holder" aria-hidden="true"><div class="articleHeaderHistoryDropzone" data-pb-dropzone="articleHeaderHistoryDropzone"><h4>Publication History</h4>




        
        <ul class="rlist article-chapter-history-list"><li><span class="item_label"><b>Received</b></span>24 September 2012</li><li><span class="item_label"><b>Published</b> online</span>12 December 2012</li><li><span class="item_label"><b>Published</b> in</span><span class="item_label-issue">issue</span> 27 December 2012</li></ul></div></div></div></div><div class="article_header-doiurl"><a href="https://doi.org/10.1021/jm301389h" title="DOI URL">https://doi.org/10.1021/jm301389h</a></div><div class="article_header-article-copyright"><strong>Copyright © 2012 American Chemical Society</strong></div><div class="article_rightPermissionsLink"><div class="articleHeaderDropzone4" data-pb-dropzone="articleHeaderDropzone4"><div class="articleRightsPermissionsLink"><a href="/servlet/linkout?type=rightslink&amp;url=startPage%3D10958%26pageCount%3D14%26copyright%3DAmerican%2BChemical%2BSociety%26author%3DMichael%2BF.%2BT.%2BKoehler%252C%2BPhilippe%2BBergeron%252C%2BElizabeth%2BBlackwood%252C%2Bet%2Bal%26orderBeanReset%3Dtrue%26imprint%3DAmerican%2BChemical%2BSociety%26volumeNum%3D55%26issueNum%3D24%26contentID%3Djm301389h%26title%3DPotent%252C%2BSelective%252C%2Band%2BOrally%2BBioavailable%2BInhibitors%2Bof%2Bthe%2BMammalian%2BTarget%2Bof%2BRapamycin%2BKinase%2BDomain%2BExhibiting%2BSingle%2BAgent%2BAntiproliferative%2BActivity%26numPages%3D14%26pa%3D%26issn%3D0022-2623%26publisherName%3Dacs%26publication%3Djmcmar%26rpt%3Dn%26endPage%3D10971%26publicationDate%3DDecember%2B2012">RIGHTS & PERMISSIONS</a></div></div></div><div class="article_header-access-block"><div class="article_header-open-access"></div><div class="article_header-access-icon"><img src="/products/achs/releasedAssets/images/subscribed.svg" alt="Subscribed Access" /></img></div></div></div><div class="article_header-meta-center pull-left"><div class="articleHeaderDropzone3" data-pb-dropzone="articleHeaderDropzone3"><div class="articleMetrics"><div class="articleMetrics_table"><div class="articleMetrics_row"><input type="hidden" name="articleMetricsDoi" value="10.1021/jm301389h"/></input><div class="articleMetrics_metric"><h6>Article Views</h6><div class="articleMetrics-val">2332</div></div><div class="articleMetrics_altmetric"><h6>Altmetric</h6><div class="articleMetrics-val articleMetrics_score">-</div><div class="altmetric-donut hidden"><div data-badge-details="right" data-badge-type="donut" data-hide-no-mentions="false" data-condensed="true" class="altmetric-embed"></div></div></div><div class="articleMetrics_count"><h6>Citations</h6><div class="articleMetrics-val"><a href="#citeThis" class="internalNav">20</a></div></div></div></div><div class="articleMetrics_about"><div class="base dropBlock"><a href="#" data-db-target-for="aboutArticleMetrics" class="article_aboutLink">LEARN ABOUT THESE METRICS</a><div data-db-target-of="aboutArticleMetrics" aria-live="polite" aria-atomic="true" role="alert" class="dropBlock__holder"><i aria-hidden="true" class="icon-close_thin"></i><p>Article Views are the COUNTER-compliant sum of full text article downloads since November 2008 (both PDF and HTML) across all institutions and individuals. These metrics are regularly updated to reflect usage leading up to the last few days.</p><p>Citations are the number of other articles citing this article, calculated by Crossref and updated daily.<a href="https://www.crossref.org/services/cited-by/" title="Find more information about Crossref citation counts"> Find more information about Crossref citation counts.</a></p><p>The Altmetric Attention Score is a quantitative measure of the attention that a research article has received online. Clicking on the donut icon will load a page at altmetric.com with additional details about the score and the social media presence for the given article. Find more information on<a href="https://help.altmetric.com/support/solutions/articles/6000233311-how-is-the-altmetric-attention-score-calculated" title="The Altmetric Attention Score and how the score is calculated"> the Altmetric Attention Score and how the score is calculated.</a></p></div></div></div></div></div></div><div class="article_header-meta-right"><div class="articleHeaderDropzone6" data-pb-dropzone="articleHeaderDropzone6"><div data-widget-def="UX3share" data-widget-id="787b5b92-0445-40f4-bdd2-9591d56f4a67" class="article_header-share share_label_visible">
        



        
        <script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="787b5b92-0445-40f4-bdd2-9591d56f4a67" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div>



        
        <div class="achs-addto-mendeley"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" class="doi" value="10.1021/jm301389h" /></input><span class="achs-addto-mendeley_label achs-addto-mendeley_addToLabel">Add to</span><span class="achs-addto-mendeley_label achs-addto-mendeley_viewInLabel">View In</span><a title="Add to mendeley button" class="achs-addto-mendeley_button" tabindex="0"><i class="achs-addto-mendeley_icon icon-mendeley"></i><i class="achs-addto-mendeley_close icon-close"></i></a><div data-db-target-of="5423a74c-bbd8-47b1-9f43-99423ee72e5c" class="achs-addto-mendeley_list dropBlock__holder"><ul><li><a href="#" title="Add Full Text with Reference" class="achs-addto-mendeley_disabled-button add-full-document"><i class="icon-bookmark-o"></i><span>Add Full Text with Reference</span></a></li><li><a href="#" title="Add Description" class="achs-mendeley_button add-metadata-description"><i class="icon-mendeley"></i><span>Add Description</span></a></li></ul></div><a href="#" title="View in mendeley button" class="achs-addto-mendeley_viewin-button"><i class="icon-mendeley"></i></a><div class="achs_loader"><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div></div><input type="hidden" name="meta-data" value="{&quot;title&quot;:&quot;Potent, Selective, and Orally Bioavailable Inhibitors of the Mammalian Target of Rapamycin Kinase Domain Exhibiting Single Agent Antiproliferative Activity&quot;,&quot;type&quot;:&quot;journal&quot;,&quot;authors&quot;:[{&quot;first_name&quot;:&quot;Michael&quot;,&quot;last_name&quot;:&quot;F. T. Koehler&quot;},{&quot;first_name&quot;:&quot;Philippe&quot;,&quot;last_name&quot;:&quot;Bergeron&quot;},{&quot;first_name&quot;:&quot;Elizabeth&quot;,&quot;last_name&quot;:&quot;Blackwood&quot;},{&quot;first_name&quot;:&quot;Krista&quot;,&quot;last_name&quot;:&quot;K. Bowman&quot;},{&quot;first_name&quot;:&quot;Yung-Hsiang&quot;,&quot;last_name&quot;:&quot;Chen&quot;},{&quot;first_name&quot;:&quot;Gauri&quot;,&quot;last_name&quot;:&quot;Deshmukh&quot;},{&quot;first_name&quot;:&quot;Xiao&quot;,&quot;last_name&quot;:&quot;Ding&quot;},{&quot;first_name&quot;:&quot;Jennifer&quot;,&quot;last_name&quot;:&quot;Epler&quot;},{&quot;first_name&quot;:&quot;Kevin&quot;,&quot;last_name&quot;:&quot;Lau&quot;},{&quot;first_name&quot;:&quot;Leslie&quot;,&quot;last_name&quot;:&quot;Lee&quot;},{&quot;first_name&quot;:&quot;Lichuan&quot;,&quot;last_name&quot;:&quot;Liu&quot;},{&quot;first_name&quot;:&quot;Cuong&quot;,&quot;last_name&quot;:&quot;Ly&quot;},{&quot;first_name&quot;:&quot;Shiva&quot;,&quot;last_name&quot;:&quot;Malek&quot;},{&quot;first_name&quot;:&quot;Jim&quot;,&quot;last_name&quot;:&quot;Nonomiya&quot;},{&quot;first_name&quot;:&quot;Jason&quot;,&quot;last_name&quot;:&quot;Oeh&quot;},{&quot;first_name&quot;:&quot;Daniel&quot;,&quot;last_name&quot;:&quot;F. Ortwine&quot;},{&quot;first_name&quot;:&quot;Deepak&quot;,&quot;last_name&quot;:&quot;Sampath&quot;},{&quot;first_name&quot;:&quot;Steve&quot;,&quot;last_name&quot;:&quot;Sideris&quot;},{&quot;first_name&quot;:&quot;Lan&quot;,&quot;last_name&quot;:&quot;Trinh&quot;},{&quot;first_name&quot;:&quot;Tom&quot;,&quot;last_name&quot;:&quot;Truong&quot;},{&quot;first_name&quot;:&quot;Jiansheng&quot;,&quot;last_name&quot;:&quot;Wu&quot;},{&quot;first_name&quot;:&quot;Zhonghua&quot;,&quot;last_name&quot;:&quot;Pei&quot;},{&quot;first_name&quot;:&quot;Joseph&quot;,&quot;last_name&quot;:&quot;P. Lyssikatos&quot;}],&quot;source&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;year&quot;:&quot;2012&quot;,&quot;month&quot;:&quot;12&quot;,&quot;day&quot;:&quot;12&quot;,&quot;issue&quot;:&quot;24&quot;,&quot;volume&quot;:&quot;55&quot;,&quot;pages&quot;:&quot;10958-10971&quot;,&quot;identifiers&quot;:{&quot;doi&quot;:&quot;10.1021/jm301389h&quot;},&quot;abstract&quot;:&quot;Selective inhibitors of mammalian target of rapamycin (mTOR) kinase based upon saturated heterocycles fused to a pyrimidine core were designed and synthesized. Each series produced compounds with Ki &lt; 10 nM for the mTOR kinase and &gt;500-fold selectivity over closely related PI3 kinases. This potency translated into strong pathway inhibition, as measured by phosphorylation of mTOR substrate proteins and antiproliferative activity in cell lines with a constitutively active PI3K pathway. Two compounds exhibiting suitable mouse PK were profiled in in vivo tumor models and were shown to suppress mTORC1 and mTORC2 signaling for over 12 h when dosed orally. Both compounds were additionally shown to suppress tumor growth in vivo in a PC3 prostate cancer model over a 14 day study.&quot;}" class="meta-data"/></input><input type="hidden" name="mendeley-api-endpoint" value="https://api.mendeley.com/documents" class="mendeley-api-endpoint"/></input><input type="hidden" name="pub-access" value="full" class="pub-access"/></input><input type="hidden" name="library-url" value="https://www.mendeley.com/library/" class="library-url"/></input><input type="hidden" name="selected-share-option" class="selected-share-option"/></input></div>




        
        <div class="cit-download-dropdown"><span class="cit-download-dropdown_label">Export</span><a href="#" data-db-target-for="cit-download-dropdown_content" title="Download citation button" class="cit-download-dropdown_button"><span>RIS</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div data-db-target-of="cit-download-dropdown_content" class="cit-download-dropdown_content"><ul><li><a href="/action/downloadCitation?doi=10.1021%2Fjm301389h&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=jm301389h" title="Citation"><span>Citation</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Fjm301389h&amp;include=abs&amp;format=ris&amp;direct=true&amp;downloadFileName=jm301389h" title="Citation and abstract"><span>Citation and abstract</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Fjm301389h&amp;include=ref&amp;format=ris&amp;direct=true&amp;downloadFileName=jm301389h" title="Citation and references"><span>Citation and references</span></a></li><li><a href="/action/showCitFormats?doi=10.1021%2Fjm301389h&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=jm301389h&amp;href=/doi/10.1021/jm301389h" title="Cite This"><i class="icon-plus-square"></i><span>More Options</span></a></li></ul></div></div>
<div data-db-target-of="787b5b92-0445-40f4-bdd2-9591d56f4a67" id="787b5b92-0445-40f4-bdd2-9591d56f4a67_Pop" class="share__block dropBlock__holder fixed"><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>Wechat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li></ul></div></div>

        </div></div></div></div><div class="article_header-footer"><div class="article_header-footer-left pull-left clearfix"><div class="article_header-links pull-left"><input class="pub-doi" type="hidden" name="pub-doi" value="10.1021/jm301389h" /></input><a href="/doi/pdf/10.1021/jm301389h" title="PDF" target="_blank" class="button_primary pdf-button"><i class="icon-file-pdf-o"></i><span>PDF (4 MB)
                            </span></a><a href="/servlet/linkout?suffix=s0&amp;dbid=16384&amp;doi=10.1021/jm301389h&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fid%3Ddoi%3A10.1021%252Fjm301389h%26sid%3Dliteratum%253Aachs%26pmid%3D23199076%26genre%3Darticle%26aulast%3DKoehler%26date%3D2012%26atitle%3DPotent%252C%2BSelective%252C%2Band%2BOrally%2BBioavailable%2BInhibitors%2Bof%2Bthe%2BMammalian%2BTarget%2Bof%2BRapamycin%2BKinase%2BDomain%2BExhibiting%2BSingle%2BAgent%2BAntiproliferative%2BActivity%26jtitle%3DJournal%2Bof%2BMedicinal%2BChemistry%26title%3DJournal%2Bof%2BMedicinal%2BChemistry%26volume%3D55%26issue%3D24%26spage%3D10958%26epage%3D10971%26issn%3D0022-2623" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a><div class="articleHeaderDropzone8" data-pb-dropzone="articleHeaderDropzone8"><div class="external-alerts-management"><input type="hidden" name="pub-type" value="article" class="pub-type"/></input><input type="hidden" name="is-enabled" value="true" class="is-enabled"/></input><input type="hidden" name="is-authenticated" value="false" class="is-authenticated"/></input><input type="hidden" name="pub-code" value="jmcmar" class="pub-code"/></input><input type="hidden" name="linkout-url" value="https://preferences.acspubs.org/journals" class="linkout-url"/></input><button data-toggle="modal" data-target="#ealertsModal" class="ealerts-toggle-btn hidden"></button><a class="button_primary_2 niHeader_getEAlerts jhHeader_sub_info"><i class="icon-send"></i><i class="icon-envelope"></i><i class="icon-check"></i><span class="ealerts-btn-text">Get e-Alerts</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div class="ux-modal-container"><div id="ealertsModal" style="display: none;" aria-live="polite" aria-atomic="true" class="modal"><div class="modal__dialog"><div class="modal__body"><iframe src="" class="ealerts-frame"></iframe></div></div></div></div><input type="hidden" id="ealertsModalSrc" value="https://preferences.acspubs.org/jmcmar?ifr=1"/></input></div></div></div></div><div class="article_header-footer-right"><div class="articleHeaderDropzone7" data-pb-dropzone="articleHeaderDropzone7"><div class="article_header-footer-right"><div class="article_header-taxonomy"><span>SUBJECTS:</span><ul class="rlist--inline loa"><li><a href="/action/doSearch?ConceptID=292524" title="Peptides and proteins">Peptides and proteins</a>,</li><li><a href="/action/doSearch?ConceptID=292464" title="Rodent models">Rodent models</a>,</li><li><a href="/action/doSearch?ConceptID=291793" title="Inhibition">Inhibition</a>,</li><li><a href="/action/doSearch?ConceptID=291711" title="Selectivity">Selectivity</a>,</li><li><a href="/action/doSearch?ConceptID=292153" title="Tumors">Tumors</a></li></ul></div></div></div></div></div></div><div class="article_header-right pull-left hidden-md hidden-sm hidden-xs"><div class="articleHeaderDropzone2" data-pb-dropzone="articleHeaderDropzone2"><div class="cover-image"><div class="cover-image__image"><a href="/toc/jmcmar/55/24" title="Go to Journal of Medicinal Chemistry "><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-24/jmcmar.2012.55.issue-24/production/jmcmar.2012.55.issue-24.largecover.jpg" alt="Go to Journal of Medicinal Chemistry "/></img></a></div></div>




        
        
<script>
 $(document).ready(function() {
   $('.article_header .external-alerts-management .niHeader_getEAlerts').each(function(){
	 var Tab = $(this).attr("href");
	   if(typeof Tab != undefined && Tab != false){
		 console.log("Testing Tab");
		 $(this).attr('href','#');
	   }
   });
 });
 $(document).on('click', '.article_header .external-alerts-management .niHeader_getEAlerts', function (e) {
	 //do something
	 if($(this).hasClass('registered')){
	  //send data to analytics for registered users
	      ga('send','event','Registered e-Alert','Article Page Click','jmcmar');
	  }else{
	     //send data to analytics for non-registered users
	      ga('send','event','Get e-Alert','Article Page Click','jmcmar');
	  }
  });
</script>





        
        <div class="pj-badge"></div>




        
        <div class="aJhp_link"></div>
<a href="/action/doUpdateAlertSettings?action=addJournal&amp;journalCode=jmcmar" class="button_primary_2"><i class="icon-send"></i><span>Get e-Alerts</span></a></div></div></div></div></div></div></div><div class="article_abstract"><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><h2 class="article_abstract-title" id="Abstract">Abstract</h2><div class="article_abstract-content hlFld-Abstract" id="abstractBox"><figure id="f_tgr1" data-index="0" class="article__inlineFigure article_abstract-img"><img class="inline-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-24/jm301389h/production/images/medium/jm-2012-01389h_0015.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-24/jm301389h/production/images/large/jm-2012-01389h_0015.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm301389h&amp;id=f_tgr1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><p class="articleBody_abstractText">Selective inhibitors of mammalian target of rapamycin (mTOR) kinase based upon saturated heterocycles fused to a pyrimidine core were designed and synthesized. Each series produced compounds with <i>K</i><sub>i</sub> < 10 nM for the mTOR kinase and >500-fold selectivity over closely related PI3 kinases. This potency translated into strong pathway inhibition, as measured by phosphorylation of mTOR substrate proteins and antiproliferative activity in cell lines with a constitutively active PI3K pathway. Two compounds exhibiting suitable mouse PK were profiled in in vivo tumor models and were shown to suppress mTORC1 and mTORC2 signaling for over 12 h when dosed orally. Both compounds were additionally shown to suppress tumor growth in vivo in a PC3 prostate cancer model over a 14 day study.</p></div></div></div></div></div><div class="article_content"><ul class="tab-nav-shortcut"><li><i class="icon-image"></i></li><li><i class="icon-link"></i></li><li><i class="icon-supporting-info"></i></li></ul><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><div class="article_content-table hlFld-FullText"><div class="article_content-row"><div class="article_content-left"><div id="sec1" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i1">Introduction</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_17666" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_17666" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">As the role of misregulation of signaling pathways in various cancers has become better understood, activating mutations in the growth factor receptor tyrosine kinase/phosphoinositide 3-kinase (PI3K)/Akt pathway stand out as being implicated in a multitude of cancers. More recent work has shown that the mammalian target of rapamycin (mTOR) serves as an essential component of this signaling pathway. mTOR is a serine-threonine protein kinase of the PI3K superfamily and forms two distinct signaling complexes, mTOR complexes 1 and 2 (mTORC1 and -2).</div><div class="NLM_p last">The mTORC1 complex is known to phosphorylate 4EBP1 and S6K1, thereby stimulating CAP-dependent translation, protein synthesis, and cell proliferation. mTORC2 has been found to phosphorylate and activate Akt upstream of mTORC1. The natural product rapamycin (<b>1a</b>) and its semisynthetic analogs temsirolimus (<b>1b</b>) and everolimus (<b>1c</b>) (Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a>) are selective allosteric inhibitors of most of the functions of mTORC1 but do not inhibit mTORC2. While everolimus has demonstrated efficacy when combined with exemestane in hormone receptor positive breast cancer,<a onclick="showRef(event, 'ref1'); return false;" href="javascript:void(0);" class="ref ref1">(1)</a> both temsirolimus and everolimus have been shown to have only modest efficacy in treating renal cell carcinoma and mantle cell lymphoma. This limited efficacy has been ascribed to the existence of two feedback pathways, mediated by mTORC2, which induce hyperphosphorylation of Akt in the presence of rapamycin.<a onclick="showRef(event, 'ref2'); return false;" href="javascript:void(0);" class="ref ref2">(2)</a> These results prompted a great interest in developing inhibitors of the kinase domain of mTOR which would inhibit both mTORC1 and mTORC2, a number of which have been reported recently.<a onclick="showRef(event, 'ref3 ref4 ref5 ref6 ref7 ref8 ref9 ref10 ref11 ref12 ref13 ref14 ref15 ref16 ref17 ref18 ref19 ref20 ref21 ref22 ref23 ref24 ref25 ref26 ref27 ref28'); return false;" href="javascript:void(0);" class="ref ref3 ref4 ref5 ref6 ref7 ref8 ref9 ref10 ref11 ref12 ref13 ref14 ref15 ref16 ref17 ref18 ref19 ref20 ref21 ref22 ref23 ref24 ref25 ref26 ref27 ref28">(3-28)</a></div></div><div id="sec2" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i2">Results and Discussion</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_18706" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_18706" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">Having previously developed both the PI3K selective<a onclick="showRef(event, 'ref29'); return false;" href="javascript:void(0);" class="ref ref29">(29)</a> compound <b>2</b> (GDC-0941, Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a>) and the potent dual PI3K/mTOR inhibitor<a onclick="showRef(event, 'ref30'); return false;" href="javascript:void(0);" class="ref ref30">(30)</a><b>3</b> (GDC-0980, Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a>), we focused on producing an inhibitor specific for mTOR that would enable us to assess the role mTOR signaling was playing in various cell lines and cancer types. Our starting point was morpholinothienopyrimidine <b>4</b>, which had been found to be a potent inhibitor of the mTOR kinase with a <i>K</i><sub>i</sub> = 3 nM that was also 20-fold selective for mTOR over PI3Kα.</div><figure id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-24/jm301389h/production/images/medium/jm-2012-01389h_0001.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-24/jm301389h/production/images/large/jm-2012-01389h_0001.jpeg" id="gr1" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Rapamycin and its analogs <b>1a</b>–<b>c</b>, selective PI3K inhibitor <b>2</b> (GDC-0941), dual PI3K/mTOR inhibitor <b>3</b> (GDC-0980), and <b>4</b>, which exhibits 20-fold mTOR selectivity.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-24/jm301389h/production/images/large/jm-2012-01389h_0001.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm301389h&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Our initial efforts were directed at moving away from the thienopyrimidine scaffold used in our previous work, which we knew from previous experience could present difficulties with solubility, oral bioavailability, and poor pharmacokinetics.<a onclick="showRef(event, 'ref30'); return false;" href="javascript:void(0);" class="ref ref30">(30)</a> In an effort to improve the predicted solubility, clogP, and predicted metabolic stability of our core, we targeted replacement of the thiophene with a saturated ring. Pyrrolidine was an attractive replacement as it provided a functional handle for further diversification after assembly of the core. Molecules of this type could be rapidly assembled from the Boc-2,4-dichloro-5-pyrrolopyrimidine <b>5</b> through nucleophilic displacement of the C4 chloride followed by a Suzuki coupling at C2. Potassium acetate was included in the coupling to minimize the cleavage of the ethyl urea, which was a major side product when sodium carbonate was the exclusive base. Final diversification was accomplished by removal of the Boc group followed by treatment with an appropriate electrophile, as shown in Scheme <a class="ref internalNav" href="#sch1" aria-label="1">1</a>.</div><div class="NLM_p">The in vitro potencies of these compounds were measured against recombinant mTOR kinase domain using a LanthaScreen FRET assay and against PI3Kα using a fluorescence polarization assay, as previously described.<a onclick="showRef(event, 'ref31'); return false;" href="javascript:void(0);" class="ref ref31">(31)</a> PI3Kα was chosen as our initial antitarget as a representative class I PI3 kinase. We were pleased to discover that, with the exception of the unsubstituted pyrrolidine, all of these compounds were potent inhibitors of the mTOR kinase domain. Unexpectedly, the compounds also exhibited improved selectivity against PI3Kα relative to the starting thienopyrimidine (Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a>). At the same time, we observed chemical instability in a subset of these molecules upon standing in DMSO solution in air. We did not characterize this instability extensively but supposed it stemmed from oxidation of the doubly activated benzylic methylenes. We therefore began investigating alternative saturated ring systems to identify those which would be tolerated in place of the pyrrolidine and would not exhibit this instability.</div><figure id="sch1" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Scheme 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-24/jm301389h/production/images/medium/jm-2012-01389h_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-24/jm301389h/production/images/large/jm-2012-01389h_0007.jpeg" id="gr7" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 1. Synthesis of Pyrrolopyrimidines <b>6a</b>–<b>e</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-24/jm301389h/production/images/large/jm-2012-01389h_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm301389h&amp;id=sch1"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (a) morpholine, DIPEA, 90%; (b) (4-ethylurido)phenylboronic acid pinacol ester, Pd(PPh<sub>3</sub>)<sub>4</sub>, KOAc, Na<sub>2</sub>CO<sub>3</sub>, H<sub>2</sub>O/CH<sub>3</sub>CN, 120 °C, 96%; (c) TFA, CH<sub>2</sub>Cl<sub>2</sub>, then PS-carbonate resin; (d) electrophile, DIPEA, CH<sub>2</sub>Cl<sub>2</sub>, (e) 2-chloropyrimidine, DIPEA, DMF, 120 °C.</p></p></figure><div class="NLM_table-wrap" id="tbl1"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 1. Inhibition Data for Pyrrolopyrimidines <b>6a</b>–<b>e</b><a class="ref internalNav" href="#t1fn1" aria-label="a">a</a></div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-24/jm301389h/production/images/medium/jm-2012-01389h_0010.gif" alt="" id="fx1" /></img><div class="scrollable-table-wrap"><table class="table" border="0"><colgroup><col align="left" /></col><col align="left" /></col><col align="char" char="." /></col><col align="char" char="." /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center"> </th><th class="colsep0 rowsep0" align="center">R</th><th class="colsep0 rowsep0" align="center" char=".">mTOR <i>K</i><sub>i</sub> (nM)</th><th class="colsep0 rowsep0" align="center" char=".">PI3Kα (fold)</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>6a</b></td><td class="colsep0 rowsep0" align="left">Boc</td><td class="colsep0 rowsep0" align="char" char=".">10</td><td class="colsep0 rowsep0" align="char" char=".">21</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>6b</b></td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="char" char=".">122</td><td class="colsep0 rowsep0" align="char" char=".">82</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>6c</b></td><td class="colsep0 rowsep0" align="left">2-pyrimidine</td><td class="colsep0 rowsep0" align="char" char=".">3.0</td><td class="colsep0 rowsep0" align="char" char=".">126</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>6d</b></td><td class="colsep0 rowsep0" align="left">SO<sub>2</sub>Me</td><td class="colsep0 rowsep0" align="char" char=".">3.7</td><td class="colsep0 rowsep0" align="char" char=".">82</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>6e</b></td><td class="colsep0 rowsep0" align="left">CONHEt</td><td class="colsep0 rowsep0" align="char" char=".">5.1</td><td class="colsep0 rowsep0" align="char" char=".">42</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t1fn1"><div class="footnote" id="t1fn1"><sup>a</sup><p class="last">Assays are described in ref <a onclick="showRef(event, 'ref30'); return false;" href="javascript:void(0);" class="ref ref30">30</a>.</p></div></div></div><div class="NLM_p">We began by investigating the possibility of expanding the pyrrolidine ring to a piperidine, thereby eliminating one of the doubly activated methylenes. Of the two possibilities, we first examined those in which the nitrogen on the saturated ring was in the 6-position. The synthesis of these compounds proved straightforward (Scheme <a class="ref internalNav" href="#sch2" aria-label="2">2</a>), beginning with the formation of the pyrimidine dione from methyl 1-benzyl-4-oxopiperidine-3-carboxylate. This could be converted to the dichloride <b>7</b> and the benzyl protecting group exchanged for Boc using ACE-Cl<a onclick="showRef(event, 'ref32'); return false;" href="javascript:void(0);" class="ref ref32">(32)</a> to give <b>8</b>. Nucleophilic aromatic substitution with a morpholine followed by Suzuki coupling and Boc removal gave compounds <b>9a</b> and <b>9b</b>, which could be functionalized as needed through acylation, sulfonylation, or nucleophilic aromatic substitution to give the desired 6-aza-tetrahydroquinazolines <b>10</b>.</div><figure id="sch2" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Scheme 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-24/jm301389h/production/images/medium/jm-2012-01389h_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-24/jm301389h/production/images/large/jm-2012-01389h_0008.jpeg" id="gr8" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 2. Synthesis of 6-Aza-tetrahydroquinazolines <b>10</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-24/jm301389h/production/images/large/jm-2012-01389h_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm301389h&amp;id=sch2"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (a) urea, MeOH, NaOMe, reflux, 64%; (b) POCl<sub>3</sub>, reflux, 75%; (c) ACE-Cl, CH<sub>2</sub>Cl<sub>2</sub>, 0 °C to rt, then reflux; (d) MeOH, reflux; (e) PS-carbonate resin, Boc<sub>2</sub>O, CH<sub>2</sub>Cl<sub>2</sub>, 88% for three steps; (f) morpholine or (<i>S</i>)-methylmorpholine, DIPEA, DMF; (g) (4-ethylurido)phenylboronic acid pinacol ester, Pd(PPh<sub>3</sub>)<sub>4</sub>, KOAc, Na<sub>2</sub>CO<sub>3</sub>, H<sub>2</sub>O/CH<sub>3</sub>CN, 120 °C; (h) TFA, CH<sub>2</sub>Cl<sub>2</sub>, then PS-carbonate resin; (i) electrophile, DIPEA, CH<sub>2</sub>Cl<sub>2</sub>.</p></p></figure><div class="NLM_p">The 6-aza-tetrahydroquinazolines <b>10a</b>–<b>h</b> proved to be less potent but more selective inhibitors of mTOR than the equivalent pyrrolopyrimidines <b>6</b>, as seen in Table <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">2</a>. Additionally, all proved stable under our typical handling conditions. To investigate the source of the diminished activity, we examined compound <b>10f</b> docked into a homology model of mTOR that was built using PI3Kγ as a template (Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a>). The model indicates that the 6-N-substituents make a close approach to the protein, but are not predicted to make unfavorable interactions. The observed loss of affinity could be partially compensated for by incorporating an (<i>S</i>)-2-methylmorpholine, which has been shown to enhance potency and selectivity for mTOR when used in place of morpholine as a hinge binder,<a onclick="showRef(event, 'ref9 ref21'); return false;" href="javascript:void(0);" class="ref ref9 ref21">(9, 21)</a> as this methyl group projects into a hydrophobic cavity created by Trp2239 that PI3Kα lacks. In the examples below, the methyl group improved mTOR potency an average of 6.6-fold, with an 8.0-fold improvement in selectivity against PI3Kα. Encouraged by the improved selectivity of these compounds for the mTOR kinase, we decided to investigate the isomeric 7-aza-tetrahydroquinazoline series, as our modeling indicated that substituents on the piperidine nitrogen would be more completely solvent exposed.</div><div class="NLM_table-wrap" id="tbl2"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 2. Inhibition Data for 6-Aza-tetrahydroquinazoline Compounds <b>10a</b>–<b>h</b><a class="ref internalNav" href="#t2fn1" aria-label="a">a</a></div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-24/jm301389h/production/images/medium/jm-2012-01389h_0011.gif" alt="" id="fx2" /></img><div class="scrollable-table-wrap"><table class="table" border="0"><colgroup><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="char" char="." /></col><col align="left" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center"> </th><th class="colsep0 rowsep0" align="center">R<sub>1</sub></th><th class="colsep0 rowsep0" align="center">R<sub>2</sub></th><th class="colsep0 rowsep0" align="center" char=".">mTOR <i>K</i><sub>i</sub> (nM)</th><th class="colsep0 rowsep0" align="center">PI3Kα/δ (fold)</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>10a</b></td><td class="colsep0 rowsep0" align="left">Boc</td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="char" char=".">48</td><td class="colsep0 rowsep0" align="left">10/48</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>10b</b></td><td class="colsep0 rowsep0" align="left">Boc</td><td class="colsep0 rowsep0" align="left">Me</td><td class="colsep0 rowsep0" align="char" char=".">12</td><td class="colsep0 rowsep0" align="left">214/224</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>10c</b></td><td class="colsep0 rowsep0" align="left">MeSO<sub>2</sub></td><td class="colsep0 rowsep0" align="left">Me</td><td class="colsep0 rowsep0" align="char" char=".">6.8</td><td class="colsep0 rowsep0" align="left">>1000/>1000</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>10d</b></td><td class="colsep0 rowsep0" align="left">Ac</td><td class="colsep0 rowsep0" align="left">Me</td><td class="colsep0 rowsep0" align="char" char=".">11</td><td class="colsep0 rowsep0" align="left">>900/>900</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>10e</b></td><td class="colsep0 rowsep0" align="left">2-pyrimidine</td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="char" char=".">17</td><td class="colsep0 rowsep0" align="left">120/61</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>10f</b></td><td class="colsep0 rowsep0" align="left">2-pyrimidine</td><td class="colsep0 rowsep0" align="left">Me</td><td class="colsep0 rowsep0" align="char" char=".">2.3</td><td class="colsep0 rowsep0" align="left">>900/>900</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>10g</b></td><td class="colsep0 rowsep0" align="left">2-pyrazine</td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="char" char=".">20</td><td class="colsep0 rowsep0" align="left">69/91</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>10h</b></td><td class="colsep0 rowsep0" align="left">2-pyrazine</td><td class="colsep0 rowsep0" align="left">Me</td><td class="colsep0 rowsep0" align="char" char=".">2.4</td><td class="colsep0 rowsep0" align="left">>1000/>1000</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t2fn1"><div class="footnote" id="t2fn1"><sup>a</sup><p class="last">Assays are described in ref <a onclick="showRef(event, 'ref30'); return false;" href="javascript:void(0);" class="ref ref30">30</a>.</p></div></div></div><figure id="fig2" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-24/jm301389h/production/images/medium/jm-2012-01389h_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-24/jm301389h/production/images/large/jm-2012-01389h_0002.jpeg" id="gr2" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. Compound <b>10f</b> docked into a homology model of mTOR that was built using PI3Kγ as a template.<a onclick="showRef(event, 'ref9'); return false;" href="javascript:void(0);" class="ref ref9">(9)</a> Residues differing from those in PI3Kγ are labeled. The molecular surfaces for both ligand and protein are shown to illustrate the intimate interaction provided by the presence of the (<i>S</i>)-methyl substituent on the morpholine. The protein surface is color coded by hydrophobicity (tan-brown is hydrophobic, cyan-blue is hydrophilic, and green is in between). The ligand surface is magenta.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-24/jm301389h/production/images/large/jm-2012-01389h_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm301389h&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">We prepared the 7-aza-tetrahydroquinolines using chemistry analogous to that developed for the synthesis of the pyrrolopyrimidines (Scheme <a class="ref internalNav" href="#sch3" aria-label="3">3</a>). When assayed (Table <a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">3</a>), we found that this series of compounds had recovered the potency and selectivity for mTOR over both PI3Kα and PI3Kδ we had observed in the pyrrolidine series, and all were again found to be stable under typical storage conditions.</div><figure id="sch3" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Scheme 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-24/jm301389h/production/images/medium/jm-2012-01389h_0009.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-24/jm301389h/production/images/large/jm-2012-01389h_0009.jpeg" id="gr9" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 3. Synthesis of 7-Aza-tetrahydroquinazolines <b>12a</b>–<b>g</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-24/jm301389h/production/images/large/jm-2012-01389h_0009.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm301389h&amp;id=sch3"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (a) morpholine, DIPEA; (b) (4-ethylurido)phenylboronic acid pinacol ester, Pd(PPh<sub>3</sub>)<sub>4</sub>, KOAc, Na<sub>2</sub>CO<sub>3</sub>, H<sub>2</sub>O/CH<sub>3</sub>CN, 120 °C; (c) TFA, CH<sub>2</sub>Cl<sub>2</sub>, then PS-carbonate resin; (d) electrophile, DIPEA, CH<sub>2</sub>Cl<sub>2</sub>; (e) 4-hydroxyphenylboronic acid pinacol ester, Pd(PPh<sub>3</sub>)<sub>4</sub>, KOAc, Na<sub>2</sub>CO<sub>3</sub>, H<sub>2</sub>O/CH<sub>3</sub>CN, 120 °C, 89%; (f) EtNCO, THF, 70 °C, 24 h, 38%; (g) 4-aminophenylboronic acid pinacol ester, Pd(PPh<sub>3</sub>)<sub>4</sub>, KOAc, Na<sub>2</sub>CO<sub>3</sub>, H<sub>2</sub>O/CH<sub>3</sub>CN, 120 °C, 86%; (h) ethyl chloroformate, THF, DIPEA, 70%.</p></p></figure><div class="NLM_p">Our initial inhibition data indicated that both polar and nonpolar functionality was tolerated on the piperidine nitrogen with little change in the biochemical potency. Docking of these molecules into a homology model of mTOR shows that N-substituents are directed into a largely solvent-exposed region of the protein (Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a>). The basic piperidine, left unmodified, reduced the potency approximately 10-fold, but reducing the basicity through formation of a carbamate, sulfonamide, urea, or ester resulted in compounds of approximately equivalent <i>K</i><sub>i</sub>. Modeling shows this nitrogen is in a fairly hydrophobic region of the protein, flanked by Ile2163, Leu2185, Trp2239, Met2345, and Ile2356, and thus poorly tolerant of a formal charge. Modifications of the ethyl urea were much less well tolerated; replacement of the nitrogen adjacent to the phenyl ring with an oxygen (<b>12f</b>) resulted in a 200-fold reduction in mTOR binding and an almost complete loss of selectivity against PI3Kα/δ. The second urea nitrogen was also replaced with oxygen (<b>12g</b>), resulting in a 20-fold reduction in binding, but no significant loss in selectivity. The requirement for hydrogen bond donors in both positions is consistent with our binding model, in which each of the urea nitrogens forms a hydrogen bond to the side chain of Asp2195.<a onclick="showRef(event, 'ref9'); return false;" href="javascript:void(0);" class="ref ref9">(9)</a></div><div class="NLM_p">Having now developed a number of compounds potent in the biochemical assay, we examined their cellular activity in two separate assays. For this, we used the pTEN-null prostate carcinoma NCI-PC3 cell line, in which the loss of pTEN leads to phosphorylation of Akt at Thr308, activating the Akt kinase, which then phosphorylates and activates mTOR along with its other substrates. In this cell line, we measured the inhibition of the phosphorylation of Ser473 of Akt, a known mTORC2 substrate, and also assessed the antiproliferative activity of our compounds more broadly through determination of an IC<sub>50</sub> in a 3-day viability assay (Table <a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">3</a>). In each case, we found that cellular potency tracked roughly with the biochemical potency of the compounds, with compound <b>12h</b> being the most potent in both assays.</div><div class="NLM_table-wrap" id="tbl3"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 3. In Vitro Data for 7-Aza-tetrahydroquinazoline Compounds <b>12a</b>–<b>h</b><a class="ref internalNav" href="#t3fn1" aria-label="a">a</a></div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-24/jm301389h/production/images/medium/jm-2012-01389h_0012.gif" alt="" id="fx3" /></img><div class="scrollable-table-wrap"><table class="table" border="0"><colgroup><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center"> </th><th class="colsep0 rowsep0" align="center"> </th><th class="colsep0 rowsep0" align="center"> </th><th class="colsep0 rowsep0" align="center"> </th><th class="colsep0 rowsep0" align="center"> </th><th class="colsep0 rowsep0" align="center"> </th><th class="rowsep1 colsep0" colspan="2" align="center">IC<sub>50</sub> (nM)</th></tr><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center"> </th><th class="colsep0 rowsep0" align="center">R<sub>1</sub></th><th class="colsep0 rowsep0" align="center">X</th><th class="colsep0 rowsep0" align="center">Y</th><th class="colsep0 rowsep0" align="center">mTOR <i>K</i><sub>i</sub> (nM)</th><th class="colsep0 rowsep0" align="center">PI3Kα/δ (fold)</th><th class="colsep0 rowsep0" align="center">pAKT</th><th class="colsep0 rowsep0" align="center">MCI-PC3</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>12a</b></td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">NH</td><td class="colsep0 rowsep0" align="left">NH</td><td class="colsep0 rowsep0" align="left">140</td><td class="colsep0 rowsep0" align="left">36/17</td><td class="colsep0 rowsep0" align="left">nd</td><td class="colsep0 rowsep0" align="left">nd</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>12b</b></td><td class="colsep0 rowsep0" align="left">Boc</td><td class="colsep0 rowsep0" align="left">NH</td><td class="colsep0 rowsep0" align="left">NH</td><td class="colsep0 rowsep0" align="left">12</td><td class="colsep0 rowsep0" align="left">48/79</td><td class="colsep0 rowsep0" align="left">22</td><td class="colsep0 rowsep0" align="left">nd</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>12c</b></td><td class="colsep0 rowsep0" align="left">MeSO<sub>2</sub></td><td class="colsep0 rowsep0" align="left">NH</td><td class="colsep0 rowsep0" align="left">NH</td><td class="colsep0 rowsep0" align="left">21</td><td class="colsep0 rowsep0" align="left">10/50</td><td class="colsep0 rowsep0" align="left">43</td><td class="colsep0 rowsep0" align="left">430</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>12d</b></td><td class="colsep0 rowsep0" align="left">CO<sub>2</sub>Me</td><td class="colsep0 rowsep0" align="left">NH</td><td class="colsep0 rowsep0" align="left">NH</td><td class="colsep0 rowsep0" align="left">12</td><td class="colsep0 rowsep0" align="left">22/92</td><td class="colsep0 rowsep0" align="left">37</td><td class="colsep0 rowsep0" align="left">220</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>12e</b></td><td class="colsep0 rowsep0" align="left">Bz</td><td class="colsep0 rowsep0" align="left">NH</td><td class="colsep0 rowsep0" align="left">NH</td><td class="colsep0 rowsep0" align="left">6.5</td><td class="colsep0 rowsep0" align="left">38/86</td><td class="colsep0 rowsep0" align="left">22</td><td class="colsep0 rowsep0" align="left">340</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>12f</b></td><td class="colsep0 rowsep0" align="left">Bz</td><td class="colsep0 rowsep0" align="left">O</td><td class="colsep0 rowsep0" align="left">NH</td><td class="colsep0 rowsep0" align="left">1500</td><td class="colsep0 rowsep0" align="left">6.5/6.5</td><td class="colsep0 rowsep0" align="left">nd</td><td class="colsep0 rowsep0" align="left">nd</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>12g</b></td><td class="colsep0 rowsep0" align="left">Bz</td><td class="colsep0 rowsep0" align="left">NH</td><td class="colsep0 rowsep0" align="left">O</td><td class="colsep0 rowsep0" align="left">130</td><td class="colsep0 rowsep0" align="left">79/79</td><td class="colsep0 rowsep0" align="left">115</td><td class="colsep0 rowsep0" align="left">4800</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>12h</b></td><td class="colsep0 rowsep0" align="left">2-pyrimidine</td><td class="colsep0 rowsep0" align="left">NH</td><td class="colsep0 rowsep0" align="left">NH</td><td class="colsep0 rowsep0" align="left">5.5</td><td class="colsep0 rowsep0" align="left">60/130</td><td class="colsep0 rowsep0" align="left">25</td><td class="colsep0 rowsep0" align="left">290</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t3fn1"><div class="footnote" id="t3fn1"><sup>a</sup><p class="last">Assays are described in ref <a onclick="showRef(event, 'ref30'); return false;" href="javascript:void(0);" class="ref ref30">30</a>; nd = not determined.</p></div></div></div><figure id="fig3" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-24/jm301389h/production/images/medium/jm-2012-01389h_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-24/jm301389h/production/images/large/jm-2012-01389h_0003.jpeg" id="gr3" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. Compound <b>12i</b> docked into a homology model of mTOR that was built using PI3Kγ as a template.<a onclick="showRef(event, 'ref9'); return false;" href="javascript:void(0);" class="ref ref9">(9)</a> Residues differing from those in PI3Kγ are labeled. Predicted hydrogen-bonding interactions with the protein are shown as dashed ovals, and the molecular surfaces for both ligand and protein are shown to illustrate the intimate interaction provided by the presence of the (<i>S</i>)-methyl substituent on the morpholine. The protein surface is color coded by hydrophobicity (tan-brown is hydrophobic, cyan-blue is hydrophilic, and green is in between). The ligand surface is yellow.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-24/jm301389h/production/images/large/jm-2012-01389h_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm301389h&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">As it had been successful in the case of the 6-aza-tetrahydroquinazolines, we again attempted to improve the in vitro potency and selectivity of the 7-aza-tetrahydroquinazoline compounds by incorporating (<i>S</i>)-2-methylmorpholine as our hinge binder (Table <a class="ref showTableEvent internalNav" data-ID="tbl4" href="#tbl4">4</a>). This proved successful, and we sought to better quantify the effect by evaluating the potency and selectivity of all 51 pairs of 7-aza-tetrahydroquinazolines in our database. Each pair contained the phenethyl urea and differed only in the presence or absence of the 2-<i>S</i>-methyl group on the morpholine. Matched pair analysis<a onclick="showRef(event, 'ref33'); return false;" href="javascript:void(0);" class="ref ref33">(33)</a> showed that the change in mTOR <i>K</i><sub>i</sub> was modest over these pairs, with those molecules containing the methyl group being 3.2-fold more potent on average. The effect on selectivity was much more pronounced, with the methyl group containing compounds producing an average increase of 19.5-fold in selectivity for PI3Kα. This is consistent with our modeling results, which predict an improved interaction with Trp2239 in mTOR as well as an unfavorable interaction with the larger phenylalanine residue in place of Leu2185 in PI3Kα. We were unable to observe any additional improvement in potency and or selectivity by incorporating a 2-<i>S</i>-ethylmorpholine in compound <b>12j</b>.</div><div class="NLM_table-wrap" id="tbl4"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 4. In Vitro Data for 7-Aza-tetrahydroquinazoline Compounds <b>12i</b>–<b>n</b><a class="ref internalNav" href="#t4fn1" aria-label="a">a</a></div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-24/jm301389h/production/images/medium/jm-2012-01389h_0013.gif" alt="" id="fx4" /></img><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-24/jm301389h/production/images/medium/jm-2012-01389h_0014.gif" alt="" id="fx5" /></img><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t4fn1"><div class="footnote" id="t4fn1"><sup>Table a</sup><p class="last">Assays are described in ref <a onclick="showRef(event, 'ref30'); return false;" href="javascript:void(0);" class="ref ref30">30</a>; nd = not determined.</p></div></div><div></div></div><div class="NLM_p">Having determined that the 7-aza-tetrahydroquinazolines with a 2-<i>S</i>-methylmorpholine as hinge binding element provided superior potency and selectivity, we varied the heterocycles appended to the 7-position of our scaffold. We examined the diazines and a few additional electron-poor heterocycles, as shown in Table <a class="ref showTableEvent internalNav" data-ID="tbl4" href="#tbl4">4</a>, and found that they exhibited similar single-digit nanomolar potency with selectivity varying, but almost always exceeding 100-fold against both PI3Kα and PI3Kδ. We observed the expected suppression of both mTORC1 and mTORC2 in a pTEN-null prostate carcinoma NCI-PC3 cell line<a onclick="showRef(event, 'ref34'); return false;" href="javascript:void(0);" class="ref ref34">(34)</a> as measured by phosphorylation of p70S6K and Akt, respectively. We were pleased to observe potent antiproliferative activity for these compounds on both the PTEN null NCI-PC3 prostate cell line as well as the MCF-7neo/Her2 breast cancer cell line, which has an activating mutation in PI3K. Additionally, compounds <b>12h</b>–<b>n</b> showed no inhibition of the cytochrome P450 (CYP) mediated metabolism of standard substrates for the 3A4 (midazolam and testosterone), 2D6 (dextromethorphan), 2C9 (warfarin), 1A2 (phenacetin), or 2C19 (mephenytoin) isoforms,<a onclick="showRef(event, 'ref35'); return false;" href="javascript:void(0);" class="ref ref35">(35)</a> indicating that they were at a reduced risk for drug–drug interactions when codosed with compounds metabolized principally by only one of these isoforms.</div><div class="NLM_p">As compounds <b>12h</b>–<b>n</b> exhibited similar potency and selectivity in our enzymatic assays as well as potent antiproliferative activity in two separate cell lines, we used a series of mouse PK studies to determine which were most suitable for advancement to in vivo tumor models. We included similar compounds <b>10f</b> and <b>10h</b> from our 6-aza-tetrahydroquinazoline series for comparison as well. We were gratified to observe that a microsomal model of metabolic stability enabled us to predict the in vivo clearance of compounds <b>12</b> in mice fairly well (Table <a class="ref showTableEvent internalNav" data-ID="tbl5" href="#tbl5">5</a>). The intravenous clearance for these compounds ranged from 24 to 49% of mouse liver blood flow while the bioavailability of these compounds ranged from 22 to 70%. Compound <b>12h</b> appeared most attractive overall, combining the lowest clearance with the highest oral bioavailability, resulting in an AUC after oral dosing which was 2-fold higher than that of the other 7-aza-tetrahydroquinazolines examined.</div><div class="NLM_table-wrap" id="tbl5"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 5. In Vitro and in Vivo PK Data for Selected 7-Aza-tetrahydroquinazolines</div></div></div><div class="scrollable-table-wrap"><table class="table" border="0"><colgroup><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center"> </th><th class="colsep0 rowsep0" align="center"> </th><th class="colsep0 rowsep0" align="center"> </th><th class="rowsep1 colsep0" colspan="5" align="center" char=".">mouse PK<a class="ref internalNav" href="#t5fn1" aria-label="a">a</a></th></tr><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center"> </th><th class="colsep0 rowsep0" align="center"> </th><th class="colsep0 rowsep0" align="center"> </th><th class="rowsep1 colsep0" colspan="3" align="center" char=".">iv (1 mg/kg)</th><th class="rowsep1 colsep0" colspan="2" align="center" char=".">po (5 mg/kg)</th></tr><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center"> </th><th class="colsep0 rowsep0" align="center">microsomal Cl<sub>hep</sub><a class="ref internalNav" href="#t5fn2" aria-label="b">b</a>[(mL/min)/kg]h/r/m<a class="ref internalNav" href="#t5fn3" aria-label="c">c</a></th><th class="colsep0 rowsep0" align="center">PPB (%) h/r/m<a class="ref internalNav" href="#t5fn3" aria-label="c">c</a></th><th class="colsep0 rowsep0" align="center" char=".">Cl [(mL/min)/kg]</th><th class="colsep0 rowsep0" align="center" char="."><i>V</i><sub>ss</sub>(L/kg)</th><th class="colsep0 rowsep0" align="center" char="."><i>t</i><sub>1/2</sub> (h)</th><th class="colsep0 rowsep0" align="center" char=".">AUC (μm·h)</th><th class="colsep0 rowsep0" align="center" char="."><i>F</i>%</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>10f</b></td><td class="colsep0 rowsep0" align="left">16/44/71</td><td class="colsep0 rowsep0" align="left">98/97/97</td><td class="colsep0 rowsep0" align="char" char=".">38</td><td class="colsep0 rowsep0" align="char" char=".">2.4</td><td class="colsep0 rowsep0" align="char" char=".">1.7</td><td class="colsep0 rowsep0" align="char" char=".">2.9</td><td class="colsep0 rowsep0" align="char" char=".">62</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>10h</b></td><td class="colsep0 rowsep0" align="left">15/44/80</td><td class="colsep0 rowsep0" align="left">97/96/97</td><td class="colsep0 rowsep0" align="char" char=".">120</td><td class="colsep0 rowsep0" align="char" char=".">1.4</td><td class="colsep0 rowsep0" align="char" char=".">0.18</td><td class="colsep0 rowsep0" align="char" char=".">0.41</td><td class="colsep0 rowsep0" align="char" char=".">29</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>12h</b></td><td class="colsep0 rowsep0" align="left">13/31/40</td><td class="colsep0 rowsep0" align="left">98/99/99</td><td class="colsep0 rowsep0" align="char" char=".">22</td><td class="colsep0 rowsep0" align="char" char=".">1.1</td><td class="colsep0 rowsep0" align="char" char=".">0.7</td><td class="colsep0 rowsep0" align="char" char=".">5.7</td><td class="colsep0 rowsep0" align="char" char=".">70</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>12i</b></td><td class="colsep0 rowsep0" align="left">15/33/61</td><td class="colsep0 rowsep0" align="left">98/97/99</td><td class="colsep0 rowsep0" align="char" char=".">36</td><td class="colsep0 rowsep0" align="char" char=".">1.2</td><td class="colsep0 rowsep0" align="char" char=".">1.7</td><td class="colsep0 rowsep0" align="char" char=".">2.0</td><td class="colsep0 rowsep0" align="char" char=".">42</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>12l</b></td><td class="colsep0 rowsep0" align="left">7.3/19/34</td><td class="colsep0 rowsep0" align="left">nd<a class="ref internalNav" href="#t5fn4" aria-label="d">d</a></td><td class="colsep0 rowsep0" align="char" char=".">44</td><td class="colsep0 rowsep0" align="char" char=".">1.7</td><td class="colsep0 rowsep0" align="char" char=".">0.75</td><td class="colsep0 rowsep0" align="char" char=".">0.87</td><td class="colsep0 rowsep0" align="char" char=".">21.8</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>12m</b></td><td class="colsep0 rowsep0" align="left">19/29/58</td><td class="colsep0 rowsep0" align="left">97/96/98</td><td class="colsep0 rowsep0" align="char" char=".">22</td><td class="colsep0 rowsep0" align="char" char=".">0.72</td><td class="colsep0 rowsep0" align="char" char=".">0.53</td><td class="colsep0 rowsep0" align="char" char=".">2.5</td><td class="colsep0 rowsep0" align="char" char=".">32</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t5fn1"><div class="footnote" id="t5fn1"><sup>a</sup><p class="last">Compound dosed iv as a solution in 80% PEG/10% EtOH and dosed po as a suspension in MCT.</p></div><div class="footnote" id="t5fn2"><sup>b</sup><p class="last">Cl<sub>hep</sub> predicted from incubation with microsomes.</p></div><div class="footnote" id="t5fn3"><sup>c</sup><p class="last">h/r/m = human/rat/mouse.</p></div><div class="footnote" id="t5fn4"><sup>d</sup><p class="last">nd = not determined</p></div></div></div><div class="NLM_p">In addition to PK analysis, compound <b>12h</b> was examined in a panel of 250 kinases at a concentration of 1 μM. It proved exquisitely selective with no inhibition greater than 25% observed in kinases other than mTOR and the three class I PI3Kα, -γ, and -δ, which were approximately 50% inhibited at 1 μM. Compounds <b>10f</b> and <b>12i</b> were spot checked against a smaller panel of 50 kinases and exhibited still greater selectivity, with no inhibition greater than 25% for any kinase assayed at 1 μM, including the PI3K isoforms. This illustrates the general nature of the selectivity derived from this scaffold and the still greater selectivity possible with 2-<i>S</i>-methylmorpholine used as the hinge binder.</div><div class="NLM_p">At this point, we had a number of potent and selective compounds in hand that exhibited sufficiently long half-lives in vivo suitable for further study of the effects suppression of mTOR kinase activity has on antiproliferative potency. We began by investigating the ability of these compounds to suppress signaling through the PI3K/Akt/mTOR pathway using NCI-PC3 prostate tumors implanted subcutaneously into Taconic NCR nude mice. Compounds <b>12h</b> and <b>12i</b> were selected for this study due to their potency, selectivity, and favorable mouse PK profile.</div><div class="NLM_p">After administration at three separate doses, tumor and plasma samples were obtained after 6 h (Figure <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a>). The plasma levels observed for the two compounds were as expected on the basis of our previous oral administration in mice. The pharmacodynamic (PD) effect of our inhibitors was assessed by measuring the fold reduction of phospho-Ser437, normalized to total Akt, as well as the fold reduction of phospho-Ser235 and -236, normalized to total S6, relative to their time-matched vehicle control. Inhibition of S6 phosphorylation is indicative of inhibition of the mTORC1 complex, while inhibition of Akt phosphorylation is indicative of inhibition of the mTORC2 complex. Both molecules potently inhibited phosphorylation of both substrates after 6 h. The performance of each drug was comparable to that of 10 mg/kg GDC-0980, which was run as a contemporaneous positive control and can be considered a benchmark of maximum knockdown for this model and assay method.<a onclick="showRef(event, 'ref36'); return false;" href="javascript:void(0);" class="ref ref36">(36)</a><b>12h</b> showed a dose response between 12.5 and 100 mg/kg, while all doses of <b>12i</b> tested performed similarly to GDC-0980. We did not repeat the study of <b>12i</b> at lower doses to determine the lowest dose capable of achieving full knockdown of mTOR substrates.</div><figure id="fig4" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-24/jm301389h/production/images/medium/jm-2012-01389h_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-24/jm301389h/production/images/large/jm-2012-01389h_0004.jpeg" id="gr4" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. Plasma levels of <b>12h</b> and <b>12i</b> 6 h following oral administration in PC3 tumor-bearing mice along with the fold decreases of phosphorylated mTORC1 and -2 substrates relative to time-matched vehicle controls. Error bars represent one standard deviation from the depicted mean value. Four mice were dosed for each compound, and phosphoprotein levels were measured in duplicate samples for each mouse.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-24/jm301389h/production/images/large/jm-2012-01389h_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm301389h&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">We next sought to evaluate the difference in inhibition profile between the present mTOR kinase inhibitors and rapamycin, which would be expected to reduce only phosphorylation of mTORC1 substrates such as S6. We therefore repeated our PK/PD experiment, sampling the tumor and blood over a 24 h period, comparing a 100 mg/kg dose of <b>12i</b> to a 10 mg/kg dose of rapamycin (Figure <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">5</a>). In this instance, we used the U87 glioma model, which is also PTEN-deficient. By extending sampling to 24 h, we were able to observe the clearance of <b>12i</b> and the recovery of phospho-Akt and phospho-S6 levels to vehicle levels by the end of the experiment. As anticipated, we found that administration of rapamycin inhibited phosphorylation of S6, but did not reduce phospho-Akt levels. Instead, we observed the previously noted hyperphosphorylation of Akt on serine 473 at all time points beyond 1 h.</div><figure id="fig5" data-index="8" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-24/jm301389h/production/images/medium/jm-2012-01389h_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-24/jm301389h/production/images/large/jm-2012-01389h_0005.jpeg" id="gr5" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. Plasma levels of <b>12i</b> and rapamycin following administration in U87 tumor-bearing mice along with the fraction of phosphorylated mTORC1 and -2 substrates relative to time-matched vehicle controls. Error bars represent one standard deviation from the depicted mean value. Four mice were dosed for each compound and time point, and phosphoprotein levels were measured in duplicate samples for each mouse.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-24/jm301389h/production/images/large/jm-2012-01389h_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm301389h&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Having obtained an understanding of the extent of PI3K/Akt/mTOR pathway inhibition we could obtain from our compounds at a given dose and time point, we decided to probe the extent to which these compounds could suppress tumor growth in vivo. A 14-day efficacy study was run in the NCI-PC3 model, with daily dosing. <b>12h</b> was administered at doses from 6.25 to 100 mg/kg QD in an effort to span the range of pathway suppression observed in our PK/PD experiments. Rapamycin was dosed at 10 mg/kg, a dose previously determined to be efficacious in this model.</div><div class="NLM_p">After 14 days of dosing, all animals remained on study, but the 100 mg/kg dose group had lost slightly more than 10% of their starting body weight, which triggers a dosing holiday in our protocol and indicates that we are approaching the maximum tolerated dose (MTD). By way of comparison, the vehicle group lost 3.7% of their body weight, as this model is mildly cachexic. The tumor growth curves (Figure <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">6</a>a) were calculated by linear mixed effects (LME) modeling, and clearly illustrate that stronger pathway inhibition results in steadily increasing inhibition of growth and that tumor stasis has not been reached at the highest dose examined. The 10 mg/kg QD ×14 course of rapamycin performed well in this model, approaching tumor stasis. While tolerated, this dose achieves a greater rapamycin exposure level in mice than can be analogously achieved in humans,<a onclick="showRef(event, 'ref37 ref38 ref39'); return false;" href="javascript:void(0);" class="ref ref37 ref38 ref39">(37-39)</a> which may account for its efficacy in this model.</div><div class="NLM_p">We subsequently examined the growth inhibitory properties of the more potent <b>12i</b> in the same model, again at a range of doses. At the highest dose of 200 mg/kg dosed QD, we again observed body weight loss exceeding 10% at the end of the study. We observed stronger tumor growth inhibition at all doses of <b>12i</b> than was observed for <b>12h</b> at the identical dose. We again noted that maximum inhibition of tumor growth was only achieved at doses greater than that which could be tolerated by the mice without a dosing holiday over the course of a 2 week study (Figure <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">6</a>b). In this study, we noted that the 50 mg/kg dose appeared more efficacious than the 100 mg/kg dose, but we attribute this to experimental variability resulting from our small cohort size of five animals per group. This was substantiated by the results of a second study performed simultaneously with material from the same lot of <b>12i</b>, in which we examined the effect of BID dosing at the same total dose per day. In this study, the 50 mg/kg/day dose resulted in slightly lower efficacy than the 100 mg/kg/day dose as measured by the average tumor volume (data not shown).</div><figure id="fig6" data-index="9" class="article__inlineFigure"><h2 class="fig-label">Figure 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-24/jm301389h/production/images/medium/jm-2012-01389h_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-24/jm301389h/production/images/large/jm-2012-01389h_0006.jpeg" id="gr6" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 6. Growth inhibition curves for compounds <b>12h</b> (a) and <b>12i</b> (b) used to treat subcutaneously implanted PC3 tumors in mice.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-24/jm301389h/production/images/large/jm-2012-01389h_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm301389h&amp;id=fig6"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p last">These studies clearly demonstrated that we had met our goal of producing a potent, selective, orally available inhibitor of the mTOR kinase. Our compounds robustly inhibited tumor growth in cell lines in which the PI3K/Akt/mTOR signaling pathway is constitutively active due to the loss of PTEN. <b>12i</b> achieved tumor stasis at the highest 200 mg/kg/day dose examined, which appears to also be approaching the limit of tolerability for this molecule.</div></div><div id="sec3" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i11">Conclusions</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_22782" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_22782" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">We have developed a novel class of potent, highly selective mTOR kinase domain antagonists. The addition of saturated heterocycles fused to the central pyrimidine ring, along with the previously described phenyl ethyl urea and <i>S</i>-methylmorpholine hinge binder provided compounds with nanomolar in vitro potency and high selectivity against PI3K and other kinases.</div><div class="NLM_p last">This biochemical potency translated into potent growth inhibition in cell lines where the PI3K/Akt/mTOR signaling pathway is constitutively active due to the loss of PTEN or due to an activating mutation in PI3K. Compounds <b>12h</b> and <b>12i</b> suppressed mTORC1 and mTORC2 in cellular and in vivo PK/PD experiments and did not induce the hyperphosphorylation of Akt as rapamycin did at time points after 3 h. This potential advantage did not, however, translate into greater efficacy in our PC3 xenograft model when rapamycin and mTOR inhibitors were compared at doses approaching their MTD in mice. This may be due in part to the fact that the rapamycin levels achieved in mice cannot be reproduced in man, limiting its efficacy. What remains to be understood is whether the tolerability in man of these different modes of pathway inhibition differs and whether mTOR can be effectively combined with other targeted chemotherapeutics. Compounds <b>12h</b> and <b>12i</b> were found to exhibit time-dependent inhibition of CYP 3A4, which prevented their progression into the clinic; however, further refinement of this scaffold enabled us to select a clinical candidate that joined the PI3K selective and dual PI3K/mTOR inhibitors undergoing human clinical trials in an effort to address these questions directly.</div></div><div id="sec4" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i12">Experimental Section</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_33684" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_33684" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">All chemicals were purchased from commercial suppliers and used as received. Flash chromatography was carried out with prepacked silica cartridges from either ISCO or SiliCycle on an ISCO Companion chromatography system using gradient elution. NMR spectra were recorded on a Bruker AV III 400 or 500 NMR spectrometer and referenced to tetramethylsilane. Preparative HPLC was performed on a Polaris C18 5 μm column (50 mm × 21 mm), eluting with mixtures of water/acetonitrile. All final compounds were purified to >95% chemical and optical purity, as assayed by LC/MS. This analysis was performed on an Agilent 1100 HPLC coupled with Agilent MSD mass spectrometer using ESI as the ionization source. The LC separation was performed using an Agilent ZORBAX SB-C18, 1.8 mm, 30 × 2.1 mm column with a flow rate of 0.4 mL/min. The gradient consisted of 3–97% acetonitrile in water, each containing 0.05% TFA, over 7 min; 97% acetonitrile was then maintained for 1.5 min, followed by reequilibration at 3% acetonitrile for 1.5 min. The LC column temperature was maintained at 40 °C. UV absorbance was measured at 220 and 254 nm along with a full scan mass spectrum. For select compounds, a longer gradient LC was used (method B). In these cases, the gradient consisted of 2–98% acetonitrile in water, each containing 0.05% TFA, over 25.5 min; 98% acetonitrile was then maintained for 2.5 min, followed by reequilibration at 2% acetonitrile for 1.5 min. UV and MS detection was performed as before.</div><div id="sec4_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i13" class="anchor-spacer"></div><h3 class="article-section__title" id="_i13"> In-Life PK–PD Study</h3><div class="NLM_p">Human prostate cancer NCI-PC3 cells (National Cancer Institute, Frederick, MD) were implanted subcutaneously into the right hind flanks of female NCR nude mice (5 × 10<sup>6</sup> cells in 100 μL of Hank’s balanced salt solution). Tumors were monitored until they reached a mean tumor volume of approximately 500 mm<sup>3</sup>. Then similarly sized tumors were randomly assigned to groups (<i>n</i> = 4). Compounds were formulated as suspensions in 0.5% methylcellulose/0.2% Tween 80 (MCT) and dosed orally at 25, 50, and 100 mg/kg (100 μL dose/25 g animal). Tumor and plasma samples were harvested at 1, 6, and 10 h postdose.</div><div class="NLM_p last">Blood samples were harvested by terminal cardiac puncture and collected into tubes containing K<sub>2</sub>EDTA as an anticoagulant. Samples were kept chilled on ice until centrifugation at (1500–2000)<i>g</i> for 5 min; plasma was transferred to a new vial and snap frozen. Tumor samples were transferred to a 1.5 mL snap-cap polypropylene tube, weighed, and then flash frozen on dry ice. Samples were stored at −80 °C prior to PD biomarker evaluation.</div></div><div id="sec4_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i14" class="anchor-spacer"></div><h3 class="article-section__title" id="_i14"> Xenograft Tumor Lysates</h3><div class="NLM_p last">Frozen tumors were lysed in ice-cold extraction buffer by mechanical disruption and agitation with a garnet/ceramic sphere matrix in a FastPrep-24 (MP Biomedicals, Solon, OH; five 20-s cycles with rest periods on wet ice). Extraction buffer (Biosource, Carlsbad, CA) was supplemented with protease inhibitors (F. Hoffman-La Roche, Mannheim, Germany), 1 mM phenylmethysufonyl fluoride, and phosphatase inhibitor cocktails 1 and 2 (Sigma-Aldrich, St. Louis, MO). After thorough disruption, tumor lysates were clarified by centrifugation at 4 °C. Protein concentrations were determined using the BCA protein assay kit (Pierce, Rockford, IL) and normalized to a standard concentration of 5 mg/mL.</div></div><div id="sec4_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i15" class="anchor-spacer"></div><h3 class="article-section__title" id="_i15"> PD Biomarker Assays</h3><div class="NLM_p">The Meso Scale Discovery Multi-Spot biomarker detection system (Meso Scale Discovery, Gaithersburg, MD) was used to determine the levels of Akt phosphorylated at Ser473 (pAkt) and S6RP phosphorylated at Ser235/236 (pS6RP). These double-determinant immunoassays quantify protein levels on the basis of measurements of electrochemoluminescence intensity. In the case of pS473 and total Akt, both of these were measured in the same well using a duplex assay plate. All other markers required separate plates to measure phosphorylated and total protein. Protein was loaded at 20 μg/well for Akt and 10 μg/well for S6RP.</div><div class="NLM_p last">Relative levels of phosphoprotein were determined by comparison of treated tumor lysates with an average of the time-matched vehicle controls.</div></div><div id="sec4_4" class="NLM_sec NLM_sec_level_2"><div id="ac_i16" class="anchor-spacer"></div><h3 class="article-section__title" id="_i16"> In-Life Efficacy Study</h3><div class="NLM_p last">NCI-PC3 cells were subcutaneously implanted as above. Tumors were grown to an average volume of 200 mm<sup>3</sup> before dosing was started. Extra mice were implanted, to ensure that each treatment group of 5 mice had similarly sized tumors. Tumor volumes were determined using digital calipers (Fred V. Fowler Co., Inc.) using the formula (<i>L</i> × <i>W</i> × <i>H</i>)/2. Average tumor volume was calculated by applying curve fitting to the log 2 transformed individual tumor volume data using a linear mixed-effects model using the R package nlme, version 3.1–97 in R v2.12.0. Percent tumor growth inhibition, %TGI, was calculated as the percentage of the area under the fitted curve (AUC) for the respective dose group per day in relation to the vehicle, such that %TGI = 100 × 1 – (AUC<sub>treatment</sub>/day)/(AUC<sub>vehicle</sub>/day). Tumors were measured and mice weighed twice per week. If weight loss was >15%, the mice were weighed daily and euthanized if weight loss reached 20%; 10% body weight loss was the limit for tolerated doses. Mice whose tumors reached 2000 mm<sup>3</sup> were euthanized.</div></div><div id="sec4_5" class="NLM_sec NLM_sec_level_2"><div id="ac_i17" class="anchor-spacer"></div><h3 class="article-section__title" id="_i17"> <i>tert</i>-Butyl 2-Chloro-4-morpholino-5<i>H</i>-pyrrolo[3,4-<i>d</i>]pyrimidine-6(7<i>H</i>)-carboxylate</h3><div class="NLM_p last">To a mixture of <i>tert</i>-butyl 2,4-dichloro-5<i>H</i>-pyrrolo[3,4-<i>d</i>]pyrimidine-6(7<i>H</i>)-carboxylate (1.2 g, 4.1 mmol) and <i>N</i>,<i>N</i>-diisopropylamine (1.4 mL, 8.3 mmol) in 2-propanol (8 mL) was added morpholine (0.430 mL, 5.0 mmol). The mixture was stirred at room temperature for 1 h and was then concentrated in vacuo. The resulting residue was purified by flash column chromatography (40% EA/Hex) to give <i>tert</i>-butyl 2-chloro-4-morpholino-5<i>H</i>-pyrrolo[3,4-<i>d</i>]pyrimidine-6(7<i>H</i>)-carboxylate (1.378 g, 98%).</div></div><div id="sec4_6" class="NLM_sec NLM_sec_level_2"><div id="ac_i18" class="anchor-spacer"></div><h3 class="article-section__title" id="_i18"> <i>tert</i>-Butyl 2-(4-(3-Ethylureido)phenyl)-4-morpholino-5<i>H</i>-pyrrolo[3,4-<i>d</i>]pyrimidine-6(7<i>H</i>)-carboxylate (<b>6a</b>)</h3><div class="NLM_p last">2-Chloro-4-morpholino-5<i>H</i>-pyrrolo[3,4-<i>d</i>]pyrimidine-6(7<i>H</i>)-carboxylate (0.366 mmol), (4-ethylureido)phenylboronic acid pinacol ester (0.439 mmol), tetrakis(triphenylphosphine)palladium (0.022 mmol), 1 M aq KOAc (0.55 mL), 1 M aq Na<sub>2</sub>CO<sub>3</sub> (0. 55 mL), and MeCN (2 mL) were mixed in a microwave reaction tube. The mixture was heated in a microwave reactor at 120 °C for 25 min. The mixture was extracted with EtOAc (3×), and the combined organic extracts were concentrated. The resulting residue was purified by flash column chromatography (40% EA/Hex) to give <b>6a</b> (149 mg, 83%). LC/MS: 4.43 min, M<sup>+</sup> = 469.2, MW = 468.6. <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>): δ 8.28 (d, <i>J</i> = 8.7, 2H), 7.38 (d, <i>J</i> = 8.8, 2H), 7.10 (d, <i>J</i> = 8.6, 1H), 6.81 (d, <i>J</i> = 8.8, 1H), 4.78 (s, 2H), 4.57 (s, 2H), 3.93–3.59 (m, 8H), 3.36–3.29 (m, 2H), 1.53 (s, 9H), 1.17 (t, <i>J</i> = 7.2, 3H).</div></div><div id="sec4_7" class="NLM_sec NLM_sec_level_2"><div id="ac_i19" class="anchor-spacer"></div><h3 class="article-section__title" id="_i19"> 1-Ethyl-3-(4-(4-morpholino-6,7-dihydro-5<i>H</i>-pyrrolo[3,4-<i>d</i>]pyrimidin-2-yl)phenyl)urea (<b>6b</b>)</h3><div class="NLM_p last"><i>tert</i>-Butyl 2-(4-(3-ethylureido)phenyl)-4-morpholino-5<i>H</i>-pyrrolo[3,4-<i>d</i>]pyrimidine-6(7<i>H</i>)-carboxylate (1.74 mmol) was dissolved in CH<sub>2</sub>Cl<sub>2</sub> (5 mL), and then TFA (3 mL) was added. The mixture was stirred at room temperature for 2 h. 2-Propanol and toluene were added, and the resulting mixture was concentrated in vacuo. The resulting residue was azeotroped with toluene two more times. Methanol and methylene chloride (4 mL of each) were added to the resulting residue, then PS-carbonate (2.5–3.5 mmol N/g resin, 1.45 g) was added. The mixture was stirred at room temperature until the pH reached >7 (∼1 h). The mixture was filtered, and the resin was washed with methanol and CH<sub>2</sub>Cl<sub>2</sub>. The filtrate was concentrated to provide <b>6b</b>, which was used without further purification in subsequent reactions. A portion of the material was purified by reverse-phase HPLC for assay. LC/MS: 2.74 min, M<sup>+</sup> = 369.2, MW = 368.4. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ 9.57 (s, 1H), 8.75 (s, 1H), 8.19 (d, <i>J</i> = 8.9, 2H), 7.50 (d, <i>J</i> = 8.9, 2H), 6.38–6.08 (m, 1H), 4.71 (s, 2H), 4.38 (s, 2H), 3.72 (s, 8H), 3.24–3.03 (m, 2H), 1.06 (t, <i>J</i> = 7.2, 3H).</div></div><div id="sec4_8" class="NLM_sec NLM_sec_level_2"><div id="ac_i20" class="anchor-spacer"></div><h3 class="article-section__title" id="_i20"> 1-Ethyl-3-(4-(4-morpholino-6-(pyrimidin-2-yl)-6,7-dihydro-5<i>H</i>-pyrrolo[3,4-<i>d</i>]pyrimidin-2-yl)phenyl)urea (<b>6c</b>)</h3><div class="NLM_p last"><b>6b</b> (0.15 mmol), 2-chloropyrimidine (0.21 mmol), and i-PrN<sub>2</sub>Et (0.6 mmol) were mixed in DMF (0.6 mL) in a microwave reaction tube. The mixture was heated to 120 °C and stirred for 15 min. After cooling to room temperature, the mixture was diluted with DMF. The resulting mixture was purified by reverse-phase HPLC to give <b>6c</b>. LC/MS: 3.80 min, M<sup>+</sup> = 447.3, MW = 446.5. <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>): δ 8.71 (s, 1H), 8.47 (d, <i>J</i> = 4.8, 2H), 8.21 (d, <i>J</i> = 8.8, 2H), 7.51 (d, <i>J</i> = 8.8, 2H), 6.77 (t, <i>J</i> = 2.5, 1H), 6.18 (m, 1H), 4.99 (s, 2H), 4.68 (s, 2H), 3.78 (m, 8H), 3.20–3.15 (m, 2H), 1.26 (t, <i>J</i> = 6.9, 3H). LC/MS: <i>m</i>/<i>z</i> = +447 (M + H)<sup>+</sup>.</div></div><div id="sec4_9" class="NLM_sec NLM_sec_level_2"><div id="ac_i21" class="anchor-spacer"></div><h3 class="article-section__title" id="_i21"> 1-Ethyl-3-(4-(6-(methylsulfonyl)-4-morpholino-6,7-dihydro-5<i>H</i>-pyrrolo[3,4-<i>d</i>]pyrimidin-2-yl)phenyl)urea (<b>6d</b>)</h3><div class="NLM_p last">LC/MS: 3.59 min, M<sup>+</sup> = 447.2, MW = 446.5. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ 8.69 (s, 1H), 8.18 (d, <i>J</i> = 8.7, 2H), 7.49 (d, <i>J</i> = 8.8, 2H), 6.19 (br s, 1H), 4.84 (s, 2H), 4.51 (s, 2H), 4.04–3.76 (m, 8H), 3.20–3.08 (m, 2H), 3.06 (s, 3H), 1.06 (t, <i>J</i> = 7.2, 3H).</div></div><div id="sec4_10" class="NLM_sec NLM_sec_level_2"><div id="ac_i22" class="anchor-spacer"></div><h3 class="article-section__title" id="_i22"> Ethyl 2-(4-(3-Ethylureido)phenyl)-4-morpholino-5<i>H</i>-pyrrolo[3,4-<i>d</i>]pyrimidine-6(7<i>H</i>)-carboxylate (<b>6e</b>)</h3><div class="NLM_p last">LC/MS: 3.53 min, M<sup>+</sup> = 440.3, MW = 439.5. <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>): δ 8.73 (s, 1H), 8.18 (d, <i>J</i> = 6.7, 2H), 7.49 (d, <i>J</i> = 8.8, 2H), 6.26–6.15 (m, 1H), 4.82 (d, <i>J</i> = 13.9, 2H), 4.50 (d, <i>J</i> = 15.2, 2H), 4.21–4.07 (m, 2H), 3.80–3.69 (m, 8H), 3.19–3.06 (m, 2H), 1.25 (t, <i>J</i> = 7.0, 3H), 1.06 (t, <i>J</i> = 7.2, 3H).</div></div><div id="sec4_11" class="NLM_sec NLM_sec_level_2"><div id="ac_i23" class="anchor-spacer"></div><h3 class="article-section__title" id="_i23"> 6-Benzyl-5,6,7,8-tetrahydropyrido[4,3-<i>d</i>]pyrimidine-2,4(1<i>H</i>,3<i>H</i>)-dione</h3><div class="NLM_p last">Methyl 1-benzyl-4-oxo-3-piperidinecarboxylate (20.194 g, 71.168 mmol) and urea (9.031 g, 150.4 mmol) were dissolved in methanol (150 mL, 3700 mmol), and 46 mL of a 1 M solution of sodium methoxide in methanol was added dropwise. Then, the reaction was heated to reflux under N<sub>2</sub> for 96 h. The reaction was cooled to 0 °C and filtered to give a white solid. This was stirred vigorously for 30 min with 50 mL of water, cooled to 0 °C, and filtered to give 6-benzyl-5,6,7,8-tetrahydropyrido[4,3-<i>d</i>]pyrimidine-2,4(1<i>H</i>,3<i>H</i>)-dione as a white solid (11.77 g, 45.7 mmol) which was dried under high vacuum overnight and then used without further purification. <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>, 400 MHz): δ 7.47–7.07 (m, 5H), 3.56 (s, 2H), 2.96 (s, 2H), 2.51 (t, 4H), 2.27 (t, <i>J</i> = 5.6, 2H).</div></div><div id="sec4_12" class="NLM_sec NLM_sec_level_2"><div id="ac_i24" class="anchor-spacer"></div><h3 class="article-section__title" id="_i24"> 6-Benzyl-2,4-dichloro-5,6,7,8-tetrahydropyrido[4,3-<i>d</i>]pyrimidine (<b>7</b>)</h3><div class="NLM_p last">6-Benzyl-5,6,7,8-tetrahydropyrido[4,3-<i>d</i>]pyrimidine-2,4(1<i>H</i>,3<i>H</i>)-dione (16.95 g, 65.88 mmol) was added to phosphoryl chloride (100 mL, 1070 mmol) in a 500 mL round-bottom flask equipped with a stirbar, and the solution was refluxed for 3 h under N<sub>2</sub>. The volatiles were removed under reduced pressure, and the concentrate was poured over 250 mL of ice. NaOH (3 M) was added to a final pH of 10, and then the aqueous phase was extracted with CH<sub>2</sub>Cl<sub>2</sub> (3 × 150 mL). The combined organics were dried over MgSO<sub>4</sub>, filtered, and concentrated to a tan oil. This crude material was dissolved in dichloromethane, concentrated onto silica gel, and subjected to column chromatography using a 120 g column, with a gradient of 0%–50% ethyl acetate in hexanes. The product-containing fractions were combined and evaporated under reduced pressure to give <b>7</b> as a pale solid (14.63 g, 49.7 mmol). <sup>1</sup>H NMR (CDCl<sub>3</sub>, 400 MHz): δ 7.41–7.27 (m, 5H), 3.77 (s, 2H), 3.62 (s, 2H), 2.99 (t, <i>J</i> = 5.8, 2H), 2.81 (t, <i>J</i> = 5.8, 2H).</div></div><div id="sec4_13" class="NLM_sec NLM_sec_level_2"><div id="ac_i25" class="anchor-spacer"></div><h3 class="article-section__title" id="_i25"> <i>tert</i>-Butyl 2,4-Dichloro-7,8-dihydropyrido[4,3-<i>d</i>]pyrimidine-6(5<i>H</i>)-carboxylate (<b>8</b>)</h3><div class="NLM_p last">Compound <b>7</b> (1.84 g, 6.25 mmol) was dissolved in methylene chloride (40 mL, 700 mmol) in a round-bottom flask equipped with a stirbar and the reaction was cooled to 0 °C. α-Chloroethyl chloroformate (0.810 mL, 7.50 mmol) was added slowly and the reaction was stirred at 0 °C for 15 min. The reaction was allowed to warm to room temperature (rt) and then was refluxed for 1 h. The volatiles were removed under reduced pressure, and the residue was redissolved in 20 mL of MeOH and heated to reflux for 30 min. The volatiles were removed under reduced pressure to give the intermediate amine hydrochloride salt. This material was dissolved in 50 mL of dry CH<sub>2</sub>Cl<sub>2</sub>, to which was added 3.1 g of tetraalkylammonium carbonate polymer-bound (2.5–3.5 mmol N/g) resin and di-<i>tert</i>-butyldicarbonate (2.45 g, 11.2 mmol). The mixture was stirred at rt for 1 h and was then filtered to remove the resin. The crude mixture was concentrated onto silica gel and subjected to column chromatography using a 12 g column, eluting with a gradient of 0–30% EtOAc in hexanes. The product-containing fractions were combined and evaporated under reduced pressure to give <b>8</b> as a clear oil which slowly crystallized (1.68 g, 5.52 mmol). <sup>1</sup>H NMR (CDCl<sub>3</sub>, 400 MHz): δ 4.56 (s, 2H), 3.75 (t, <i>J</i> = 5.9, 2H), 2.97 (t, <i>J</i> = 5.8, 2H), 1.50 (s, 9H).</div></div><div id="sec4_14" class="NLM_sec NLM_sec_level_2"><div id="ac_i26" class="anchor-spacer"></div><h3 class="article-section__title" id="_i26"> <i>tert</i>-Butyl 2-(4-(3-Ethylureido)phenyl)-4-morpholino-7,8-dihydropyrido[4,3-<i>d</i>]pyrimidine-6(5<i>H</i>)-carboxylate (<b>10a</b>)</h3><div class="NLM_p last">LC/MS: 4.97 min, M<sup>+</sup> = 483.3, MW = 482.6. <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>, 400 MHz): δ 8.67 (s, 1H), 8.19 (d, <i>J</i> = 8.7, 2H), 7.48 (d, <i>J</i> = 8.8, 2H), 6.18 (t, <i>J</i> = 5.5, 1H), 4.42 (s, 2H), 3.78–3.70 (m, <i>J</i> = 4.6, 4H), 3.67 (t, <i>J</i> = 6.2, 2H), 3.44–3.36 (m, <i>J</i> = 4.5, 4H), 3.17–3.05 (m, 2H), 2.85 (t, <i>J</i> = 6.2, 2H), 1.41 (s, 9H), 1.06 (t, <i>J</i> = 7.2, 3H).</div></div><div id="sec4_15" class="NLM_sec NLM_sec_level_2"><div id="ac_i27" class="anchor-spacer"></div><h3 class="article-section__title" id="_i27"> (<i>S</i>)-<i>tert</i>-Butyl 2-(4-(3-Ethylureido)phenyl)-4-(3-methylmorpholino)-7,8-dihydropyrido[4,3-<i>d</i>]pyrimidine-6(5<i>H</i>)-carboxylate (<b>10b</b>)</h3><div class="NLM_p last">LC/MS: 5.22 min, M<sup>+</sup> = 497.3, MW = 496.6. <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>, 400 MHz): δ 8.66 (s, 1H), 8.18 (d, <i>J</i> = 8.8, 2H), 7.48 (d, <i>J</i> = 8.8, 2H), 6.18 (s, 1H), 4.47 (d, <i>J</i> = 16.0, 1H), 4.38 (d, 1H), 3.88 (d, <i>J</i> = 11.4, 2H), 3.76–3.35 (m, 7H), 3.19–3.03 (m, 2H), 2.85 (t, <i>J</i> = 6.2, 2H), 1.41 (s, 9H), 1.25 (d, <i>J</i> = 6.2, 3H), 1.06 (t, <i>J</i> = 7.2, 3H).</div></div><div id="sec4_16" class="NLM_sec NLM_sec_level_2"><div id="ac_i28" class="anchor-spacer"></div><h3 class="article-section__title" id="_i28"> (<i>S</i>)-1-Ethyl-3-(4-(4-(3-methylmorpholino)-6-(methylsulfonyl)-5,6,7,8-tetrahydropyrido[4,3-<i>d</i>]pyrimidin-2-yl)phenyl)urea (<b>10c</b>)</h3><div class="NLM_p last">LC/MS: 2.51 min, M<sup>+</sup> = 475.2, MW = 474.6. <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>): δ 8.69 (s, 1H), 8.26–8.11 (m, 2H), 7.59–7.40 (m, 2H), 6.18 (t, <i>J</i> = 5.5 Hz, 1H), 4.34–4.12 (m, 2H), 4.01–3.80 (m, 2H), 3.72 (dd, <i>J</i> = 11.4, 2.9 Hz, 1H), 3.70–3.56 (m, 3H), 3.54–3.39 (m, 3H), 3.12 (dt, <i>J</i> = 12.7, 7.0 Hz, 2H), 3.03 (s, 3H), 2.99 (t, <i>J</i> = 6.4 Hz, 2H), 2.08 (s, 1H), 1.22 (d, <i>J</i> = 6.5 Hz, 3H), 1.06 (t, <i>J</i> = 7.2 Hz, 3H).</div></div><div id="sec4_17" class="NLM_sec NLM_sec_level_2"><div id="ac_i29" class="anchor-spacer"></div><h3 class="article-section__title" id="_i29"> (<i>S</i>)-1-(4-(6-Acetyl-4-(3-methylmorpholino)-5,6,7,8-tetrahydropyrido[4,3-<i>d</i>]pyrimidin-2-yl)phenyl)-3-ethylurea (<b>10d</b>)</h3><div class="NLM_p last">LC/MS: 2.25 min, M<sup>+</sup> = 439.2, MW = 438.5. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ 8.66 (s, 1H), 8.24–8.12 (m, 2H), 7.53–7.42 (m, 2H), 6.17 (t, <i>J</i> = 5.7 Hz, 1H), 4.71–4.33 (m, 2H), 4.03–3.55 (m, 6H), 3.54–3.37 (m, 2H), 3.12 (qd, <i>J</i> = 7.2, 5.6 Hz, 2H), 2.95 (t, <i>J</i> = 5.9 Hz, 1H), 2.82 (t, <i>J</i> = 6.4 Hz, 1H), 2.15–2.02 (m, 3H), 1.32–1.19 (m, 3H), 1.06 (t, <i>J</i> = 7.2 Hz, 3H).</div></div><div id="sec4_18" class="NLM_sec NLM_sec_level_2"><div id="ac_i30" class="anchor-spacer"></div><h3 class="article-section__title" id="_i30"> 1-Ethyl-3-(4-(4-morpholino-6-(pyrimidin-2-yl)-6,7-dihydro-5<i>H</i>-pyrrolo[3,4-<i>d</i>]pyrimidin-2-yl)phenyl)urea (<b>10e</b>)</h3><div class="NLM_p last">1-Ethyl-3-(4-(4-morpholino-6,7-dihydro-5<i>H</i>-pyrrolo[3,4-<i>d</i>]pyrimidin-2-yl)phenyl)urea (0.15 mmol), 2-chloropyrimidine (0.21 mmol) and DIPEA (0.6 mmol) were mixed in DMF (0.6 mL) in a microwave reaction tube. The mixture was heated to 120 °C and stirred for 15 min. After cooling to room temperature, the mixture was diluted with DMF. The resulting mixture was purified by reverse-phase HPLC to give <b>9e</b>. LC/MS: 3.94 min, M<sup>+</sup> = 461.3, MW = 460.5. <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>, 400 MHz): δ 8.64 (s, 1H), 8.40 (d, <i>J</i> = 4.7, 2H), 8.18 (d, <i>J</i> = 8.7, 2H), 7.47 (d, <i>J</i> = 8.8, 2H), 6.66 (t, <i>J</i> = 4.7, 1H), 6.15 (t, <i>J</i> = 5.6, 1H), 4.85 (s, 2H), 4.10 (t, <i>J</i> = 6.2, 2H), 3.83–3.72 (m, 4H), 3.52–3.42 (m, 4H), 3.18–3.04 (m, 2H), 2.92 (t, <i>J</i> = 6.1, 2H), 1.06 (t, <i>J</i> = 7.2, 3H).</div></div><div id="sec4_19" class="NLM_sec NLM_sec_level_2"><div id="ac_i31" class="anchor-spacer"></div><h3 class="article-section__title" id="_i31"> (<i>S</i>)-1-Ethyl-3-(4-(4-(3-methylmorpholino)-6-(pyrimidin-2-yl)-5,6,7,8-tetrahydropyrido[4,3-<i>d</i>]pyrimidin-2-yl)phenyl)urea (<b>10f</b>)</h3><div class="NLM_p last">LC/MS: 4.92 min, M<sup>+</sup> = 475.3, MW = 474.6. <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>, 400 MHz): δ 8.66 (s, 1H), 8.40 (d, <i>J</i> = 4.7, 2H), 8.17 (d, <i>J</i> = 8.7, 2H), 7.47 (d, <i>J</i> = 8.8, 2H), 6.65 (t, <i>J</i> = 4.7, 1H), 6.18 (t, <i>J</i> = 5.5, 1H), 4.93 (d, <i>J</i> = 16.1, 1H), 4.75 (d, <i>J</i> = 16.1, 1H), 4.25–4.12 (m, 1H), 4.06–3.95 (m, 2H), 3.90 (d, <i>J</i> = 11.3, 1H), 3.79–3.60 (m, 3H), 3.58–3.41 (m, 2H), 3.17–3.05 (m, 2H), 2.93 (t, <i>J</i> = 6.1, 2H), 1.27 (d, <i>J</i> = 6.6, 3H), 1.06 (t, <i>J</i> = 7.2, 3H).</div></div><div id="sec4_20" class="NLM_sec NLM_sec_level_2"><div id="ac_i32" class="anchor-spacer"></div><h3 class="article-section__title" id="_i32"> 1-Ethyl-3-(4-(4-morpholino-6-(pyrazin-2-yl)-5,6,7,8-tetrahydropyrido[4,3-<i>d</i>]pyrimidin-2-yl)phenyl)urea (<b>10g</b>)</h3><div class="NLM_p last">LC/MS: 3.83 min, M<sup>+</sup> = 461.3, MW = 460.5. <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>, 400 MHz): δ 8.64 (s, 1H), 8.42 (s, 1H), 8.18 (d, <i>J</i> = 8.7, 2H), 8.11 (s, 1H), 7.85 (d, <i>J</i> = 2.6, 1H), 7.47 (d, <i>J</i> = 8.7, 2H), 6.16 (t, <i>J</i> = 5.6, 1H), 4.70 (s, 2H), 3.98 (t, <i>J</i> = 6.2, 2H), 3.86–3.72 (m, 5H), 3.52–3.41 (m, 4H), 3.19–3.05 (m, 2H), 2.97 (t, <i>J</i> = 6.1, 2H), 1.06 (t, <i>J</i> = 7.2, 3H).</div></div><div id="sec4_21" class="NLM_sec NLM_sec_level_2"><div id="ac_i33" class="anchor-spacer"></div><h3 class="article-section__title" id="_i33"> (<i>S</i>)-1-Ethyl-3-(4-(4-(3-methylmorpholino)-6-(pyrazin-2-yl)-5,6,7,8-tetrahydropyrido[4,3-<i>d</i>]pyrimidin-2-yl)phenyl)urea (<b>10h</b>)</h3><div class="NLM_p last">LC/MS: 4.72 min, M<sup>+</sup> = 475.3, MW = 474.6. <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>, 400 MHz): δ 8.65 (s, 1H), 8.41 (s, 1H), 8.17 (d, <i>J</i> = 8.7, 2H), 7.85 (d, <i>J</i> = 2.6, 1H), 7.47 (d, <i>J</i> = 8.8, 2H), 6.17 (t, <i>J</i> = 5.5, 1H), 4.76 (d, <i>J</i> = 16.1, 1H), 4.61 (d, <i>J</i> = 16.1, 1H), 4.08–3.98 (m, 2H), 3.96–3.84 (m, 3H), 3.78 (d, <i>J</i> = 8.6, 1H), 3.66 (t, <i>J</i> = 9.8, 3H), 3.56–3.42 (m, 3H), 3.17–3.05 (m, 2H), 2.97 (t, <i>J</i> = 6.1, 2H), 1.27 (d, <i>J</i> = 6.6, 4H), 1.06 (t, <i>J</i> = 7.2, 3H).</div></div><div id="sec4_22" class="NLM_sec NLM_sec_level_2"><div id="ac_i34" class="anchor-spacer"></div><h3 class="article-section__title" id="_i34"> <i>tert</i>-Butyl 2-Chloro-4-morpholino-5,6-dihydropyrido[3,4-<i>d</i>]pyrimidine-7(8<i>H</i>)-carboxylate (<b>11</b>)</h3><div class="NLM_p last">To a solution of <i>tert</i>-butyl 2,4-dichloro-5,6-dihydropyrido-[3,4-<i>d</i>]pyrimidine-7(8<i>H</i>)-carboxylate (1.020 g, 3.353 mmol) in isopropyl alcohol (8.00 mL, 0.104 mol) was added <i>N</i>,<i>N</i>-diisopropylethylamine (1.15 mL, 0.006 60 mol) followed by addition of morpholine (0.350 mL, 0.004 01 mol) in a single portion. The resulting solution was stirred for 2 h at rt. The volatiles were removed under reduced pressure, and then the resulting white residue was partitioned between EtOAc (100 mL) and water (100 mL). The layers were separated, and the aqueous layer was washed with EtOAc (2 × 50 mL). The combined organic extracts were dried over MgSO<sub>4</sub>, filtered, and concentrated to a white solid. This crude material was dissolved in CH<sub>2</sub>Cl<sub>2</sub> and concentrated onto silica gel before being subjected to column chromatography using a 40 g column, with a gradient of 0% to 40% ethyl acetate in hexanes. The product-containing fractions were combined and evaporated under reduced pressure to give <i>tert</i>-butyl 2-chloro-4-morpholino-5,6-dihydropyrido[3,4-<i>d</i>]pyrimidine-7(8<i>H</i>)-carboxylate as a white solid (1.114 g, 3.14 mmol).</div></div><div id="sec4_23" class="NLM_sec NLM_sec_level_2"><div id="ac_i35" class="anchor-spacer"></div><h3 class="article-section__title" id="_i35"> <i>tert</i>-Butyl 2-(4-(3-Ethylureido)phenyl)-4-morpholino-5,6-dihydropyrido[3,4-<i>d</i>]pyrimidine-7(8<i>H</i>)-carboxylate (<b>12b</b>)</h3><div class="NLM_p last"><i>tert</i>-Butyl 2-chloro-4-morpholino-5,6-dihydropyrido[3,4-<i>d</i>]pyrimidine-7(8<i>H</i>)-carboxylate (0.5784 g, 1.630 mmol), [4-(ethylureido)phenyl]boronic acid, pinacol ester (0.5749 g, 1.981 mmol), and tetrakis(triphenylphosphine)palladium(0) (205 mg, 0.177 mmol) were weighed into a microwave vial. Acetonitrile (6 mL, 100 mmol), degassed 1 M Na<sub>2</sub>CO<sub>3</sub> in water (2.2 mL), and degassed 1 M KOAc in water (2.2 mL) were added, and the mixture was heated to 120 °C for 15 min. The reaction was diluted with 50 mL of water and extracted with EtOAc (3 × 50 mL). Approximately ∼10 mL of brine was added to aid in separating the layers. The combined organic extracts were dried with MgSO<sub>4</sub>, filtered, and concentrated onto silica gel. This crude material was then subjected to column chromatography using a 40 g column, with a gradient of 20%–50% ethyl acetate in CH<sub>2</sub>Cl<sub>2</sub>. The product-containing fractions were combined and evaporated under reduced pressure to give <b>12b</b> (0.785 g, 1.63 mmol). LC/MS: 4.53 min, M<sup>+</sup> = 483.3, MW = 482.6. <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>, 400 MHz): δ 8.63 (s, 1H), 8.18 (d, <i>J</i> = 8.7, 2H), 7.48 (d, <i>J</i> = 8.8, 2H), 6.14 (s, 1H), 4.46 (s, 2H), 3.90 (s, 1H), 3.73 (s, 4H), 3.49 (d, <i>J</i> = 22.0, 6H), 3.18–3.06 (m, 2H), 2.66 (s, 2H), 1.46 (s, 9H), 1.09–1.03 (m, 8H).</div></div><div id="sec4_24" class="NLM_sec NLM_sec_level_2"><div id="ac_i36" class="anchor-spacer"></div><h3 class="article-section__title" id="_i36"> 1-Ethyl-3-(4-(4-morpholino-5,6,7,8-tetrahydropyrido[3,4-<i>d</i>]pyrimidin-2-yl)phenyl)urea (<b>12a</b>)</h3><div class="NLM_p last">To <b>12b</b> (0.568 g, 1.00 mmol) in a 100 mL round-bottom flask equipped with a stirbar was added TFA (3.0 mL, 39 mmol) in a single portion. The reaction was stirred at rt for 1 h. The volatiles were removed under reduced pressure, and the resulting oil was washed with Et<sub>2</sub>O, which produced a white solid precipitate. The precipitate was filtered off, dissolved in CH<sub>2</sub>Cl<sub>2</sub> and MeOH, and stirred with 1.0 g of PS-carbonate resin (2.5–3.6 mmol N/g) for 1 h at rt. The resin was filtered off and washed with CH<sub>2</sub>Cl<sub>2</sub>. The filtrate was then concentrated to give <b>12a</b> as a white solid (0.326 g, 8.52 mmol), which was used without further purification in subsequent reactions. A portion of the material was purified by reverse-phase HPLC for assay. LC/MS: 2.99 min, M<sup>+</sup> = 383.3, MW = 382.5. <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>, 400 MHz): δ 8.66 (s, 1H), 8.18 (d, <i>J</i> = 8.8, 2H), 7.47 (d, <i>J</i> = 8.8, 2H), 6.17 (t, <i>J</i> = 5.6, 1H), 3.86 (s, 2H), 3.77–3.70 (m, 4H), 3.47–3.40 (m, 4H), 3.15–3.06 (m, 2H), 2.93–2.85 (m, 2H), 2.62–2.56 (m, 2H), 1.06 (t, <i>J</i> = 7.2, 3H).</div></div><div id="sec4_25" class="NLM_sec NLM_sec_level_2"><div id="ac_i37" class="anchor-spacer"></div><h3 class="article-section__title" id="_i37"> 1-Ethyl-3-(4-(7-(methylsulfonyl)-4-morpholino-5,6,7,8-tetrahydropyrido[3,4-<i>d</i>]pyrimidin-2-yl)phenyl)urea (<b>12c</b>)</h3><div class="NLM_p last">LC/MS (ESI): M<sup>+</sup> = 461, MW = 460.55. <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>, 400 MHz): δ 9.01 (s, 1H), 8.18 (d, <i>J</i> = 8.8, 2H), 7.49 (d, <i>J</i> = 8.8, 2H), 6.43 (s, 1H), 4.32 (s, 2H), 3.72 (s, 4H), 3.49 (d, <i>J</i> = 4.0 Hz, 4H), 3.12 (t, <i>J</i> = 6.4 Hz, 2H), 3.01 (s, 3H), 2.79 (s, 2H), 2.53 (s, 1H), 2.31 (s, 1H), 1.06 (t, <i>J</i> = 7.2 Hz, 3H). The purity of this compound was 87% by UV at 254 nm.</div></div><div id="sec4_26" class="NLM_sec NLM_sec_level_2"><div id="ac_i38" class="anchor-spacer"></div><h3 class="article-section__title" id="_i38"> Methyl 2-(4-(3-Ethylureido)phenyl)-4-morpholino-5,6-dihydropyrido[3,4-<i>d</i>]pyrimidine-7(8<i>H</i>)-carboxylate (<b>12d</b>)</h3><div class="NLM_p last">LC/MS (ESI): M<sup>+</sup> = 441, MW = 440.5. <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>, 400 MHz): δ 8.75 (s, 1H), 8.17 (d, <i>J</i> = 8.4 Hz, 2H), 7.51 (d, <i>J</i> = 8.4 Hz, 2H), 6.22 (s, 1H), 4.53 (s, 2H), 3.72–3.55 (m, 13H), 3.12 (t, <i>J</i> = 5.2 Hz, 2H), 2.69 (t, <i>J</i> = 5.2 Hz, 2H), 1.07 (t, <i>J</i> = 7.2 Hz, 3H). The purity of this compound was 94% by UV at 254 nm.</div></div><div id="sec4_27" class="NLM_sec NLM_sec_level_2"><div id="ac_i39" class="anchor-spacer"></div><h3 class="article-section__title" id="_i39"> 1-(4-(7-Benzoyl-4-morpholino-5,6,7,8-tetrahydropyrido[3,4-<i>d</i>]pyrimidin-2-yl)phenyl)-3-ethylurea (<b>12e</b>)</h3><div class="NLM_p last"><b>12a</b> (111.6 mg, 0.2918 mmol) was weighed into a reaction vial. CH<sub>2</sub>Cl<sub>2</sub> (5.0 mL, 78 mmol) and <i>N</i>,<i>N</i>-diisopropylethylamine (150 μL, 0.86 mmol) were added and then benzoyl chloride (45 μL, 0.39 mmol). The reaction was stirred at rt for 2 h, and then the reaction was diluted with 8 mL of CH<sub>2</sub>Cl<sub>2</sub> and shaken with 10 mL of 1 N HCl. The layers were separated and then extracted with CH<sub>2</sub>Cl<sub>2</sub> (2 × 5 mL). The combined organic extracts were dried with MgSO<sub>4</sub>, filtered, and concentrated. The resulting material was purified by reverse-phase chromatography. LC/MS: 4.11 min, M<sup>+</sup> = 487.2, MW = 486.6. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ 10.12–9.97 (m, <i>J</i> = 23.6, 2H), 9.35 (s, 1H), 9.09 (s, 1H), 7.62 (d, <i>J</i> = 9.0, 1H), 6.97 (d, <i>J</i> = 8.7, 2H), 5.69 (s, 1H), 3.40–3.24 (m, <i>J</i> = 6.3, 13.6, 7H), 3.17 (s, 1H), 3.04–2.91 (m, 1H), 1.20 (t, <i>J</i> = 7.2, 3H), 0.97 (t, <i>J</i> = 7.2, 2H).</div></div><div id="sec4_28" class="NLM_sec NLM_sec_level_2"><div id="ac_i40" class="anchor-spacer"></div><h3 class="article-section__title" id="_i40"> Ethyl (4-(7-Benzoyl-4-morpholino-5,6,7,8-tetrahydropyrido[3,4-<i>d</i>]pyrimidin-2-yl)phenyl)carbamate (<b>12f</b>)</h3><div class="NLM_p last">LC/MS: 4.68 min, M<sup>+</sup> = 488.3, MW = 486.6. <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>, 400 MHz): δ 9.80 (s, 1H), 8.31–8.10 (m, 2H), 7.62–7.45 (m, 6H), 4.72 (br s, 1H), 4.53 (br s, 1H), 4.14 (q, <i>J</i> = 7.1 Hz, 2H), 3.83 (br s, 1H), 3.78–3.68 (m, 4H), 3.57–3.45 (m, 5H), 2.77 (t, <i>J</i> = 5.0 Hz, 2H), 1.26 (t, <i>J</i> = 7.1 Hz, 3H).</div></div><div id="sec4_29" class="NLM_sec NLM_sec_level_2"><div id="ac_i41" class="anchor-spacer"></div><h3 class="article-section__title" id="_i41"> 4-(7-Benzoyl-4-morpholino-5,6,7,8-tetrahydropyrido[3,4-<i>d</i>]pyrimidin-2-yl)phenyl Ethylcarbamate (<b>12g</b>)</h3><div class="NLM_p last">LC/MS: 5.45 min, M<sup>+</sup> = 488.3, MW = 487.6. <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>, 400 MHz): δ 3.79–3.69 (m, 4H), 3.59–3.44 (m, 5H), 3.11 (p, <i>J</i> = 6.6 Hz, 2H), 2.78 (t, <i>J</i> = 5.1 Hz, 2H), 1.10 (t, <i>J</i> = 7.2 Hz, 3H), 3.91–3.79 (m, 1H), 8.43–8.15 (m, 2H), 7.82–7.73 (m, 1H), 7.57–7.46 (m, 4H), 7.26–7.09 (m, 2H), 4.80–4.47 (m, 2H).</div></div><div id="sec4_30" class="NLM_sec NLM_sec_level_2"><div id="ac_i42" class="anchor-spacer"></div><h3 class="article-section__title" id="_i42"> 1-Ethyl-3-(4-(4-morpholino-7-(pyrimidin-2-yl)-5,6,7,8-tetrahydropyrido[3,4-<i>d</i>]pyrimidin-2-yl)phenyl)urea (<b>12h</b>)</h3><div class="NLM_p last">LC/MS: 3.97 min, M<sup>+</sup> = 461.2, MW = 460.5. <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>, 400 MHz): δ 8.64 (s, 1H), 8.43 (d, <i>J</i> = 4.7, 2H), 8.21 (d, <i>J</i> = 8.7, 2H), 7.49 (d, <i>J</i> = 8.8, 2H), 6.69 (t, <i>J</i> = 4.7, 1H), 6.16 (t, <i>J</i> = 5.5, 1H), 4.81 (s, 2H), 3.98 (s, 2H), 3.73 (d, <i>J</i> = 4.5, 4H), 3.47 (d, <i>J</i> = 4.4, 4H), 3.19–3.02 (m, 2H), 2.75 (s, 2H), 1.06 (t, <i>J</i> = 7.2, 3H).</div></div><div id="sec4_31" class="NLM_sec NLM_sec_level_2"><div id="ac_i43" class="anchor-spacer"></div><h3 class="article-section__title" id="_i43"> (<i>S</i>)-1-Ethyl-3-(4-(4-(3-methylmorpholino)-7-(pyrimidin-2-yl)-5,6,7,8-tetrahydropyrido[3,4-<i>d</i>]pyrimidin-2-yl)phenyl)urea (<b>12i</b>)</h3><div class="NLM_p last">LC/MS: 4.82 min, M<sup>+</sup> = 475.3, MW = 474.6. <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>, 400 MHz): δ 8.68 (s, 1H), 8.44 (d, <i>J</i> = 4.7, 2H), 8.20 (d, <i>J</i> = 8.8, 2H), 7.49 (d, <i>J</i> = 8.8, 2H), 6.69 (t, <i>J</i> = 4.7, 1H), 6.19 (t, <i>J</i> = 5.6, 1H), 4.90 (d, <i>J</i> = 18.7, 1H), 4.73 (d, <i>J</i> = 18.7, 1H), 4.19–4.06 (m, 2H), 3.94–3.76 (m, 2H), 3.74–3.54 (m, 4H), 3.50–3.36 (m, 1H), 3.17–3.06 (m, 2H), 2.80–2.68 (m, 2H), 1.25 (d, <i>J</i> = 6.6, 3H), 1.06 (t, <i>J</i> = 7.2, 3H).</div></div><div id="sec4_32" class="NLM_sec NLM_sec_level_2"><div id="ac_i44" class="anchor-spacer"></div><h3 class="article-section__title" id="_i44"> (<i>S</i>)-1-Ethyl-3-(4-(4-(3-ethylmorpholino)-7-(pyrimidin-2-yl)-5,6,7,8-tetrahydropyrido[3,4-<i>d</i>]pyrimidin-2-yl)phenyl)urea (<b>12j</b>)</h3><div class="NLM_p last">LC/MS: 3.56 min, M<sup>+</sup> = 489.3, MW = 488.6. <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>, 400 MHz): δ 8.39 (d, <i>J</i> = 4.8 Hz, 2H), 8.30–8.16 (m, 2H), 7.50–7.38 (m, 2H), 6.70–6.55 (m, 1H), 5.06 (d, <i>J</i> = 18.7 Hz, 1H), 4.68 (d, <i>J</i> = 18.7 Hz, 1H), 4.39 (dt, <i>J</i> = 13.2, 4.8 Hz, 1H), 4.03 (s, 1H), 3.95–3.61 (m, 6H), 3.61–3.50 (m, 1H), 3.34 (s, 1H), 3.24 (d, <i>J</i> = 7.2 Hz, 1H), 2.94–2.62 (m, 2H), 1.90 (ddd, <i>J</i> = 13.8, 9.9, 6.7 Hz, 2H), 1.17 (t, <i>J</i> = 7.2 Hz, 3H), 0.98–0.80 (m, 3H).</div></div><div id="sec4_33" class="NLM_sec NLM_sec_level_2"><div id="ac_i45" class="anchor-spacer"></div><h3 class="article-section__title" id="_i45"> (<i>S</i>)-1-ethyl-3-(4-(4-(3-methylmorpholino)-7-(pyrazin-2-yl)-5,6,7,8-tetrahydropyrido[3,4-<i>d</i>]pyrimidin-2-yl)phenyl)urea (<b>12k</b>)</h3><div class="NLM_p last">LC/MS: 3.05 min, M<sup>+</sup>=475.2, MW = 474.6. <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>, 400 MHz): δ 8.67 (s, 1H), 8.43 (d, <i>J</i> = 1.5 Hz, 1H), 8.24–8.16 (m, 2H), 8.13 (dd, <i>J</i> = 2.6, 1.5 Hz, 1H), 7.87 (d, <i>J</i> = 2.6 Hz, 1H), 7.55–7.44 (m, 2H), 6.19 (t, <i>J</i> = 5.5 Hz, 1H), 4.87–4.49 (m, 2H), 4.14 (d, <i>J</i> = 7.4 Hz, 1H), 3.99 (dt, <i>J</i> = 12.8, 5.0 Hz, 1H), 3.94–3.82 (m, 1H), 3.82–3.52 (m, 5H), 3.51–3.37 (m, 1H), 3.12 (dt, <i>J</i> = 12.7, 7.1 Hz, 2H), 2.78 (t, <i>J</i> = 5.5 Hz, 2H), 1.26 (d, <i>J</i> = 6.6 Hz, 3H), 1.06 (t, <i>J</i> = 7.2 Hz, 3H).</div></div><div id="sec4_34" class="NLM_sec NLM_sec_level_2"><div id="ac_i46" class="anchor-spacer"></div><h3 class="article-section__title" id="_i46"> (<i>S</i>)-1-Ethyl-3-(4-(4-(3-methylmorpholino)-7-(pyridazin-3-yl)-5,6,7,8-tetrahydropyrido[3,4-<i>d</i>]pyrimidin-2-yl)phenyl)urea (<b>12l</b>)</h3><div class="NLM_p last">LC/MS: 3.63 min, M<sup>+</sup> = 475.2, MW = 474.6. <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>, 400 MHz): δ 8.66 (s, 1H), 8.58 (dd, <i>J</i> = 4.3, 1.3 Hz, 1H), 8.21 (d, <i>J</i> = 8.8 Hz, 2H), 7.50 (d, <i>J</i> = 8.8 Hz, 2H), 7.46–7.36 (m, 2H), 6.17 (t, <i>J</i> = 5.6 Hz, 1H), 4.78 (d, <i>J</i> = 18.1 Hz, 1H), 4.66 (d, <i>J</i> = 18.1 Hz, 1H), 4.17–4.00 (m, 2H), 3.93–3.84 (m, 1H), 3.82–3.56 (m, 5H), 3.48–3.39 (m, 1H), 3.17–3.07 (m, 2H), 2.83–2.75 (m, 2H), 1.26 (d, <i>J</i> = 6.7 Hz, 3H), 1.06 (t, <i>J</i> = 7.2 Hz, 3H). The purity of this compound was 89% by UV at 254 nm.</div></div><div id="sec4_35" class="NLM_sec NLM_sec_level_2"><div id="ac_i47" class="anchor-spacer"></div><h3 class="article-section__title" id="_i47"> (<i>S</i>)-1-Ethyl-3-(4-(7-(3-methyl-1,2,4-thiadiazol-5-yl)-4-(3-methylmorpholino)-5,6,7,8-tetrahydropyrido[3,4-<i>d</i>]pyrimidin-2-yl)phenyl)urea (<b>12m</b>)</h3><div class="NLM_p last">LC/MS: 3.58 min, M<sup>+</sup> = 495.2, MW = 494.6. <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>, 400 MHz): δ 8.78 (s, 1H), 8.19 (d, <i>J</i> = 8.8 Hz, 2H), 7.50 (d, J=8.8 Hz, 2H), 6.29 (t, <i>J</i> = 5.7 Hz, 1H), 4.59 (d, <i>J</i> = 4.8 Hz, 2H), 4.14–4.08 (m, 2H), 3.90–3.58 (m, 5H), 3.47–3.42 (m, 1H), 3.15–3.08 (m, 2H), 2.85–2.81 (m, 2H), 2.69–2.66 (m, 1H), 2.33 (s, 3H), 1.26 (d, <i>i</i> = 6.7 Hz, 3H), 1.06 (t, <i>J</i> = 7.2 Hz, 3H).</div></div><div id="sec4_36" class="NLM_sec NLM_sec_level_2"><div id="ac_i48" class="anchor-spacer"></div><h3 class="article-section__title" id="_i48"> (<i>S</i>)-1-Ethyl-3-(4-(7-(5-methyl-1,3,4-oxadiazol-2-yl)-4-(3-methylmorpholino)-5,6,7,8-tetrahydropyrido[3,4-<i>d</i>]pyrimidin-2-yl)phenyl)urea (<b>12n</b>)</h3><div class="NLM_p last">LC/MS (ESI): M<sup>+</sup> = 479.3, MW = 478.55. <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>, 400 MHz): δ 8.73 (s, 1H), 8.09 (d, <i>J</i> = 8.8 Hz, 2H), 7.45(d, <i>J</i> = 8.8 Hz, 2H), 6.20 (s, 1H), 4.51 (s, 1H), 4.25 (s, 1H), 3.59–3.44 (m, 8H), 3.05 (d, <i>J</i> = 5.6 Hz, 2H), 2.29 (s, 3H), 1.23 (d, <i>J</i> = 6.4 Hz, 3H), 0.99 (t, <i>J</i> = 7.2 Hz, 3H).</div></div><div id="sec4_37" class="NLM_sec NLM_sec_level_2"><div id="ac_i49" class="anchor-spacer"></div><h3 class="article-section__title" id="_i49"> Molecular Modeling</h3><div class="NLM_p last">A homology model of the mTOR kinase domain was built from publicly available PI3Kγ crystal structures (PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=3IBE">3IBE</a>) using the Fugue and Orchestrar modules of Sybyl, version 8.1 (Tripos Associates, St. Louis, MO), and further optimized using the Maximin module within Sybyl (all atoms, Amber FF02 charges on protein, MMFF94 charges on ligand) including the bound ligand from <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=3IBE">3IBE</a>. Docking studies were conducted using Gold, version 4.1, with a single hydrogen bond constraint to the hinge Val backbone NH, allowing flexible Lys and Asp side chains so appropriate hydrogen bond geometry between the ligand urea moiety and protein could be attained. A 10 Å sphere arond the centroid of the ligand was used to define the active site region.</div></div></div><div class="NLM_back"><div class="article_supporting-info" id=""></div><div class="testing" data-doi="10.1021/jm301389h" data-url="https://widgets.figshare.com/static/figshare.js" id="figshare-widget"></div><div class="authorInformationSection"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="authorInformationSection">Author Information</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_53215" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_53215" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><ul><li><span class="author-information-subsection-header">Corresponding Author</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Michael F. T. Koehler</span> - <span class="hlFld-Affiliation affiliation">†Department
of Discovery Chemistry, ‡Department of Translational Oncology, §Department of Structural
Biology, ∥Department of Small Molecule Biochemical Pharmacology, #Department of Drug Metabolism
and Pharmacokinetics, and ∇Department of Protein Chemistry, Genentech, Inc., 1 DNA Way, South San Francisco, California
94080, United States</span>; 
    <span class="author-email">
                Email: <a href="/cdn-cgi/l/email-protection#fd909692989591988fbd9a989398d39e9290"><span class="__cf_email__" data-cfemail="076a6c68626f6b627547606269622964686a">[email protected]</span></a></span></div></li></ul></li><li><span class="author-information-subsection-header">Authors</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Philippe Bergeron</span> - <span class="hlFld-Affiliation affiliation">†Department
of Discovery Chemistry, ‡Department of Translational Oncology, §Department of Structural
Biology, ∥Department of Small Molecule Biochemical Pharmacology, #Department of Drug Metabolism
and Pharmacokinetics, and ∇Department of Protein Chemistry, Genentech, Inc., 1 DNA Way, South San Francisco, California
94080, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Elizabeth Blackwood</span> - <span class="hlFld-Affiliation affiliation">†Department
of Discovery Chemistry, ‡Department of Translational Oncology, §Department of Structural
Biology, ∥Department of Small Molecule Biochemical Pharmacology, #Department of Drug Metabolism
and Pharmacokinetics, and ∇Department of Protein Chemistry, Genentech, Inc., 1 DNA Way, South San Francisco, California
94080, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Krista K. Bowman</span> - <span class="hlFld-Affiliation affiliation">†Department
of Discovery Chemistry, ‡Department of Translational Oncology, §Department of Structural
Biology, ∥Department of Small Molecule Biochemical Pharmacology, #Department of Drug Metabolism
and Pharmacokinetics, and ∇Department of Protein Chemistry, Genentech, Inc., 1 DNA Way, South San Francisco, California
94080, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Yung-Hsiang Chen</span> - <span class="hlFld-Affiliation affiliation">†Department
of Discovery Chemistry, ‡Department of Translational Oncology, §Department of Structural
Biology, ∥Department of Small Molecule Biochemical Pharmacology, #Department of Drug Metabolism
and Pharmacokinetics, and ∇Department of Protein Chemistry, Genentech, Inc., 1 DNA Way, South San Francisco, California
94080, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Gauri Deshmukh</span> - <span class="hlFld-Affiliation affiliation">†Department
of Discovery Chemistry, ‡Department of Translational Oncology, §Department of Structural
Biology, ∥Department of Small Molecule Biochemical Pharmacology, #Department of Drug Metabolism
and Pharmacokinetics, and ∇Department of Protein Chemistry, Genentech, Inc., 1 DNA Way, South San Francisco, California
94080, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Xiao Ding</span> - <span class="hlFld-Affiliation affiliation">†Department
of Discovery Chemistry, ‡Department of Translational Oncology, §Department of Structural
Biology, ∥Department of Small Molecule Biochemical Pharmacology, #Department of Drug Metabolism
and Pharmacokinetics, and ∇Department of Protein Chemistry, Genentech, Inc., 1 DNA Way, South San Francisco, California
94080, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Jennifer Epler</span> - <span class="hlFld-Affiliation affiliation">†Department
of Discovery Chemistry, ‡Department of Translational Oncology, §Department of Structural
Biology, ∥Department of Small Molecule Biochemical Pharmacology, #Department of Drug Metabolism
and Pharmacokinetics, and ∇Department of Protein Chemistry, Genentech, Inc., 1 DNA Way, South San Francisco, California
94080, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Kevin Lau</span> - <span class="hlFld-Affiliation affiliation">†Department
of Discovery Chemistry, ‡Department of Translational Oncology, §Department of Structural
Biology, ∥Department of Small Molecule Biochemical Pharmacology, #Department of Drug Metabolism
and Pharmacokinetics, and ∇Department of Protein Chemistry, Genentech, Inc., 1 DNA Way, South San Francisco, California
94080, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Leslie Lee</span> - <span class="hlFld-Affiliation affiliation">†Department
of Discovery Chemistry, ‡Department of Translational Oncology, §Department of Structural
Biology, ∥Department of Small Molecule Biochemical Pharmacology, #Department of Drug Metabolism
and Pharmacokinetics, and ∇Department of Protein Chemistry, Genentech, Inc., 1 DNA Way, South San Francisco, California
94080, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Lichuan Liu</span> - <span class="hlFld-Affiliation affiliation">†Department
of Discovery Chemistry, ‡Department of Translational Oncology, §Department of Structural
Biology, ∥Department of Small Molecule Biochemical Pharmacology, #Department of Drug Metabolism
and Pharmacokinetics, and ∇Department of Protein Chemistry, Genentech, Inc., 1 DNA Way, South San Francisco, California
94080, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Cuong Ly</span> - <span class="hlFld-Affiliation affiliation">†Department
of Discovery Chemistry, ‡Department of Translational Oncology, §Department of Structural
Biology, ∥Department of Small Molecule Biochemical Pharmacology, #Department of Drug Metabolism
and Pharmacokinetics, and ∇Department of Protein Chemistry, Genentech, Inc., 1 DNA Way, South San Francisco, California
94080, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Shiva Malek</span> - <span class="hlFld-Affiliation affiliation">†Department
of Discovery Chemistry, ‡Department of Translational Oncology, §Department of Structural
Biology, ∥Department of Small Molecule Biochemical Pharmacology, #Department of Drug Metabolism
and Pharmacokinetics, and ∇Department of Protein Chemistry, Genentech, Inc., 1 DNA Way, South San Francisco, California
94080, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Jim Nonomiya</span> - <span class="hlFld-Affiliation affiliation">†Department
of Discovery Chemistry, ‡Department of Translational Oncology, §Department of Structural
Biology, ∥Department of Small Molecule Biochemical Pharmacology, #Department of Drug Metabolism
and Pharmacokinetics, and ∇Department of Protein Chemistry, Genentech, Inc., 1 DNA Way, South San Francisco, California
94080, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Jason Oeh</span> - <span class="hlFld-Affiliation affiliation">†Department
of Discovery Chemistry, ‡Department of Translational Oncology, §Department of Structural
Biology, ∥Department of Small Molecule Biochemical Pharmacology, #Department of Drug Metabolism
and Pharmacokinetics, and ∇Department of Protein Chemistry, Genentech, Inc., 1 DNA Way, South San Francisco, California
94080, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Daniel F. Ortwine</span> - <span class="hlFld-Affiliation affiliation">†Department
of Discovery Chemistry, ‡Department of Translational Oncology, §Department of Structural
Biology, ∥Department of Small Molecule Biochemical Pharmacology, #Department of Drug Metabolism
and Pharmacokinetics, and ∇Department of Protein Chemistry, Genentech, Inc., 1 DNA Way, South San Francisco, California
94080, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Deepak Sampath</span> - <span class="hlFld-Affiliation affiliation">†Department
of Discovery Chemistry, ‡Department of Translational Oncology, §Department of Structural
Biology, ∥Department of Small Molecule Biochemical Pharmacology, #Department of Drug Metabolism
and Pharmacokinetics, and ∇Department of Protein Chemistry, Genentech, Inc., 1 DNA Way, South San Francisco, California
94080, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Steve Sideris</span> - <span class="hlFld-Affiliation affiliation">†Department
of Discovery Chemistry, ‡Department of Translational Oncology, §Department of Structural
Biology, ∥Department of Small Molecule Biochemical Pharmacology, #Department of Drug Metabolism
and Pharmacokinetics, and ∇Department of Protein Chemistry, Genentech, Inc., 1 DNA Way, South San Francisco, California
94080, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Lan Trinh</span> - <span class="hlFld-Affiliation affiliation">†Department
of Discovery Chemistry, ‡Department of Translational Oncology, §Department of Structural
Biology, ∥Department of Small Molecule Biochemical Pharmacology, #Department of Drug Metabolism
and Pharmacokinetics, and ∇Department of Protein Chemistry, Genentech, Inc., 1 DNA Way, South San Francisco, California
94080, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Tom Truong</span> - <span class="hlFld-Affiliation affiliation">†Department
of Discovery Chemistry, ‡Department of Translational Oncology, §Department of Structural
Biology, ∥Department of Small Molecule Biochemical Pharmacology, #Department of Drug Metabolism
and Pharmacokinetics, and ∇Department of Protein Chemistry, Genentech, Inc., 1 DNA Way, South San Francisco, California
94080, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Jiansheng Wu</span> - <span class="hlFld-Affiliation affiliation">†Department
of Discovery Chemistry, ‡Department of Translational Oncology, §Department of Structural
Biology, ∥Department of Small Molecule Biochemical Pharmacology, #Department of Drug Metabolism
and Pharmacokinetics, and ∇Department of Protein Chemistry, Genentech, Inc., 1 DNA Way, South San Francisco, California
94080, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Zhonghua Pei</span> - <span class="hlFld-Affiliation affiliation">†Department
of Discovery Chemistry, ‡Department of Translational Oncology, §Department of Structural
Biology, ∥Department of Small Molecule Biochemical Pharmacology, #Department of Drug Metabolism
and Pharmacokinetics, and ∇Department of Protein Chemistry, Genentech, Inc., 1 DNA Way, South San Francisco, California
94080, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Joseph P. Lyssikatos</span> - <span class="hlFld-Affiliation affiliation">†Department
of Discovery Chemistry, ‡Department of Translational Oncology, §Department of Structural
Biology, ∥Department of Small Molecule Biochemical Pharmacology, #Department of Drug Metabolism
and Pharmacokinetics, and ∇Department of Protein Chemistry, Genentech, Inc., 1 DNA Way, South San Francisco, California
94080, United States</span></div></li></ul></li><li></li><li></li><li><span class="author-information-subsection-header">Notes</span><div class="authorInformation_notesSection">The authors declare the following competing financial interests: M.F.T.K. is an employee of Genentech, Inc. and a stockholder of F. Hoffman-La Roche Ltd.<br /></br></div></li></ul></div><div class="ack" id="ACK-d2548e3391-autogenerated"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i50">Acknowledgment</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_70325" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_70325" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">We thank members of the DMPK and Purification groups within Genentech Small Molecule Drug Discovery for analytical support.</p></div><div id="" class="NLM_sec NLM_sec_level_1"><div id="ac_i51" class="anchor-spacer"></div><h2 class="article-section__title section__title" id="_i51"> </h2><div class="NLM_p last"><table summary="" class="NLM_def-list" id="dl1"><div id="ac_i52" class="anchor-spacer"></div><h2 class="article-section__title section__title" id="_i52"> Abbreviations Used</h2><tr><td class="NLM_term">mTOR</td><td class="NLM_def"><p class="first last">mammalian target of rapamycin</p></td></tr><tr><td class="NLM_term">PI3K</td><td class="NLM_def"><p class="first last">phosphatidylinositol 3 kinase</p></td></tr><tr><td class="NLM_term">mTORC</td><td class="NLM_def"><p class="first last">mammalian target of rapamycin complex</p></td></tr><tr><td class="NLM_term">LC/MS</td><td class="NLM_def"><p class="first last">liquid chromatography–mass spectrometry</p></td></tr><tr><td class="NLM_term">TPSA</td><td class="NLM_def"><p class="first last">topological polar surface area</p></td></tr><tr><td class="NLM_term">PPB</td><td class="NLM_def"><p class="first last">plasma protein binding</p></td></tr><tr><td class="NLM_term">PTEN</td><td class="NLM_def"><p class="first last">phosphatase and tensin homologue</p></td></tr><tr><td class="NLM_term">CYP</td><td class="NLM_def"><p class="first last">cytochrome P450.</p></td></tr></table></div></div><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i53">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_18521" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_18521" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="references-count">
            This article references 39 other publications.
        </p><ol id="references" class="useLabel"><li id="ref1"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref1'); return false;" data-citation="" class="refNumLink">1</a></strong><div class="NLM_citation" id="cit1"><span><span class="NLM_contrib-group">Baselga, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Campone, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Piccart, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Burris, H. A.,  III</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rugo, H. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sahmoud, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Noguchi, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gnant, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pritchard, K. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lebrun, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Beck, J. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ito, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yardley, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Deleu, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Perez, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bachelot, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vittori, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xu, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mukhopadhyay, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lebwohl, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hortobagyi, G. N.</span><span> </span><span class="NLM_article-title">Everolimus in Postmenopausal Hormone-Receptor–Positive Advanced Breast Cancer</span> <span class="citation_source-journal">N. Engl. J. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">366</span><span class="NLM_x">, </span> <span class="NLM_fpage">520</span><span class="NLM_x">–</span> <span class="NLM_lpage">529</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=16&amp;doi=10.1021%2Fjm301389h&amp;key=10.1056%2FNEJMoa1109653" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=8&amp;doi=10.1021%2Fjm301389h&amp;key=22149876" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=366&publication_year=2011&pages=520-529&author=J.+Baselgaauthor=M.+Camponeauthor=M.+Piccartauthor=H.+A.+Burrisauthor=H.+S.+Rugoauthor=T.+Sahmoudauthor=S.+Noguchiauthor=M.+Gnantauthor=K.+I.+Pritchardauthor=F.+Lebrunauthor=J.+T.+Beckauthor=Y.+Itoauthor=D.+Yardleyauthor=I.+Deleuauthor=A.+Perezauthor=T.+Bachelotauthor=L.+Vittoriauthor=Z.+Xuauthor=P.+Mukhopadhyayauthor=D.+Lebwohlauthor=G.+N.+Hortobagyi&title=Everolimus+in+Postmenopausal+Hormone-Receptor%E2%80%93Positive+Advanced+Breast+Cancer"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa1109653&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa1109653%26sid%3Dliteratum%253Aachs%26aulast%3DBaselga%26aufirst%3DJ.%26aulast%3DCampone%26aufirst%3DM.%26aulast%3DPiccart%26aufirst%3DM.%26aulast%3DBurris%26aufirst%3DH.%2BA.%26aulast%3DRugo%26aufirst%3DH.%2BS.%26aulast%3DSahmoud%26aufirst%3DT.%26aulast%3DNoguchi%26aufirst%3DS.%26aulast%3DGnant%26aufirst%3DM.%26aulast%3DPritchard%26aufirst%3DK.%2BI.%26aulast%3DLebrun%26aufirst%3DF.%26aulast%3DBeck%26aufirst%3DJ.%2BT.%26aulast%3DIto%26aufirst%3DY.%26aulast%3DYardley%26aufirst%3DD.%26aulast%3DDeleu%26aufirst%3DI.%26aulast%3DPerez%26aufirst%3DA.%26aulast%3DBachelot%26aufirst%3DT.%26aulast%3DVittori%26aufirst%3DL.%26aulast%3DXu%26aufirst%3DZ.%26aulast%3DMukhopadhyay%26aufirst%3DP.%26aulast%3DLebwohl%26aufirst%3DD.%26aulast%3DHortobagyi%26aufirst%3DG.%2BN.%26atitle%3DEverolimus%2520in%2520Postmenopausal%2520Hormone-Receptor%25E2%2580%2593Positive%2520Advanced%2520Breast%2520Cancer%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2011%26volume%3D366%26spage%3D520%26epage%3D529" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref2"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref2'); return false;" data-citation="" class="refNumLink">2</a></strong><div class="NLM_citation" id="cit2"><span><span class="NLM_contrib-group">Sabatini, D. M.</span><span> </span><span class="NLM_article-title">mTOR and cancer: Insights into a complex relationship</span> <span class="citation_source-journal">Nat. Rev. Cancer</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">6</span><span class="NLM_x">, </span> <span class="NLM_fpage">729</span><span class="NLM_x">–</span> <span class="NLM_lpage">734</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=16&amp;doi=10.1021%2Fjm301389h&amp;key=10.1038%2Fnrc1974" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=8&amp;doi=10.1021%2Fjm301389h&amp;key=16915295" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=32&amp;doi=10.1021%2Fjm301389h&amp;key=1%3ACAS%3A528%3ADC%252BD28XosVOmsb8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2006&pages=729-734&author=D.+M.+Sabatini&title=mTOR+and+cancer%3A+Insights+into+a+complex+relationship"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit2R"><div class="casContent"><span class="casTitleNuber">2</span><div class="casTitle"><span class="NLM_cas:atitle">mTOR and cancer: insights into a complex relationship</span></div><div class="casAuthors">Sabatini, David M.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Cancer</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">729-734</span>CODEN:
                <span class="NLM_cas:coden">NRCAC4</span>;
        ISSN:<span class="NLM_cas:issn">1474-175X</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  MTOR (mammalian target of rapamycin) has come a long way since its humble beginnings as a kinase of unknown function.  As part of the mTORC1 and mTORC2 complexes mTOR has key roles in several pathways that are involved in human cancer, stimulating interest in mTOR inhibitors and placing it on the radar of the pharmaceutical industry.  Here, I discuss the rationale for the use of drugs that target mTOR, the unexpectedly complex mechanism of action of existing mTOR inhibitors and the potential benefits of developing drugs that function through different mechanisms.  The purpose is not to cover all aspects of mTOR history and signaling, but rather to foster discussion by presenting some occasionally provocative ideas.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrpzXc4_s5VirVg90H21EOLACvtfcHk0lifTJBhtW41Rg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XosVOmsb8%253D&md5=9d55f700e24be158715ecb13200d9cbf</span></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.1038%2Fnrc1974&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrc1974%26sid%3Dliteratum%253Aachs%26aulast%3DSabatini%26aufirst%3DD.%2BM.%26atitle%3DmTOR%2520and%2520cancer%253A%2520Insights%2520into%2520a%2520complex%2520relationship%26jtitle%3DNat.%2520Rev.%2520Cancer%26date%3D2006%26volume%3D6%26spage%3D729%26epage%3D734" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref3"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref3'); return false;" data-citation="" class="refNumLink">3</a></strong><div class="NLM_citation" id="cit3"><span><span class="NLM_contrib-group">Liu, K. K. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bailey, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dinh, D. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lam, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wells, P. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yin, M.-J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zou, A.</span><span> </span><span class="NLM_article-title">Conformationally-restricted cyclic sulfones as potent and selective mTOR kinase inhibitors</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">22</span><span class="NLM_x">, </span> <span class="NLM_fpage">5114</span><span class="NLM_x">–</span> <span class="NLM_lpage">5117</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Fjm301389h&amp;key=10.1016%2Fj.bmcl.2012.05.104" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=8&amp;doi=10.1021%2Fjm301389h&amp;key=22765900" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=32&amp;doi=10.1021%2Fjm301389h&amp;key=1%3ACAS%3A528%3ADC%252BC38Xps1Kmsro%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=2012&pages=5114-5117&author=K.+K.+C.+Liuauthor=S.+Baileyauthor=D.+M.+Dinhauthor=H.+Lamauthor=C.+Liauthor=P.+A.+Wellsauthor=M.-J.+Yinauthor=A.+Zou&title=Conformationally-restricted+cyclic+sulfones+as+potent+and+selective+mTOR+kinase+inhibitors"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit3R"><div class="casContent"><span class="casTitleNuber">3</span><div class="casTitle"><span class="NLM_cas:atitle">Conformationally-restricted cyclic sulfones as potent and selective mTOR kinase inhibitors</span></div><div class="casAuthors">Liu, Kevin K.-C.; Bailey, Simon; Dinh, Dac M.; Lam, Hieu; Li, Chunze; Wells, Peter A.; Yin, Min-Jean; Zou, Aihua</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">22</span>
        (<span class="NLM_cas:issue">15</span>),
    <span class="NLM_cas:pages">5114-5117</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Novel conformationally-restricted mTOR kinase inhibitors with cyclic sulfone scaffold were designed.  Synthesis and structure-activity relationship (SAR) studies are described with emphasis on optimization of the mTOR potency and selectivity against class I PI3Kα kinase.  PF-05139962 I was identified with excellent mTOR biochem. inhibition, cellular potency, kinase selectivity and in vitro ADME properties.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrmuwjN05w_4LVg90H21EOLACvtfcHk0lifTJBhtW41Rg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xps1Kmsro%253D&md5=c1abe951c4d17f22a2301004eff55d91</span></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2012.05.104&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2012.05.104%26sid%3Dliteratum%253Aachs%26aulast%3DLiu%26aufirst%3DK.%2BK.%2BC.%26aulast%3DBailey%26aufirst%3DS.%26aulast%3DDinh%26aufirst%3DD.%2BM.%26aulast%3DLam%26aufirst%3DH.%26aulast%3DLi%26aufirst%3DC.%26aulast%3DWells%26aufirst%3DP.%2BA.%26aulast%3DYin%26aufirst%3DM.-J.%26aulast%3DZou%26aufirst%3DA.%26atitle%3DConformationally-restricted%2520cyclic%2520sulfones%2520as%2520potent%2520and%2520selective%2520mTOR%2520kinase%2520inhibitors%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2012%26volume%3D22%26spage%3D5114%26epage%3D5117" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref4"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref4'); return false;" data-citation="" class="refNumLink">4</a></strong><div class="NLM_citation" id="cit4"><span><span class="NLM_contrib-group">Peterson, E. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Boezio, A. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Andrews, P. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Boezio, C. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bush, T. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cheng, A. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Choquette, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Coats, J. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Colletti, A. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Copeland, K. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">DuPont, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Graceffa, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Grubinska, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, J. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lewis, R. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mullady, E. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Potashman, M. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Romero, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shaffer, P. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stanton, M. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stellwagen, J. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Teffera, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yi, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cai, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">La, D. S.</span><span> </span><span class="NLM_article-title">Discovery and optimization of potent and selective imidazopyridine and imidazopyridazine mTOR inhibitors</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">22</span><span class="NLM_x">, </span> <span class="NLM_fpage">4967</span><span class="NLM_x">–</span> <span class="NLM_lpage">4974</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=2012&pages=4967-4974&author=E.+A.+Petersonauthor=A.+A.+Boezioauthor=P.+S.+Andrewsauthor=C.+M.+Boezioauthor=T.+L.+Bushauthor=A.+C.+Chengauthor=D.+Choquetteauthor=J.+R.+Coatsauthor=A.+E.+Collettiauthor=K.+W.+Copelandauthor=M.+DuPontauthor=R.+Graceffaauthor=B.+Grubinskaauthor=J.+L.+Kimauthor=R.+T.+Lewisauthor=J.+Liuauthor=E.+L.+Mulladyauthor=M.+H.+Potashmanauthor=K.+Romeroauthor=P.+L.+Shafferauthor=M.+K.+Stantonauthor=J.+C.+Stellwagenauthor=Y.+Tefferaauthor=S.+Yiauthor=T.+Caiauthor=D.+S.+La&title=Discovery+and+optimization+of+potent+and+selective+imidazopyridine+and+imidazopyridazine+mTOR+inhibitors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DPeterson%26aufirst%3DE.%2BA.%26aulast%3DBoezio%26aufirst%3DA.%2BA.%26aulast%3DAndrews%26aufirst%3DP.%2BS.%26aulast%3DBoezio%26aufirst%3DC.%2BM.%26aulast%3DBush%26aufirst%3DT.%2BL.%26aulast%3DCheng%26aufirst%3DA.%2BC.%26aulast%3DChoquette%26aufirst%3DD.%26aulast%3DCoats%26aufirst%3DJ.%2BR.%26aulast%3DColletti%26aufirst%3DA.%2BE.%26aulast%3DCopeland%26aufirst%3DK.%2BW.%26aulast%3DDuPont%26aufirst%3DM.%26aulast%3DGraceffa%26aufirst%3DR.%26aulast%3DGrubinska%26aufirst%3DB.%26aulast%3DKim%26aufirst%3DJ.%2BL.%26aulast%3DLewis%26aufirst%3DR.%2BT.%26aulast%3DLiu%26aufirst%3DJ.%26aulast%3DMullady%26aufirst%3DE.%2BL.%26aulast%3DPotashman%26aufirst%3DM.%2BH.%26aulast%3DRomero%26aufirst%3DK.%26aulast%3DShaffer%26aufirst%3DP.%2BL.%26aulast%3DStanton%26aufirst%3DM.%2BK.%26aulast%3DStellwagen%26aufirst%3DJ.%2BC.%26aulast%3DTeffera%26aufirst%3DY.%26aulast%3DYi%26aufirst%3DS.%26aulast%3DCai%26aufirst%3DT.%26aulast%3DLa%26aufirst%3DD.%2BS.%26atitle%3DDiscovery%2520and%2520optimization%2520of%2520potent%2520and%2520selective%2520imidazopyridine%2520and%2520imidazopyridazine%2520mTOR%2520inhibitors%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2012%26volume%3D22%26spage%3D4967%26epage%3D4974" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref5"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref5'); return false;" data-citation="" class="refNumLink">5</a></strong><div class="NLM_citation" id="cit5"><span><span class="NLM_contrib-group">Finlay, M. R. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Buttar, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Critchlow, S. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dishington, A. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fillery, S. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fisher, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Glossop, S. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Graham, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Johnson, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lamont, G. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mutton, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Perkins, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pike, K. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Slater, A. M.</span><span> </span><span class="NLM_article-title">Sulfonyl-morpholino-pyrimidines: SAR and development of a novel class of selective mTOR kinase inhibitor</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">22</span><span class="NLM_x">, </span> <span class="NLM_fpage">4163</span><span class="NLM_x">–</span> <span class="NLM_lpage">4168</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=2012&pages=4163-4168&author=M.+R.+V.+Finlayauthor=D.+Buttarauthor=S.+E.+Critchlowauthor=A.+P.+Dishingtonauthor=S.+M.+Filleryauthor=E.+Fisherauthor=S.+C.+Glossopauthor=M.+A.+Grahamauthor=T.+Johnsonauthor=G.+M.+Lamontauthor=S.+Muttonauthor=P.+Perkinsauthor=K.+G.+Pikeauthor=A.+M.+Slater&title=Sulfonyl-morpholino-pyrimidines%3A+SAR+and+development+of+a+novel+class+of+selective+mTOR+kinase+inhibitor"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DFinlay%26aufirst%3DM.%2BR.%2BV.%26aulast%3DButtar%26aufirst%3DD.%26aulast%3DCritchlow%26aufirst%3DS.%2BE.%26aulast%3DDishington%26aufirst%3DA.%2BP.%26aulast%3DFillery%26aufirst%3DS.%2BM.%26aulast%3DFisher%26aufirst%3DE.%26aulast%3DGlossop%26aufirst%3DS.%2BC.%26aulast%3DGraham%26aufirst%3DM.%2BA.%26aulast%3DJohnson%26aufirst%3DT.%26aulast%3DLamont%26aufirst%3DG.%2BM.%26aulast%3DMutton%26aufirst%3DS.%26aulast%3DPerkins%26aufirst%3DP.%26aulast%3DPike%26aufirst%3DK.%2BG.%26aulast%3DSlater%26aufirst%3DA.%2BM.%26atitle%3DSulfonyl-morpholino-pyrimidines%253A%2520SAR%2520and%2520development%2520of%2520a%2520novel%2520class%2520of%2520selective%2520mTOR%2520kinase%2520inhibitor%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2012%26volume%3D22%26spage%3D4163%26epage%3D4168" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref6"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref6'); return false;" data-citation="" class="refNumLink">6</a></strong><div class="NLM_citation" id="cit6"><span><span class="NLM_contrib-group">Mortensen, D. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Perrin-Ninkovic, S. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Harris, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, B. G. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shevlin, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hickman, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Khambatta, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bisonette, R. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fultz, K. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sankar, S.</span><span> </span><span class="NLM_article-title">Discovery and SAR exploration of a novel series of imidazo[4,5-<i>b</i>]pyrazin-2-ones as potent and selective mTOR kinase inhibitors</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">21</span><span class="NLM_x">, </span> <span class="NLM_fpage">6793</span><span class="NLM_x">–</span> <span class="NLM_lpage">6799</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=16&amp;doi=10.1021%2Fjm301389h&amp;key=10.1016%2Fj.bmcl.2011.09.035" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=8&amp;doi=10.1021%2Fjm301389h&amp;key=21978683" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=32&amp;doi=10.1021%2Fjm301389h&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhtlKktr3P" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2011&pages=6793-6799&author=D.+S.+Mortensenauthor=S.+M.+Perrin-Ninkovicauthor=R.+Harrisauthor=B.+G.+S.+Leeauthor=G.+Shevlinauthor=M.+Hickmanauthor=G.+Khambattaauthor=R.+R.+Bisonetteauthor=K.+E.+Fultzauthor=S.+Sankar&title=Discovery+and+SAR+exploration+of+a+novel+series+of+imidazo%5B4%2C5-b%5Dpyrazin-2-ones+as+potent+and+selective+mTOR+kinase+inhibitors"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit6R"><div class="casContent"><span class="casTitleNuber">6</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery and SAR exploration of a novel series of imidazo[4,5-b]pyrazin-2-ones as potent and selective mTOR kinase inhibitors</span></div><div class="casAuthors">Mortensen, Deborah S.; Perrin-Ninkovic, Sophie M.; Harris, Roy; Lee, Branden G. S.; Shevlin, Graziella; Hickman, Matt; Khambatta, Gody; Bisonette, Rene R.; Fultz, Kimberly E.; Sankar, Sabita</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">21</span>
        (<span class="NLM_cas:issue">22</span>),
    <span class="NLM_cas:pages">6793-6799</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">We report here the discovery of a novel series of selective mTOR kinase inhibitors.  A series of imidazo[4,5-b]pyrazin-2-ones, represented by screening hit 1, was developed into lead compds. with excellent mTOR potency and exquisite kinase selectivity.  Potent compds. from this series show >1000-fold selectivity over the related PI3Kα lipid kinase.  Further, compds. such as 2 achieve mTOR pathway inhibition, blocking both mTORC1 and mTORC2 signaling, in PC3 cancer cells as measured by inhibition of pS6 and pAkt (S473).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrWly4sBJXgerVg90H21EOLACvtfcHk0linKVyYX9-31Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhtlKktr3P&md5=d422a7d505c1032951547d997ac2e033</span></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2011.09.035&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2011.09.035%26sid%3Dliteratum%253Aachs%26aulast%3DMortensen%26aufirst%3DD.%2BS.%26aulast%3DPerrin-Ninkovic%26aufirst%3DS.%2BM.%26aulast%3DHarris%26aufirst%3DR.%26aulast%3DLee%26aufirst%3DB.%2BG.%2BS.%26aulast%3DShevlin%26aufirst%3DG.%26aulast%3DHickman%26aufirst%3DM.%26aulast%3DKhambatta%26aufirst%3DG.%26aulast%3DBisonette%26aufirst%3DR.%2BR.%26aulast%3DFultz%26aufirst%3DK.%2BE.%26aulast%3DSankar%26aufirst%3DS.%26atitle%3DDiscovery%2520and%2520SAR%2520exploration%2520of%2520a%2520novel%2520series%2520of%2520imidazo%255B4%252C5-b%255Dpyrazin-2-ones%2520as%2520potent%2520and%2520selective%2520mTOR%2520kinase%2520inhibitors%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2011%26volume%3D21%26spage%3D6793%26epage%3D6799" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref7"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref7'); return false;" data-citation="" class="refNumLink">7</a></strong><div class="NLM_citation" id="cit7"><span><span class="NLM_contrib-group">Bhagwat, S. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gokhale, P. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Crew, A. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cooke, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yao, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mantis, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kahler, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Workman, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bittner, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dudkin, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Epstein, D. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gibson, N. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wild, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Arnold, L. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Houghton, P. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pachter, J. A.</span><span> </span><span class="NLM_article-title">Preclinical Characterization of OSI-027, a Potent and Selective Inhibitor of mTORC1 and mTORC2: Distinct from Rapamycin</span> <span class="citation_source-journal">Mol. Cancer Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">10</span><span class="NLM_x">, </span> <span class="NLM_fpage">1394</span><span class="NLM_x">–</span> <span class="NLM_lpage">1406</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=16&amp;doi=10.1021%2Fjm301389h&amp;key=10.1158%2F1535-7163.MCT-10-1099" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=8&amp;doi=10.1021%2Fjm301389h&amp;key=21673091" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=32&amp;doi=10.1021%2Fjm301389h&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhtFSqtLnF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2011&pages=1394-1406&author=S.+V.+Bhagwatauthor=P.+C.+Gokhaleauthor=A.+P.+Crewauthor=A.+Cookeauthor=Y.+Yaoauthor=C.+Mantisauthor=J.+Kahlerauthor=J.+Workmanauthor=M.+Bittnerauthor=L.+Dudkinauthor=D.+M.+Epsteinauthor=N.+W.+Gibsonauthor=R.+Wildauthor=L.+D.+Arnoldauthor=P.+J.+Houghtonauthor=J.+A.+Pachter&title=Preclinical+Characterization+of+OSI-027%2C+a+Potent+and+Selective+Inhibitor+of+mTORC1+and+mTORC2%3A+Distinct+from+Rapamycin"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit7R"><div class="casContent"><span class="casTitleNuber">7</span><div class="casTitle"><span class="NLM_cas:atitle">Preclinical characterization of OSI-027, a potent and selective inhibitor of mTORC1 and mTORC2: distinct from rapamycin</span></div><div class="casAuthors">Bhagwat, Shripad V.; Gokhale, Prafulla C.; Crew, Andrew P.; Cooke, Andy; Yao, Yan; Mantis, Christine; Kahler, Jennifer; Workman, Jennifer; Bittner, Mark; Dudkin, Lorina; Epstein, David M.; Gibson, Neil W.; Wild, Robert; Arnold, Lee D.; Houghton, Peter J.; Pachter, Jonathan A.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer Therapeutics</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">1394-1406</span>CODEN:
                <span class="NLM_cas:coden">MCTOCF</span>;
        ISSN:<span class="NLM_cas:issn">1535-7163</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">The phosphoinositide 3-kinase (PI3K)/AKT/mTOR pathway is frequently activated in human cancers, and mTOR is a clin. validated target.  MTOR forms two distinct multiprotein complexes, mTORC1 and mTORC2, which regulate cell growth, metab., proliferation, and survival.  Rapamycin and its analogs partially inhibit mTOR through allosteric binding to mTORC1, but not mTORC2, and have shown clin. utility in certain cancers.  Here, we report the preclin. characterization of OSI-027, a selective and potent dual inhibitor of mTORC1 and mTORC2 with biochem. IC50 values of 22 nmol/L and 65 nmol/L, resp.  OSI-027 shows more than 100-fold selectivity for mTOR relative to PI3Kα, PI3Kβ, PI3Kγ, and DNA-PK.  OSI-027 inhibits phosphorylation of the mTORC1 substrates 4E-BP1 and S6K1 as well as the mTORC2 substrate AKT in diverse cancer models in vitro and in vivo.  OSI-027 and OXA-01 (close analog of OSI-027) potently inhibit proliferation of several rapamycin-sensitive and -insensitive nonengineered and engineered cancer cell lines and also, induce cell death in tumor cell lines with activated PI3K-AKT signaling.  OSI-027 shows concn.-dependent pharmacodynamic effects on phosphorylation of 4E-BP1 and AKT in tumor tissue with resulting tumor growth inhibition.  OSI-027 shows robust antitumor activity in several different human xenograft models representing various histologies.  Furthermore, in COLO 205 and GEO colon cancer xenograft models, OSI-027 shows superior efficacy compared with rapamycin.  Our results further support the important role of mTOR as a driver of tumor growth and establish OSI-027 as a potent anticancer agent.  OSI-027 is currently in phase I clin. trials in cancer patients.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqLyA6Bn0nZqbVg90H21EOLACvtfcHk0linKVyYX9-31Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhtFSqtLnF&md5=8d91103e12ab5c632571f17510b3ee7f</span></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.1158%2F1535-7163.MCT-10-1099&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1535-7163.MCT-10-1099%26sid%3Dliteratum%253Aachs%26aulast%3DBhagwat%26aufirst%3DS.%2BV.%26aulast%3DGokhale%26aufirst%3DP.%2BC.%26aulast%3DCrew%26aufirst%3DA.%2BP.%26aulast%3DCooke%26aufirst%3DA.%26aulast%3DYao%26aufirst%3DY.%26aulast%3DMantis%26aufirst%3DC.%26aulast%3DKahler%26aufirst%3DJ.%26aulast%3DWorkman%26aufirst%3DJ.%26aulast%3DBittner%26aufirst%3DM.%26aulast%3DDudkin%26aufirst%3DL.%26aulast%3DEpstein%26aufirst%3DD.%2BM.%26aulast%3DGibson%26aufirst%3DN.%2BW.%26aulast%3DWild%26aufirst%3DR.%26aulast%3DArnold%26aufirst%3DL.%2BD.%26aulast%3DHoughton%26aufirst%3DP.%2BJ.%26aulast%3DPachter%26aufirst%3DJ.%2BA.%26atitle%3DPreclinical%2520Characterization%2520of%2520OSI-027%252C%2520a%2520Potent%2520and%2520Selective%2520Inhibitor%2520of%2520mTORC1%2520and%2520mTORC2%253A%2520Distinct%2520from%2520Rapamycin%26jtitle%3DMol.%2520Cancer%2520Ther.%26date%3D2011%26volume%3D10%26spage%3D1394%26epage%3D1406" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref8"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref8'); return false;" data-citation="" class="refNumLink">8</a></strong><div class="NLM_citation" id="cit8"><span><span class="NLM_contrib-group">Liu, Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kang, S. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thoreen, C. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hur, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Choi, H. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Waller, D. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sim, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sabatini, D. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gray, N. S.</span><span> </span><span class="NLM_article-title">Discovery and optimization of potent and selective benzonaphthyridinone analogs as small molecule mTOR inhibitors with improved mouse microsome stability</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">21</span><span class="NLM_x">, </span> <span class="NLM_fpage">4036</span><span class="NLM_x">–</span> <span class="NLM_lpage">4040</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2011&pages=4036-4040&author=Q.+Liuauthor=J.+Wangauthor=S.+A.+Kangauthor=C.+C.+Thoreenauthor=W.+Hurauthor=H.+G.+Choiauthor=D.+L.+Wallerauthor=T.+Simauthor=D.+M.+Sabatiniauthor=N.+S.+Gray&title=Discovery+and+optimization+of+potent+and+selective+benzonaphthyridinone+analogs+as+small+molecule+mTOR+inhibitors+with+improved+mouse+microsome+stability"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DLiu%26aufirst%3DQ.%26aulast%3DWang%26aufirst%3DJ.%26aulast%3DKang%26aufirst%3DS.%2BA.%26aulast%3DThoreen%26aufirst%3DC.%2BC.%26aulast%3DHur%26aufirst%3DW.%26aulast%3DChoi%26aufirst%3DH.%2BG.%26aulast%3DWaller%26aufirst%3DD.%2BL.%26aulast%3DSim%26aufirst%3DT.%26aulast%3DSabatini%26aufirst%3DD.%2BM.%26aulast%3DGray%26aufirst%3DN.%2BS.%26atitle%3DDiscovery%2520and%2520optimization%2520of%2520potent%2520and%2520selective%2520benzonaphthyridinone%2520analogs%2520as%2520small%2520molecule%2520mTOR%2520inhibitors%2520with%2520improved%2520mouse%2520microsome%2520stability%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2011%26volume%3D21%26spage%3D4036%26epage%3D4040" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref9"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref9'); return false;" data-citation="" class="refNumLink">9</a></strong><div class="NLM_citation" id="cit9"><span><span class="NLM_contrib-group">Cohen, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bergeron, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Blackwood, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bowman, K. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dipasquale, A. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Epler, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Koehler, M. F. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lau, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lewis, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ly, C. Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Malek, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nonomiya, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ortwine, D. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pei, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Robarge, K. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sideris, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Trinh, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Truong, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wu, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhao, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lyssikatos, J. P.</span><span> </span><span class="NLM_article-title">Potent, selective, and orally bioavailable inhibitors of mammalian target of rapamycin (mTOR) kinase based on a quaternary substituted dihydrofuropyrimidine</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">54</span><span class="NLM_x">, </span> <span class="NLM_fpage">3426</span><span class="NLM_x">–</span> <span class="NLM_lpage">3435</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm200215y" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=54&publication_year=2011&pages=3426-3435&author=F.+Cohenauthor=P.+Bergeronauthor=E.+Blackwoodauthor=K.+K.+Bowmanauthor=H.+Chenauthor=A.+G.+Dipasqualeauthor=J.+A.+Eplerauthor=M.+F.+T.+Koehlerauthor=K.+Lauauthor=C.+Lewisauthor=L.+Liuauthor=C.+Q.+Lyauthor=S.+Malekauthor=J.+Nonomiyaauthor=D.+F.+Ortwineauthor=Z.+Peiauthor=K.+D.+Robargeauthor=S.+Siderisauthor=L.+Trinhauthor=T.+Truongauthor=J.+Wuauthor=X.+Zhaoauthor=J.+P.+Lyssikatos&title=Potent%2C+selective%2C+and+orally+bioavailable+inhibitors+of+mammalian+target+of+rapamycin+%28mTOR%29+kinase+based+on+a+quaternary+substituted+dihydrofuropyrimidine"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.1021%2Fjm200215y&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm200215y%26sid%3Dliteratum%253Aachs%26aulast%3DCohen%26aufirst%3DF.%26aulast%3DBergeron%26aufirst%3DP.%26aulast%3DBlackwood%26aufirst%3DE.%26aulast%3DBowman%26aufirst%3DK.%2BK.%26aulast%3DChen%26aufirst%3DH.%26aulast%3DDipasquale%26aufirst%3DA.%2BG.%26aulast%3DEpler%26aufirst%3DJ.%2BA.%26aulast%3DKoehler%26aufirst%3DM.%2BF.%2BT.%26aulast%3DLau%26aufirst%3DK.%26aulast%3DLewis%26aufirst%3DC.%26aulast%3DLiu%26aufirst%3DL.%26aulast%3DLy%26aufirst%3DC.%2BQ.%26aulast%3DMalek%26aufirst%3DS.%26aulast%3DNonomiya%26aufirst%3DJ.%26aulast%3DOrtwine%26aufirst%3DD.%2BF.%26aulast%3DPei%26aufirst%3DZ.%26aulast%3DRobarge%26aufirst%3DK.%2BD.%26aulast%3DSideris%26aufirst%3DS.%26aulast%3DTrinh%26aufirst%3DL.%26aulast%3DTruong%26aufirst%3DT.%26aulast%3DWu%26aufirst%3DJ.%26aulast%3DZhao%26aufirst%3DX.%26aulast%3DLyssikatos%26aufirst%3DJ.%2BP.%26atitle%3DPotent%252C%2520selective%252C%2520and%2520orally%2520bioavailable%2520inhibitors%2520of%2520mammalian%2520target%2520of%2520rapamycin%2520%2528mTOR%2529%2520kinase%2520based%2520on%2520a%2520quaternary%2520substituted%2520dihydrofuropyrimidine%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2011%26volume%3D54%26spage%3D3426%26epage%3D3435" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref10"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref10'); return false;" data-citation="" class="refNumLink">10</a></strong><div class="NLM_citation" id="cit10"><span><span class="NLM_contrib-group">Crew, A. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bhagwat, S. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dong, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bittner, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chan, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Coate, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cooke, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gokhale, P. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Honda, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jin, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kahler, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mantis, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mulvihill, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tavares-Greco, P. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Volk, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Werner, D. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Arnold, L. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pachter, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wild, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gibson, N. W.</span><span> </span><span class="NLM_article-title">Imidazo[1,5-<i>a</i>]pyrazines: Orally efficacious inhibitors of mTORC1 and mTORC2</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">21</span><span class="NLM_x">, </span> <span class="NLM_fpage">2092</span><span class="NLM_x">–</span> <span class="NLM_lpage">2097</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2011&pages=2092-2097&author=A.+P.+Crewauthor=S.+V.+Bhagwatauthor=H.+Dongauthor=M.+A.+Bittnerauthor=A.+Chanauthor=X.+Chenauthor=H.+Coateauthor=A.+Cookeauthor=P.+C.+Gokhaleauthor=A.+Hondaauthor=M.+Jinauthor=J.+Kahlerauthor=C.+Mantisauthor=M.+J.+Mulvihillauthor=P.+A.+Tavares-Grecoauthor=B.+Volkauthor=J.+Wangauthor=D.+S.+Wernerauthor=L.+D.+Arnoldauthor=J.+A.+Pachterauthor=R.+Wildauthor=N.+W.+Gibson&title=Imidazo%5B1%2C5-a%5Dpyrazines%3A+Orally+efficacious+inhibitors+of+mTORC1+and+mTORC2"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DCrew%26aufirst%3DA.%2BP.%26aulast%3DBhagwat%26aufirst%3DS.%2BV.%26aulast%3DDong%26aufirst%3DH.%26aulast%3DBittner%26aufirst%3DM.%2BA.%26aulast%3DChan%26aufirst%3DA.%26aulast%3DChen%26aufirst%3DX.%26aulast%3DCoate%26aufirst%3DH.%26aulast%3DCooke%26aufirst%3DA.%26aulast%3DGokhale%26aufirst%3DP.%2BC.%26aulast%3DHonda%26aufirst%3DA.%26aulast%3DJin%26aufirst%3DM.%26aulast%3DKahler%26aufirst%3DJ.%26aulast%3DMantis%26aufirst%3DC.%26aulast%3DMulvihill%26aufirst%3DM.%2BJ.%26aulast%3DTavares-Greco%26aufirst%3DP.%2BA.%26aulast%3DVolk%26aufirst%3DB.%26aulast%3DWang%26aufirst%3DJ.%26aulast%3DWerner%26aufirst%3DD.%2BS.%26aulast%3DArnold%26aufirst%3DL.%2BD.%26aulast%3DPachter%26aufirst%3DJ.%2BA.%26aulast%3DWild%26aufirst%3DR.%26aulast%3DGibson%26aufirst%3DN.%2BW.%26atitle%3DImidazo%255B1%252C5-a%255Dpyrazines%253A%2520Orally%2520efficacious%2520inhibitors%2520of%2520mTORC1%2520and%2520mTORC2%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2011%26volume%3D21%26spage%3D2092%26epage%3D2097" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref11"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref11'); return false;" data-citation="" class="refNumLink">11</a></strong><div class="NLM_citation" id="cit11"><span><span class="NLM_contrib-group">Peterson, E. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Andrews, P. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Be, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Boezio, A. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bush, T. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cheng, A. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Coats, J. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Colletti, A. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Copeland, K. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">DuPont, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Graceffa, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Grubinska, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Harmange, J.-C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, J. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mullady, E. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Olivieri, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schenkel, L. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stanton, M. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Teffera, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Whittington, D. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cai, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">La, D. S.</span><span> </span><span class="NLM_article-title">Discovery of triazine-benzimidazoles as selective inhibitors of mTOR</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">21</span><span class="NLM_x">, </span> <span class="NLM_fpage">2064</span><span class="NLM_x">–</span> <span class="NLM_lpage">2070</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2011&pages=2064-2070&author=E.+A.+Petersonauthor=P.+S.+Andrewsauthor=X.+Beauthor=A.+A.+Boezioauthor=T.+L.+Bushauthor=A.+C.+Chengauthor=J.+R.+Coatsauthor=A.+E.+Collettiauthor=K.+W.+Copelandauthor=M.+DuPontauthor=R.+Graceffaauthor=B.+Grubinskaauthor=J.-C.+Harmangeauthor=J.+L.+Kimauthor=E.+L.+Mulladyauthor=P.+Olivieriauthor=L.+B.+Schenkelauthor=M.+K.+Stantonauthor=Y.+Tefferaauthor=D.+A.+Whittingtonauthor=T.+Caiauthor=D.+S.+La&title=Discovery+of+triazine-benzimidazoles+as+selective+inhibitors+of+mTOR"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DPeterson%26aufirst%3DE.%2BA.%26aulast%3DAndrews%26aufirst%3DP.%2BS.%26aulast%3DBe%26aufirst%3DX.%26aulast%3DBoezio%26aufirst%3DA.%2BA.%26aulast%3DBush%26aufirst%3DT.%2BL.%26aulast%3DCheng%26aufirst%3DA.%2BC.%26aulast%3DCoats%26aufirst%3DJ.%2BR.%26aulast%3DColletti%26aufirst%3DA.%2BE.%26aulast%3DCopeland%26aufirst%3DK.%2BW.%26aulast%3DDuPont%26aufirst%3DM.%26aulast%3DGraceffa%26aufirst%3DR.%26aulast%3DGrubinska%26aufirst%3DB.%26aulast%3DHarmange%26aufirst%3DJ.-C.%26aulast%3DKim%26aufirst%3DJ.%2BL.%26aulast%3DMullady%26aufirst%3DE.%2BL.%26aulast%3DOlivieri%26aufirst%3DP.%26aulast%3DSchenkel%26aufirst%3DL.%2BB.%26aulast%3DStanton%26aufirst%3DM.%2BK.%26aulast%3DTeffera%26aufirst%3DY.%26aulast%3DWhittington%26aufirst%3DD.%2BA.%26aulast%3DCai%26aufirst%3DT.%26aulast%3DLa%26aufirst%3DD.%2BS.%26atitle%3DDiscovery%2520of%2520triazine-benzimidazoles%2520as%2520selective%2520inhibitors%2520of%2520mTOR%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2011%26volume%3D21%26spage%3D2064%26epage%3D2070" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref12"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref12'); return false;" data-citation="" class="refNumLink">12</a></strong><div class="NLM_citation" id="cit12"><span><span class="NLM_contrib-group">Liu, Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kang, S. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thoreen, C. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hur, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ahmed, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sabatini, D. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gray, N. S.</span><span> </span><span class="NLM_article-title">Discovery of 9-(6-aminopyridin-3-yl)-1-(3-(trifluoromethyl)phenyl)benzo[<i>h</i>][1,6]naphthyridin-2(1<i>H</i>)-one (Torin2) as a potent, selective, and orally available mammalian target of rapamycin (mTOR) inhibitor for treatment of cancer</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">54</span><span class="NLM_x">, </span> <span class="NLM_fpage">1473</span><span class="NLM_x">–</span> <span class="NLM_lpage">1480</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm101520v" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=54&publication_year=2011&pages=1473-1480&author=Q.+Liuauthor=J.+Wangauthor=S.+A.+Kangauthor=C.+C.+Thoreenauthor=W.+Hurauthor=T.+Ahmedauthor=D.+M.+Sabatiniauthor=N.+S.+Gray&title=Discovery+of+9-%286-aminopyridin-3-yl%29-1-%283-%28trifluoromethyl%29phenyl%29benzo%5Bh%5D%5B1%2C6%5Dnaphthyridin-2%281H%29-one+%28Torin2%29+as+a+potent%2C+selective%2C+and+orally+available+mammalian+target+of+rapamycin+%28mTOR%29+inhibitor+for+treatment+of+cancer"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.1021%2Fjm101520v&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm101520v%26sid%3Dliteratum%253Aachs%26aulast%3DLiu%26aufirst%3DQ.%26aulast%3DWang%26aufirst%3DJ.%26aulast%3DKang%26aufirst%3DS.%2BA.%26aulast%3DThoreen%26aufirst%3DC.%2BC.%26aulast%3DHur%26aufirst%3DW.%26aulast%3DAhmed%26aufirst%3DT.%26aulast%3DSabatini%26aufirst%3DD.%2BM.%26aulast%3DGray%26aufirst%3DN.%2BS.%26atitle%3DDiscovery%2520of%25209-%25286-aminopyridin-3-yl%2529-1-%25283-%2528trifluoromethyl%2529phenyl%2529benzo%255Bh%255D%255B1%252C6%255Dnaphthyridin-2%25281H%2529-one%2520%2528Torin2%2529%2520as%2520a%2520potent%252C%2520selective%252C%2520and%2520orally%2520available%2520mammalian%2520target%2520of%2520rapamycin%2520%2528mTOR%2529%2520inhibitor%2520for%2520treatment%2520of%2520cancer%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2011%26volume%3D54%26spage%3D1473%26epage%3D1480" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref13"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref13'); return false;" data-citation="" class="refNumLink">13</a></strong><div class="NLM_citation" id="cit13"><span><span class="NLM_contrib-group">Liu, Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chang, J. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kang, S. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thoreen, C. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Markhard, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hur, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sim, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sabatini, D. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gray, N. S.</span><span> </span><span class="NLM_article-title">Discovery of 1-(4-(4-propionylpiperazin-1-yl)-3-(trifluoromethyl)phenyl)-9-(quinolin-3-yl)benzo[<i>h</i>][1,6]naphthyridin-2(1<i>H</i>)-one as a highly potent, selective mammalian target of rapamycin (mTOR) inhibitor for the treatment of cancer</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">53</span><span class="NLM_x">, </span> <span class="NLM_fpage">7146</span><span class="NLM_x">–</span> <span class="NLM_lpage">7155</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm101144f" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=53&publication_year=2010&pages=7146-7155&author=Q.+Liuauthor=J.+W.+Changauthor=J.+Wangauthor=S.+A.+Kangauthor=C.+C.+Thoreenauthor=A.+Markhardauthor=W.+Hurauthor=J.+Zhangauthor=T.+Simauthor=D.+M.+Sabatiniauthor=N.+S.+Gray&title=Discovery+of+1-%284-%284-propionylpiperazin-1-yl%29-3-%28trifluoromethyl%29phenyl%29-9-%28quinolin-3-yl%29benzo%5Bh%5D%5B1%2C6%5Dnaphthyridin-2%281H%29-one+as+a+highly+potent%2C+selective+mammalian+target+of+rapamycin+%28mTOR%29+inhibitor+for+the+treatment+of+cancer"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.1021%2Fjm101144f&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm101144f%26sid%3Dliteratum%253Aachs%26aulast%3DLiu%26aufirst%3DQ.%26aulast%3DChang%26aufirst%3DJ.%2BW.%26aulast%3DWang%26aufirst%3DJ.%26aulast%3DKang%26aufirst%3DS.%2BA.%26aulast%3DThoreen%26aufirst%3DC.%2BC.%26aulast%3DMarkhard%26aufirst%3DA.%26aulast%3DHur%26aufirst%3DW.%26aulast%3DZhang%26aufirst%3DJ.%26aulast%3DSim%26aufirst%3DT.%26aulast%3DSabatini%26aufirst%3DD.%2BM.%26aulast%3DGray%26aufirst%3DN.%2BS.%26atitle%3DDiscovery%2520of%25201-%25284-%25284-propionylpiperazin-1-yl%2529-3-%2528trifluoromethyl%2529phenyl%2529-9-%2528quinolin-3-yl%2529benzo%255Bh%255D%255B1%252C6%255Dnaphthyridin-2%25281H%2529-one%2520as%2520a%2520highly%2520potent%252C%2520selective%2520mammalian%2520target%2520of%2520rapamycin%2520%2528mTOR%2529%2520inhibitor%2520for%2520the%2520treatment%2520of%2520cancer%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2010%26volume%3D53%26spage%3D7146%26epage%3D7155" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref14"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref14'); return false;" data-citation="" class="refNumLink">14</a></strong><div class="NLM_citation" id="cit14"><span><span class="NLM_contrib-group">Richard, D. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Verheijen, J. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yu, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zask, A.</span><span> </span><span class="NLM_article-title">Triazines incorporating (<i>R</i>)-3-methylmorpholine are potent inhibitors of the mammalian target of rapamycin (mTOR) with selectivity over PI3Kalpha</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">20</span><span class="NLM_x">, </span> <span class="NLM_fpage">2654</span><span class="NLM_x">–</span> <span class="NLM_lpage">2657</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2010&pages=2654-2657&author=D.+J.+Richardauthor=J.+C.+Verheijenauthor=K.+Yuauthor=A.+Zask&title=Triazines+incorporating+%28R%29-3-methylmorpholine+are+potent+inhibitors+of+the+mammalian+target+of+rapamycin+%28mTOR%29+with+selectivity+over+PI3Kalpha"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DRichard%26aufirst%3DD.%2BJ.%26aulast%3DVerheijen%26aufirst%3DJ.%2BC.%26aulast%3DYu%26aufirst%3DK.%26aulast%3DZask%26aufirst%3DA.%26atitle%3DTriazines%2520incorporating%2520%2528R%2529-3-methylmorpholine%2520are%2520potent%2520inhibitors%2520of%2520the%2520mammalian%2520target%2520of%2520rapamycin%2520%2528mTOR%2529%2520with%2520selectivity%2520over%2520PI3Kalpha%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2010%26volume%3D20%26spage%3D2654%26epage%3D2657" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref15"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref15'); return false;" data-citation="" class="refNumLink">15</a></strong><div class="NLM_citation" id="cit15"><span><span class="NLM_contrib-group">Zask, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Verheijen, J. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Richard, D. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kaplan, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Curran, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Toral-Barza, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lucas, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hollander, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yu, K.</span><span> </span><span class="NLM_article-title">Discovery of 2-ureidophenyltriazines bearing bridged morpholines as potent and selective ATP-competitive mTOR inhibitors</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">20</span><span class="NLM_x">, </span> <span class="NLM_fpage">2644</span><span class="NLM_x">–</span> <span class="NLM_lpage">2647</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=16&amp;doi=10.1021%2Fjm301389h&amp;key=10.1016%2Fj.bmcl.2010.02.045" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=8&amp;doi=10.1021%2Fjm301389h&amp;key=20227881" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=32&amp;doi=10.1021%2Fjm301389h&amp;key=1%3ACAS%3A528%3ADC%252BC3cXksVGntro%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2010&pages=2644-2647&author=A.+Zaskauthor=J.+C.+Verheijenauthor=D.+J.+Richardauthor=J.+Kaplanauthor=K.+Curranauthor=L.+Toral-Barzaauthor=J.+Lucasauthor=I.+Hollanderauthor=K.+Yu&title=Discovery+of+2-ureidophenyltriazines+bearing+bridged+morpholines+as+potent+and+selective+ATP-competitive+mTOR+inhibitors"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit15R"><div class="casContent"><span class="casTitleNuber">15</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of 2-ureidophenyltriazines bearing bridged morpholines as potent and selective ATP-competitive mTOR inhibitors</span></div><div class="casAuthors">Zask, Arie; Verheijen, Jeroen C.; Richard, David J.; Kaplan, Joshua; Curran, Kevin; Toral-Barza, Lourdes; Lucas, Judy; Hollander, Irwin; Yu, Ker</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">20</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">2644-2647</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Incorporation of bridged morpholines in monocyclic triazine PI3K/mTOR inhibitors gave compds. with increased mTOR selectivity relative to the corresponding morpholine analogs.  Compds. with ureidophenyl groups gave highly potent and selective mTOR inhibitors.  Potency and selectivity was demonstrated both in vitro and in vivo through biomarker suppression studies.  Select compds. exhibited potent inhibition of tumor growth in nude mouse xenograft assays upon PO and IV administration.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpUPE--c1OgzbVg90H21EOLACvtfcHk0lg56qJud1iLFw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXksVGntro%253D&md5=d5008526e962f9dd110bfb47306c551e</span></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2010.02.045&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2010.02.045%26sid%3Dliteratum%253Aachs%26aulast%3DZask%26aufirst%3DA.%26aulast%3DVerheijen%26aufirst%3DJ.%2BC.%26aulast%3DRichard%26aufirst%3DD.%2BJ.%26aulast%3DKaplan%26aufirst%3DJ.%26aulast%3DCurran%26aufirst%3DK.%26aulast%3DToral-Barza%26aufirst%3DL.%26aulast%3DLucas%26aufirst%3DJ.%26aulast%3DHollander%26aufirst%3DI.%26aulast%3DYu%26aufirst%3DK.%26atitle%3DDiscovery%2520of%25202-ureidophenyltriazines%2520bearing%2520bridged%2520morpholines%2520as%2520potent%2520and%2520selective%2520ATP-competitive%2520mTOR%2520inhibitors%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2010%26volume%3D20%26spage%3D2644%26epage%3D2647" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref16"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref16'); return false;" data-citation="" class="refNumLink">16</a></strong><div class="NLM_citation" id="cit16"><span><span class="NLM_contrib-group">Tsou, H.-R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">MacEwan, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Birnberg, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brooijmans, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Toral-Barza, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hollander, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ayral-Kaloustian, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yu, K.</span><span> </span><span class="NLM_article-title">4-Substituted-7-azaindoles bearing a ureidobenzofuranone moiety as potent and selective, ATP-competitive inhibitors of the mammalian target of rapamycin (mTOR)</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">20</span><span class="NLM_x">, </span> <span class="NLM_fpage">2259</span><span class="NLM_x">–</span> <span class="NLM_lpage">2263</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2010&pages=2259-2263&author=H.-R.+Tsouauthor=G.+MacEwanauthor=G.+Birnbergauthor=N.+Zhangauthor=N.+Brooijmansauthor=L.+Toral-Barzaauthor=I.+Hollanderauthor=S.+Ayral-Kaloustianauthor=K.+Yu&title=4-Substituted-7-azaindoles+bearing+a+ureidobenzofuranone+moiety+as+potent+and+selective%2C+ATP-competitive+inhibitors+of+the+mammalian+target+of+rapamycin+%28mTOR%29"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DTsou%26aufirst%3DH.-R.%26aulast%3DMacEwan%26aufirst%3DG.%26aulast%3DBirnberg%26aufirst%3DG.%26aulast%3DZhang%26aufirst%3DN.%26aulast%3DBrooijmans%26aufirst%3DN.%26aulast%3DToral-Barza%26aufirst%3DL.%26aulast%3DHollander%26aufirst%3DI.%26aulast%3DAyral-Kaloustian%26aufirst%3DS.%26aulast%3DYu%26aufirst%3DK.%26atitle%3D4-Substituted-7-azaindoles%2520bearing%2520a%2520ureidobenzofuranone%2520moiety%2520as%2520potent%2520and%2520selective%252C%2520ATP-competitive%2520inhibitors%2520of%2520the%2520mammalian%2520target%2520of%2520rapamycin%2520%2528mTOR%2529%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2010%26volume%3D20%26spage%3D2259%26epage%3D2263" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref17"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref17'); return false;" data-citation="" class="refNumLink">17</a></strong><div class="NLM_citation" id="cit17"><span><span class="NLM_contrib-group">Curran, K. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Verheijen, J. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kaplan, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Richard, D. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Toral-Barza, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hollander, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lucas, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ayral-Kaloustian, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yu, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zask, A.</span><span> </span><span class="NLM_article-title">Pyrazolopyrimidines as highly potent and selective, ATP-competitive inhibitors of the mammalian target of rapamycin (mTOR): Optimization of the 1-substituent</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">20</span><span class="NLM_x">, </span> <span class="NLM_fpage">1440</span><span class="NLM_x">–</span> <span class="NLM_lpage">1444</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2010&pages=1440-1444&author=K.+J.+Curranauthor=J.+C.+Verheijenauthor=J.+Kaplanauthor=D.+J.+Richardauthor=L.+Toral-Barzaauthor=I.+Hollanderauthor=J.+Lucasauthor=S.+Ayral-Kaloustianauthor=K.+Yuauthor=A.+Zask&title=Pyrazolopyrimidines+as+highly+potent+and+selective%2C+ATP-competitive+inhibitors+of+the+mammalian+target+of+rapamycin+%28mTOR%29%3A+Optimization+of+the+1-substituent"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DCurran%26aufirst%3DK.%2BJ.%26aulast%3DVerheijen%26aufirst%3DJ.%2BC.%26aulast%3DKaplan%26aufirst%3DJ.%26aulast%3DRichard%26aufirst%3DD.%2BJ.%26aulast%3DToral-Barza%26aufirst%3DL.%26aulast%3DHollander%26aufirst%3DI.%26aulast%3DLucas%26aufirst%3DJ.%26aulast%3DAyral-Kaloustian%26aufirst%3DS.%26aulast%3DYu%26aufirst%3DK.%26aulast%3DZask%26aufirst%3DA.%26atitle%3DPyrazolopyrimidines%2520as%2520highly%2520potent%2520and%2520selective%252C%2520ATP-competitive%2520inhibitors%2520of%2520the%2520mammalian%2520target%2520of%2520rapamycin%2520%2528mTOR%2529%253A%2520Optimization%2520of%2520the%25201-substituent%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2010%26volume%3D20%26spage%3D1440%26epage%3D1444" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref18"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref18'); return false;" data-citation="" class="refNumLink">18</a></strong><div class="NLM_citation" id="cit18"><span><span class="NLM_contrib-group">Kaplan, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Verheijen, J. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brooijmans, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Toral-Barza, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hollander, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yu, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zask, A.</span><span> </span><span class="NLM_article-title">Discovery of 3,6-dihydro-2<i>H</i>-pyran as a morpholine replacement in 6-aryl-1<i>H</i>-pyrazolo[3,4-<i>d</i>]pyrimidines and 2-arylthieno[3,2-<i>d</i>]pyrimidines: ATP-competitive inhibitors of the mammalian target of rapamycin (mTOR)</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">20</span><span class="NLM_x">, </span> <span class="NLM_fpage">640</span><span class="NLM_x">–</span> <span class="NLM_lpage">643</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=16&amp;doi=10.1021%2Fjm301389h&amp;key=10.1016%2Fj.bmcl.2009.11.050" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=8&amp;doi=10.1021%2Fjm301389h&amp;key=19963384" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=32&amp;doi=10.1021%2Fjm301389h&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhsF2itbfE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2010&pages=640-643&author=J.+Kaplanauthor=J.+C.+Verheijenauthor=N.+Brooijmansauthor=L.+Toral-Barzaauthor=I.+Hollanderauthor=K.+Yuauthor=A.+Zask&title=Discovery+of+3%2C6-dihydro-2H-pyran+as+a+morpholine+replacement+in+6-aryl-1H-pyrazolo%5B3%2C4-d%5Dpyrimidines+and+2-arylthieno%5B3%2C2-d%5Dpyrimidines%3A+ATP-competitive+inhibitors+of+the+mammalian+target+of+rapamycin+%28mTOR%29"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit18R"><div class="casContent"><span class="casTitleNuber">18</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of 3,6-dihydro-2H-pyran as a morpholine replacement in 6-aryl-1H-pyrazolo[3,4-d]pyrimidines and 2-arylthieno[3,2-d]pyrimidines: ATP-competitive inhibitors of the mammalian target of rapamycin (mTOR)</span></div><div class="casAuthors">Kaplan, Joshua; Verheijen, Jeroen C.; Brooijmans, Natasja; Toral-Barza, Lourdes; Hollander, Irwin; Yu, Ker; Zask, Arie</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">20</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">640-643</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">The morpholine hinge-region binding group on a series of pyrazolopyrimidine and thienopyrimidine mammalian target of rapamycin (mTOR) inhibitors was replaced with 3,6-dihydro-2H-pyran (DHP), giving compds. of equiv. potency and selectivity vs. PI3K.  These results establish the DHP group as a hinge-region binding motif for the prepn. of highly potent and selective mTOR inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrBTLsFT9FBubVg90H21EOLACvtfcHk0li46-xpbr-buQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhsF2itbfE&md5=9398107e05207e302a8358103f31fb2f</span></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2009.11.050&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2009.11.050%26sid%3Dliteratum%253Aachs%26aulast%3DKaplan%26aufirst%3DJ.%26aulast%3DVerheijen%26aufirst%3DJ.%2BC.%26aulast%3DBrooijmans%26aufirst%3DN.%26aulast%3DToral-Barza%26aufirst%3DL.%26aulast%3DHollander%26aufirst%3DI.%26aulast%3DYu%26aufirst%3DK.%26aulast%3DZask%26aufirst%3DA.%26atitle%3DDiscovery%2520of%25203%252C6-dihydro-2H-pyran%2520as%2520a%2520morpholine%2520replacement%2520in%25206-aryl-1H-pyrazolo%255B3%252C4-d%255Dpyrimidines%2520and%25202-arylthieno%255B3%252C2-d%255Dpyrimidines%253A%2520ATP-competitive%2520inhibitors%2520of%2520the%2520mammalian%2520target%2520of%2520rapamycin%2520%2528mTOR%2529%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2010%26volume%3D20%26spage%3D640%26epage%3D643" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref19"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref19'); return false;" data-citation="" class="refNumLink">19</a></strong><div class="NLM_citation" id="cit19"><span><span class="NLM_contrib-group">Chresta, C. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Davies, B. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hickson, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Harding, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cosulich, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Critchlow, S. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vincent, J. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ellston, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jones, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sini, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">James, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Howard, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dudley, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hughes, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smith, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Maguire, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hummersone, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Malagu, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Menear, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jenkins, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jacobsen, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smith, G. C. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Guichard, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pass, M.</span><span> </span><span class="NLM_article-title">AZD8055 is a potent, selective, and orally bioavailable ATP-competitive mammalian target of rapamycin kinase inhibitor with in vitro and in vivo antitumor activity</span> <span class="citation_source-journal">Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">70</span><span class="NLM_x">, </span> <span class="NLM_fpage">288</span><span class="NLM_x">–</span> <span class="NLM_lpage">298</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=70&publication_year=2010&pages=288-298&author=C.+M.+Chrestaauthor=B.+R.+Daviesauthor=I.+Hicksonauthor=T.+Hardingauthor=S.+Cosulichauthor=S.+E.+Critchlowauthor=J.+P.+Vincentauthor=R.+Ellstonauthor=D.+Jonesauthor=P.+Siniauthor=D.+Jamesauthor=Z.+Howardauthor=P.+Dudleyauthor=G.+Hughesauthor=L.+Smithauthor=S.+Maguireauthor=M.+Hummersoneauthor=K.+Malaguauthor=K.+Menearauthor=R.+Jenkinsauthor=M.+Jacobsenauthor=G.+C.+M.+Smithauthor=S.+Guichardauthor=M.+Pass&title=AZD8055+is+a+potent%2C+selective%2C+and+orally+bioavailable+ATP-competitive+mammalian+target+of+rapamycin+kinase+inhibitor+with+in+vitro+and+in+vivo+antitumor+activity"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DChresta%26aufirst%3DC.%2BM.%26aulast%3DDavies%26aufirst%3DB.%2BR.%26aulast%3DHickson%26aufirst%3DI.%26aulast%3DHarding%26aufirst%3DT.%26aulast%3DCosulich%26aufirst%3DS.%26aulast%3DCritchlow%26aufirst%3DS.%2BE.%26aulast%3DVincent%26aufirst%3DJ.%2BP.%26aulast%3DEllston%26aufirst%3DR.%26aulast%3DJones%26aufirst%3DD.%26aulast%3DSini%26aufirst%3DP.%26aulast%3DJames%26aufirst%3DD.%26aulast%3DHoward%26aufirst%3DZ.%26aulast%3DDudley%26aufirst%3DP.%26aulast%3DHughes%26aufirst%3DG.%26aulast%3DSmith%26aufirst%3DL.%26aulast%3DMaguire%26aufirst%3DS.%26aulast%3DHummersone%26aufirst%3DM.%26aulast%3DMalagu%26aufirst%3DK.%26aulast%3DMenear%26aufirst%3DK.%26aulast%3DJenkins%26aufirst%3DR.%26aulast%3DJacobsen%26aufirst%3DM.%26aulast%3DSmith%26aufirst%3DG.%2BC.%2BM.%26aulast%3DGuichard%26aufirst%3DS.%26aulast%3DPass%26aufirst%3DM.%26atitle%3DAZD8055%2520is%2520a%2520potent%252C%2520selective%252C%2520and%2520orally%2520bioavailable%2520ATP-competitive%2520mammalian%2520target%2520of%2520rapamycin%2520kinase%2520inhibitor%2520with%2520in%2520vitro%2520and%2520in%2520vivo%2520antitumor%2520activity%26jtitle%3DCancer%2520Res.%26date%3D2010%26volume%3D70%26spage%3D288%26epage%3D298" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref20"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref20'); return false;" data-citation="" class="refNumLink">20</a></strong><div class="NLM_citation" id="cit20"><span><span class="NLM_contrib-group">Verheijen, J. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yu, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Toral-Barza, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hollander, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zask, A.</span><span> </span><span class="NLM_article-title">Discovery of 2-arylthieno[3,2-<i>d</i>]pyrimidines containing 8-oxa-3-azabi-cyclo[3.2.1]octane in the 4-position as potent inhibitors of mTOR with selectivity over PI3K</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">20</span><span class="NLM_x">, </span> <span class="NLM_fpage">375</span><span class="NLM_x">–</span> <span class="NLM_lpage">379</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2010&pages=375-379&author=J.+C.+Verheijenauthor=K.+Yuauthor=L.+Toral-Barzaauthor=I.+Hollanderauthor=A.+Zask&title=Discovery+of+2-arylthieno%5B3%2C2-d%5Dpyrimidines+containing+8-oxa-3-azabi-cyclo%5B3.2.1%5Doctane+in+the+4-position+as+potent+inhibitors+of+mTOR+with+selectivity+over+PI3K"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DVerheijen%26aufirst%3DJ.%2BC.%26aulast%3DYu%26aufirst%3DK.%26aulast%3DToral-Barza%26aufirst%3DL.%26aulast%3DHollander%26aufirst%3DI.%26aulast%3DZask%26aufirst%3DA.%26atitle%3DDiscovery%2520of%25202-arylthieno%255B3%252C2-d%255Dpyrimidines%2520containing%25208-oxa-3-azabi-cyclo%255B3.2.1%255Doctane%2520in%2520the%25204-position%2520as%2520potent%2520inhibitors%2520of%2520mTOR%2520with%2520selectivity%2520over%2520PI3K%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2010%26volume%3D20%26spage%3D375%26epage%3D379" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref21"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref21'); return false;" data-citation="" class="refNumLink">21</a></strong><div class="NLM_citation" id="cit21"><span><span class="NLM_contrib-group">Zask, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kaplan, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Verheijen, J. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Richard, D. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Curran, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brooijmans, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bennett, E. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Toral-Barza, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hollander, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ayral-Kaloustian, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yu, K.</span><span> </span><span class="NLM_article-title">Morpholine derivatives greatly enhance the selectivity of mammalian target of rapamycin (mTOR) inhibitors</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">52</span><span class="NLM_x">, </span> <span class="NLM_fpage">7942</span><span class="NLM_x">–</span> <span class="NLM_lpage">7945</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm901415x" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=32&amp;doi=10.1021%2Fjm301389h&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhsVWrtb3J" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=52&publication_year=2009&pages=7942-7945&author=A.+Zaskauthor=J.+Kaplanauthor=J.+C.+Verheijenauthor=D.+J.+Richardauthor=K.+Curranauthor=N.+Brooijmansauthor=E.+M.+Bennettauthor=L.+Toral-Barzaauthor=I.+Hollanderauthor=S.+Ayral-Kaloustianauthor=K.+Yu&title=Morpholine+derivatives+greatly+enhance+the+selectivity+of+mammalian+target+of+rapamycin+%28mTOR%29+inhibitors"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit21R"><div class="casContent"><span class="casTitleNuber">21</span><div class="casTitle"><span class="NLM_cas:atitle">Morpholine Derivatives Greatly Enhance the Selectivity of Mammalian Target of Rapamycin (mTOR) Inhibitors</span></div><div class="casAuthors">Zask, Arie; Kaplan, Joshua; Verheijen, Jeroen C.; Richard, David J.; Curran, Kevin; Brooijmans, Natasja; Bennett, Eric M.; Toral-Barza, Lourdes; Hollander, Irwin; Ayral-Kaloustian, Semiramis; Yu, Ker</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">52</span>
        (<span class="NLM_cas:issue">24</span>),
    <span class="NLM_cas:pages">7942-7945</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Dramatic improvements in mTOR-targeting selectivity were achieved by replacing morpholine in pyrazolopyrimidine inhibitors with bridged morpholines.  Analogs I [R1 = (R)- or (S)-3-methyl-4-morpholinyl, 2-methyl-4-morpholinyl, 8-oxa-3-azabicyclo[3.2.1]octan-3-yl, etc.; R2 = Me, Et, cyclopropyl, FCH2CH2, 3-pyridyl, 4-pyridyl; R3 = F3CCH2, 1-methoxycarbonyl-4-piperidinyl, 1-ethoxycarbonyl-4-piperidinyl, 3-pyridylmethyl] with subnanomolar mTOR IC50 values and up to 26000-fold selectivity vs. PI3Kα were prepd.  Chiral morpholines gave inhibitors whose enantiomers had different selectivity and potency profiles.  Mol. modeling suggests that a single amino acid difference between PI3K and mTOR (Phe961Leu) accounts for the profound selectivity seen by creating a deeper pocket in mTOR that can accommodate bridged morpholines.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpK2HnMHqTHqbVg90H21EOLACvtfcHk0lhvNuXy5qAz3A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhsVWrtb3J&md5=5ef1eee5aa79531970049d3d26b46eb2</span></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.1021%2Fjm901415x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm901415x%26sid%3Dliteratum%253Aachs%26aulast%3DZask%26aufirst%3DA.%26aulast%3DKaplan%26aufirst%3DJ.%26aulast%3DVerheijen%26aufirst%3DJ.%2BC.%26aulast%3DRichard%26aufirst%3DD.%2BJ.%26aulast%3DCurran%26aufirst%3DK.%26aulast%3DBrooijmans%26aufirst%3DN.%26aulast%3DBennett%26aufirst%3DE.%2BM.%26aulast%3DToral-Barza%26aufirst%3DL.%26aulast%3DHollander%26aufirst%3DI.%26aulast%3DAyral-Kaloustian%26aufirst%3DS.%26aulast%3DYu%26aufirst%3DK.%26atitle%3DMorpholine%2520derivatives%2520greatly%2520enhance%2520the%2520selectivity%2520of%2520mammalian%2520target%2520of%2520rapamycin%2520%2528mTOR%2529%2520inhibitors%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2009%26volume%3D52%26spage%3D7942%26epage%3D7945" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref22"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref22'); return false;" data-citation="" class="refNumLink">22</a></strong><div class="NLM_citation" id="cit22"><span><span class="NLM_contrib-group">Nowak, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cole, D. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brooijmans, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bursavich, M. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Curran, K. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ellingboe, J. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gibbons, J. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hollander, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hu, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kaplan, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Malwitz, D. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Toral-Barza, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Verheijen, J. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zask, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, W.-G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yu, K.</span><span> </span><span class="NLM_article-title">Discovery of potent and selective inhibitors of the mammalian target of rapamycin (mTOR) kinase</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">52</span><span class="NLM_x">, </span> <span class="NLM_fpage">7081</span><span class="NLM_x">–</span> <span class="NLM_lpage">7089</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm9012642" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=52&publication_year=2009&pages=7081-7089&author=P.+Nowakauthor=D.+C.+Coleauthor=N.+Brooijmansauthor=M.+G.+Bursavichauthor=K.+J.+Curranauthor=J.+W.+Ellingboeauthor=J.+J.+Gibbonsauthor=I.+Hollanderauthor=Y.+Huauthor=J.+Kaplanauthor=D.+J.+Malwitzauthor=L.+Toral-Barzaauthor=J.+C.+Verheijenauthor=A.+Zaskauthor=W.-G.+Zhangauthor=K.+Yu&title=Discovery+of+potent+and+selective+inhibitors+of+the+mammalian+target+of+rapamycin+%28mTOR%29+kinase"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=10.1021%2Fjm9012642&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm9012642%26sid%3Dliteratum%253Aachs%26aulast%3DNowak%26aufirst%3DP.%26aulast%3DCole%26aufirst%3DD.%2BC.%26aulast%3DBrooijmans%26aufirst%3DN.%26aulast%3DBursavich%26aufirst%3DM.%2BG.%26aulast%3DCurran%26aufirst%3DK.%2BJ.%26aulast%3DEllingboe%26aufirst%3DJ.%2BW.%26aulast%3DGibbons%26aufirst%3DJ.%2BJ.%26aulast%3DHollander%26aufirst%3DI.%26aulast%3DHu%26aufirst%3DY.%26aulast%3DKaplan%26aufirst%3DJ.%26aulast%3DMalwitz%26aufirst%3DD.%2BJ.%26aulast%3DToral-Barza%26aufirst%3DL.%26aulast%3DVerheijen%26aufirst%3DJ.%2BC.%26aulast%3DZask%26aufirst%3DA.%26aulast%3DZhang%26aufirst%3DW.-G.%26aulast%3DYu%26aufirst%3DK.%26atitle%3DDiscovery%2520of%2520potent%2520and%2520selective%2520inhibitors%2520of%2520the%2520mammalian%2520target%2520of%2520rapamycin%2520%2528mTOR%2529%2520kinase%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2009%26volume%3D52%26spage%3D7081%26epage%3D7089" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref23"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref23'); return false;" data-citation="" class="refNumLink">23</a></strong><div class="NLM_citation" id="cit23"><span><span class="NLM_contrib-group">Malagu, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Duggan, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Menear, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hummersone, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gomez, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bailey, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Edwards, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Drzewiecki, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Leroux, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Quesada, M. J.</span><span> </span><span class="NLM_article-title">The discovery and optimization of pyrido[2,3-<i>d</i>]pyrimidine-2,4-diamines as potent and selective inhibitors of mTOR kinase</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">19</span><span class="NLM_x">, </span> <span class="NLM_fpage">5950</span><span class="NLM_x">–</span> <span class="NLM_lpage">5953</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2009&pages=5950-5953&author=K.+Malaguauthor=H.+Dugganauthor=K.+Menearauthor=M.+Hummersoneauthor=S.+Gomezauthor=C.+Baileyauthor=P.+Edwardsauthor=J.+Drzewieckiauthor=F.+Lerouxauthor=M.+J.+Quesada&title=The+discovery+and+optimization+of+pyrido%5B2%2C3-d%5Dpyrimidine-2%2C4-diamines+as+potent+and+selective+inhibitors+of+mTOR+kinase"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DMalagu%26aufirst%3DK.%26aulast%3DDuggan%26aufirst%3DH.%26aulast%3DMenear%26aufirst%3DK.%26aulast%3DHummersone%26aufirst%3DM.%26aulast%3DGomez%26aufirst%3DS.%26aulast%3DBailey%26aufirst%3DC.%26aulast%3DEdwards%26aufirst%3DP.%26aulast%3DDrzewiecki%26aufirst%3DJ.%26aulast%3DLeroux%26aufirst%3DF.%26aulast%3DQuesada%26aufirst%3DM.%2BJ.%26atitle%3DThe%2520discovery%2520and%2520optimization%2520of%2520pyrido%255B2%252C3-d%255Dpyrimidine-2%252C4-diamines%2520as%2520potent%2520and%2520selective%2520inhibitors%2520of%2520mTOR%2520kinase%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2009%26volume%3D19%26spage%3D5950%26epage%3D5953" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref24"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref24'); return false;" data-citation="" class="refNumLink">24</a></strong><div class="NLM_citation" id="cit24"><span><span class="NLM_contrib-group">Menear, K. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gomez, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Malagu, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bailey, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Blackburn, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cockcroft, X.-L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ewen, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fundo, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gall, A. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hermann, G.</span><span> </span><span class="NLM_article-title">Identification and optimization of novel and selective small molecular weight kinase inhibitors of mTOR</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">19</span><span class="NLM_x">, </span> <span class="NLM_fpage">5898</span><span class="NLM_x">–</span> <span class="NLM_lpage">5901</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2009&pages=5898-5901&author=K.+A.+Menearauthor=S.+Gomezauthor=K.+Malaguauthor=C.+Baileyauthor=K.+Blackburnauthor=X.-L.+Cockcroftauthor=S.+Ewenauthor=A.+Fundoauthor=A.+L.+Gallauthor=G.+Hermann&title=Identification+and+optimization+of+novel+and+selective+small+molecular+weight+kinase+inhibitors+of+mTOR"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DMenear%26aufirst%3DK.%2BA.%26aulast%3DGomez%26aufirst%3DS.%26aulast%3DMalagu%26aufirst%3DK.%26aulast%3DBailey%26aufirst%3DC.%26aulast%3DBlackburn%26aufirst%3DK.%26aulast%3DCockcroft%26aufirst%3DX.-L.%26aulast%3DEwen%26aufirst%3DS.%26aulast%3DFundo%26aufirst%3DA.%26aulast%3DGall%26aufirst%3DA.%2BL.%26aulast%3DHermann%26aufirst%3DG.%26atitle%3DIdentification%2520and%2520optimization%2520of%2520novel%2520and%2520selective%2520small%2520molecular%2520weight%2520kinase%2520inhibitors%2520of%2520mTOR%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2009%26volume%3D19%26spage%3D5898%26epage%3D5901" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref25"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref25'); return false;" data-citation="" class="refNumLink">25</a></strong><div class="NLM_citation" id="cit25"><span><span class="NLM_contrib-group">Zask, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Verheijen, J. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Curran, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kaplan, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Richard, D. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nowak, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Malwitz, D. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brooijmans, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bard, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Svenson, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lucas, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Toral-Barza, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, W.-G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hollander, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gibbons, J. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Abraham, R. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ayral-Kaloustian, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mansour, T. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yu, K.</span><span> </span><span class="NLM_article-title">ATP-competitive inhibitors of the mammalian target of rapamycin: Design and synthesis of highly potent and selective pyrazolopyrimidines</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">52</span><span class="NLM_x">, </span> <span class="NLM_fpage">5013</span><span class="NLM_x">–</span> <span class="NLM_lpage">5016</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm900851f" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=52&publication_year=2009&pages=5013-5016&author=A.+Zaskauthor=J.+C.+Verheijenauthor=K.+Curranauthor=J.+Kaplanauthor=D.+J.+Richardauthor=P.+Nowakauthor=D.+J.+Malwitzauthor=N.+Brooijmansauthor=J.+Bardauthor=K.+Svensonauthor=J.+Lucasauthor=L.+Toral-Barzaauthor=W.-G.+Zhangauthor=I.+Hollanderauthor=J.+J.+Gibbonsauthor=R.+T.+Abrahamauthor=S.+Ayral-Kaloustianauthor=T.+S.+Mansourauthor=K.+Yu&title=ATP-competitive+inhibitors+of+the+mammalian+target+of+rapamycin%3A+Design+and+synthesis+of+highly+potent+and+selective+pyrazolopyrimidines"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=10.1021%2Fjm900851f&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm900851f%26sid%3Dliteratum%253Aachs%26aulast%3DZask%26aufirst%3DA.%26aulast%3DVerheijen%26aufirst%3DJ.%2BC.%26aulast%3DCurran%26aufirst%3DK.%26aulast%3DKaplan%26aufirst%3DJ.%26aulast%3DRichard%26aufirst%3DD.%2BJ.%26aulast%3DNowak%26aufirst%3DP.%26aulast%3DMalwitz%26aufirst%3DD.%2BJ.%26aulast%3DBrooijmans%26aufirst%3DN.%26aulast%3DBard%26aufirst%3DJ.%26aulast%3DSvenson%26aufirst%3DK.%26aulast%3DLucas%26aufirst%3DJ.%26aulast%3DToral-Barza%26aufirst%3DL.%26aulast%3DZhang%26aufirst%3DW.-G.%26aulast%3DHollander%26aufirst%3DI.%26aulast%3DGibbons%26aufirst%3DJ.%2BJ.%26aulast%3DAbraham%26aufirst%3DR.%2BT.%26aulast%3DAyral-Kaloustian%26aufirst%3DS.%26aulast%3DMansour%26aufirst%3DT.%2BS.%26aulast%3DYu%26aufirst%3DK.%26atitle%3DATP-competitive%2520inhibitors%2520of%2520the%2520mammalian%2520target%2520of%2520rapamycin%253A%2520Design%2520and%2520synthesis%2520of%2520highly%2520potent%2520and%2520selective%2520pyrazolopyrimidines%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2009%26volume%3D52%26spage%3D5013%26epage%3D5016" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref26"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref26'); return false;" data-citation="" class="refNumLink">26</a></strong><div class="NLM_citation" id="cit26"><span><span class="NLM_contrib-group">Yu, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Toral-Barza, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shi, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, W.-G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lucas, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shor, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Verheijen, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Curran, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Malwitz, D. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cole, D. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ellingboe, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ayral-Kaloustian, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mansour, T. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gibbons, J. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Abraham, R. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nowak, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zask, A.</span><span> </span><span class="NLM_article-title">Biochemical, cellular, and in vivo activity of novel ATP-competitive and selective inhibitors of the mammalian target of rapamycin</span> <span class="citation_source-journal">Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">69</span><span class="NLM_x">, </span> <span class="NLM_fpage">6232</span><span class="NLM_x">–</span> <span class="NLM_lpage">6240</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=69&publication_year=2009&pages=6232-6240&author=K.+Yuauthor=L.+Toral-Barzaauthor=C.+Shiauthor=W.-G.+Zhangauthor=J.+Lucasauthor=B.+Shorauthor=J.+Kimauthor=J.+Verheijenauthor=K.+Curranauthor=D.+J.+Malwitzauthor=D.+C.+Coleauthor=J.+Ellingboeauthor=S.+Ayral-Kaloustianauthor=T.+S.+Mansourauthor=J.+J.+Gibbonsauthor=R.+T.+Abrahamauthor=P.+Nowakauthor=A.+Zask&title=Biochemical%2C+cellular%2C+and+in+vivo+activity+of+novel+ATP-competitive+and+selective+inhibitors+of+the+mammalian+target+of+rapamycin"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DYu%26aufirst%3DK.%26aulast%3DToral-Barza%26aufirst%3DL.%26aulast%3DShi%26aufirst%3DC.%26aulast%3DZhang%26aufirst%3DW.-G.%26aulast%3DLucas%26aufirst%3DJ.%26aulast%3DShor%26aufirst%3DB.%26aulast%3DKim%26aufirst%3DJ.%26aulast%3DVerheijen%26aufirst%3DJ.%26aulast%3DCurran%26aufirst%3DK.%26aulast%3DMalwitz%26aufirst%3DD.%2BJ.%26aulast%3DCole%26aufirst%3DD.%2BC.%26aulast%3DEllingboe%26aufirst%3DJ.%26aulast%3DAyral-Kaloustian%26aufirst%3DS.%26aulast%3DMansour%26aufirst%3DT.%2BS.%26aulast%3DGibbons%26aufirst%3DJ.%2BJ.%26aulast%3DAbraham%26aufirst%3DR.%2BT.%26aulast%3DNowak%26aufirst%3DP.%26aulast%3DZask%26aufirst%3DA.%26atitle%3DBiochemical%252C%2520cellular%252C%2520and%2520in%2520vivo%2520activity%2520of%2520novel%2520ATP-competitive%2520and%2520selective%2520inhibitors%2520of%2520the%2520mammalian%2520target%2520of%2520rapamycin%26jtitle%3DCancer%2520Res.%26date%3D2009%26volume%3D69%26spage%3D6232%26epage%3D6240" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref27"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref27'); return false;" data-citation="" class="refNumLink">27</a></strong><div class="NLM_citation" id="cit27"><span><span class="NLM_contrib-group">García Martínez, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Moran, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Clarke, R. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gray, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cosulich, S. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chresta, C. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Alessi, D. R.</span><span> </span><span class="NLM_article-title">Ku-0063794 is a specific inhibitor of the mammalian target of rapamycin (mTOR)</span> <span class="citation_source-journal">Biochem. J.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">421</span><span class="NLM_x">, </span> <span class="NLM_fpage">29</span><span class="NLM_x">–</span> <span class="NLM_lpage">42</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=421&publication_year=2009&pages=29-42&author=J.+M.+Garc%C3%ADa+Mart%C3%ADnezauthor=J.+Moranauthor=R.+G.+Clarkeauthor=A.+Grayauthor=S.+C.+Cosulichauthor=C.+M.+Chrestaauthor=D.+R.+Alessi&title=Ku-0063794+is+a+specific+inhibitor+of+the+mammalian+target+of+rapamycin+%28mTOR%29"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DGarc%25C3%25ADa%2BMart%25C3%25ADnez%26aufirst%3DJ.%2BM.%26aulast%3DMoran%26aufirst%3DJ.%26aulast%3DClarke%26aufirst%3DR.%2BG.%26aulast%3DGray%26aufirst%3DA.%26aulast%3DCosulich%26aufirst%3DS.%2BC.%26aulast%3DChresta%26aufirst%3DC.%2BM.%26aulast%3DAlessi%26aufirst%3DD.%2BR.%26atitle%3DKu-0063794%2520is%2520a%2520specific%2520inhibitor%2520of%2520the%2520mammalian%2520target%2520of%2520rapamycin%2520%2528mTOR%2529%26jtitle%3DBiochem.%2520J.%26date%3D2009%26volume%3D421%26spage%3D29%26epage%3D42" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref28"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref28'); return false;" data-citation="" class="refNumLink">28</a></strong><div class="NLM_citation" id="cit28"><span><span class="NLM_contrib-group">Feldman, M. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Apsel, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Uotila, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Loewith, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Knight, Z. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ruggero, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shokat, K. M.</span><span> </span><span class="NLM_article-title">Active-site inhibitors of mTOR target rapamycin-resistant outputs of mTORC1 and mTORC2</span> <span class="citation_source-journal">Plos Biol</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">7</span><span class="NLM_x">, </span> <span class="NLM_fpage">e38</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2009&pages=e38&author=M.+E.+Feldmanauthor=B.+Apselauthor=A.+Uotilaauthor=R.+Loewithauthor=Z.+A.+Knightauthor=D.+Ruggeroauthor=K.+M.+Shokat&title=Active-site+inhibitors+of+mTOR+target+rapamycin-resistant+outputs+of+mTORC1+and+mTORC2"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DFeldman%26aufirst%3DM.%2BE.%26aulast%3DApsel%26aufirst%3DB.%26aulast%3DUotila%26aufirst%3DA.%26aulast%3DLoewith%26aufirst%3DR.%26aulast%3DKnight%26aufirst%3DZ.%2BA.%26aulast%3DRuggero%26aufirst%3DD.%26aulast%3DShokat%26aufirst%3DK.%2BM.%26atitle%3DActive-site%2520inhibitors%2520of%2520mTOR%2520target%2520rapamycin-resistant%2520outputs%2520of%2520mTORC1%2520and%2520mTORC2%26jtitle%3DPlos%2520Biol%26date%3D2009%26volume%3D7%26spage%3De38" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref29"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref29'); return false;" data-citation="" class="refNumLink">29</a></strong><div class="NLM_citation" id="cit29"><span><span class="NLM_contrib-group">Folkes, A. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ahmadi, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Alderton, W. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Alix, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Baker, S. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Box, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chuckowree, I. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Clarke, P. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Depledge, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Eccles, S. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Friedman, L. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hayes, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hancox, T. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kugendradas, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lensun, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Moore, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Olivero, A. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pang, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Patel, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pergl-Wilson, G. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Raynaud, F. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Robson, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Saghir, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Salphati, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sohal, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ultsch, M. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Valenti, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wallweber, H. J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wan, N. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wiesmann, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Workman, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhyvoloup, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zvelebil, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shuttleworth, S. J.</span><span> </span><span class="NLM_article-title">The identification of 2-(1<i>H</i>-indazol-4-yl)-6-(4-methanesulfonyl-piperazin-1-ylmethyl)-4-morpholin-4-yl-thieno[3,2-<i>d</i>]pyrimidine (GDC-0941) as a potent, selective, orally bioavailable inhibitor of class I PI3 kinase for the treatment of cancer</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">51</span><span class="NLM_x">, </span> <span class="NLM_fpage">5522</span><span class="NLM_x">–</span> <span class="NLM_lpage">5532</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm800295d" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=32&amp;doi=10.1021%2Fjm301389h&amp;key=1%3ACAS%3A528%3ADC%252BD1cXhtVCmsr7E" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=51&publication_year=2008&pages=5522-5532&author=A.+J.+Folkesauthor=K.+Ahmadiauthor=W.+K.+Aldertonauthor=S.+Alixauthor=S.+J.+Bakerauthor=G.+Boxauthor=I.+S.+Chuckowreeauthor=P.+A.+Clarkeauthor=P.+Depledgeauthor=S.+A.+Ecclesauthor=L.+S.+Friedmanauthor=A.+Hayesauthor=T.+C.+Hancoxauthor=A.+Kugendradasauthor=L.+Lensunauthor=P.+Mooreauthor=A.+G.+Oliveroauthor=J.+Pangauthor=S.+Patelauthor=G.+H.+Pergl-Wilsonauthor=F.+I.+Raynaudauthor=A.+Robsonauthor=N.+Saghirauthor=L.+Salphatiauthor=S.+Sohalauthor=M.+H.+Ultschauthor=M.+Valentiauthor=H.+J.+A.+Wallweberauthor=N.+C.+Wanauthor=C.+Wiesmannauthor=P.+Workmanauthor=A.+Zhyvoloupauthor=M.+J.+Zvelebilauthor=S.+J.+Shuttleworth&title=The+identification+of+2-%281H-indazol-4-yl%29-6-%284-methanesulfonyl-piperazin-1-ylmethyl%29-4-morpholin-4-yl-thieno%5B3%2C2-d%5Dpyrimidine+%28GDC-0941%29+as+a+potent%2C+selective%2C+orally+bioavailable+inhibitor+of+class+I+PI3+kinase+for+the+treatment+of+cancer"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit29R"><div class="casContent"><span class="casTitleNuber">29</span><div class="casTitle"><span class="NLM_cas:atitle">The identification of 2-(1H-indazol-4-yl)-6-(4-methanesulfonyl-piperazin-1-ylmethyl)-4-morpholin-4-yl-thieno[3,2-d]pyrimidine (GDC-0941) as a potent, selective, orally bioavailable inhibitor of class I PI3 kinase for the treatment of cancer</span></div><div class="casAuthors">Folkes, Adrian J.; Ahmadi, Khatereh; Alderton, Wendy K.; Alix, Sonia; Baker, Stewart J.; Box, Gary; Chuckowree, Irina S.; Clarke, Paul A.; Depledge, Paul; Eccles, Suzanne A.; Friedman, Lori S.; Hayes, Angela; Hancox, Timothy C.; Kugendradas, Arumugam; Lensun, Letitia; Moore, Pauline; Olivero, Alan G.; Pang, Jodie; Patel, Sonal; Pergl-Wilson, Giles H.; Raynaud, Florence I.; Robson, Anthony; Saghir, Nahid; Salphati, Laurent; Sohal, Sukhjit; Ultsch, Mark H.; Valenti, Melanie; Wallweber, Heidi J. A.; Wan, Nan Chi; Wiesmann, Christian; Workman, Paul; Zhyvoloup, Alexander; Zvelebil, Marketa J.; Shuttleworth, Stephen J.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">51</span>
        (<span class="NLM_cas:issue">18</span>),
    <span class="NLM_cas:pages">5522-5532</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Phosphatidylinositol-3-kinase (PI3K) is an important target in cancer due to the deregulation of the PI3K/Akt signaling pathway in a wide variety of tumors.  A series of thieno[3,2-d]pyrimidine derivs. were prepd. and evaluated as inhibitors of PI3 kinase p110α.  The synthesis, biol. activity, and further profiling of these compds. are described.  This work resulted in the discovery of GDC-0941 (I) which is a potent, selective, orally bioavailable inhibitor of PI3K and is currently being evaluated in human clin. trials for the treatment of cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGojkFv29FXqO7Vg90H21EOLACvtfcHk0liuol8PPgaKZQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXhtVCmsr7E&md5=742084954685353ceaf18660ab3a0703</span></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=10.1021%2Fjm800295d&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm800295d%26sid%3Dliteratum%253Aachs%26aulast%3DFolkes%26aufirst%3DA.%2BJ.%26aulast%3DAhmadi%26aufirst%3DK.%26aulast%3DAlderton%26aufirst%3DW.%2BK.%26aulast%3DAlix%26aufirst%3DS.%26aulast%3DBaker%26aufirst%3DS.%2BJ.%26aulast%3DBox%26aufirst%3DG.%26aulast%3DChuckowree%26aufirst%3DI.%2BS.%26aulast%3DClarke%26aufirst%3DP.%2BA.%26aulast%3DDepledge%26aufirst%3DP.%26aulast%3DEccles%26aufirst%3DS.%2BA.%26aulast%3DFriedman%26aufirst%3DL.%2BS.%26aulast%3DHayes%26aufirst%3DA.%26aulast%3DHancox%26aufirst%3DT.%2BC.%26aulast%3DKugendradas%26aufirst%3DA.%26aulast%3DLensun%26aufirst%3DL.%26aulast%3DMoore%26aufirst%3DP.%26aulast%3DOlivero%26aufirst%3DA.%2BG.%26aulast%3DPang%26aufirst%3DJ.%26aulast%3DPatel%26aufirst%3DS.%26aulast%3DPergl-Wilson%26aufirst%3DG.%2BH.%26aulast%3DRaynaud%26aufirst%3DF.%2BI.%26aulast%3DRobson%26aufirst%3DA.%26aulast%3DSaghir%26aufirst%3DN.%26aulast%3DSalphati%26aufirst%3DL.%26aulast%3DSohal%26aufirst%3DS.%26aulast%3DUltsch%26aufirst%3DM.%2BH.%26aulast%3DValenti%26aufirst%3DM.%26aulast%3DWallweber%26aufirst%3DH.%2BJ.%2BA.%26aulast%3DWan%26aufirst%3DN.%2BC.%26aulast%3DWiesmann%26aufirst%3DC.%26aulast%3DWorkman%26aufirst%3DP.%26aulast%3DZhyvoloup%26aufirst%3DA.%26aulast%3DZvelebil%26aufirst%3DM.%2BJ.%26aulast%3DShuttleworth%26aufirst%3DS.%2BJ.%26atitle%3DThe%2520identification%2520of%25202-%25281H-indazol-4-yl%2529-6-%25284-methanesulfonyl-piperazin-1-ylmethyl%2529-4-morpholin-4-yl-thieno%255B3%252C2-d%255Dpyrimidine%2520%2528GDC-0941%2529%2520as%2520a%2520potent%252C%2520selective%252C%2520orally%2520bioavailable%2520inhibitor%2520of%2520class%2520I%2520PI3%2520kinase%2520for%2520the%2520treatment%2520of%2520cancer%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2008%26volume%3D51%26spage%3D5522%26epage%3D5532" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref30"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref30'); return false;" data-citation="" class="refNumLink">30</a></strong><div class="NLM_citation" id="cit30"><span><span class="NLM_contrib-group">Sutherlin, D. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bao, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Berry, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Castanedo, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chuckowree, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dotson, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Folks, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Friedman, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Goldsmith, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gunzner, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Heffron, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lesnick, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lewis, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mathieu, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Murray, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nonomiya, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pang, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pegg, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Prior, W. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rouge, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Salphati, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sampath, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tian, Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tsui, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wan, N. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wei, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wiesmann, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wu, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhu, B.-Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Olivero, A.</span><span> </span><span class="NLM_article-title">Discovery of a potent, selective, and orally available class I phosphatidylinositol 3-kinase (PI3K)/mammalian target of rapamycin (mTOR) kinase inhibitor (GDC-0980) for the treatment of cancer</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">54</span><span class="NLM_x">, </span> <span class="NLM_fpage">7579</span><span class="NLM_x">–</span> <span class="NLM_lpage">7587</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm2009327" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=32&amp;doi=10.1021%2Fjm301389h&amp;key=1%3ACAS%3A528%3ADC%252BC3MXht1Ort7%252FJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=54&publication_year=2011&pages=7579-7587&author=D.+P.+Sutherlinauthor=L.+Baoauthor=M.+Berryauthor=G.+Castanedoauthor=I.+Chuckowreeauthor=J.+Dotsonauthor=A.+Folksauthor=L.+Friedmanauthor=R.+Goldsmithauthor=J.+Gunznerauthor=T.+Heffronauthor=J.+Lesnickauthor=C.+Lewisauthor=S.+Mathieuauthor=J.+Murrayauthor=J.+Nonomiyaauthor=J.+Pangauthor=N.+Peggauthor=W.+W.+Priorauthor=L.+Rougeauthor=L.+Salphatiauthor=D.+Sampathauthor=Q.+Tianauthor=V.+Tsuiauthor=N.+C.+Wanauthor=S.+Wangauthor=B.+Weiauthor=C.+Wiesmannauthor=P.+Wuauthor=B.-Y.+Zhuauthor=A.+Olivero&title=Discovery+of+a+potent%2C+selective%2C+and+orally+available+class+I+phosphatidylinositol+3-kinase+%28PI3K%29%2Fmammalian+target+of+rapamycin+%28mTOR%29+kinase+inhibitor+%28GDC-0980%29+for+the+treatment+of+cancer"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit30R"><div class="casContent"><span class="casTitleNuber">30</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of a Potent, Selective, and Orally Available Class I Phosphatidylinositol 3-Kinase (PI3K)/Mammalian Target of Rapamycin (mTOR) Kinase Inhibitor (GDC-0980) for the Treatment of Cancer</span></div><div class="casAuthors">Sutherlin, Daniel P.; Bao, Linda; Berry, Megan; Castanedo, Georgette; Chuckowree, Irina; Dotson, Jenna; Folks, Adrian; Friedman, Lori; Goldsmith, Richard; Gunzner, Janet; Heffron, Timothy; Lesnick, John; Lewis, Cristina; Mathieu, Simon; Murray, Jeremy; Nonomiya, Jim; Pang, Jodie; Pegg, Niel; Prior, Wei Wei; Rouge, Lionel; Salphati, Laurent; Sampath, Deepak; Tian, Qingping; Tsui, Vickie; Wan, Nan Chi; Wang, Shumei; Wei, Bin Qing; Wiesmann, Christian; Wu, Ping; Zhu, Bing-Yan; Olivero, Alan</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">54</span>
        (<span class="NLM_cas:issue">21</span>),
    <span class="NLM_cas:pages">7579-7587</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The discovery of 2 (GDC-0980, I), a class I PI3K and mTOR kinase inhibitor for oncol. indications, is described. mTOR inhibition was added to the class I PI3K inhibitor 1 (GDC-0941) scaffold primarily through the substitution of the indazole in 1 for a 2-aminopyrimidine.  This substitution also increased the microsomal stability and the free fraction of compds. as evidenced through a pairwise comparison of mols. that were otherwise identical.  Highlighted in detail are analogs of an advanced compd. 4 that were designed to improve soly., resulting in 2.  This compd., is potent across PI3K class I isoforms with IC50s of 5, 27, 7, and 14 nM for PI3Kα, β, δ, and γ, resp., inhibits mTOR with a Ki of 17 nM yet is highly selective vs. a large panel of kinases including others in the PIKK family.  On the basis of the cell potency, low clearance in mouse, and high free fraction, 2 demonstrated significant efficacy in mouse xenografts when dosed as low as 1 mg/kg orally and is currently in phase I clin. trials for cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp-3-5KDI509bVg90H21EOLACvtfcHk0lgj0X4TTv_KwQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXht1Ort7%252FJ&md5=ba7ede710885b51fffa63977fc64d3f5</span></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=10.1021%2Fjm2009327&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm2009327%26sid%3Dliteratum%253Aachs%26aulast%3DSutherlin%26aufirst%3DD.%2BP.%26aulast%3DBao%26aufirst%3DL.%26aulast%3DBerry%26aufirst%3DM.%26aulast%3DCastanedo%26aufirst%3DG.%26aulast%3DChuckowree%26aufirst%3DI.%26aulast%3DDotson%26aufirst%3DJ.%26aulast%3DFolks%26aufirst%3DA.%26aulast%3DFriedman%26aufirst%3DL.%26aulast%3DGoldsmith%26aufirst%3DR.%26aulast%3DGunzner%26aufirst%3DJ.%26aulast%3DHeffron%26aufirst%3DT.%26aulast%3DLesnick%26aufirst%3DJ.%26aulast%3DLewis%26aufirst%3DC.%26aulast%3DMathieu%26aufirst%3DS.%26aulast%3DMurray%26aufirst%3DJ.%26aulast%3DNonomiya%26aufirst%3DJ.%26aulast%3DPang%26aufirst%3DJ.%26aulast%3DPegg%26aufirst%3DN.%26aulast%3DPrior%26aufirst%3DW.%2BW.%26aulast%3DRouge%26aufirst%3DL.%26aulast%3DSalphati%26aufirst%3DL.%26aulast%3DSampath%26aufirst%3DD.%26aulast%3DTian%26aufirst%3DQ.%26aulast%3DTsui%26aufirst%3DV.%26aulast%3DWan%26aufirst%3DN.%2BC.%26aulast%3DWang%26aufirst%3DS.%26aulast%3DWei%26aufirst%3DB.%26aulast%3DWiesmann%26aufirst%3DC.%26aulast%3DWu%26aufirst%3DP.%26aulast%3DZhu%26aufirst%3DB.-Y.%26aulast%3DOlivero%26aufirst%3DA.%26atitle%3DDiscovery%2520of%2520a%2520potent%252C%2520selective%252C%2520and%2520orally%2520available%2520class%2520I%2520phosphatidylinositol%25203-kinase%2520%2528PI3K%2529%252Fmammalian%2520target%2520of%2520rapamycin%2520%2528mTOR%2529%2520kinase%2520inhibitor%2520%2528GDC-0980%2529%2520for%2520the%2520treatment%2520of%2520cancer%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2011%26volume%3D54%26spage%3D7579%26epage%3D7587" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref31"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref31'); return false;" data-citation="" class="refNumLink">31</a></strong><div class="NLM_citation" id="cit31"><span><span class="NLM_contrib-group">Sutherlin, D. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sampath, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Berry, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Castanedo, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chang, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chuckowree, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dotson, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Folkes, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Friedman, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Goldsmith, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Heffron, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lesnick, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lewis, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mathieu, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nonomiya, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Olivero, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pang, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Prior, W. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Salphati, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sideris, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tian, Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tsui, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wan, N. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wiesmann, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wong, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhu, B.-Y.</span><span> </span><span class="NLM_article-title">Discovery of (thienopyrimidin-2-yl)aminopyrimidines as potent, selective, and orally available pan-PI3-kinase and dual pan-PI3-kinase/mTOR inhibitors for the treatment of cancer</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">53</span><span class="NLM_x">, </span> <span class="NLM_fpage">1086</span><span class="NLM_x">–</span> <span class="NLM_lpage">1097</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm901284w" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=53&publication_year=2010&pages=1086-1097&author=D.+P.+Sutherlinauthor=D.+Sampathauthor=M.+Berryauthor=G.+Castanedoauthor=Z.+Changauthor=I.+Chuckowreeauthor=J.+Dotsonauthor=A.+Folkesauthor=L.+Friedmanauthor=R.+Goldsmithauthor=T.+Heffronauthor=L.+Leeauthor=J.+Lesnickauthor=C.+Lewisauthor=S.+Mathieuauthor=J.+Nonomiyaauthor=A.+Oliveroauthor=J.+Pangauthor=W.+W.+Priorauthor=L.+Salphatiauthor=S.+Siderisauthor=Q.+Tianauthor=V.+Tsuiauthor=N.+C.+Wanauthor=S.+Wangauthor=C.+Wiesmannauthor=S.+Wongauthor=B.-Y.+Zhu&title=Discovery+of+%28thienopyrimidin-2-yl%29aminopyrimidines+as+potent%2C+selective%2C+and+orally+available+pan-PI3-kinase+and+dual+pan-PI3-kinase%2FmTOR+inhibitors+for+the+treatment+of+cancer"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=10.1021%2Fjm901284w&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm901284w%26sid%3Dliteratum%253Aachs%26aulast%3DSutherlin%26aufirst%3DD.%2BP.%26aulast%3DSampath%26aufirst%3DD.%26aulast%3DBerry%26aufirst%3DM.%26aulast%3DCastanedo%26aufirst%3DG.%26aulast%3DChang%26aufirst%3DZ.%26aulast%3DChuckowree%26aufirst%3DI.%26aulast%3DDotson%26aufirst%3DJ.%26aulast%3DFolkes%26aufirst%3DA.%26aulast%3DFriedman%26aufirst%3DL.%26aulast%3DGoldsmith%26aufirst%3DR.%26aulast%3DHeffron%26aufirst%3DT.%26aulast%3DLee%26aufirst%3DL.%26aulast%3DLesnick%26aufirst%3DJ.%26aulast%3DLewis%26aufirst%3DC.%26aulast%3DMathieu%26aufirst%3DS.%26aulast%3DNonomiya%26aufirst%3DJ.%26aulast%3DOlivero%26aufirst%3DA.%26aulast%3DPang%26aufirst%3DJ.%26aulast%3DPrior%26aufirst%3DW.%2BW.%26aulast%3DSalphati%26aufirst%3DL.%26aulast%3DSideris%26aufirst%3DS.%26aulast%3DTian%26aufirst%3DQ.%26aulast%3DTsui%26aufirst%3DV.%26aulast%3DWan%26aufirst%3DN.%2BC.%26aulast%3DWang%26aufirst%3DS.%26aulast%3DWiesmann%26aufirst%3DC.%26aulast%3DWong%26aufirst%3DS.%26aulast%3DZhu%26aufirst%3DB.-Y.%26atitle%3DDiscovery%2520of%2520%2528thienopyrimidin-2-yl%2529aminopyrimidines%2520as%2520potent%252C%2520selective%252C%2520and%2520orally%2520available%2520pan-PI3-kinase%2520and%2520dual%2520pan-PI3-kinase%252FmTOR%2520inhibitors%2520for%2520the%2520treatment%2520of%2520cancer%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2010%26volume%3D53%26spage%3D1086%26epage%3D1097" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref32"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref32'); return false;" data-citation="" class="refNumLink">32</a></strong><div class="NLM_citation" id="cit32"><span><span class="NLM_contrib-group">Yang, B. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">O’Rourke, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, J.</span><span> </span><span class="NLM_article-title">Mild and selective debenzylation of tertiary amines using α-chloroethyl chloroformate</span> <span class="citation_source-journal">Synlett</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1993</span><span class="NLM_x">, </span> <span class="NLM_volume">1993</span><span class="NLM_x">, </span> <span class="NLM_fpage">195</span><span class="NLM_x">–</span> <span class="NLM_lpage">196</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=16&amp;doi=10.1021%2Fjm301389h&amp;key=10.1055%2Fs-1993-22398" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1993&publication_year=1993&pages=195-196&author=B.+V.+Yangauthor=D.+O%E2%80%99Rourkeauthor=J.+Li&title=Mild+and+selective+debenzylation+of+tertiary+amines+using+%CE%B1-chloroethyl+chloroformate"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit32&amp;dbid=16384&amp;doi=10.1055%2Fs-1993-22398&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1055%252Fs-1993-22398%26sid%3Dliteratum%253Aachs%26aulast%3DYang%26aufirst%3DB.%2BV.%26aulast%3DO%25E2%2580%2599Rourke%26aufirst%3DD.%26aulast%3DLi%26aufirst%3DJ.%26atitle%3DMild%2520and%2520selective%2520debenzylation%2520of%2520tertiary%2520amines%2520using%2520%25CE%25B1-chloroethyl%2520chloroformate%26jtitle%3DSynlett%26date%3D1993%26volume%3D1993%26spage%3D195%26epage%3D196" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref33"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref33'); return false;" data-citation="" class="refNumLink">33</a></strong><div class="NLM_citation" id="cit33"><span><span class="NLM_contrib-group">Leach, A. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jones, H. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cosgrove, D. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kenny, P. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ruston, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">MacFaul, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wood, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Colclough, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Law, B.</span><span> </span><span class="NLM_article-title">Matched molecular pairs as a guide in the optimization of pharmaceutical properties; a study of aqueous solubility, plasma protein binding and oral exposure</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">49</span><span class="NLM_x">, </span> <span class="NLM_fpage">6672</span><span class="NLM_x">–</span> <span class="NLM_lpage">6682</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm0605233" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=32&amp;doi=10.1021%2Fjm301389h&amp;key=1%3ACAS%3A528%3ADC%252BD28XhtV2gtLnO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=49&publication_year=2006&pages=6672-6682&author=A.+G.+Leachauthor=H.+D.+Jonesauthor=D.+A.+Cosgroveauthor=P.+W.+Kennyauthor=L.+Rustonauthor=P.+MacFaulauthor=J.+M.+Woodauthor=N.+Colcloughauthor=B.+Law&title=Matched+molecular+pairs+as+a+guide+in+the+optimization+of+pharmaceutical+properties%3B+a+study+of+aqueous+solubility%2C+plasma+protein+binding+and+oral+exposure"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit33R"><div class="casContent"><span class="casTitleNuber">33</span><div class="casTitle"><span class="NLM_cas:atitle">Matched Molecular Pairs as a Guide in the Optimization of Pharmaceutical Properties; a Study of Aqueous Solubility, Plasma Protein Binding and Oral Exposure</span></div><div class="casAuthors">Leach, Andrew G.; Jones, Huw D.; Cosgrove, David A.; Kenny, Peter W.; Ruston, Linette; MacFaul, Philip; Wood, J. Matthew; Colclough, Nicola; Law, Brian</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">49</span>
        (<span class="NLM_cas:issue">23</span>),
    <span class="NLM_cas:pages">6672-6682</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">By identifying every pair of mols. that differ only by a particular, well-defined, structural transformation in a database of measured properties and computing the corresponding change in property, we obtain an overview of the effect that structural change has upon the property and set an expectation for what will happen when that transformation is applied elsewhere.  The mean change indicates the expected magnitude of the change in the property and the no. of cases in which the property increases give the probability that the structural transformation will cause the property to increase.  Outliers indicate potential ways of avoiding the general trend.  Comparing to changes in lipophilicity highlights structural transformations that have unusual effects, some of which can be explained by conformational changes.  In this paper, we focus upon the effects on aq. soly., plasma protein binding and oral exposure of adding substituents to arom. rings and methylating heteroatoms.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpcyrloR79Oq7Vg90H21EOLACvtfcHk0ljy72NtmJuzrQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XhtV2gtLnO&md5=2c143b424aee3ddb6c34616aff699ee0</span></div><a href="/servlet/linkout?suffix=cit33&amp;dbid=16384&amp;doi=10.1021%2Fjm0605233&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm0605233%26sid%3Dliteratum%253Aachs%26aulast%3DLeach%26aufirst%3DA.%2BG.%26aulast%3DJones%26aufirst%3DH.%2BD.%26aulast%3DCosgrove%26aufirst%3DD.%2BA.%26aulast%3DKenny%26aufirst%3DP.%2BW.%26aulast%3DRuston%26aufirst%3DL.%26aulast%3DMacFaul%26aufirst%3DP.%26aulast%3DWood%26aufirst%3DJ.%2BM.%26aulast%3DColclough%26aufirst%3DN.%26aulast%3DLaw%26aufirst%3DB.%26atitle%3DMatched%2520molecular%2520pairs%2520as%2520a%2520guide%2520in%2520the%2520optimization%2520of%2520pharmaceutical%2520properties%253B%2520a%2520study%2520of%2520aqueous%2520solubility%252C%2520plasma%2520protein%2520binding%2520and%2520oral%2520exposure%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2006%26volume%3D49%26spage%3D6672%26epage%3D6682" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref34"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref34'); return false;" data-citation="" class="refNumLink">34</a></strong><div class="NLM_citation" id="cit34"><span><span class="NLM_contrib-group">Grünwald, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">DeGraffenried, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Russel, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Friedrichs, W. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ray, R. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hidalgo, M.</span><span> </span><span class="NLM_article-title">Inhibitors of mTOR reverse doxorubicin resistance conferred by PTEN status in prostate cancer cells</span> <span class="citation_source-journal">Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2002</span><span class="NLM_x">, </span> <span class="NLM_volume">62</span><span class="NLM_x">, </span> <span class="NLM_fpage">6141</span><span class="NLM_x">–</span> <span class="NLM_lpage">6145</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=62&publication_year=2002&pages=6141-6145&author=V.+Gr%C3%BCnwaldauthor=L.+DeGraffenriedauthor=D.+Russelauthor=W.+E.+Friedrichsauthor=R.+B.+Rayauthor=M.+Hidalgo&title=Inhibitors+of+mTOR+reverse+doxorubicin+resistance+conferred+by+PTEN+status+in+prostate+cancer+cells"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit34&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DGr%25C3%25BCnwald%26aufirst%3DV.%26aulast%3DDeGraffenried%26aufirst%3DL.%26aulast%3DRussel%26aufirst%3DD.%26aulast%3DFriedrichs%26aufirst%3DW.%2BE.%26aulast%3DRay%26aufirst%3DR.%2BB.%26aulast%3DHidalgo%26aufirst%3DM.%26atitle%3DInhibitors%2520of%2520mTOR%2520reverse%2520doxorubicin%2520resistance%2520conferred%2520by%2520PTEN%2520status%2520in%2520prostate%2520cancer%2520cells%26jtitle%3DCancer%2520Res.%26date%3D2002%26volume%3D62%26spage%3D6141%26epage%3D6145" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref35"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref35'); return false;" data-citation="" class="refNumLink">35</a></strong><div class="NLM_citation" id="cit35"><span><span class="NLM_contrib-group">Halladay, J. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Delarosa, E. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tran, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wong, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Khojasteh, S. C.</span><span> </span><span class="NLM_article-title">High-throughput, 384-well, LC–MS/MS CYP inhibition assay using automation, cassette-analysis technique, and streamlined data analysis</span> <span class="citation_source-journal">Drug Metab. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">5</span><span class="NLM_x">, </span> <span class="NLM_fpage">220</span><span class="NLM_x">–</span> <span class="NLM_lpage">230</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=16&amp;doi=10.1021%2Fjm301389h&amp;key=10.2174%2F187231211796905017" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=8&amp;doi=10.1021%2Fjm301389h&amp;key=21867481" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=32&amp;doi=10.1021%2Fjm301389h&amp;key=1%3ACAS%3A528%3ADC%252BC3MXht1Cit7bL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2011&pages=220-230&author=J.+S.+Halladayauthor=E.+M.+Delarosaauthor=D.+Tranauthor=L.+Wangauthor=S.+Wongauthor=S.+C.+Khojasteh&title=High-throughput%2C+384-well%2C+LC%E2%80%93MS%2FMS+CYP+inhibition+assay+using+automation%2C+cassette-analysis+technique%2C+and+streamlined+data+analysis"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit35R"><div class="casContent"><span class="casTitleNuber">35</span><div class="casTitle"><span class="NLM_cas:atitle">High-throughput, 384-well, LC-MS/MS CYP inhibition assay using automation, cassette-analysis technique and streamlined data analysis</span></div><div class="casAuthors">Halladay, Jason S.; Delarosa, Erlie Marie; Tran, Daniel; Wang, Leslie; Wong, Susan; Khojasteh, S. Cyrus</div><div class="citationInfo"><span class="NLM_cas:title">Drug Metabolism Letters</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">220-230</span>CODEN:
                <span class="NLM_cas:coden">DMLRBM</span>;
        ISSN:<span class="NLM_cas:issn">1872-3128</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">Here we describe a high capacity and high-throughput, automated, 384-well CYP inhibition assay using well-known HLM-based MS probes.  We provide consistently robust IC50 values at the lead optimization stage of the drug discovery process.  Our method uses the Agilent Technologies/Velocity11 BioCel 1200 system, timesaving techniques for sample anal., and streamlined data processing steps.  For each expt., we generate IC50 values for up to 344 compds. and pos. controls for five major CYP isoforms (probe substrate): CYP1A2 (phenacetin), CYP2C9 [(S)-warfarin], CYP2C19 [(S)-mephenytoin], CYP2D6 (dextromethorphan), and CYP3A4/5 (testosterone and midazolam).  Each compd. is incubated sep. at four concns. with each CYP probe substrate under the optimized incubation condition.  Each incubation is quenched with acetonitrile contg. the deuterated internal std. of the resp. metabolite for each probe substrate.  To minimize the no. of samples to be analyzed by LC-MS/MS and reduce the amt. of valuable MS runtime, we utilize timesaving techniques of cassette anal. (pooling the incubation samples at the end of each CYP probe incubation into one) and column switching (reducing the amt. of MS runtime).  Here we also report on the comparison of IC50 results for five major CYP isoforms using our method compared to values reported in the literature.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr6LFWUX9244rVg90H21EOLACvtfcHk0lg056KZhqHgBg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXht1Cit7bL&md5=87db89d19026e12386ba06d594eeb727</span></div><a href="/servlet/linkout?suffix=cit35&amp;dbid=16384&amp;doi=10.2174%2F187231211796905017&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F187231211796905017%26sid%3Dliteratum%253Aachs%26aulast%3DHalladay%26aufirst%3DJ.%2BS.%26aulast%3DDelarosa%26aufirst%3DE.%2BM.%26aulast%3DTran%26aufirst%3DD.%26aulast%3DWang%26aufirst%3DL.%26aulast%3DWong%26aufirst%3DS.%26aulast%3DKhojasteh%26aufirst%3DS.%2BC.%26atitle%3DHigh-throughput%252C%2520384-well%252C%2520LC%25E2%2580%2593MS%252FMS%2520CYP%2520inhibition%2520assay%2520using%2520automation%252C%2520cassette-analysis%2520technique%252C%2520and%2520streamlined%2520data%2520analysis%26jtitle%3DDrug%2520Metab.%2520Lett.%26date%3D2011%26volume%3D5%26spage%3D220%26epage%3D230" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref36"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref36'); return false;" data-citation="" class="refNumLink">36</a></strong><div class="NLM_citation" id="cit36"><span><span class="NLM_contrib-group">Wallin, J. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Edgar, K. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Guan, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Berry, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Prior, W. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lesnick, J. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lewis, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nonomiya, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pang, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Salphati, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Olivero, A. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sutherlin, D. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">O’Brien, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Spoerke, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Patel, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lensun, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kassees, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ross, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lackner, M. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sampath, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Belvin, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Friedman, L. S.</span><span> </span><span class="NLM_article-title">GDC-0980 is a novel class I PI3K/mTOR kinase inhibitor with robust activity in cancer models driven by the PI3K pathway</span> <span class="citation_source-journal">Mol. Cancer Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">10</span><span class="NLM_x">, </span> <span class="NLM_fpage">2426</span><span class="NLM_x">–</span> <span class="NLM_lpage">2436</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=16&amp;doi=10.1021%2Fjm301389h&amp;key=10.1158%2F1535-7163.MCT-11-0446" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=8&amp;doi=10.1021%2Fjm301389h&amp;key=21998291" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=32&amp;doi=10.1021%2Fjm301389h&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhsFylurfJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2011&pages=2426-2436&author=J.+J.+Wallinauthor=K.+A.+Edgarauthor=J.+Guanauthor=M.+Berryauthor=W.+W.+Priorauthor=L.+Leeauthor=J.+D.+Lesnickauthor=C.+Lewisauthor=J.+Nonomiyaauthor=J.+Pangauthor=L.+Salphatiauthor=A.+G.+Oliveroauthor=D.+P.+Sutherlinauthor=C.+O%E2%80%99Brienauthor=J.+M.+Spoerkeauthor=S.+Patelauthor=L.+Lensunauthor=R.+Kasseesauthor=L.+Rossauthor=M.+R.+Lacknerauthor=D.+Sampathauthor=M.+Belvinauthor=L.+S.+Friedman&title=GDC-0980+is+a+novel+class+I+PI3K%2FmTOR+kinase+inhibitor+with+robust+activity+in+cancer+models+driven+by+the+PI3K+pathway"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit36R"><div class="casContent"><span class="casTitleNuber">36</span><div class="casTitle"><span class="NLM_cas:atitle">GDC-0980 Is a Novel Class I PI3K/mTOR Kinase Inhibitor with Robust Activity in Cancer Models Driven by the PI3K Pathway</span></div><div class="casAuthors">Wallin, Jeffrey J.; Edgar, Kyle A.; Guan, Jane; Berry, Megan; Prior, Wei Wei; Lee, Leslie; Lesnick, John D.; Lewis, Cristina; Nonomiya, Jim; Pang, Jodie; Salphati, Laurent; Olivero, Alan G.; Sutherlin, Daniel P.; O'Brien, Carol; Spoerke, Jill M.; Patel, Sonal; Lensun, Letitia; Kassees, Robert; Ross, Leanne; Lackner, Mark R.; Sampath, Deepak; Belvin, Marcia; Friedman, Lori S.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer Therapeutics</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">2426-2436</span>CODEN:
                <span class="NLM_cas:coden">MCTOCF</span>;
        ISSN:<span class="NLM_cas:issn">1535-7163</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Alterations of the phosphoinositide-3 kinase (PI3K)/Akt signaling pathway occur broadly in cancer via multiple mechanisms including mutation of the PIK3CA gene, loss or mutation of phosphatase and tensin homolog (PTEN), and deregulation of mammalian target of rapamycin (mTOR) complexes.  The dysregulation of this pathway has been implicated in tumor initiation, cell growth and survival, invasion and angiogenesis, thus, PI3K and mTOR are promising therapeutic targets for cancer.  We discovered GDC-0980, a selective, potent, orally bioavailable inhibitor of Class I PI3 kinase and mTOR kinase (TORC1/2) with excellent pharmacokinetic and pharmaceutical properties.  GDC-0980 potently inhibits signal transduction downstream of both PI3K and mTOR, as measured by pharmacodynamic (PD) biomarkers, thereby acting upon two key pathway nodes to produce the strongest attainable inhibition of signaling in the pathway.  Correspondingly, GDC-0980 was potent across a broad panel of cancer cell lines, with the greatest potency in breast, prostate, and lung cancers and less activity in melanoma and pancreatic cancers, consistent with KRAS and BRAF acting as resistance markers.  Treatment of cancer cell lines with GDC-0980 resulted in G1 cell-cycle arrest, and in contrast to mTOR inhibitors, GDC-0980 induced apoptosis in certain cancer cell lines, including those with direct pathway activation via PI3K and PTEN.  Low doses of GDC-0980 potently inhibited tumor growth in xenograft models including those with activated PI3K, loss of LKB1 or PTEN, and elicited an exposure-related decrease in PD biomarkers.  These preclin. data show that GDC-0980 is a potent and effective dual PI3K/mTOR inhibitor with promise for the clinic.  Mol Cancer Ther; 10(12); 2426-36.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp4yjwxW7TM3bVg90H21EOLACvtfcHk0lg056KZhqHgBg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhsFylurfJ&md5=756410aaf86377284a63d8ee70ad36ec</span></div><a href="/servlet/linkout?suffix=cit36&amp;dbid=16384&amp;doi=10.1158%2F1535-7163.MCT-11-0446&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1535-7163.MCT-11-0446%26sid%3Dliteratum%253Aachs%26aulast%3DWallin%26aufirst%3DJ.%2BJ.%26aulast%3DEdgar%26aufirst%3DK.%2BA.%26aulast%3DGuan%26aufirst%3DJ.%26aulast%3DBerry%26aufirst%3DM.%26aulast%3DPrior%26aufirst%3DW.%2BW.%26aulast%3DLee%26aufirst%3DL.%26aulast%3DLesnick%26aufirst%3DJ.%2BD.%26aulast%3DLewis%26aufirst%3DC.%26aulast%3DNonomiya%26aufirst%3DJ.%26aulast%3DPang%26aufirst%3DJ.%26aulast%3DSalphati%26aufirst%3DL.%26aulast%3DOlivero%26aufirst%3DA.%2BG.%26aulast%3DSutherlin%26aufirst%3DD.%2BP.%26aulast%3DO%25E2%2580%2599Brien%26aufirst%3DC.%26aulast%3DSpoerke%26aufirst%3DJ.%2BM.%26aulast%3DPatel%26aufirst%3DS.%26aulast%3DLensun%26aufirst%3DL.%26aulast%3DKassees%26aufirst%3DR.%26aulast%3DRoss%26aufirst%3DL.%26aulast%3DLackner%26aufirst%3DM.%2BR.%26aulast%3DSampath%26aufirst%3DD.%26aulast%3DBelvin%26aufirst%3DM.%26aulast%3DFriedman%26aufirst%3DL.%2BS.%26atitle%3DGDC-0980%2520is%2520a%2520novel%2520class%2520I%2520PI3K%252FmTOR%2520kinase%2520inhibitor%2520with%2520robust%2520activity%2520in%2520cancer%2520models%2520driven%2520by%2520the%2520PI3K%2520pathway%26jtitle%3DMol.%2520Cancer%2520Ther.%26date%3D2011%26volume%3D10%26spage%3D2426%26epage%3D2436" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref37"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref37'); return false;" data-citation="" class="refNumLink">37</a></strong><div class="NLM_citation" id="cit37"><span><span class="NLM_contrib-group">Hidalgo, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Buckner, J. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Erlichman, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pollack, M. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Boni, J. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dukart, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Marshall, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Speicher, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Moore, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rowinsky, E. K.</span><span> </span><span class="NLM_article-title">A phase I and pharmacokinetic study of temsirolimus (CCI-779) administered intravenously daily for 5 days every 2 weeks to patients with advanced cancer</span> <span class="citation_source-journal">Clin. Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">12</span><span class="NLM_x">, </span> <span class="NLM_fpage">5755</span><span class="NLM_x">–</span> <span class="NLM_lpage">5763</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=16&amp;doi=10.1021%2Fjm301389h&amp;key=10.1158%2F1078-0432.CCR-06-0118" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=8&amp;doi=10.1021%2Fjm301389h&amp;key=17020981" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=32&amp;doi=10.1021%2Fjm301389h&amp;key=1%3ACAS%3A528%3ADC%252BD28XhtVartbvK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2006&pages=5755-5763&author=M.+Hidalgoauthor=J.+C.+Bucknerauthor=C.+Erlichmanauthor=M.+S.+Pollackauthor=J.+P.+Boniauthor=G.+Dukartauthor=B.+Marshallauthor=L.+Speicherauthor=L.+Mooreauthor=E.+K.+Rowinsky&title=A+phase+I+and+pharmacokinetic+study+of+temsirolimus+%28CCI-779%29+administered+intravenously+daily+for+5+days+every+2+weeks+to+patients+with+advanced+cancer"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit37R"><div class="casContent"><span class="casTitleNuber">37</span><div class="casTitle"><span class="NLM_cas:atitle">A Phase I and Pharmacokinetic Study of Temsirolimus (CCI-779) Administered Intravenously Daily for 5 Days Every 2 Weeks to Patients with Advanced Cancer</span></div><div class="casAuthors">Hidalgo, Manuel; Buckner, Jan C.; Erlichman, Charles; Pollack, Marilyn S.; Boni, Joseph P.; Dukart, Gary; Marshall, Bonnie; Speicher, Lisa; Moore, Laurence; Rowinsky, Eric K.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">19</span>),
    <span class="NLM_cas:pages">5755-5763</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Purpose: Patients with advanced cancer received temsirolimus (Torisel, CCI-779), a novel inhibitor of mammalian target of rapamycin, i.v. once daily for 5 days every 2 wk to det. the max. tolerated dose, toxicity profile, pharmacokinetics, and preliminary antitumor efficacy.  Exptl. Design: Doses were escalated in successive cohorts of patients using a conventional phase I clin. trial design.  Samples of whole blood and plasma were collected to det. the pharmacokinetics of temsirolimus and sirolimus, its principal metabolite.  Results: Sixty-three patients were treated with temsirolimus (0.75-24 mg/m2/d).  The most common drug-related toxicities were asthenia, mucositis, nausea, and cutaneous toxicity.  The max. tolerated dose was 15 mg/m2/d for patients with extensive prior treatment because, in the 19 mg/m2/d cohort, two patients had dose-limiting toxicities (one with grade 3 vomiting, diarrhea, and asthenia and one with elevated transaminases) and three patients required dose redns.  For minimally pretreated patients, in the 24 mg/m2/d cohort, one patient developed a dose-limiting toxicity of grade 3 stomatitis and two patients required dose redns., establishing 19 mg/m2/d as the max. acceptable dose.  Immunol. studies did not show any consistent trend toward immunosuppression.  Temsirolimus exposure increased with dose in a less than proportional manner.  Terminal half-life was 13 to 25 h.  Sirolimus-to-temsirolimus exposure ratios were 0.6 to 1.8.  A patient with non-small cell lung cancer achieved a confirmed partial response, which lasted for 12.7 mo.  Three patients had unconfirmed partial responses; two patients had stable disease for ≥24 wk.  Conclusion: Temsirolimus was generally well tolerated on this intermittent schedule.  Encouraging preliminary antitumor activity was obsd.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq8PhKgWPGD_7Vg90H21EOLACvtfcHk0ljIc5Jyhvp5Tg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XhtVartbvK&md5=00690373c9826dd9ad1f24d5f56b4962</span></div><a href="/servlet/linkout?suffix=cit37&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-06-0118&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-06-0118%26sid%3Dliteratum%253Aachs%26aulast%3DHidalgo%26aufirst%3DM.%26aulast%3DBuckner%26aufirst%3DJ.%2BC.%26aulast%3DErlichman%26aufirst%3DC.%26aulast%3DPollack%26aufirst%3DM.%2BS.%26aulast%3DBoni%26aufirst%3DJ.%2BP.%26aulast%3DDukart%26aufirst%3DG.%26aulast%3DMarshall%26aufirst%3DB.%26aulast%3DSpeicher%26aufirst%3DL.%26aulast%3DMoore%26aufirst%3DL.%26aulast%3DRowinsky%26aufirst%3DE.%2BK.%26atitle%3DA%2520phase%2520I%2520and%2520pharmacokinetic%2520study%2520of%2520temsirolimus%2520%2528CCI-779%2529%2520administered%2520intravenously%2520daily%2520for%25205%2520days%2520every%25202%2520weeks%2520to%2520patients%2520with%2520advanced%2520cancer%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2006%26volume%3D12%26spage%3D5755%26epage%3D5763" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref38"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref38'); return false;" data-citation="" class="refNumLink">38</a></strong><div class="NLM_citation" id="cit38"><span><span class="NLM_contrib-group">Cloughesy, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yoshimoto, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nghiemphu, P.</span><span> </span><span class="NLM_article-title">Antitumor activity of rapamycin in a phase I trial for patients with recurrent PTEN-deficient glioblastoma</span> <span class="citation_source-journal">PLoS Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">5</span><span class="NLM_x">, </span> <span class="NLM_fpage">e8</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2008&pages=e8&author=T.+Cloughesyauthor=K.+Yoshimotoauthor=P.+Nghiemphu&title=Antitumor+activity+of+rapamycin+in+a+phase+I+trial+for+patients+with+recurrent+PTEN-deficient+glioblastoma"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit38&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DCloughesy%26aufirst%3DT.%26aulast%3DYoshimoto%26aufirst%3DK.%26aulast%3DNghiemphu%26aufirst%3DP.%26atitle%3DAntitumor%2520activity%2520of%2520rapamycin%2520in%2520a%2520phase%2520I%2520trial%2520for%2520patients%2520with%2520recurrent%2520PTEN-deficient%2520glioblastoma%26jtitle%3DPLoS%2520Med.%26date%3D2008%26volume%3D5%26spage%3De8" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref39"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref39'); return false;" data-citation="" class="refNumLink">39</a></strong><div class="NLM_citation" id="cit39"><span><span class="NLM_contrib-group">Tabernero, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rojo, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Calvo, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Burris, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Judson, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hazell, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Martinelli, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cajal, S. R. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jones, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vidal, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shand, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Macarulla, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ramos, F. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dimitrijevic, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zoellner, U.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tang, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stumm, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lane, H. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lebwohl, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Baselga, J.</span><span> </span><span class="NLM_article-title">Dose- and schedule-dependent inhibition of the mammalian target of rapamycin pathway with everolimus: A phase I tumor pharmacodynamic study in patients with advanced solid tumors</span> <span class="citation_source-journal">J. Clin. Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">26</span><span class="NLM_x">, </span> <span class="NLM_fpage">1603</span><span class="NLM_x">–</span> <span class="NLM_lpage">1610</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=16&amp;doi=10.1021%2Fjm301389h&amp;key=10.1200%2FJCO.2007.14.5482" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=8&amp;doi=10.1021%2Fjm301389h&amp;key=18332469" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=32&amp;doi=10.1021%2Fjm301389h&amp;key=1%3ACAS%3A528%3ADC%252BD1cXltlWiu7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=2008&pages=1603-1610&author=J.+Taberneroauthor=F.+Rojoauthor=E.+Calvoauthor=H.+Burrisauthor=I.+Judsonauthor=K.+Hazellauthor=E.+Martinelliauthor=S.+R.+Y.+Cajalauthor=S.+Jonesauthor=L.+Vidalauthor=N.+Shandauthor=T.+Macarullaauthor=F.+J.+Ramosauthor=S.+Dimitrijevicauthor=U.+Zoellnerauthor=P.+Tangauthor=M.+Stummauthor=H.+A.+Laneauthor=D.+Lebwohlauthor=J.+Baselga&title=Dose-+and+schedule-dependent+inhibition+of+the+mammalian+target+of+rapamycin+pathway+with+everolimus%3A+A+phase+I+tumor+pharmacodynamic+study+in+patients+with+advanced+solid+tumors"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit39R"><div class="casContent"><span class="casTitleNuber">39</span><div class="casTitle"><span class="NLM_cas:atitle">Dose- and schedule-dependent inhibition of the mammalian target of rapamycin pathway with everolimus: a phase I tumor pharmacodynamic study in patients with advanced solid tumors</span></div><div class="casAuthors">Tabernero, Josep; Rojo, Federico; Calvo, Emiliano; Burris, Howard; Judson, Ian; Hazell, Katharine; Martinelli, Erika; Ramon y Cajal, Santiago; Jones, Suzanne; Vidal, Laura; Shand, Nicholas; Macarulla, Teresa; Ramos, Francisco Javier; Dimitrijevic, Sasa; Zoellner, Ulrike; Tang, Pui; Stumm, Michael; Lane, Heidi A.; Lebwohl, David; Baselga, Jose</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Clinical Oncology</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">26</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">1603-1610</span>CODEN:
                <span class="NLM_cas:coden">JCONDN</span>;
        ISSN:<span class="NLM_cas:issn">0732-183X</span>.
    
            (<span class="NLM_cas:orgname">American Society of Clinical Oncology</span>)
        </div><div class="casAbstract">Purpose: Everolimus is a selective mammalian target of rapamycin (mTOR) inhibitor with promising anticancer activity.  In order to identify a rationally based dose and schedule for cancer treatment, we have conducted a tumor pharmacodynamic phase I study in patients with advanced solid tumors.  Patients and Methods: Fifty-five patients were treated with everolimus in cohorts of 20, 50, and 70 mg weekly or 5 and 10 mg daily.  Dose escalation depended on dose limiting toxicity (DLT) rate during the first 4-wk period.  Pre- and on-treatment steady-state tumor and skin biopsies were evaluated for total and phosphorylated (p) protein S6 kinase 1, eukaryotic initiation factor 4E (eIF-4E) binding protein 1 (4E-BP1), eukaryotic initiation factor 4G (eIF-4G), AKT, and Ki-67 expression.  Plasma trough levels of everolimus were detd. on a weekly basis before dosing during the first 4 wk.  Results: We obsd. a dose- and schedule-dependent inhibition of the mTOR pathway with a near complete inhibition of pS6 and pelF-4G at 10 mg/d and ≥ 50 mg/wk.  In addn., pAKT was upregulated in 50% of the treated tumors.  In the daily schedule, there was a correlation between everolimus plasma trough concns. and inhibition of peIF4G and p4E-BP1.  There was good concordance of mTOR pathway inhibition between skin and tumor.  Clin. benefit was obsd. in four patients including one patient with advanced colorectal cancer achieving a partial response.  DLTs occurred in five patients: one patient at 10 mg/d (grade 3 stomatitis) and four patients at 70 mg/wk (two with grade 3 stomatitis, one with grade 3 neutropenia, and one with grade 3 hyperglycemia).  Conclusion: Everolimus achieved mTOR signaling inhibition at doses below the DLT.  A dosage of 10 mg/d or 50 mg/wk is recommended for further development.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpFaBqnJ0l_47Vg90H21EOLACvtfcHk0ljIc5Jyhvp5Tg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXltlWiu7c%253D&md5=663073a6224755c94c42575a00989bbf</span></div><a href="/servlet/linkout?suffix=cit39&amp;dbid=16384&amp;doi=10.1200%2FJCO.2007.14.5482&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1200%252FJCO.2007.14.5482%26sid%3Dliteratum%253Aachs%26aulast%3DTabernero%26aufirst%3DJ.%26aulast%3DRojo%26aufirst%3DF.%26aulast%3DCalvo%26aufirst%3DE.%26aulast%3DBurris%26aufirst%3DH.%26aulast%3DJudson%26aufirst%3DI.%26aulast%3DHazell%26aufirst%3DK.%26aulast%3DMartinelli%26aufirst%3DE.%26aulast%3DCajal%26aufirst%3DS.%2BR.%2BY.%26aulast%3DJones%26aufirst%3DS.%26aulast%3DVidal%26aufirst%3DL.%26aulast%3DShand%26aufirst%3DN.%26aulast%3DMacarulla%26aufirst%3DT.%26aulast%3DRamos%26aufirst%3DF.%2BJ.%26aulast%3DDimitrijevic%26aufirst%3DS.%26aulast%3DZoellner%26aufirst%3DU.%26aulast%3DTang%26aufirst%3DP.%26aulast%3DStumm%26aufirst%3DM.%26aulast%3DLane%26aufirst%3DH.%2BA.%26aulast%3DLebwohl%26aufirst%3DD.%26aulast%3DBaselga%26aufirst%3DJ.%26atitle%3DDose-%2520and%2520schedule-dependent%2520inhibition%2520of%2520the%2520mammalian%2520target%2520of%2520rapamycin%2520pathway%2520with%2520everolimus%253A%2520A%2520phase%2520I%2520tumor%2520pharmacodynamic%2520study%2520in%2520patients%2520with%2520advanced%2520solid%2520tumors%26jtitle%3DJ.%2520Clin.%2520Oncol.%26date%3D2008%26volume%3D26%26spage%3D1603%26epage%3D1610" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></div><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript">window.refViewer={'ref1':['cit1'],'ref2':['cit2'],'ref3':['cit3'],'ref4':['cit4'],'ref5':['cit5'],'ref6':['cit6'],'ref7':['cit7'],'ref8':['cit8'],'ref9':['cit9'],'ref10':['cit10'],'ref11':['cit11'],'ref12':['cit12'],'ref13':['cit13'],'ref14':['cit14'],'ref15':['cit15'],'ref16':['cit16'],'ref17':['cit17'],'ref18':['cit18'],'ref19':['cit19'],'ref20':['cit20'],'ref21':['cit21'],'ref22':['cit22'],'ref23':['cit23'],'ref24':['cit24'],'ref25':['cit25'],'ref26':['cit26'],'ref27':['cit27'],'ref28':['cit28'],'ref29':['cit29'],'ref30':['cit30'],'ref31':['cit31'],'ref32':['cit32'],'ref33':['cit33'],'ref34':['cit34'],'ref35':['cit35'],'ref36':['cit36'],'ref37':['cit37'],'ref38':['cit38'],'ref39':['cit39']}</script><div class="articleCitedByDropzone" data-pb-dropzone="articleCitedByDropzone"><div class="cited-by"><div class="article_content-header cited-content_header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="citeThis">Cited By</h2></div></div></div><hr/></hr><div class="cited-by__content"><div class="cited-content hlFld-Abstract"><p>This article is cited by 20 publications.</p><ol class="cited-content_cbyCitation"><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Han-Jie  Zhou</span>, <span class="hlFld-ContribAuthor ">Jinhai  Wang</span>, <span class="hlFld-ContribAuthor ">Bing  Yao</span>, <span class="hlFld-ContribAuthor ">Steve  Wong</span>, <span class="hlFld-ContribAuthor ">Stevan  Djakovic</span>, <span class="hlFld-ContribAuthor ">Brajesh  Kumar</span>, <span class="hlFld-ContribAuthor ">Julie  Rice</span>, <span class="hlFld-ContribAuthor ">Eduardo  Valle</span>, <span class="hlFld-ContribAuthor ">Ferdie  Soriano</span>, <span class="hlFld-ContribAuthor ">Mary-Kamala  Menon</span>, <span class="hlFld-ContribAuthor ">Antonett  Madriaga</span>, <span class="hlFld-ContribAuthor ">Szerenke  Kiss von Soly</span>, <span class="hlFld-ContribAuthor ">Abhinav  Kumar</span>, <span class="hlFld-ContribAuthor ">Francesco  Parlati</span>, <span class="hlFld-ContribAuthor ">F. Michael  Yakes</span>, <span class="hlFld-ContribAuthor ">Laura  Shawver</span>, <span class="hlFld-ContribAuthor ">Ronan  Le Moigne</span>, <span class="hlFld-ContribAuthor ">Daniel J.  Anderson</span>, <span class="hlFld-ContribAuthor ">Mark  Rolfe</span>, and <span class="hlFld-ContribAuthor ">David  Wustrow</span>  . </span><span class="cited-content_cbyCitation_article-title">Discovery of a First-in-Class, Potent, Selective, and Orally Bioavailable Inhibitor of the p97 AAA ATPase (CB-5083). </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2015,</strong> <em>58 </em>
                                    (24)
                                     , 9480-9497. <a href="https://doi.org/10.1021/acs.jmedchem.5b01346" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.5b01346</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.5b01346&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.5b01346%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDiscovery%252Bof%252Ba%252BFirst-in-Class%25252C%252BPotent%25252C%252BSelective%25252C%252Band%252BOrally%252BBioavailable%252BInhibitor%252Bof%252Bthe%252Bp97%252BAAA%252BATPase%252B%252528CB-5083%252529%26aulast%3DZhou%26aufirst%3DHan-Jie%26date%3D2015%26date%3D2015%26date%3D2015%26date%3D31082015%26date%3D04122015%26date%3D24122015%26date%3D13112015%26volume%3D58%26issue%3D24%26spage%3D9480%26epage%3D9497" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Martin  Andrs</span>, <span class="hlFld-ContribAuthor ">Jan  Korabecny</span>, <span class="hlFld-ContribAuthor ">Daniel  Jun</span>, <span class="hlFld-ContribAuthor ">Zdenek  Hodny</span>, <span class="hlFld-ContribAuthor ">Jiri  Bartek</span>, and <span class="hlFld-ContribAuthor ">Kamil  Kuca</span>  . </span><span class="cited-content_cbyCitation_article-title">Phosphatidylinositol 3-Kinase (PI3K) and Phosphatidylinositol 3-Kinase-Related Kinase (PIKK) Inhibitors: Importance of the Morpholine Ring. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2015,</strong> <em>58 </em>
                                    (1)
                                     , 41-71. <a href="https://doi.org/10.1021/jm501026z" title="DOI URL">https://doi.org/10.1021/jm501026z</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/jm501026z&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Fjm501026z%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DPhosphatidylinositol%252B3-Kinase%252B%252528PI3K%252529%252Band%252BPhosphatidylinositol%252B3-Kinase-Related%252BKinase%252B%252528PIKK%252529%252BInhibitors%25253A%252BImportance%252Bof%252Bthe%252BMorpholine%252BRing%26aulast%3DAndrs%26aufirst%3DMartin%26date%3D2015%26date%3D2014%26date%3D2014%26date%3D08072014%26date%3D05122014%26date%3D08012015%26date%3D11112014%26volume%3D58%26issue%3D1%26spage%3D41%26epage%3D71" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Benoit  Pasquier</span>, <span class="hlFld-ContribAuthor ">Youssef  El-Ahmad</span>, <span class="hlFld-ContribAuthor ">Bruno  Filoche-Rommé</span>, <span class="hlFld-ContribAuthor ">Christine  Dureuil</span>, <span class="hlFld-ContribAuthor ">Florence  Fassy</span>, <span class="hlFld-ContribAuthor ">Pierre-Yves  Abecassis</span>, <span class="hlFld-ContribAuthor ">Magali  Mathieu</span>, <span class="hlFld-ContribAuthor ">Thomas  Bertrand</span>, <span class="hlFld-ContribAuthor ">Tsiala  Benard</span>, <span class="hlFld-ContribAuthor ">Cédric  Barrière</span>, <span class="hlFld-ContribAuthor ">Samira  El Batti</span>, <span class="hlFld-ContribAuthor ">Jean-Philippe  Letallec</span>, <span class="hlFld-ContribAuthor ">Véronique  Sonnefraud</span>, <span class="hlFld-ContribAuthor ">Maurice  Brollo</span>, <span class="hlFld-ContribAuthor ">Laurence  Delbarre</span>, <span class="hlFld-ContribAuthor ">Véronique  Loyau</span>, <span class="hlFld-ContribAuthor ">Fabienne  Pilorge</span>, <span class="hlFld-ContribAuthor ">Luc  Bertin</span>, <span class="hlFld-ContribAuthor ">Patrick  Richepin</span>, <span class="hlFld-ContribAuthor ">Jérôme  Arigon</span>, <span class="hlFld-ContribAuthor ">Jean-Robert  Labrosse</span>, <span class="hlFld-ContribAuthor ">Jacques  Clément</span>, <span class="hlFld-ContribAuthor ">Florence  Durand</span>, <span class="hlFld-ContribAuthor ">Romain  Combet</span>, <span class="hlFld-ContribAuthor ">Pierre  Perraut</span>, <span class="hlFld-ContribAuthor ">Vincent  Leroy</span>, <span class="hlFld-ContribAuthor ">Frédéric  Gay</span>, <span class="hlFld-ContribAuthor ">Dominique  Lefrançois</span>, <span class="hlFld-ContribAuthor ">François  Bretin</span>, <span class="hlFld-ContribAuthor ">Jean-Pierre  Marquette</span>, <span class="hlFld-ContribAuthor ">Nadine  Michot</span>, <span class="hlFld-ContribAuthor ">Anne  Caron</span>, <span class="hlFld-ContribAuthor ">Christelle  Castell</span>, <span class="hlFld-ContribAuthor ">Laurent  Schio</span>, <span class="hlFld-ContribAuthor ">Gary  McCort</span>, <span class="hlFld-ContribAuthor ">Hélène  Goulaouic</span>, <span class="hlFld-ContribAuthor ">Carlos  Garcia-Echeverria</span>, and <span class="hlFld-ContribAuthor ">Baptiste  Ronan</span>  . </span><span class="cited-content_cbyCitation_article-title">Discovery of (2S)-8-[(3R)-3-Methylmorpholin-4-yl]-1-(3-methyl-2-oxobutyl)-2-(trifluoromethyl)-3,4-dihydro-2H-pyrimido[1,2-a]pyrimidin-6-one: A Novel Potent and Selective Inhibitor of Vps34 for the Treatment of Solid Tumors. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2015,</strong> <em>58 </em>
                                    (1)
                                     , 376-400. <a href="https://doi.org/10.1021/jm5013352" title="DOI URL">https://doi.org/10.1021/jm5013352</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/jm5013352&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Fjm5013352%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDiscovery%252Bof%252B%2525282S%252529-8-%25255B%2525283R%252529-3-Methylmorpholin-4-yl%25255D-1-%2525283-methyl-2-oxobutyl%252529-2-%252528trifluoromethyl%252529-3%25252C4-dihydro-2H-pyrimido%25255B1%25252C2-a%25255Dpyrimidin-6-one%25253A%252BA%252BNovel%252BPotent%252Band%252BSelective%252BInhibitor%252Bof%252BVps34%252Bfor%252Bthe%252BTreatment%252Bof%252BSolid%252BTumors%26aulast%3DPasquier%26aufirst%3DBenoit%26date%3D2015%26date%3D2014%26date%3D2014%26date%3D01092014%26date%3D26112014%26date%3D08012015%26date%3D17112014%26volume%3D58%26issue%3D1%26spage%3D376%26epage%3D400" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Anthony A.  Estrada</span>, <span class="hlFld-ContribAuthor ">Daniel G.  Shore</span>, <span class="hlFld-ContribAuthor ">Elizabeth  Blackwood</span>, <span class="hlFld-ContribAuthor ">Yung-Hsiang  Chen</span>, <span class="hlFld-ContribAuthor ">Gauri  Deshmukh</span>, <span class="hlFld-ContribAuthor ">Xiao  Ding</span>, <span class="hlFld-ContribAuthor ">Antonio G.  DiPasquale</span>, <span class="hlFld-ContribAuthor ">Jennifer A.  Epler</span>, <span class="hlFld-ContribAuthor ">Lori S.  Friedman</span>, <span class="hlFld-ContribAuthor ">Michael F. T.  Koehler</span>, <span class="hlFld-ContribAuthor ">Lichuan  Liu</span>, <span class="hlFld-ContribAuthor ">Shiva  Malek</span>, <span class="hlFld-ContribAuthor ">Jim  Nonomiya</span>, <span class="hlFld-ContribAuthor ">Daniel F.  Ortwine</span>, <span class="hlFld-ContribAuthor ">Zhonghua  Pei</span>, <span class="hlFld-ContribAuthor ">Steve  Sideris</span>, <span class="hlFld-ContribAuthor ">Frederic  St-Jean</span>, <span class="hlFld-ContribAuthor ">Lan  Trinh</span>, <span class="hlFld-ContribAuthor ">Tom  Truong</span>, and <span class="hlFld-ContribAuthor ">Joseph P.  Lyssikatos</span>  . </span><span class="cited-content_cbyCitation_article-title">Pyrimidoaminotropanes as Potent, Selective, and Efficacious Small Molecule Kinase Inhibitors of the Mammalian Target of Rapamycin (mTOR). </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2013,</strong> <em>56 </em>
                                    (7)
                                     , 3090-3101. <a href="https://doi.org/10.1021/jm400194n" title="DOI URL">https://doi.org/10.1021/jm400194n</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/jm400194n&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Fjm400194n%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DPyrimidoaminotropanes%252Bas%252BPotent%25252C%252BSelective%25252C%252Band%252BEfficacious%252BSmall%252BMolecule%252BKinase%252BInhibitors%252Bof%252Bthe%252BMammalian%252BTarget%252Bof%252BRapamycin%252B%252528mTOR%252529%26aulast%3DEstrada%26aufirst%3DAnthony%2BA.%26date%3D2013%26date%3D2013%26date%3D2013%26date%3D06022013%26date%3D29032013%26date%3D11042013%26date%3D08032013%26volume%3D56%26issue%3D7%26spage%3D3090%26epage%3D3101" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Mingming  Zhang</span>, <span class="hlFld-ContribAuthor ">Wei  Wei</span>, <span class="hlFld-ContribAuthor ">Chengjun  Peng</span>, <span class="hlFld-ContribAuthor ">Xiaodong  Ma</span>, <span class="hlFld-ContribAuthor ">Xiao  He</span>, <span class="hlFld-ContribAuthor ">Heng  Zhang</span>, <span class="hlFld-ContribAuthor ">Mingkang  Zhou</span>. </span><span class="cited-content_cbyCitation_article-title">Discovery of novel pyrazolopyrimidine derivatives as potent mTOR/HDAC bi-functional inhibitors via pharmacophore-merging strategy. </span><span class="cited-content_cbyCitation_journal-name">Bioorganic & Medicinal Chemistry Letters</span><span> <strong>2021,</strong> <em>49 </em>, 128286. <a href="https://doi.org/10.1016/j.bmcl.2021.128286" title="DOI URL">https://doi.org/10.1016/j.bmcl.2021.128286</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bmcl.2021.128286&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bmcl.2021.128286%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520%2526%2520Medicinal%2520Chemistry%2520Letters%26atitle%3DDiscovery%252Bof%252Bnovel%252Bpyrazolopyrimidine%252Bderivatives%252Bas%252Bpotent%252BmTOR%25252FHDAC%252Bbi-functional%252Binhibitors%252Bvia%252Bpharmacophore-merging%252Bstrategy%26aulast%3DZhang%26aufirst%3DMingming%26date%3D2021%26volume%3D49%26spage%3D128286" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Nazanin Momeni  Roudsari</span>, <span class="hlFld-ContribAuthor ">Naser-Aldin  Lashgari</span>, <span class="hlFld-ContribAuthor ">Saeideh  Momtaz</span>, <span class="hlFld-ContribAuthor ">Shaghayegh  Abaft</span>, <span class="hlFld-ContribAuthor ">Fatemeh  Jamali</span>, <span class="hlFld-ContribAuthor ">Pardis  Safaiepour</span>, <span class="hlFld-ContribAuthor ">Kiyana  Narimisa</span>, <span class="hlFld-ContribAuthor ">Gloria  Jackson</span>, <span class="hlFld-ContribAuthor ">Anusha  Bishayee</span>, <span class="hlFld-ContribAuthor ">Nima  Rezaei</span>, <span class="hlFld-ContribAuthor ">Amir Hossein  Abdolghaffari</span>, <span class="hlFld-ContribAuthor ">Anupam  Bishayee</span>. </span><span class="cited-content_cbyCitation_article-title">Inhibitors of the PI3K/Akt/mTOR Pathway in Prostate Cancer Chemoprevention and Intervention. </span><span class="cited-content_cbyCitation_journal-name">Pharmaceutics</span><span> <strong>2021,</strong> <em>13 </em>
                                    (8)
                                     , 1195. <a href="https://doi.org/10.3390/pharmaceutics13081195" title="DOI URL">https://doi.org/10.3390/pharmaceutics13081195</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3390/pharmaceutics13081195&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3390%2Fpharmaceutics13081195%26sid%3Dliteratum%253Aachs%26jtitle%3DPharmaceutics%26atitle%3DInhibitors%252Bof%252Bthe%252BPI3K%25252FAkt%25252FmTOR%252BPathway%252Bin%252BProstate%252BCancer%252BChemoprevention%252Band%252BIntervention%26aulast%3DRoudsari%26aufirst%3DNazanin%2BMomeni%26date%3D2021%26date%3D2021%26volume%3D13%26issue%3D8%26spage%3D1195" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Tian  Xu</span>, <span class="hlFld-ContribAuthor ">Dejuan  Sun</span>, <span class="hlFld-ContribAuthor ">Yi  Chen</span>, <span class="hlFld-ContribAuthor ">Liang  Ouyang</span>. </span><span class="cited-content_cbyCitation_article-title">Targeting mTOR for fighting diseases: A revisited review of mTOR inhibitors. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2020,</strong> <em>199 </em>, 112391. <a href="https://doi.org/10.1016/j.ejmech.2020.112391" title="DOI URL">https://doi.org/10.1016/j.ejmech.2020.112391</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2020.112391&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2020.112391%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DTargeting%252BmTOR%252Bfor%252Bfighting%252Bdiseases%25253A%252BA%252Brevisited%252Breview%252Bof%252BmTOR%252Binhibitors%26aulast%3DXu%26aufirst%3DTian%26date%3D2020%26volume%3D199%26spage%3D112391" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Chao  Tian</span>, <span class="hlFld-ContribAuthor ">Xuanzhen  Chen</span>, <span class="hlFld-ContribAuthor ">Zhili  Zhang</span>, <span class="hlFld-ContribAuthor ">Xiaowei  Wang</span>, <span class="hlFld-ContribAuthor ">Junyi  Liu</span>. </span><span class="cited-content_cbyCitation_article-title">Design and synthesis of (2-(phenylamino)thieno[3,2-d]pyrimidin-4-yl)(3,4,5-trimethoxyphenyl)methanone analogues as potent anti-tubulin polymerization agents. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2019,</strong> <em>183 </em>, 111679. <a href="https://doi.org/10.1016/j.ejmech.2019.111679" title="DOI URL">https://doi.org/10.1016/j.ejmech.2019.111679</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2019.111679&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2019.111679%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDesign%252Band%252Bsynthesis%252Bof%252B%2525282-%252528phenylamino%252529thieno%25255B3%25252C2-d%25255Dpyrimidin-4-yl%252529%2525283%25252C4%25252C5-trimethoxyphenyl%252529methanone%252Banalogues%252Bas%252Bpotent%252Banti-tubulin%252Bpolymerization%252Bagents%26aulast%3DTian%26aufirst%3DChao%26date%3D2019%26volume%3D183%26spage%3D111679" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Mohammed S.  Abdel‐Maksoud</span>, <span class="hlFld-ContribAuthor ">Mohammed I.  El‐Gamal</span>, <span class="hlFld-ContribAuthor ">Dalia Reyane  Benhalilou</span>, <span class="hlFld-ContribAuthor ">Sandy  Ashraf</span>, <span class="hlFld-ContribAuthor ">Shatha Abdulghaffar  Mohammed</span>, <span class="hlFld-ContribAuthor ">Chang‐Hyun  Oh</span>. </span><span class="cited-content_cbyCitation_article-title">Mechanistic/mammalian target of rapamycin: Recent pathological aspects and inhibitors. </span><span class="cited-content_cbyCitation_journal-name">Medicinal Research Reviews</span><span> <strong>2019,</strong> <em>39 </em>
                                    (2)
                                     , 631-664. <a href="https://doi.org/10.1002/med.21535" title="DOI URL">https://doi.org/10.1002/med.21535</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/med.21535&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fmed.21535%26sid%3Dliteratum%253Aachs%26jtitle%3DMedicinal%2520Research%2520Reviews%26atitle%3DMechanistic%25252Fmammalian%252Btarget%252Bof%252Brapamycin%25253A%252BRecent%252Bpathological%252Baspects%252Band%252Binhibitors%26aulast%3DAbdel%25E2%2580%2590Maksoud%26aufirst%3DMohammed%2BS.%26date%3D2019%26date%3D2018%26volume%3D39%26issue%3D2%26spage%3D631%26epage%3D664" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Chao  Tian</span>, <span class="hlFld-ContribAuthor ">Zifei  Han</span>, <span class="hlFld-ContribAuthor ">Yuanxin  Li</span>, <span class="hlFld-ContribAuthor ">Meng  Wang</span>, <span class="hlFld-ContribAuthor ">Jiajia  Yang</span>, <span class="hlFld-ContribAuthor ">Xiaowei  Wang</span>, <span class="hlFld-ContribAuthor ">Zhili  Zhang</span>, <span class="hlFld-ContribAuthor ">Junyi  Liu</span>. </span><span class="cited-content_cbyCitation_article-title">Synthesis and biological evaluation of 2,6-disubstituted-9H-purine, 2,4-disubstitued-thieno[3,2-d]pyrimidine and -7H-pyrrolo[2,3-d]pyrimidine analogues as novel CHK1 inhibitors. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2018,</strong> <em>151 </em>, 836-848. <a href="https://doi.org/10.1016/j.ejmech.2018.03.075" title="DOI URL">https://doi.org/10.1016/j.ejmech.2018.03.075</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2018.03.075&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2018.03.075%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DSynthesis%252Band%252Bbiological%252Bevaluation%252Bof%252B2%25252C6-disubstituted-9H-purine%25252C%252B2%25252C4-disubstitued-thieno%25255B3%25252C2-d%25255Dpyrimidine%252Band%252B-7H-pyrrolo%25255B2%25252C3-d%25255Dpyrimidine%252Banalogues%252Bas%252Bnovel%252BCHK1%252Binhibitors%26aulast%3DTian%26aufirst%3DChao%26date%3D2018%26volume%3D151%26spage%3D836%26epage%3D848" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Luca  Costantino</span>, <span class="hlFld-ContribAuthor ">Daniela  Barlocco</span>. </span><span class="cited-content_cbyCitation_article-title">Designing Approaches to Multitarget Drugs. </span><span class="cited-content_cbyCitation_journal-name"></span><span> <strong>2017,</strong>,, 161-205. <a href="https://doi.org/10.1002/9783527674381.ch7" title="DOI URL">https://doi.org/10.1002/9783527674381.ch7</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/9783527674381.ch7&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2F9783527674381.ch7%26sid%3Dliteratum%253Aachs%26atitle%3DDesigning%252BApproaches%252Bto%252BMultitarget%252BDrugs%26aulast%3DCostantino%26aufirst%3DLuca%26date%3D2017%26date%3D2017%26spage%3D161%26epage%3D205%26pub%3DWiley-VCH%2520Verlag%2520GmbH%2520%2526%2520Co.%2520KGaA%26atitle%3DDrug%252BSelectivity%26aulast%3DHandler%26aufirst%3DNorbert%26date%3D2017%26volume%3D5" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Udit  Chaube</span>, <span class="hlFld-ContribAuthor ">Hardik  Bhatt</span>. </span><span class="cited-content_cbyCitation_article-title">3D-QSAR, molecular dynamics simulations, and molecular docking studies on pyridoaminotropanes and tetrahydroquinazoline as mTOR inhibitors. </span><span class="cited-content_cbyCitation_journal-name">Molecular Diversity</span><span> <strong>2017,</strong> <em>21 </em>
                                    (3)
                                     , 741-759. <a href="https://doi.org/10.1007/s11030-017-9752-9" title="DOI URL">https://doi.org/10.1007/s11030-017-9752-9</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1007/s11030-017-9752-9&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1007%2Fs11030-017-9752-9%26sid%3Dliteratum%253Aachs%26jtitle%3DMolecular%2520Diversity%26atitle%3D3D-QSAR%25252C%252Bmolecular%252Bdynamics%252Bsimulations%25252C%252Band%252Bmolecular%252Bdocking%252Bstudies%252Bon%252Bpyridoaminotropanes%252Band%252Btetrahydroquinazoline%252Bas%252BmTOR%252Binhibitors%26aulast%3DChaube%26aufirst%3DUdit%26date%3D2017%26date%3D2017%26volume%3D21%26issue%3D3%26spage%3D741%26epage%3D759" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Beibei  Mao</span>, <span class="hlFld-ContribAuthor ">Shanyun  Gao</span>, <span class="hlFld-ContribAuthor ">Yiran  Weng</span>, <span class="hlFld-ContribAuthor ">Liangren  Zhang</span>, <span class="hlFld-ContribAuthor ">Lihe  Zhang</span>. </span><span class="cited-content_cbyCitation_article-title">Design, synthesis, and biological evaluation of imidazo[1,2- b ]pyridazine derivatives as mTOR inhibitors. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2017,</strong> <em>129 </em>, 135-150. <a href="https://doi.org/10.1016/j.ejmech.2017.02.015" title="DOI URL">https://doi.org/10.1016/j.ejmech.2017.02.015</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2017.02.015&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2017.02.015%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDesign%25252C%252Bsynthesis%25252C%252Band%252Bbiological%252Bevaluation%252Bof%252Bimidazo%25255B1%25252C2-%252Bb%252B%25255Dpyridazine%252Bderivatives%252Bas%252BmTOR%252Binhibitors%26aulast%3DMao%26aufirst%3DBeibei%26date%3D2017%26volume%3D129%26spage%3D135%26epage%3D150" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Yu  Liu</span>, <span class="hlFld-ContribAuthor ">Wen-zhu  Wan</span>, <span class="hlFld-ContribAuthor ">Yan  Li</span>, <span class="hlFld-ContribAuthor ">Guan-lian  Zhou</span>, <span class="hlFld-ContribAuthor ">Xin-guang  Liu</span>. </span><span class="cited-content_cbyCitation_article-title">Recent development of ATP-competitive small molecule phosphatidylinostitol-3-kinase inhibitors as anticancer agents. </span><span class="cited-content_cbyCitation_journal-name">Oncotarget</span><span> <strong>2017,</strong> <em>8 </em>
                                    (4)
                                     , 7181-7200. <a href="https://doi.org/10.18632/oncotarget.12742" title="DOI URL">https://doi.org/10.18632/oncotarget.12742</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.18632/oncotarget.12742&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.18632%2Foncotarget.12742%26sid%3Dliteratum%253Aachs%26jtitle%3DOncotarget%26atitle%3DRecent%252Bdevelopment%252Bof%252BATP-competitive%252Bsmall%252Bmolecule%252Bphosphatidylinostitol-3-kinase%252Binhibitors%252Bas%252Banticancer%252Bagents%26aulast%3DLiu%26aufirst%3DYu%26date%3D2017%26date%3D2016%26volume%3D8%26issue%3D4%26spage%3D7181%26epage%3D7200" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Xiaodong  Ma</span>, <span class="hlFld-ContribAuthor ">Xiaoqing  Lv</span>, <span class="hlFld-ContribAuthor ">Ni  Qiu</span>, <span class="hlFld-ContribAuthor ">Bo  Yang</span>, <span class="hlFld-ContribAuthor ">Qiaojun  He</span>, <span class="hlFld-ContribAuthor ">Yongzhou  Hu</span>. </span><span class="cited-content_cbyCitation_article-title">Discovery of novel quinoline-based mTOR inhibitors via introducing intra-molecular hydrogen bonding scaffold (iMHBS): The design, synthesis and biological evaluation. </span><span class="cited-content_cbyCitation_journal-name">Bioorganic & Medicinal Chemistry</span><span> <strong>2015,</strong> <em>23 </em>
                                    (24)
                                     , 7585-7596. <a href="https://doi.org/10.1016/j.bmc.2015.11.003" title="DOI URL">https://doi.org/10.1016/j.bmc.2015.11.003</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bmc.2015.11.003&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bmc.2015.11.003%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520%2526%2520Medicinal%2520Chemistry%26atitle%3DDiscovery%252Bof%252Bnovel%252Bquinoline-based%252BmTOR%252Binhibitors%252Bvia%252Bintroducing%252Bintra-molecular%252Bhydrogen%252Bbonding%252Bscaffold%252B%252528iMHBS%252529%25253A%252BThe%252Bdesign%25252C%252Bsynthesis%252Band%252Bbiological%252Bevaluation%26aulast%3DMa%26aufirst%3DXiaodong%26date%3D2015%26volume%3D23%26issue%3D24%26spage%3D7585%26epage%3D7596" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Yong  Zhang</span>, <span class="hlFld-ContribAuthor ">Kai  Zhang</span>, <span class="hlFld-ContribAuthor ">Meng  Zhao</span>, <span class="hlFld-ContribAuthor ">Lixia  Zhang</span>, <span class="hlFld-ContribAuthor ">Mingze  Qin</span>, <span class="hlFld-ContribAuthor ">Shuchun  Guo</span>, <span class="hlFld-ContribAuthor ">Yanfang  Zhao</span>, <span class="hlFld-ContribAuthor ">Ping  Gong</span>. </span><span class="cited-content_cbyCitation_article-title">Discovery of a novel class anti-proliferative agents and potential inhibitors of EGFR tyrosine kinases based on 4-anilinotetrahydropyrido[4,3-d]pyrimidine scaffold: Design, synthesis and biological evaluations. </span><span class="cited-content_cbyCitation_journal-name">Bioorganic & Medicinal Chemistry</span><span> <strong>2015,</strong> <em>23 </em>
                                    (15)
                                     , 4591-4607. <a href="https://doi.org/10.1016/j.bmc.2015.05.059" title="DOI URL">https://doi.org/10.1016/j.bmc.2015.05.059</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bmc.2015.05.059&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bmc.2015.05.059%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520%2526%2520Medicinal%2520Chemistry%26atitle%3DDiscovery%252Bof%252Ba%252Bnovel%252Bclass%252Banti-proliferative%252Bagents%252Band%252Bpotential%252Binhibitors%252Bof%252BEGFR%252Btyrosine%252Bkinases%252Bbased%252Bon%252B4-anilinotetrahydropyrido%25255B4%25252C3-d%25255Dpyrimidine%252Bscaffold%25253A%252BDesign%25252C%252Bsynthesis%252Band%252Bbiological%252Bevaluations%26aulast%3DZhang%26aufirst%3DYong%26date%3D2015%26volume%3D23%26issue%3D15%26spage%3D4591%26epage%3D4607" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Wufu  Zhu</span>, <span class="hlFld-ContribAuthor ">Chengyu  Sun</span>, <span class="hlFld-ContribAuthor ">Shan  Xu</span>, <span class="hlFld-ContribAuthor ">Chunjiang  Wu</span>, <span class="hlFld-ContribAuthor ">Jielian  Wu</span>, <span class="hlFld-ContribAuthor ">Mengze  Xu</span>, <span class="hlFld-ContribAuthor ">He  Zhao</span>, <span class="hlFld-ContribAuthor ">Le  Chen</span>, <span class="hlFld-ContribAuthor ">Weipeng  Zeng</span>, <span class="hlFld-ContribAuthor ">Pengwu  Zheng</span>. </span><span class="cited-content_cbyCitation_article-title">Design, synthesis, anticancer activity and docking studies of novel 4-morpholino-7,8-dihydro-5H-thiopyrano[4,3-d]pyrimidine derivatives as mTOR inhibitors. </span><span class="cited-content_cbyCitation_journal-name">Bioorganic & Medicinal Chemistry</span><span> <strong>2014,</strong> <em>22 </em>
                                    (24)
                                     , 6746-6754. <a href="https://doi.org/10.1016/j.bmc.2014.11.003" title="DOI URL">https://doi.org/10.1016/j.bmc.2014.11.003</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bmc.2014.11.003&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bmc.2014.11.003%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520%2526%2520Medicinal%2520Chemistry%26atitle%3DDesign%25252C%252Bsynthesis%25252C%252Banticancer%252Bactivity%252Band%252Bdocking%252Bstudies%252Bof%252Bnovel%252B4-morpholino-7%25252C8-dihydro-5H-thiopyrano%25255B4%25252C3-d%25255Dpyrimidine%252Bderivatives%252Bas%252BmTOR%252Binhibitors%26aulast%3DZhu%26aufirst%3DWufu%26date%3D2014%26volume%3D22%26issue%3D24%26spage%3D6746%26epage%3D6754" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Xiaoqing  Lv</span>, <span class="hlFld-ContribAuthor ">Xiaodong  Ma</span>, <span class="hlFld-ContribAuthor ">Yongzhou  Hu</span>. </span><span class="cited-content_cbyCitation_article-title">Furthering the design and the discovery of small molecule ATP-competitive mTOR inhibitors as an effective cancer treatment. </span><span class="cited-content_cbyCitation_journal-name">Expert Opinion on Drug Discovery</span><span> <strong>2013,</strong> <em>8 </em>
                                    (8)
                                     , 991-1012. <a href="https://doi.org/10.1517/17460441.2013.800479" title="DOI URL">https://doi.org/10.1517/17460441.2013.800479</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1517/17460441.2013.800479&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1517%2F17460441.2013.800479%26sid%3Dliteratum%253Aachs%26jtitle%3DExpert%2520Opinion%2520on%2520Drug%2520Discovery%26atitle%3DFurthering%252Bthe%252Bdesign%252Band%252Bthe%252Bdiscovery%252Bof%252Bsmall%252Bmolecule%252BATP-competitive%252BmTOR%252Binhibitors%252Bas%252Ban%252Beffective%252Bcancer%252Btreatment%26aulast%3DLv%26aufirst%3DXiaoqing%26date%3D2013%26date%3D2013%26volume%3D8%26issue%3D8%26spage%3D991%26epage%3D1012" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Wendy  Lee</span>, <span class="hlFld-ContribAuthor ">Daniel F.  Ortwine</span>, <span class="hlFld-ContribAuthor ">Philippe  Bergeron</span>, <span class="hlFld-ContribAuthor ">Kevin  Lau</span>, <span class="hlFld-ContribAuthor ">Lichuan  Lin</span>, <span class="hlFld-ContribAuthor ">Shiva  Malek</span>, <span class="hlFld-ContribAuthor ">Jim  Nonomiya</span>, <span class="hlFld-ContribAuthor ">Zhonghua  Pei</span>, <span class="hlFld-ContribAuthor ">Kirk D.  Robarge</span>, <span class="hlFld-ContribAuthor ">Stephen  Schmidt</span>, <span class="hlFld-ContribAuthor ">Steve  Sideris</span>, <span class="hlFld-ContribAuthor ">Joseph P.  Lyssikatos</span>. </span><span class="cited-content_cbyCitation_article-title">A hit to lead discovery of novel N-methylated imidazolo-, pyrrolo-, and pyrazolo-pyrimidines as potent and selective mTOR inhibitors. </span><span class="cited-content_cbyCitation_journal-name">Bioorganic & Medicinal Chemistry Letters</span><span> <strong>2013,</strong> <em>23 </em>
                                    (18)
                                     , 5097-5104. <a href="https://doi.org/10.1016/j.bmcl.2013.07.027" title="DOI URL">https://doi.org/10.1016/j.bmcl.2013.07.027</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bmcl.2013.07.027&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bmcl.2013.07.027%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520%2526%2520Medicinal%2520Chemistry%2520Letters%26atitle%3DA%252Bhit%252Bto%252Blead%252Bdiscovery%252Bof%252Bnovel%252BN-methylated%252Bimidazolo-%25252C%252Bpyrrolo-%25252C%252Band%252Bpyrazolo-pyrimidines%252Bas%252Bpotent%252Band%252Bselective%252BmTOR%252Binhibitors%26aulast%3DLee%26aufirst%3DWendy%26date%3D2013%26volume%3D23%26issue%3D18%26spage%3D5097%26epage%3D5104" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Deepak  Sampath</span>, <span class="hlFld-ContribAuthor ">Jason  Oeh</span>, <span class="hlFld-ContribAuthor ">Shelby K.  Wyatt</span>, <span class="hlFld-ContribAuthor ">Tim C.  Cao</span>, <span class="hlFld-ContribAuthor ">Hartmut  Koeppen</span>, <span class="hlFld-ContribAuthor ">Jeffrey  Eastham-Anderson</span>, <span class="hlFld-ContribAuthor ">Liliane  Robillard</span>, <span class="hlFld-ContribAuthor ">Calvin C.K.  Ho</span>, <span class="hlFld-ContribAuthor ">Jed  Ross</span>, <span class="hlFld-ContribAuthor ">Guanglei  Zhuang</span>, <span class="hlFld-ContribAuthor ">Hani Bou  Reslan</span>, <span class="hlFld-ContribAuthor ">Philip  Vitorino</span>, <span class="hlFld-ContribAuthor ">Kai H.  Barck</span>, <span class="hlFld-ContribAuthor ">Sharon E.  Ungersma</span>, <span class="hlFld-ContribAuthor ">Jean Michel  Vernes</span>, <span class="hlFld-ContribAuthor ">Maresa  Caunt</span>, <span class="hlFld-ContribAuthor ">Nick  Van Bruggen</span>, <span class="hlFld-ContribAuthor ">Weilan  Ye</span>, <span class="hlFld-ContribAuthor ">Ulka  Vijapurkar</span>, <span class="hlFld-ContribAuthor ">Yu-Ju Gloria  Meng</span>, <span class="hlFld-ContribAuthor ">Napoleone  Ferrara</span>, <span class="hlFld-ContribAuthor ">Lori S.  Friedman</span>, <span class="hlFld-ContribAuthor ">Richard A.D.  Carano</span>. </span><span class="cited-content_cbyCitation_article-title">Multimodal Microvascular Imaging Reveals that Selective Inhibition of Class I PI3K Is Sufficient to Induce an Antivascular Response. </span><span class="cited-content_cbyCitation_journal-name">Neoplasia</span><span> <strong>2013,</strong> <em>15 </em>
                                    (7)
                                     , 694-IN4. <a href="https://doi.org/10.1593/neo.13470" title="DOI URL">https://doi.org/10.1593/neo.13470</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1593/neo.13470&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1593%2Fneo.13470%26sid%3Dliteratum%253Aachs%26jtitle%3DNeoplasia%26atitle%3DMultimodal%252BMicrovascular%252BImaging%252BReveals%252Bthat%252BSelective%252BInhibition%252Bof%252BClass%252BI%252BPI3K%252BIs%252BSufficient%252Bto%252BInduce%252Ban%252BAntivascular%252BResponse%26aulast%3DSampath%26aufirst%3DDeepak%26date%3D2013%26volume%3D15%26issue%3D7%26spage%3D694%26epage%3DIN4" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li></ol></div></div></div></div></div><div class="article_content-right" id="article_content-right" tabindex="0"><div class="tab tab--flex"><div class="tab__close"><i class="icon-close" tabindex="0" aria-label="close the sidebar."></i></div><ul role="tablist" class="rlist tab__nav"><li role="presentation" class="active"><a id="pane-m1con" href="#pane-m1" aria-controls="pane-m1" role="tab" data-toggle="tab" title="Figures" aria-selected="true" class="active empty" aria-label="Figures"><i class="icon-image"></i><span>Figures</span></a></li><li role="presentation"><a id="pane-m2con" href="#pane-m2" aria-controls="pane-m2" role="tab" data-toggle="tab" title="References" aria-selected="false" class="empty"><i class="icon-link"></i><span>References</span></a></li><li role="presentation"><a id="pane-m3con" href="#pane-m3" aria-controls="pane-m3" role="tab" data-toggle="tab" title="Support Info" aria-selected="false" class="empty tab__nav-suppInfo"><i class="icon-supporting-info"></i><span>Support Info</span></a></li></ul><div class="paneContainer"><ul class="rlist tab__content"><li id="pane-m1" aria-labelledby="pane-m1" class="tab__pane tab__pane-figures active empty"><figure data-id="f_tgr1" data-index="0" class="article__inlineFigure"><h2 class="fig-label">Abstract</h2><img class="rightTab-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-24/jm301389h/production/images/medium/jm-2012-01389h_0015.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-24/jm301389h/production/images/large/jm-2012-01389h_0015.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm301389h&amp;id=f_tgr1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-24/jm301389h/production/images/medium/jm-2012-01389h_0001.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-24/jm301389h/production/images/large/jm-2012-01389h_0001.jpeg" id="rightTab-gr1" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Rapamycin and its analogs <b>1a</b>–<b>c</b>, selective PI3K inhibitor <b>2</b> (GDC-0941), dual PI3K/mTOR inhibitor <b>3</b> (GDC-0980), and <b>4</b>, which exhibits 20-fold mTOR selectivity.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-24/jm301389h/production/images/large/jm-2012-01389h_0001.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm301389h&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch1" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Scheme 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-24/jm301389h/production/images/medium/jm-2012-01389h_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-24/jm301389h/production/images/large/jm-2012-01389h_0007.jpeg" id="rightTab-gr7" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 1. Synthesis of Pyrrolopyrimidines <b>6a</b>–<b>e</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-24/jm301389h/production/images/large/jm-2012-01389h_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm301389h&amp;id=sch1"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (a) morpholine, DIPEA, 90%; (b) (4-ethylurido)phenylboronic acid pinacol ester, Pd(PPh<sub>3</sub>)<sub>4</sub>, KOAc, Na<sub>2</sub>CO<sub>3</sub>, H<sub>2</sub>O/CH<sub>3</sub>CN, 120 °C, 96%; (c) TFA, CH<sub>2</sub>Cl<sub>2</sub>, then PS-carbonate resin; (d) electrophile, DIPEA, CH<sub>2</sub>Cl<sub>2</sub>, (e) 2-chloropyrimidine, DIPEA, DMF, 120 °C.</p></p></figure><figure data-id="sch2" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Scheme 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-24/jm301389h/production/images/medium/jm-2012-01389h_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-24/jm301389h/production/images/large/jm-2012-01389h_0008.jpeg" id="rightTab-gr8" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 2. Synthesis of 6-Aza-tetrahydroquinazolines <b>10</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-24/jm301389h/production/images/large/jm-2012-01389h_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm301389h&amp;id=sch2"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (a) urea, MeOH, NaOMe, reflux, 64%; (b) POCl<sub>3</sub>, reflux, 75%; (c) ACE-Cl, CH<sub>2</sub>Cl<sub>2</sub>, 0 °C to rt, then reflux; (d) MeOH, reflux; (e) PS-carbonate resin, Boc<sub>2</sub>O, CH<sub>2</sub>Cl<sub>2</sub>, 88% for three steps; (f) morpholine or (<i>S</i>)-methylmorpholine, DIPEA, DMF; (g) (4-ethylurido)phenylboronic acid pinacol ester, Pd(PPh<sub>3</sub>)<sub>4</sub>, KOAc, Na<sub>2</sub>CO<sub>3</sub>, H<sub>2</sub>O/CH<sub>3</sub>CN, 120 °C; (h) TFA, CH<sub>2</sub>Cl<sub>2</sub>, then PS-carbonate resin; (i) electrophile, DIPEA, CH<sub>2</sub>Cl<sub>2</sub>.</p></p></figure><figure data-id="fig2" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-24/jm301389h/production/images/medium/jm-2012-01389h_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-24/jm301389h/production/images/large/jm-2012-01389h_0002.jpeg" id="rightTab-gr2" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. Compound <b>10f</b> docked into a homology model of mTOR that was built using PI3Kγ as a template.<a onclick="showRef(event, 'ref9'); return false;" href="javascript:void(0);" class="ref ref9">(9)</a> Residues differing from those in PI3Kγ are labeled. The molecular surfaces for both ligand and protein are shown to illustrate the intimate interaction provided by the presence of the (<i>S</i>)-methyl substituent on the morpholine. The protein surface is color coded by hydrophobicity (tan-brown is hydrophobic, cyan-blue is hydrophilic, and green is in between). The ligand surface is magenta.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-24/jm301389h/production/images/large/jm-2012-01389h_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm301389h&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch3" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Scheme 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-24/jm301389h/production/images/medium/jm-2012-01389h_0009.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-24/jm301389h/production/images/large/jm-2012-01389h_0009.jpeg" id="rightTab-gr9" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 3. Synthesis of 7-Aza-tetrahydroquinazolines <b>12a</b>–<b>g</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-24/jm301389h/production/images/large/jm-2012-01389h_0009.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm301389h&amp;id=sch3"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (a) morpholine, DIPEA; (b) (4-ethylurido)phenylboronic acid pinacol ester, Pd(PPh<sub>3</sub>)<sub>4</sub>, KOAc, Na<sub>2</sub>CO<sub>3</sub>, H<sub>2</sub>O/CH<sub>3</sub>CN, 120 °C; (c) TFA, CH<sub>2</sub>Cl<sub>2</sub>, then PS-carbonate resin; (d) electrophile, DIPEA, CH<sub>2</sub>Cl<sub>2</sub>; (e) 4-hydroxyphenylboronic acid pinacol ester, Pd(PPh<sub>3</sub>)<sub>4</sub>, KOAc, Na<sub>2</sub>CO<sub>3</sub>, H<sub>2</sub>O/CH<sub>3</sub>CN, 120 °C, 89%; (f) EtNCO, THF, 70 °C, 24 h, 38%; (g) 4-aminophenylboronic acid pinacol ester, Pd(PPh<sub>3</sub>)<sub>4</sub>, KOAc, Na<sub>2</sub>CO<sub>3</sub>, H<sub>2</sub>O/CH<sub>3</sub>CN, 120 °C, 86%; (h) ethyl chloroformate, THF, DIPEA, 70%.</p></p></figure><figure data-id="fig3" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-24/jm301389h/production/images/medium/jm-2012-01389h_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-24/jm301389h/production/images/large/jm-2012-01389h_0003.jpeg" id="rightTab-gr3" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. Compound <b>12i</b> docked into a homology model of mTOR that was built using PI3Kγ as a template.<a onclick="showRef(event, 'ref9'); return false;" href="javascript:void(0);" class="ref ref9">(9)</a> Residues differing from those in PI3Kγ are labeled. Predicted hydrogen-bonding interactions with the protein are shown as dashed ovals, and the molecular surfaces for both ligand and protein are shown to illustrate the intimate interaction provided by the presence of the (<i>S</i>)-methyl substituent on the morpholine. The protein surface is color coded by hydrophobicity (tan-brown is hydrophobic, cyan-blue is hydrophilic, and green is in between). The ligand surface is yellow.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-24/jm301389h/production/images/large/jm-2012-01389h_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm301389h&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig4" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-24/jm301389h/production/images/medium/jm-2012-01389h_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-24/jm301389h/production/images/large/jm-2012-01389h_0004.jpeg" id="rightTab-gr4" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. Plasma levels of <b>12h</b> and <b>12i</b> 6 h following oral administration in PC3 tumor-bearing mice along with the fold decreases of phosphorylated mTORC1 and -2 substrates relative to time-matched vehicle controls. Error bars represent one standard deviation from the depicted mean value. Four mice were dosed for each compound, and phosphoprotein levels were measured in duplicate samples for each mouse.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-24/jm301389h/production/images/large/jm-2012-01389h_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm301389h&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig5" data-index="8" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-24/jm301389h/production/images/medium/jm-2012-01389h_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-24/jm301389h/production/images/large/jm-2012-01389h_0005.jpeg" id="rightTab-gr5" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. Plasma levels of <b>12i</b> and rapamycin following administration in U87 tumor-bearing mice along with the fraction of phosphorylated mTORC1 and -2 substrates relative to time-matched vehicle controls. Error bars represent one standard deviation from the depicted mean value. Four mice were dosed for each compound and time point, and phosphoprotein levels were measured in duplicate samples for each mouse.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-24/jm301389h/production/images/large/jm-2012-01389h_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm301389h&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig6" data-index="9" class="article__inlineFigure"><h2 class="fig-label">Figure 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-24/jm301389h/production/images/medium/jm-2012-01389h_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-24/jm301389h/production/images/large/jm-2012-01389h_0006.jpeg" id="rightTab-gr6" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 6. Growth inhibition curves for compounds <b>12h</b> (a) and <b>12i</b> (b) used to treat subcutaneously implanted PC3 tumors in mice.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-24/jm301389h/production/images/large/jm-2012-01389h_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm301389h&amp;id=fig6"><span>Download MS PowerPoint Slide</span></a></div></div></figure></li><li id="pane-m2" aria-labelledby="pane-m2" class="tab__pane tab__pane-references empty"><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-_i53">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_72482" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_72482" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="rightTab-references-count">
            This article references 39 other publications.
        </p><ol id="rightTab-references" class="useLabel"><li id="rightTab-ref1"><div class="reference"><strong class="refLabel"><a href="#ref1" class="rightTabRefNumLink">1</a></strong><div class="NLM_citation" id="rightTab-cit1"><span><span class="NLM_contrib-group">Baselga, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Campone, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Piccart, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Burris, H. A.,  III</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rugo, H. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sahmoud, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Noguchi, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gnant, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pritchard, K. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lebrun, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Beck, J. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ito, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yardley, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Deleu, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Perez, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bachelot, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vittori, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xu, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mukhopadhyay, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lebwohl, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hortobagyi, G. N.</span><span> </span><span class="NLM_article-title">Everolimus in Postmenopausal Hormone-Receptor–Positive Advanced Breast Cancer</span> <span class="citation_source-journal">N. Engl. J. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">366</span><span class="NLM_x">, </span> <span class="NLM_fpage">520</span><span class="NLM_x">–</span> <span class="NLM_lpage">529</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=16&amp;doi=10.1021%2Fjm301389h&amp;key=10.1056%2FNEJMoa1109653" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=8&amp;doi=10.1021%2Fjm301389h&amp;key=22149876" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=366&publication_year=2011&pages=520-529&author=J.+Baselgaauthor=M.+Camponeauthor=M.+Piccartauthor=H.+A.+Burrisauthor=H.+S.+Rugoauthor=T.+Sahmoudauthor=S.+Noguchiauthor=M.+Gnantauthor=K.+I.+Pritchardauthor=F.+Lebrunauthor=J.+T.+Beckauthor=Y.+Itoauthor=D.+Yardleyauthor=I.+Deleuauthor=A.+Perezauthor=T.+Bachelotauthor=L.+Vittoriauthor=Z.+Xuauthor=P.+Mukhopadhyayauthor=D.+Lebwohlauthor=G.+N.+Hortobagyi&title=Everolimus+in+Postmenopausal+Hormone-Receptor%E2%80%93Positive+Advanced+Breast+Cancer"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa1109653&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa1109653%26sid%3Dliteratum%253Aachs%26aulast%3DBaselga%26aufirst%3DJ.%26aulast%3DCampone%26aufirst%3DM.%26aulast%3DPiccart%26aufirst%3DM.%26aulast%3DBurris%26aufirst%3DH.%2BA.%26aulast%3DRugo%26aufirst%3DH.%2BS.%26aulast%3DSahmoud%26aufirst%3DT.%26aulast%3DNoguchi%26aufirst%3DS.%26aulast%3DGnant%26aufirst%3DM.%26aulast%3DPritchard%26aufirst%3DK.%2BI.%26aulast%3DLebrun%26aufirst%3DF.%26aulast%3DBeck%26aufirst%3DJ.%2BT.%26aulast%3DIto%26aufirst%3DY.%26aulast%3DYardley%26aufirst%3DD.%26aulast%3DDeleu%26aufirst%3DI.%26aulast%3DPerez%26aufirst%3DA.%26aulast%3DBachelot%26aufirst%3DT.%26aulast%3DVittori%26aufirst%3DL.%26aulast%3DXu%26aufirst%3DZ.%26aulast%3DMukhopadhyay%26aufirst%3DP.%26aulast%3DLebwohl%26aufirst%3DD.%26aulast%3DHortobagyi%26aufirst%3DG.%2BN.%26atitle%3DEverolimus%2520in%2520Postmenopausal%2520Hormone-Receptor%25E2%2580%2593Positive%2520Advanced%2520Breast%2520Cancer%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2011%26volume%3D366%26spage%3D520%26epage%3D529" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref2"><div class="reference"><strong class="refLabel"><a href="#ref2" class="rightTabRefNumLink">2</a></strong><div class="NLM_citation" id="rightTab-cit2"><span><span class="NLM_contrib-group">Sabatini, D. M.</span><span> </span><span class="NLM_article-title">mTOR and cancer: Insights into a complex relationship</span> <span class="citation_source-journal">Nat. Rev. Cancer</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">6</span><span class="NLM_x">, </span> <span class="NLM_fpage">729</span><span class="NLM_x">–</span> <span class="NLM_lpage">734</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=16&amp;doi=10.1021%2Fjm301389h&amp;key=10.1038%2Fnrc1974" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=8&amp;doi=10.1021%2Fjm301389h&amp;key=16915295" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=32&amp;doi=10.1021%2Fjm301389h&amp;key=1%3ACAS%3A528%3ADC%252BD28XosVOmsb8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2006&pages=729-734&author=D.+M.+Sabatini&title=mTOR+and+cancer%3A+Insights+into+a+complex+relationship"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit2R"><div class="casContent"><span class="casTitleNuber">2</span><div class="casTitle"><span class="NLM_cas:atitle">mTOR and cancer: insights into a complex relationship</span></div><div class="casAuthors">Sabatini, David M.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Cancer</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">729-734</span>CODEN:
                <span class="NLM_cas:coden">NRCAC4</span>;
        ISSN:<span class="NLM_cas:issn">1474-175X</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  MTOR (mammalian target of rapamycin) has come a long way since its humble beginnings as a kinase of unknown function.  As part of the mTORC1 and mTORC2 complexes mTOR has key roles in several pathways that are involved in human cancer, stimulating interest in mTOR inhibitors and placing it on the radar of the pharmaceutical industry.  Here, I discuss the rationale for the use of drugs that target mTOR, the unexpectedly complex mechanism of action of existing mTOR inhibitors and the potential benefits of developing drugs that function through different mechanisms.  The purpose is not to cover all aspects of mTOR history and signaling, but rather to foster discussion by presenting some occasionally provocative ideas.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrpzXc4_s5VirVg90H21EOLACvtfcHk0lhWlvyJIdGz6A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XosVOmsb8%253D&md5=9d55f700e24be158715ecb13200d9cbf</span></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.1038%2Fnrc1974&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrc1974%26sid%3Dliteratum%253Aachs%26aulast%3DSabatini%26aufirst%3DD.%2BM.%26atitle%3DmTOR%2520and%2520cancer%253A%2520Insights%2520into%2520a%2520complex%2520relationship%26jtitle%3DNat.%2520Rev.%2520Cancer%26date%3D2006%26volume%3D6%26spage%3D729%26epage%3D734" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref3"><div class="reference"><strong class="refLabel"><a href="#ref3" class="rightTabRefNumLink">3</a></strong><div class="NLM_citation" id="rightTab-cit3"><span><span class="NLM_contrib-group">Liu, K. K. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bailey, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dinh, D. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lam, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wells, P. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yin, M.-J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zou, A.</span><span> </span><span class="NLM_article-title">Conformationally-restricted cyclic sulfones as potent and selective mTOR kinase inhibitors</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">22</span><span class="NLM_x">, </span> <span class="NLM_fpage">5114</span><span class="NLM_x">–</span> <span class="NLM_lpage">5117</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Fjm301389h&amp;key=10.1016%2Fj.bmcl.2012.05.104" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=8&amp;doi=10.1021%2Fjm301389h&amp;key=22765900" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=32&amp;doi=10.1021%2Fjm301389h&amp;key=1%3ACAS%3A528%3ADC%252BC38Xps1Kmsro%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=2012&pages=5114-5117&author=K.+K.+C.+Liuauthor=S.+Baileyauthor=D.+M.+Dinhauthor=H.+Lamauthor=C.+Liauthor=P.+A.+Wellsauthor=M.-J.+Yinauthor=A.+Zou&title=Conformationally-restricted+cyclic+sulfones+as+potent+and+selective+mTOR+kinase+inhibitors"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit3R"><div class="casContent"><span class="casTitleNuber">3</span><div class="casTitle"><span class="NLM_cas:atitle">Conformationally-restricted cyclic sulfones as potent and selective mTOR kinase inhibitors</span></div><div class="casAuthors">Liu, Kevin K.-C.; Bailey, Simon; Dinh, Dac M.; Lam, Hieu; Li, Chunze; Wells, Peter A.; Yin, Min-Jean; Zou, Aihua</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">22</span>
        (<span class="NLM_cas:issue">15</span>),
    <span class="NLM_cas:pages">5114-5117</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Novel conformationally-restricted mTOR kinase inhibitors with cyclic sulfone scaffold were designed.  Synthesis and structure-activity relationship (SAR) studies are described with emphasis on optimization of the mTOR potency and selectivity against class I PI3Kα kinase.  PF-05139962 I was identified with excellent mTOR biochem. inhibition, cellular potency, kinase selectivity and in vitro ADME properties.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrmuwjN05w_4LVg90H21EOLACvtfcHk0lhWlvyJIdGz6A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xps1Kmsro%253D&md5=c1abe951c4d17f22a2301004eff55d91</span></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2012.05.104&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2012.05.104%26sid%3Dliteratum%253Aachs%26aulast%3DLiu%26aufirst%3DK.%2BK.%2BC.%26aulast%3DBailey%26aufirst%3DS.%26aulast%3DDinh%26aufirst%3DD.%2BM.%26aulast%3DLam%26aufirst%3DH.%26aulast%3DLi%26aufirst%3DC.%26aulast%3DWells%26aufirst%3DP.%2BA.%26aulast%3DYin%26aufirst%3DM.-J.%26aulast%3DZou%26aufirst%3DA.%26atitle%3DConformationally-restricted%2520cyclic%2520sulfones%2520as%2520potent%2520and%2520selective%2520mTOR%2520kinase%2520inhibitors%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2012%26volume%3D22%26spage%3D5114%26epage%3D5117" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref4"><div class="reference"><strong class="refLabel"><a href="#ref4" class="rightTabRefNumLink">4</a></strong><div class="NLM_citation" id="rightTab-cit4"><span><span class="NLM_contrib-group">Peterson, E. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Boezio, A. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Andrews, P. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Boezio, C. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bush, T. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cheng, A. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Choquette, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Coats, J. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Colletti, A. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Copeland, K. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">DuPont, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Graceffa, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Grubinska, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, J. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lewis, R. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mullady, E. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Potashman, M. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Romero, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shaffer, P. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stanton, M. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stellwagen, J. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Teffera, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yi, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cai, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">La, D. S.</span><span> </span><span class="NLM_article-title">Discovery and optimization of potent and selective imidazopyridine and imidazopyridazine mTOR inhibitors</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">22</span><span class="NLM_x">, </span> <span class="NLM_fpage">4967</span><span class="NLM_x">–</span> <span class="NLM_lpage">4974</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=2012&pages=4967-4974&author=E.+A.+Petersonauthor=A.+A.+Boezioauthor=P.+S.+Andrewsauthor=C.+M.+Boezioauthor=T.+L.+Bushauthor=A.+C.+Chengauthor=D.+Choquetteauthor=J.+R.+Coatsauthor=A.+E.+Collettiauthor=K.+W.+Copelandauthor=M.+DuPontauthor=R.+Graceffaauthor=B.+Grubinskaauthor=J.+L.+Kimauthor=R.+T.+Lewisauthor=J.+Liuauthor=E.+L.+Mulladyauthor=M.+H.+Potashmanauthor=K.+Romeroauthor=P.+L.+Shafferauthor=M.+K.+Stantonauthor=J.+C.+Stellwagenauthor=Y.+Tefferaauthor=S.+Yiauthor=T.+Caiauthor=D.+S.+La&title=Discovery+and+optimization+of+potent+and+selective+imidazopyridine+and+imidazopyridazine+mTOR+inhibitors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DPeterson%26aufirst%3DE.%2BA.%26aulast%3DBoezio%26aufirst%3DA.%2BA.%26aulast%3DAndrews%26aufirst%3DP.%2BS.%26aulast%3DBoezio%26aufirst%3DC.%2BM.%26aulast%3DBush%26aufirst%3DT.%2BL.%26aulast%3DCheng%26aufirst%3DA.%2BC.%26aulast%3DChoquette%26aufirst%3DD.%26aulast%3DCoats%26aufirst%3DJ.%2BR.%26aulast%3DColletti%26aufirst%3DA.%2BE.%26aulast%3DCopeland%26aufirst%3DK.%2BW.%26aulast%3DDuPont%26aufirst%3DM.%26aulast%3DGraceffa%26aufirst%3DR.%26aulast%3DGrubinska%26aufirst%3DB.%26aulast%3DKim%26aufirst%3DJ.%2BL.%26aulast%3DLewis%26aufirst%3DR.%2BT.%26aulast%3DLiu%26aufirst%3DJ.%26aulast%3DMullady%26aufirst%3DE.%2BL.%26aulast%3DPotashman%26aufirst%3DM.%2BH.%26aulast%3DRomero%26aufirst%3DK.%26aulast%3DShaffer%26aufirst%3DP.%2BL.%26aulast%3DStanton%26aufirst%3DM.%2BK.%26aulast%3DStellwagen%26aufirst%3DJ.%2BC.%26aulast%3DTeffera%26aufirst%3DY.%26aulast%3DYi%26aufirst%3DS.%26aulast%3DCai%26aufirst%3DT.%26aulast%3DLa%26aufirst%3DD.%2BS.%26atitle%3DDiscovery%2520and%2520optimization%2520of%2520potent%2520and%2520selective%2520imidazopyridine%2520and%2520imidazopyridazine%2520mTOR%2520inhibitors%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2012%26volume%3D22%26spage%3D4967%26epage%3D4974" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref5"><div class="reference"><strong class="refLabel"><a href="#ref5" class="rightTabRefNumLink">5</a></strong><div class="NLM_citation" id="rightTab-cit5"><span><span class="NLM_contrib-group">Finlay, M. R. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Buttar, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Critchlow, S. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dishington, A. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fillery, S. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fisher, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Glossop, S. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Graham, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Johnson, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lamont, G. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mutton, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Perkins, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pike, K. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Slater, A. M.</span><span> </span><span class="NLM_article-title">Sulfonyl-morpholino-pyrimidines: SAR and development of a novel class of selective mTOR kinase inhibitor</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">22</span><span class="NLM_x">, </span> <span class="NLM_fpage">4163</span><span class="NLM_x">–</span> <span class="NLM_lpage">4168</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=2012&pages=4163-4168&author=M.+R.+V.+Finlayauthor=D.+Buttarauthor=S.+E.+Critchlowauthor=A.+P.+Dishingtonauthor=S.+M.+Filleryauthor=E.+Fisherauthor=S.+C.+Glossopauthor=M.+A.+Grahamauthor=T.+Johnsonauthor=G.+M.+Lamontauthor=S.+Muttonauthor=P.+Perkinsauthor=K.+G.+Pikeauthor=A.+M.+Slater&title=Sulfonyl-morpholino-pyrimidines%3A+SAR+and+development+of+a+novel+class+of+selective+mTOR+kinase+inhibitor"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DFinlay%26aufirst%3DM.%2BR.%2BV.%26aulast%3DButtar%26aufirst%3DD.%26aulast%3DCritchlow%26aufirst%3DS.%2BE.%26aulast%3DDishington%26aufirst%3DA.%2BP.%26aulast%3DFillery%26aufirst%3DS.%2BM.%26aulast%3DFisher%26aufirst%3DE.%26aulast%3DGlossop%26aufirst%3DS.%2BC.%26aulast%3DGraham%26aufirst%3DM.%2BA.%26aulast%3DJohnson%26aufirst%3DT.%26aulast%3DLamont%26aufirst%3DG.%2BM.%26aulast%3DMutton%26aufirst%3DS.%26aulast%3DPerkins%26aufirst%3DP.%26aulast%3DPike%26aufirst%3DK.%2BG.%26aulast%3DSlater%26aufirst%3DA.%2BM.%26atitle%3DSulfonyl-morpholino-pyrimidines%253A%2520SAR%2520and%2520development%2520of%2520a%2520novel%2520class%2520of%2520selective%2520mTOR%2520kinase%2520inhibitor%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2012%26volume%3D22%26spage%3D4163%26epage%3D4168" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref6"><div class="reference"><strong class="refLabel"><a href="#ref6" class="rightTabRefNumLink">6</a></strong><div class="NLM_citation" id="rightTab-cit6"><span><span class="NLM_contrib-group">Mortensen, D. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Perrin-Ninkovic, S. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Harris, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, B. G. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shevlin, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hickman, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Khambatta, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bisonette, R. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fultz, K. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sankar, S.</span><span> </span><span class="NLM_article-title">Discovery and SAR exploration of a novel series of imidazo[4,5-<i>b</i>]pyrazin-2-ones as potent and selective mTOR kinase inhibitors</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">21</span><span class="NLM_x">, </span> <span class="NLM_fpage">6793</span><span class="NLM_x">–</span> <span class="NLM_lpage">6799</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=16&amp;doi=10.1021%2Fjm301389h&amp;key=10.1016%2Fj.bmcl.2011.09.035" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=8&amp;doi=10.1021%2Fjm301389h&amp;key=21978683" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=32&amp;doi=10.1021%2Fjm301389h&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhtlKktr3P" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2011&pages=6793-6799&author=D.+S.+Mortensenauthor=S.+M.+Perrin-Ninkovicauthor=R.+Harrisauthor=B.+G.+S.+Leeauthor=G.+Shevlinauthor=M.+Hickmanauthor=G.+Khambattaauthor=R.+R.+Bisonetteauthor=K.+E.+Fultzauthor=S.+Sankar&title=Discovery+and+SAR+exploration+of+a+novel+series+of+imidazo%5B4%2C5-b%5Dpyrazin-2-ones+as+potent+and+selective+mTOR+kinase+inhibitors"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit6R"><div class="casContent"><span class="casTitleNuber">6</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery and SAR exploration of a novel series of imidazo[4,5-b]pyrazin-2-ones as potent and selective mTOR kinase inhibitors</span></div><div class="casAuthors">Mortensen, Deborah S.; Perrin-Ninkovic, Sophie M.; Harris, Roy; Lee, Branden G. S.; Shevlin, Graziella; Hickman, Matt; Khambatta, Gody; Bisonette, Rene R.; Fultz, Kimberly E.; Sankar, Sabita</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">21</span>
        (<span class="NLM_cas:issue">22</span>),
    <span class="NLM_cas:pages">6793-6799</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">We report here the discovery of a novel series of selective mTOR kinase inhibitors.  A series of imidazo[4,5-b]pyrazin-2-ones, represented by screening hit 1, was developed into lead compds. with excellent mTOR potency and exquisite kinase selectivity.  Potent compds. from this series show >1000-fold selectivity over the related PI3Kα lipid kinase.  Further, compds. such as 2 achieve mTOR pathway inhibition, blocking both mTORC1 and mTORC2 signaling, in PC3 cancer cells as measured by inhibition of pS6 and pAkt (S473).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrWly4sBJXgerVg90H21EOLACvtfcHk0liYN7ccNTFnqQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhtlKktr3P&md5=d422a7d505c1032951547d997ac2e033</span></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2011.09.035&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2011.09.035%26sid%3Dliteratum%253Aachs%26aulast%3DMortensen%26aufirst%3DD.%2BS.%26aulast%3DPerrin-Ninkovic%26aufirst%3DS.%2BM.%26aulast%3DHarris%26aufirst%3DR.%26aulast%3DLee%26aufirst%3DB.%2BG.%2BS.%26aulast%3DShevlin%26aufirst%3DG.%26aulast%3DHickman%26aufirst%3DM.%26aulast%3DKhambatta%26aufirst%3DG.%26aulast%3DBisonette%26aufirst%3DR.%2BR.%26aulast%3DFultz%26aufirst%3DK.%2BE.%26aulast%3DSankar%26aufirst%3DS.%26atitle%3DDiscovery%2520and%2520SAR%2520exploration%2520of%2520a%2520novel%2520series%2520of%2520imidazo%255B4%252C5-b%255Dpyrazin-2-ones%2520as%2520potent%2520and%2520selective%2520mTOR%2520kinase%2520inhibitors%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2011%26volume%3D21%26spage%3D6793%26epage%3D6799" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref7"><div class="reference"><strong class="refLabel"><a href="#ref7" class="rightTabRefNumLink">7</a></strong><div class="NLM_citation" id="rightTab-cit7"><span><span class="NLM_contrib-group">Bhagwat, S. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gokhale, P. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Crew, A. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cooke, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yao, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mantis, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kahler, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Workman, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bittner, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dudkin, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Epstein, D. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gibson, N. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wild, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Arnold, L. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Houghton, P. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pachter, J. A.</span><span> </span><span class="NLM_article-title">Preclinical Characterization of OSI-027, a Potent and Selective Inhibitor of mTORC1 and mTORC2: Distinct from Rapamycin</span> <span class="citation_source-journal">Mol. Cancer Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">10</span><span class="NLM_x">, </span> <span class="NLM_fpage">1394</span><span class="NLM_x">–</span> <span class="NLM_lpage">1406</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=16&amp;doi=10.1021%2Fjm301389h&amp;key=10.1158%2F1535-7163.MCT-10-1099" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=8&amp;doi=10.1021%2Fjm301389h&amp;key=21673091" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=32&amp;doi=10.1021%2Fjm301389h&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhtFSqtLnF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2011&pages=1394-1406&author=S.+V.+Bhagwatauthor=P.+C.+Gokhaleauthor=A.+P.+Crewauthor=A.+Cookeauthor=Y.+Yaoauthor=C.+Mantisauthor=J.+Kahlerauthor=J.+Workmanauthor=M.+Bittnerauthor=L.+Dudkinauthor=D.+M.+Epsteinauthor=N.+W.+Gibsonauthor=R.+Wildauthor=L.+D.+Arnoldauthor=P.+J.+Houghtonauthor=J.+A.+Pachter&title=Preclinical+Characterization+of+OSI-027%2C+a+Potent+and+Selective+Inhibitor+of+mTORC1+and+mTORC2%3A+Distinct+from+Rapamycin"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit7R"><div class="casContent"><span class="casTitleNuber">7</span><div class="casTitle"><span class="NLM_cas:atitle">Preclinical characterization of OSI-027, a potent and selective inhibitor of mTORC1 and mTORC2: distinct from rapamycin</span></div><div class="casAuthors">Bhagwat, Shripad V.; Gokhale, Prafulla C.; Crew, Andrew P.; Cooke, Andy; Yao, Yan; Mantis, Christine; Kahler, Jennifer; Workman, Jennifer; Bittner, Mark; Dudkin, Lorina; Epstein, David M.; Gibson, Neil W.; Wild, Robert; Arnold, Lee D.; Houghton, Peter J.; Pachter, Jonathan A.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer Therapeutics</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">1394-1406</span>CODEN:
                <span class="NLM_cas:coden">MCTOCF</span>;
        ISSN:<span class="NLM_cas:issn">1535-7163</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">The phosphoinositide 3-kinase (PI3K)/AKT/mTOR pathway is frequently activated in human cancers, and mTOR is a clin. validated target.  MTOR forms two distinct multiprotein complexes, mTORC1 and mTORC2, which regulate cell growth, metab., proliferation, and survival.  Rapamycin and its analogs partially inhibit mTOR through allosteric binding to mTORC1, but not mTORC2, and have shown clin. utility in certain cancers.  Here, we report the preclin. characterization of OSI-027, a selective and potent dual inhibitor of mTORC1 and mTORC2 with biochem. IC50 values of 22 nmol/L and 65 nmol/L, resp.  OSI-027 shows more than 100-fold selectivity for mTOR relative to PI3Kα, PI3Kβ, PI3Kγ, and DNA-PK.  OSI-027 inhibits phosphorylation of the mTORC1 substrates 4E-BP1 and S6K1 as well as the mTORC2 substrate AKT in diverse cancer models in vitro and in vivo.  OSI-027 and OXA-01 (close analog of OSI-027) potently inhibit proliferation of several rapamycin-sensitive and -insensitive nonengineered and engineered cancer cell lines and also, induce cell death in tumor cell lines with activated PI3K-AKT signaling.  OSI-027 shows concn.-dependent pharmacodynamic effects on phosphorylation of 4E-BP1 and AKT in tumor tissue with resulting tumor growth inhibition.  OSI-027 shows robust antitumor activity in several different human xenograft models representing various histologies.  Furthermore, in COLO 205 and GEO colon cancer xenograft models, OSI-027 shows superior efficacy compared with rapamycin.  Our results further support the important role of mTOR as a driver of tumor growth and establish OSI-027 as a potent anticancer agent.  OSI-027 is currently in phase I clin. trials in cancer patients.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqLyA6Bn0nZqbVg90H21EOLACvtfcHk0liYN7ccNTFnqQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhtFSqtLnF&md5=8d91103e12ab5c632571f17510b3ee7f</span></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.1158%2F1535-7163.MCT-10-1099&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1535-7163.MCT-10-1099%26sid%3Dliteratum%253Aachs%26aulast%3DBhagwat%26aufirst%3DS.%2BV.%26aulast%3DGokhale%26aufirst%3DP.%2BC.%26aulast%3DCrew%26aufirst%3DA.%2BP.%26aulast%3DCooke%26aufirst%3DA.%26aulast%3DYao%26aufirst%3DY.%26aulast%3DMantis%26aufirst%3DC.%26aulast%3DKahler%26aufirst%3DJ.%26aulast%3DWorkman%26aufirst%3DJ.%26aulast%3DBittner%26aufirst%3DM.%26aulast%3DDudkin%26aufirst%3DL.%26aulast%3DEpstein%26aufirst%3DD.%2BM.%26aulast%3DGibson%26aufirst%3DN.%2BW.%26aulast%3DWild%26aufirst%3DR.%26aulast%3DArnold%26aufirst%3DL.%2BD.%26aulast%3DHoughton%26aufirst%3DP.%2BJ.%26aulast%3DPachter%26aufirst%3DJ.%2BA.%26atitle%3DPreclinical%2520Characterization%2520of%2520OSI-027%252C%2520a%2520Potent%2520and%2520Selective%2520Inhibitor%2520of%2520mTORC1%2520and%2520mTORC2%253A%2520Distinct%2520from%2520Rapamycin%26jtitle%3DMol.%2520Cancer%2520Ther.%26date%3D2011%26volume%3D10%26spage%3D1394%26epage%3D1406" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref8"><div class="reference"><strong class="refLabel"><a href="#ref8" class="rightTabRefNumLink">8</a></strong><div class="NLM_citation" id="rightTab-cit8"><span><span class="NLM_contrib-group">Liu, Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kang, S. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thoreen, C. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hur, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Choi, H. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Waller, D. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sim, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sabatini, D. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gray, N. S.</span><span> </span><span class="NLM_article-title">Discovery and optimization of potent and selective benzonaphthyridinone analogs as small molecule mTOR inhibitors with improved mouse microsome stability</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">21</span><span class="NLM_x">, </span> <span class="NLM_fpage">4036</span><span class="NLM_x">–</span> <span class="NLM_lpage">4040</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2011&pages=4036-4040&author=Q.+Liuauthor=J.+Wangauthor=S.+A.+Kangauthor=C.+C.+Thoreenauthor=W.+Hurauthor=H.+G.+Choiauthor=D.+L.+Wallerauthor=T.+Simauthor=D.+M.+Sabatiniauthor=N.+S.+Gray&title=Discovery+and+optimization+of+potent+and+selective+benzonaphthyridinone+analogs+as+small+molecule+mTOR+inhibitors+with+improved+mouse+microsome+stability"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DLiu%26aufirst%3DQ.%26aulast%3DWang%26aufirst%3DJ.%26aulast%3DKang%26aufirst%3DS.%2BA.%26aulast%3DThoreen%26aufirst%3DC.%2BC.%26aulast%3DHur%26aufirst%3DW.%26aulast%3DChoi%26aufirst%3DH.%2BG.%26aulast%3DWaller%26aufirst%3DD.%2BL.%26aulast%3DSim%26aufirst%3DT.%26aulast%3DSabatini%26aufirst%3DD.%2BM.%26aulast%3DGray%26aufirst%3DN.%2BS.%26atitle%3DDiscovery%2520and%2520optimization%2520of%2520potent%2520and%2520selective%2520benzonaphthyridinone%2520analogs%2520as%2520small%2520molecule%2520mTOR%2520inhibitors%2520with%2520improved%2520mouse%2520microsome%2520stability%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2011%26volume%3D21%26spage%3D4036%26epage%3D4040" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref9"><div class="reference"><strong class="refLabel"><a href="#ref9" class="rightTabRefNumLink">9</a></strong><div class="NLM_citation" id="rightTab-cit9"><span><span class="NLM_contrib-group">Cohen, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bergeron, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Blackwood, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bowman, K. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dipasquale, A. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Epler, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Koehler, M. F. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lau, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lewis, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ly, C. Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Malek, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nonomiya, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ortwine, D. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pei, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Robarge, K. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sideris, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Trinh, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Truong, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wu, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhao, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lyssikatos, J. P.</span><span> </span><span class="NLM_article-title">Potent, selective, and orally bioavailable inhibitors of mammalian target of rapamycin (mTOR) kinase based on a quaternary substituted dihydrofuropyrimidine</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">54</span><span class="NLM_x">, </span> <span class="NLM_fpage">3426</span><span class="NLM_x">–</span> <span class="NLM_lpage">3435</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm200215y" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=54&publication_year=2011&pages=3426-3435&author=F.+Cohenauthor=P.+Bergeronauthor=E.+Blackwoodauthor=K.+K.+Bowmanauthor=H.+Chenauthor=A.+G.+Dipasqualeauthor=J.+A.+Eplerauthor=M.+F.+T.+Koehlerauthor=K.+Lauauthor=C.+Lewisauthor=L.+Liuauthor=C.+Q.+Lyauthor=S.+Malekauthor=J.+Nonomiyaauthor=D.+F.+Ortwineauthor=Z.+Peiauthor=K.+D.+Robargeauthor=S.+Siderisauthor=L.+Trinhauthor=T.+Truongauthor=J.+Wuauthor=X.+Zhaoauthor=J.+P.+Lyssikatos&title=Potent%2C+selective%2C+and+orally+bioavailable+inhibitors+of+mammalian+target+of+rapamycin+%28mTOR%29+kinase+based+on+a+quaternary+substituted+dihydrofuropyrimidine"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.1021%2Fjm200215y&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm200215y%26sid%3Dliteratum%253Aachs%26aulast%3DCohen%26aufirst%3DF.%26aulast%3DBergeron%26aufirst%3DP.%26aulast%3DBlackwood%26aufirst%3DE.%26aulast%3DBowman%26aufirst%3DK.%2BK.%26aulast%3DChen%26aufirst%3DH.%26aulast%3DDipasquale%26aufirst%3DA.%2BG.%26aulast%3DEpler%26aufirst%3DJ.%2BA.%26aulast%3DKoehler%26aufirst%3DM.%2BF.%2BT.%26aulast%3DLau%26aufirst%3DK.%26aulast%3DLewis%26aufirst%3DC.%26aulast%3DLiu%26aufirst%3DL.%26aulast%3DLy%26aufirst%3DC.%2BQ.%26aulast%3DMalek%26aufirst%3DS.%26aulast%3DNonomiya%26aufirst%3DJ.%26aulast%3DOrtwine%26aufirst%3DD.%2BF.%26aulast%3DPei%26aufirst%3DZ.%26aulast%3DRobarge%26aufirst%3DK.%2BD.%26aulast%3DSideris%26aufirst%3DS.%26aulast%3DTrinh%26aufirst%3DL.%26aulast%3DTruong%26aufirst%3DT.%26aulast%3DWu%26aufirst%3DJ.%26aulast%3DZhao%26aufirst%3DX.%26aulast%3DLyssikatos%26aufirst%3DJ.%2BP.%26atitle%3DPotent%252C%2520selective%252C%2520and%2520orally%2520bioavailable%2520inhibitors%2520of%2520mammalian%2520target%2520of%2520rapamycin%2520%2528mTOR%2529%2520kinase%2520based%2520on%2520a%2520quaternary%2520substituted%2520dihydrofuropyrimidine%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2011%26volume%3D54%26spage%3D3426%26epage%3D3435" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref10"><div class="reference"><strong class="refLabel"><a href="#ref10" class="rightTabRefNumLink">10</a></strong><div class="NLM_citation" id="rightTab-cit10"><span><span class="NLM_contrib-group">Crew, A. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bhagwat, S. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dong, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bittner, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chan, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Coate, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cooke, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gokhale, P. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Honda, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jin, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kahler, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mantis, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mulvihill, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tavares-Greco, P. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Volk, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Werner, D. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Arnold, L. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pachter, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wild, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gibson, N. W.</span><span> </span><span class="NLM_article-title">Imidazo[1,5-<i>a</i>]pyrazines: Orally efficacious inhibitors of mTORC1 and mTORC2</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">21</span><span class="NLM_x">, </span> <span class="NLM_fpage">2092</span><span class="NLM_x">–</span> <span class="NLM_lpage">2097</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2011&pages=2092-2097&author=A.+P.+Crewauthor=S.+V.+Bhagwatauthor=H.+Dongauthor=M.+A.+Bittnerauthor=A.+Chanauthor=X.+Chenauthor=H.+Coateauthor=A.+Cookeauthor=P.+C.+Gokhaleauthor=A.+Hondaauthor=M.+Jinauthor=J.+Kahlerauthor=C.+Mantisauthor=M.+J.+Mulvihillauthor=P.+A.+Tavares-Grecoauthor=B.+Volkauthor=J.+Wangauthor=D.+S.+Wernerauthor=L.+D.+Arnoldauthor=J.+A.+Pachterauthor=R.+Wildauthor=N.+W.+Gibson&title=Imidazo%5B1%2C5-a%5Dpyrazines%3A+Orally+efficacious+inhibitors+of+mTORC1+and+mTORC2"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DCrew%26aufirst%3DA.%2BP.%26aulast%3DBhagwat%26aufirst%3DS.%2BV.%26aulast%3DDong%26aufirst%3DH.%26aulast%3DBittner%26aufirst%3DM.%2BA.%26aulast%3DChan%26aufirst%3DA.%26aulast%3DChen%26aufirst%3DX.%26aulast%3DCoate%26aufirst%3DH.%26aulast%3DCooke%26aufirst%3DA.%26aulast%3DGokhale%26aufirst%3DP.%2BC.%26aulast%3DHonda%26aufirst%3DA.%26aulast%3DJin%26aufirst%3DM.%26aulast%3DKahler%26aufirst%3DJ.%26aulast%3DMantis%26aufirst%3DC.%26aulast%3DMulvihill%26aufirst%3DM.%2BJ.%26aulast%3DTavares-Greco%26aufirst%3DP.%2BA.%26aulast%3DVolk%26aufirst%3DB.%26aulast%3DWang%26aufirst%3DJ.%26aulast%3DWerner%26aufirst%3DD.%2BS.%26aulast%3DArnold%26aufirst%3DL.%2BD.%26aulast%3DPachter%26aufirst%3DJ.%2BA.%26aulast%3DWild%26aufirst%3DR.%26aulast%3DGibson%26aufirst%3DN.%2BW.%26atitle%3DImidazo%255B1%252C5-a%255Dpyrazines%253A%2520Orally%2520efficacious%2520inhibitors%2520of%2520mTORC1%2520and%2520mTORC2%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2011%26volume%3D21%26spage%3D2092%26epage%3D2097" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref11"><div class="reference"><strong class="refLabel"><a href="#ref11" class="rightTabRefNumLink">11</a></strong><div class="NLM_citation" id="rightTab-cit11"><span><span class="NLM_contrib-group">Peterson, E. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Andrews, P. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Be, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Boezio, A. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bush, T. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cheng, A. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Coats, J. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Colletti, A. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Copeland, K. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">DuPont, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Graceffa, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Grubinska, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Harmange, J.-C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, J. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mullady, E. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Olivieri, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schenkel, L. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stanton, M. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Teffera, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Whittington, D. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cai, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">La, D. S.</span><span> </span><span class="NLM_article-title">Discovery of triazine-benzimidazoles as selective inhibitors of mTOR</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">21</span><span class="NLM_x">, </span> <span class="NLM_fpage">2064</span><span class="NLM_x">–</span> <span class="NLM_lpage">2070</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2011&pages=2064-2070&author=E.+A.+Petersonauthor=P.+S.+Andrewsauthor=X.+Beauthor=A.+A.+Boezioauthor=T.+L.+Bushauthor=A.+C.+Chengauthor=J.+R.+Coatsauthor=A.+E.+Collettiauthor=K.+W.+Copelandauthor=M.+DuPontauthor=R.+Graceffaauthor=B.+Grubinskaauthor=J.-C.+Harmangeauthor=J.+L.+Kimauthor=E.+L.+Mulladyauthor=P.+Olivieriauthor=L.+B.+Schenkelauthor=M.+K.+Stantonauthor=Y.+Tefferaauthor=D.+A.+Whittingtonauthor=T.+Caiauthor=D.+S.+La&title=Discovery+of+triazine-benzimidazoles+as+selective+inhibitors+of+mTOR"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DPeterson%26aufirst%3DE.%2BA.%26aulast%3DAndrews%26aufirst%3DP.%2BS.%26aulast%3DBe%26aufirst%3DX.%26aulast%3DBoezio%26aufirst%3DA.%2BA.%26aulast%3DBush%26aufirst%3DT.%2BL.%26aulast%3DCheng%26aufirst%3DA.%2BC.%26aulast%3DCoats%26aufirst%3DJ.%2BR.%26aulast%3DColletti%26aufirst%3DA.%2BE.%26aulast%3DCopeland%26aufirst%3DK.%2BW.%26aulast%3DDuPont%26aufirst%3DM.%26aulast%3DGraceffa%26aufirst%3DR.%26aulast%3DGrubinska%26aufirst%3DB.%26aulast%3DHarmange%26aufirst%3DJ.-C.%26aulast%3DKim%26aufirst%3DJ.%2BL.%26aulast%3DMullady%26aufirst%3DE.%2BL.%26aulast%3DOlivieri%26aufirst%3DP.%26aulast%3DSchenkel%26aufirst%3DL.%2BB.%26aulast%3DStanton%26aufirst%3DM.%2BK.%26aulast%3DTeffera%26aufirst%3DY.%26aulast%3DWhittington%26aufirst%3DD.%2BA.%26aulast%3DCai%26aufirst%3DT.%26aulast%3DLa%26aufirst%3DD.%2BS.%26atitle%3DDiscovery%2520of%2520triazine-benzimidazoles%2520as%2520selective%2520inhibitors%2520of%2520mTOR%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2011%26volume%3D21%26spage%3D2064%26epage%3D2070" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref12"><div class="reference"><strong class="refLabel"><a href="#ref12" class="rightTabRefNumLink">12</a></strong><div class="NLM_citation" id="rightTab-cit12"><span><span class="NLM_contrib-group">Liu, Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kang, S. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thoreen, C. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hur, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ahmed, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sabatini, D. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gray, N. S.</span><span> </span><span class="NLM_article-title">Discovery of 9-(6-aminopyridin-3-yl)-1-(3-(trifluoromethyl)phenyl)benzo[<i>h</i>][1,6]naphthyridin-2(1<i>H</i>)-one (Torin2) as a potent, selective, and orally available mammalian target of rapamycin (mTOR) inhibitor for treatment of cancer</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">54</span><span class="NLM_x">, </span> <span class="NLM_fpage">1473</span><span class="NLM_x">–</span> <span class="NLM_lpage">1480</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm101520v" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=54&publication_year=2011&pages=1473-1480&author=Q.+Liuauthor=J.+Wangauthor=S.+A.+Kangauthor=C.+C.+Thoreenauthor=W.+Hurauthor=T.+Ahmedauthor=D.+M.+Sabatiniauthor=N.+S.+Gray&title=Discovery+of+9-%286-aminopyridin-3-yl%29-1-%283-%28trifluoromethyl%29phenyl%29benzo%5Bh%5D%5B1%2C6%5Dnaphthyridin-2%281H%29-one+%28Torin2%29+as+a+potent%2C+selective%2C+and+orally+available+mammalian+target+of+rapamycin+%28mTOR%29+inhibitor+for+treatment+of+cancer"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.1021%2Fjm101520v&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm101520v%26sid%3Dliteratum%253Aachs%26aulast%3DLiu%26aufirst%3DQ.%26aulast%3DWang%26aufirst%3DJ.%26aulast%3DKang%26aufirst%3DS.%2BA.%26aulast%3DThoreen%26aufirst%3DC.%2BC.%26aulast%3DHur%26aufirst%3DW.%26aulast%3DAhmed%26aufirst%3DT.%26aulast%3DSabatini%26aufirst%3DD.%2BM.%26aulast%3DGray%26aufirst%3DN.%2BS.%26atitle%3DDiscovery%2520of%25209-%25286-aminopyridin-3-yl%2529-1-%25283-%2528trifluoromethyl%2529phenyl%2529benzo%255Bh%255D%255B1%252C6%255Dnaphthyridin-2%25281H%2529-one%2520%2528Torin2%2529%2520as%2520a%2520potent%252C%2520selective%252C%2520and%2520orally%2520available%2520mammalian%2520target%2520of%2520rapamycin%2520%2528mTOR%2529%2520inhibitor%2520for%2520treatment%2520of%2520cancer%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2011%26volume%3D54%26spage%3D1473%26epage%3D1480" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref13"><div class="reference"><strong class="refLabel"><a href="#ref13" class="rightTabRefNumLink">13</a></strong><div class="NLM_citation" id="rightTab-cit13"><span><span class="NLM_contrib-group">Liu, Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chang, J. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kang, S. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thoreen, C. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Markhard, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hur, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sim, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sabatini, D. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gray, N. S.</span><span> </span><span class="NLM_article-title">Discovery of 1-(4-(4-propionylpiperazin-1-yl)-3-(trifluoromethyl)phenyl)-9-(quinolin-3-yl)benzo[<i>h</i>][1,6]naphthyridin-2(1<i>H</i>)-one as a highly potent, selective mammalian target of rapamycin (mTOR) inhibitor for the treatment of cancer</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">53</span><span class="NLM_x">, </span> <span class="NLM_fpage">7146</span><span class="NLM_x">–</span> <span class="NLM_lpage">7155</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm101144f" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=53&publication_year=2010&pages=7146-7155&author=Q.+Liuauthor=J.+W.+Changauthor=J.+Wangauthor=S.+A.+Kangauthor=C.+C.+Thoreenauthor=A.+Markhardauthor=W.+Hurauthor=J.+Zhangauthor=T.+Simauthor=D.+M.+Sabatiniauthor=N.+S.+Gray&title=Discovery+of+1-%284-%284-propionylpiperazin-1-yl%29-3-%28trifluoromethyl%29phenyl%29-9-%28quinolin-3-yl%29benzo%5Bh%5D%5B1%2C6%5Dnaphthyridin-2%281H%29-one+as+a+highly+potent%2C+selective+mammalian+target+of+rapamycin+%28mTOR%29+inhibitor+for+the+treatment+of+cancer"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.1021%2Fjm101144f&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm101144f%26sid%3Dliteratum%253Aachs%26aulast%3DLiu%26aufirst%3DQ.%26aulast%3DChang%26aufirst%3DJ.%2BW.%26aulast%3DWang%26aufirst%3DJ.%26aulast%3DKang%26aufirst%3DS.%2BA.%26aulast%3DThoreen%26aufirst%3DC.%2BC.%26aulast%3DMarkhard%26aufirst%3DA.%26aulast%3DHur%26aufirst%3DW.%26aulast%3DZhang%26aufirst%3DJ.%26aulast%3DSim%26aufirst%3DT.%26aulast%3DSabatini%26aufirst%3DD.%2BM.%26aulast%3DGray%26aufirst%3DN.%2BS.%26atitle%3DDiscovery%2520of%25201-%25284-%25284-propionylpiperazin-1-yl%2529-3-%2528trifluoromethyl%2529phenyl%2529-9-%2528quinolin-3-yl%2529benzo%255Bh%255D%255B1%252C6%255Dnaphthyridin-2%25281H%2529-one%2520as%2520a%2520highly%2520potent%252C%2520selective%2520mammalian%2520target%2520of%2520rapamycin%2520%2528mTOR%2529%2520inhibitor%2520for%2520the%2520treatment%2520of%2520cancer%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2010%26volume%3D53%26spage%3D7146%26epage%3D7155" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref14"><div class="reference"><strong class="refLabel"><a href="#ref14" class="rightTabRefNumLink">14</a></strong><div class="NLM_citation" id="rightTab-cit14"><span><span class="NLM_contrib-group">Richard, D. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Verheijen, J. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yu, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zask, A.</span><span> </span><span class="NLM_article-title">Triazines incorporating (<i>R</i>)-3-methylmorpholine are potent inhibitors of the mammalian target of rapamycin (mTOR) with selectivity over PI3Kalpha</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">20</span><span class="NLM_x">, </span> <span class="NLM_fpage">2654</span><span class="NLM_x">–</span> <span class="NLM_lpage">2657</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2010&pages=2654-2657&author=D.+J.+Richardauthor=J.+C.+Verheijenauthor=K.+Yuauthor=A.+Zask&title=Triazines+incorporating+%28R%29-3-methylmorpholine+are+potent+inhibitors+of+the+mammalian+target+of+rapamycin+%28mTOR%29+with+selectivity+over+PI3Kalpha"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DRichard%26aufirst%3DD.%2BJ.%26aulast%3DVerheijen%26aufirst%3DJ.%2BC.%26aulast%3DYu%26aufirst%3DK.%26aulast%3DZask%26aufirst%3DA.%26atitle%3DTriazines%2520incorporating%2520%2528R%2529-3-methylmorpholine%2520are%2520potent%2520inhibitors%2520of%2520the%2520mammalian%2520target%2520of%2520rapamycin%2520%2528mTOR%2529%2520with%2520selectivity%2520over%2520PI3Kalpha%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2010%26volume%3D20%26spage%3D2654%26epage%3D2657" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref15"><div class="reference"><strong class="refLabel"><a href="#ref15" class="rightTabRefNumLink">15</a></strong><div class="NLM_citation" id="rightTab-cit15"><span><span class="NLM_contrib-group">Zask, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Verheijen, J. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Richard, D. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kaplan, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Curran, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Toral-Barza, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lucas, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hollander, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yu, K.</span><span> </span><span class="NLM_article-title">Discovery of 2-ureidophenyltriazines bearing bridged morpholines as potent and selective ATP-competitive mTOR inhibitors</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">20</span><span class="NLM_x">, </span> <span class="NLM_fpage">2644</span><span class="NLM_x">–</span> <span class="NLM_lpage">2647</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=16&amp;doi=10.1021%2Fjm301389h&amp;key=10.1016%2Fj.bmcl.2010.02.045" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=8&amp;doi=10.1021%2Fjm301389h&amp;key=20227881" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=32&amp;doi=10.1021%2Fjm301389h&amp;key=1%3ACAS%3A528%3ADC%252BC3cXksVGntro%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2010&pages=2644-2647&author=A.+Zaskauthor=J.+C.+Verheijenauthor=D.+J.+Richardauthor=J.+Kaplanauthor=K.+Curranauthor=L.+Toral-Barzaauthor=J.+Lucasauthor=I.+Hollanderauthor=K.+Yu&title=Discovery+of+2-ureidophenyltriazines+bearing+bridged+morpholines+as+potent+and+selective+ATP-competitive+mTOR+inhibitors"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit15R"><div class="casContent"><span class="casTitleNuber">15</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of 2-ureidophenyltriazines bearing bridged morpholines as potent and selective ATP-competitive mTOR inhibitors</span></div><div class="casAuthors">Zask, Arie; Verheijen, Jeroen C.; Richard, David J.; Kaplan, Joshua; Curran, Kevin; Toral-Barza, Lourdes; Lucas, Judy; Hollander, Irwin; Yu, Ker</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">20</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">2644-2647</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Incorporation of bridged morpholines in monocyclic triazine PI3K/mTOR inhibitors gave compds. with increased mTOR selectivity relative to the corresponding morpholine analogs.  Compds. with ureidophenyl groups gave highly potent and selective mTOR inhibitors.  Potency and selectivity was demonstrated both in vitro and in vivo through biomarker suppression studies.  Select compds. exhibited potent inhibition of tumor growth in nude mouse xenograft assays upon PO and IV administration.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpUPE--c1OgzbVg90H21EOLACvtfcHk0lgehVRdh8Txxg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXksVGntro%253D&md5=d5008526e962f9dd110bfb47306c551e</span></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2010.02.045&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2010.02.045%26sid%3Dliteratum%253Aachs%26aulast%3DZask%26aufirst%3DA.%26aulast%3DVerheijen%26aufirst%3DJ.%2BC.%26aulast%3DRichard%26aufirst%3DD.%2BJ.%26aulast%3DKaplan%26aufirst%3DJ.%26aulast%3DCurran%26aufirst%3DK.%26aulast%3DToral-Barza%26aufirst%3DL.%26aulast%3DLucas%26aufirst%3DJ.%26aulast%3DHollander%26aufirst%3DI.%26aulast%3DYu%26aufirst%3DK.%26atitle%3DDiscovery%2520of%25202-ureidophenyltriazines%2520bearing%2520bridged%2520morpholines%2520as%2520potent%2520and%2520selective%2520ATP-competitive%2520mTOR%2520inhibitors%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2010%26volume%3D20%26spage%3D2644%26epage%3D2647" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref16"><div class="reference"><strong class="refLabel"><a href="#ref16" class="rightTabRefNumLink">16</a></strong><div class="NLM_citation" id="rightTab-cit16"><span><span class="NLM_contrib-group">Tsou, H.-R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">MacEwan, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Birnberg, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brooijmans, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Toral-Barza, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hollander, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ayral-Kaloustian, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yu, K.</span><span> </span><span class="NLM_article-title">4-Substituted-7-azaindoles bearing a ureidobenzofuranone moiety as potent and selective, ATP-competitive inhibitors of the mammalian target of rapamycin (mTOR)</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">20</span><span class="NLM_x">, </span> <span class="NLM_fpage">2259</span><span class="NLM_x">–</span> <span class="NLM_lpage">2263</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2010&pages=2259-2263&author=H.-R.+Tsouauthor=G.+MacEwanauthor=G.+Birnbergauthor=N.+Zhangauthor=N.+Brooijmansauthor=L.+Toral-Barzaauthor=I.+Hollanderauthor=S.+Ayral-Kaloustianauthor=K.+Yu&title=4-Substituted-7-azaindoles+bearing+a+ureidobenzofuranone+moiety+as+potent+and+selective%2C+ATP-competitive+inhibitors+of+the+mammalian+target+of+rapamycin+%28mTOR%29"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DTsou%26aufirst%3DH.-R.%26aulast%3DMacEwan%26aufirst%3DG.%26aulast%3DBirnberg%26aufirst%3DG.%26aulast%3DZhang%26aufirst%3DN.%26aulast%3DBrooijmans%26aufirst%3DN.%26aulast%3DToral-Barza%26aufirst%3DL.%26aulast%3DHollander%26aufirst%3DI.%26aulast%3DAyral-Kaloustian%26aufirst%3DS.%26aulast%3DYu%26aufirst%3DK.%26atitle%3D4-Substituted-7-azaindoles%2520bearing%2520a%2520ureidobenzofuranone%2520moiety%2520as%2520potent%2520and%2520selective%252C%2520ATP-competitive%2520inhibitors%2520of%2520the%2520mammalian%2520target%2520of%2520rapamycin%2520%2528mTOR%2529%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2010%26volume%3D20%26spage%3D2259%26epage%3D2263" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref17"><div class="reference"><strong class="refLabel"><a href="#ref17" class="rightTabRefNumLink">17</a></strong><div class="NLM_citation" id="rightTab-cit17"><span><span class="NLM_contrib-group">Curran, K. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Verheijen, J. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kaplan, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Richard, D. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Toral-Barza, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hollander, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lucas, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ayral-Kaloustian, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yu, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zask, A.</span><span> </span><span class="NLM_article-title">Pyrazolopyrimidines as highly potent and selective, ATP-competitive inhibitors of the mammalian target of rapamycin (mTOR): Optimization of the 1-substituent</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">20</span><span class="NLM_x">, </span> <span class="NLM_fpage">1440</span><span class="NLM_x">–</span> <span class="NLM_lpage">1444</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2010&pages=1440-1444&author=K.+J.+Curranauthor=J.+C.+Verheijenauthor=J.+Kaplanauthor=D.+J.+Richardauthor=L.+Toral-Barzaauthor=I.+Hollanderauthor=J.+Lucasauthor=S.+Ayral-Kaloustianauthor=K.+Yuauthor=A.+Zask&title=Pyrazolopyrimidines+as+highly+potent+and+selective%2C+ATP-competitive+inhibitors+of+the+mammalian+target+of+rapamycin+%28mTOR%29%3A+Optimization+of+the+1-substituent"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DCurran%26aufirst%3DK.%2BJ.%26aulast%3DVerheijen%26aufirst%3DJ.%2BC.%26aulast%3DKaplan%26aufirst%3DJ.%26aulast%3DRichard%26aufirst%3DD.%2BJ.%26aulast%3DToral-Barza%26aufirst%3DL.%26aulast%3DHollander%26aufirst%3DI.%26aulast%3DLucas%26aufirst%3DJ.%26aulast%3DAyral-Kaloustian%26aufirst%3DS.%26aulast%3DYu%26aufirst%3DK.%26aulast%3DZask%26aufirst%3DA.%26atitle%3DPyrazolopyrimidines%2520as%2520highly%2520potent%2520and%2520selective%252C%2520ATP-competitive%2520inhibitors%2520of%2520the%2520mammalian%2520target%2520of%2520rapamycin%2520%2528mTOR%2529%253A%2520Optimization%2520of%2520the%25201-substituent%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2010%26volume%3D20%26spage%3D1440%26epage%3D1444" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref18"><div class="reference"><strong class="refLabel"><a href="#ref18" class="rightTabRefNumLink">18</a></strong><div class="NLM_citation" id="rightTab-cit18"><span><span class="NLM_contrib-group">Kaplan, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Verheijen, J. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brooijmans, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Toral-Barza, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hollander, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yu, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zask, A.</span><span> </span><span class="NLM_article-title">Discovery of 3,6-dihydro-2<i>H</i>-pyran as a morpholine replacement in 6-aryl-1<i>H</i>-pyrazolo[3,4-<i>d</i>]pyrimidines and 2-arylthieno[3,2-<i>d</i>]pyrimidines: ATP-competitive inhibitors of the mammalian target of rapamycin (mTOR)</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">20</span><span class="NLM_x">, </span> <span class="NLM_fpage">640</span><span class="NLM_x">–</span> <span class="NLM_lpage">643</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=16&amp;doi=10.1021%2Fjm301389h&amp;key=10.1016%2Fj.bmcl.2009.11.050" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=8&amp;doi=10.1021%2Fjm301389h&amp;key=19963384" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=32&amp;doi=10.1021%2Fjm301389h&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhsF2itbfE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2010&pages=640-643&author=J.+Kaplanauthor=J.+C.+Verheijenauthor=N.+Brooijmansauthor=L.+Toral-Barzaauthor=I.+Hollanderauthor=K.+Yuauthor=A.+Zask&title=Discovery+of+3%2C6-dihydro-2H-pyran+as+a+morpholine+replacement+in+6-aryl-1H-pyrazolo%5B3%2C4-d%5Dpyrimidines+and+2-arylthieno%5B3%2C2-d%5Dpyrimidines%3A+ATP-competitive+inhibitors+of+the+mammalian+target+of+rapamycin+%28mTOR%29"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit18R"><div class="casContent"><span class="casTitleNuber">18</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of 3,6-dihydro-2H-pyran as a morpholine replacement in 6-aryl-1H-pyrazolo[3,4-d]pyrimidines and 2-arylthieno[3,2-d]pyrimidines: ATP-competitive inhibitors of the mammalian target of rapamycin (mTOR)</span></div><div class="casAuthors">Kaplan, Joshua; Verheijen, Jeroen C.; Brooijmans, Natasja; Toral-Barza, Lourdes; Hollander, Irwin; Yu, Ker; Zask, Arie</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">20</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">640-643</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">The morpholine hinge-region binding group on a series of pyrazolopyrimidine and thienopyrimidine mammalian target of rapamycin (mTOR) inhibitors was replaced with 3,6-dihydro-2H-pyran (DHP), giving compds. of equiv. potency and selectivity vs. PI3K.  These results establish the DHP group as a hinge-region binding motif for the prepn. of highly potent and selective mTOR inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrBTLsFT9FBubVg90H21EOLACvtfcHk0lhOPK2wEeeamg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhsF2itbfE&md5=9398107e05207e302a8358103f31fb2f</span></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2009.11.050&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2009.11.050%26sid%3Dliteratum%253Aachs%26aulast%3DKaplan%26aufirst%3DJ.%26aulast%3DVerheijen%26aufirst%3DJ.%2BC.%26aulast%3DBrooijmans%26aufirst%3DN.%26aulast%3DToral-Barza%26aufirst%3DL.%26aulast%3DHollander%26aufirst%3DI.%26aulast%3DYu%26aufirst%3DK.%26aulast%3DZask%26aufirst%3DA.%26atitle%3DDiscovery%2520of%25203%252C6-dihydro-2H-pyran%2520as%2520a%2520morpholine%2520replacement%2520in%25206-aryl-1H-pyrazolo%255B3%252C4-d%255Dpyrimidines%2520and%25202-arylthieno%255B3%252C2-d%255Dpyrimidines%253A%2520ATP-competitive%2520inhibitors%2520of%2520the%2520mammalian%2520target%2520of%2520rapamycin%2520%2528mTOR%2529%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2010%26volume%3D20%26spage%3D640%26epage%3D643" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref19"><div class="reference"><strong class="refLabel"><a href="#ref19" class="rightTabRefNumLink">19</a></strong><div class="NLM_citation" id="rightTab-cit19"><span><span class="NLM_contrib-group">Chresta, C. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Davies, B. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hickson, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Harding, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cosulich, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Critchlow, S. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vincent, J. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ellston, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jones, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sini, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">James, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Howard, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dudley, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hughes, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smith, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Maguire, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hummersone, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Malagu, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Menear, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jenkins, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jacobsen, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smith, G. C. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Guichard, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pass, M.</span><span> </span><span class="NLM_article-title">AZD8055 is a potent, selective, and orally bioavailable ATP-competitive mammalian target of rapamycin kinase inhibitor with in vitro and in vivo antitumor activity</span> <span class="citation_source-journal">Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">70</span><span class="NLM_x">, </span> <span class="NLM_fpage">288</span><span class="NLM_x">–</span> <span class="NLM_lpage">298</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=70&publication_year=2010&pages=288-298&author=C.+M.+Chrestaauthor=B.+R.+Daviesauthor=I.+Hicksonauthor=T.+Hardingauthor=S.+Cosulichauthor=S.+E.+Critchlowauthor=J.+P.+Vincentauthor=R.+Ellstonauthor=D.+Jonesauthor=P.+Siniauthor=D.+Jamesauthor=Z.+Howardauthor=P.+Dudleyauthor=G.+Hughesauthor=L.+Smithauthor=S.+Maguireauthor=M.+Hummersoneauthor=K.+Malaguauthor=K.+Menearauthor=R.+Jenkinsauthor=M.+Jacobsenauthor=G.+C.+M.+Smithauthor=S.+Guichardauthor=M.+Pass&title=AZD8055+is+a+potent%2C+selective%2C+and+orally+bioavailable+ATP-competitive+mammalian+target+of+rapamycin+kinase+inhibitor+with+in+vitro+and+in+vivo+antitumor+activity"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DChresta%26aufirst%3DC.%2BM.%26aulast%3DDavies%26aufirst%3DB.%2BR.%26aulast%3DHickson%26aufirst%3DI.%26aulast%3DHarding%26aufirst%3DT.%26aulast%3DCosulich%26aufirst%3DS.%26aulast%3DCritchlow%26aufirst%3DS.%2BE.%26aulast%3DVincent%26aufirst%3DJ.%2BP.%26aulast%3DEllston%26aufirst%3DR.%26aulast%3DJones%26aufirst%3DD.%26aulast%3DSini%26aufirst%3DP.%26aulast%3DJames%26aufirst%3DD.%26aulast%3DHoward%26aufirst%3DZ.%26aulast%3DDudley%26aufirst%3DP.%26aulast%3DHughes%26aufirst%3DG.%26aulast%3DSmith%26aufirst%3DL.%26aulast%3DMaguire%26aufirst%3DS.%26aulast%3DHummersone%26aufirst%3DM.%26aulast%3DMalagu%26aufirst%3DK.%26aulast%3DMenear%26aufirst%3DK.%26aulast%3DJenkins%26aufirst%3DR.%26aulast%3DJacobsen%26aufirst%3DM.%26aulast%3DSmith%26aufirst%3DG.%2BC.%2BM.%26aulast%3DGuichard%26aufirst%3DS.%26aulast%3DPass%26aufirst%3DM.%26atitle%3DAZD8055%2520is%2520a%2520potent%252C%2520selective%252C%2520and%2520orally%2520bioavailable%2520ATP-competitive%2520mammalian%2520target%2520of%2520rapamycin%2520kinase%2520inhibitor%2520with%2520in%2520vitro%2520and%2520in%2520vivo%2520antitumor%2520activity%26jtitle%3DCancer%2520Res.%26date%3D2010%26volume%3D70%26spage%3D288%26epage%3D298" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref20"><div class="reference"><strong class="refLabel"><a href="#ref20" class="rightTabRefNumLink">20</a></strong><div class="NLM_citation" id="rightTab-cit20"><span><span class="NLM_contrib-group">Verheijen, J. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yu, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Toral-Barza, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hollander, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zask, A.</span><span> </span><span class="NLM_article-title">Discovery of 2-arylthieno[3,2-<i>d</i>]pyrimidines containing 8-oxa-3-azabi-cyclo[3.2.1]octane in the 4-position as potent inhibitors of mTOR with selectivity over PI3K</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">20</span><span class="NLM_x">, </span> <span class="NLM_fpage">375</span><span class="NLM_x">–</span> <span class="NLM_lpage">379</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2010&pages=375-379&author=J.+C.+Verheijenauthor=K.+Yuauthor=L.+Toral-Barzaauthor=I.+Hollanderauthor=A.+Zask&title=Discovery+of+2-arylthieno%5B3%2C2-d%5Dpyrimidines+containing+8-oxa-3-azabi-cyclo%5B3.2.1%5Doctane+in+the+4-position+as+potent+inhibitors+of+mTOR+with+selectivity+over+PI3K"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DVerheijen%26aufirst%3DJ.%2BC.%26aulast%3DYu%26aufirst%3DK.%26aulast%3DToral-Barza%26aufirst%3DL.%26aulast%3DHollander%26aufirst%3DI.%26aulast%3DZask%26aufirst%3DA.%26atitle%3DDiscovery%2520of%25202-arylthieno%255B3%252C2-d%255Dpyrimidines%2520containing%25208-oxa-3-azabi-cyclo%255B3.2.1%255Doctane%2520in%2520the%25204-position%2520as%2520potent%2520inhibitors%2520of%2520mTOR%2520with%2520selectivity%2520over%2520PI3K%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2010%26volume%3D20%26spage%3D375%26epage%3D379" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref21"><div class="reference"><strong class="refLabel"><a href="#ref21" class="rightTabRefNumLink">21</a></strong><div class="NLM_citation" id="rightTab-cit21"><span><span class="NLM_contrib-group">Zask, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kaplan, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Verheijen, J. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Richard, D. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Curran, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brooijmans, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bennett, E. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Toral-Barza, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hollander, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ayral-Kaloustian, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yu, K.</span><span> </span><span class="NLM_article-title">Morpholine derivatives greatly enhance the selectivity of mammalian target of rapamycin (mTOR) inhibitors</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">52</span><span class="NLM_x">, </span> <span class="NLM_fpage">7942</span><span class="NLM_x">–</span> <span class="NLM_lpage">7945</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm901415x" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=32&amp;doi=10.1021%2Fjm301389h&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhsVWrtb3J" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=52&publication_year=2009&pages=7942-7945&author=A.+Zaskauthor=J.+Kaplanauthor=J.+C.+Verheijenauthor=D.+J.+Richardauthor=K.+Curranauthor=N.+Brooijmansauthor=E.+M.+Bennettauthor=L.+Toral-Barzaauthor=I.+Hollanderauthor=S.+Ayral-Kaloustianauthor=K.+Yu&title=Morpholine+derivatives+greatly+enhance+the+selectivity+of+mammalian+target+of+rapamycin+%28mTOR%29+inhibitors"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit21R"><div class="casContent"><span class="casTitleNuber">21</span><div class="casTitle"><span class="NLM_cas:atitle">Morpholine Derivatives Greatly Enhance the Selectivity of Mammalian Target of Rapamycin (mTOR) Inhibitors</span></div><div class="casAuthors">Zask, Arie; Kaplan, Joshua; Verheijen, Jeroen C.; Richard, David J.; Curran, Kevin; Brooijmans, Natasja; Bennett, Eric M.; Toral-Barza, Lourdes; Hollander, Irwin; Ayral-Kaloustian, Semiramis; Yu, Ker</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">52</span>
        (<span class="NLM_cas:issue">24</span>),
    <span class="NLM_cas:pages">7942-7945</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Dramatic improvements in mTOR-targeting selectivity were achieved by replacing morpholine in pyrazolopyrimidine inhibitors with bridged morpholines.  Analogs I [R1 = (R)- or (S)-3-methyl-4-morpholinyl, 2-methyl-4-morpholinyl, 8-oxa-3-azabicyclo[3.2.1]octan-3-yl, etc.; R2 = Me, Et, cyclopropyl, FCH2CH2, 3-pyridyl, 4-pyridyl; R3 = F3CCH2, 1-methoxycarbonyl-4-piperidinyl, 1-ethoxycarbonyl-4-piperidinyl, 3-pyridylmethyl] with subnanomolar mTOR IC50 values and up to 26000-fold selectivity vs. PI3Kα were prepd.  Chiral morpholines gave inhibitors whose enantiomers had different selectivity and potency profiles.  Mol. modeling suggests that a single amino acid difference between PI3K and mTOR (Phe961Leu) accounts for the profound selectivity seen by creating a deeper pocket in mTOR that can accommodate bridged morpholines.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpK2HnMHqTHqbVg90H21EOLACvtfcHk0lhOPK2wEeeamg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhsVWrtb3J&md5=5ef1eee5aa79531970049d3d26b46eb2</span></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.1021%2Fjm901415x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm901415x%26sid%3Dliteratum%253Aachs%26aulast%3DZask%26aufirst%3DA.%26aulast%3DKaplan%26aufirst%3DJ.%26aulast%3DVerheijen%26aufirst%3DJ.%2BC.%26aulast%3DRichard%26aufirst%3DD.%2BJ.%26aulast%3DCurran%26aufirst%3DK.%26aulast%3DBrooijmans%26aufirst%3DN.%26aulast%3DBennett%26aufirst%3DE.%2BM.%26aulast%3DToral-Barza%26aufirst%3DL.%26aulast%3DHollander%26aufirst%3DI.%26aulast%3DAyral-Kaloustian%26aufirst%3DS.%26aulast%3DYu%26aufirst%3DK.%26atitle%3DMorpholine%2520derivatives%2520greatly%2520enhance%2520the%2520selectivity%2520of%2520mammalian%2520target%2520of%2520rapamycin%2520%2528mTOR%2529%2520inhibitors%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2009%26volume%3D52%26spage%3D7942%26epage%3D7945" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref22"><div class="reference"><strong class="refLabel"><a href="#ref22" class="rightTabRefNumLink">22</a></strong><div class="NLM_citation" id="rightTab-cit22"><span><span class="NLM_contrib-group">Nowak, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cole, D. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brooijmans, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bursavich, M. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Curran, K. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ellingboe, J. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gibbons, J. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hollander, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hu, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kaplan, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Malwitz, D. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Toral-Barza, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Verheijen, J. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zask, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, W.-G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yu, K.</span><span> </span><span class="NLM_article-title">Discovery of potent and selective inhibitors of the mammalian target of rapamycin (mTOR) kinase</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">52</span><span class="NLM_x">, </span> <span class="NLM_fpage">7081</span><span class="NLM_x">–</span> <span class="NLM_lpage">7089</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm9012642" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=52&publication_year=2009&pages=7081-7089&author=P.+Nowakauthor=D.+C.+Coleauthor=N.+Brooijmansauthor=M.+G.+Bursavichauthor=K.+J.+Curranauthor=J.+W.+Ellingboeauthor=J.+J.+Gibbonsauthor=I.+Hollanderauthor=Y.+Huauthor=J.+Kaplanauthor=D.+J.+Malwitzauthor=L.+Toral-Barzaauthor=J.+C.+Verheijenauthor=A.+Zaskauthor=W.-G.+Zhangauthor=K.+Yu&title=Discovery+of+potent+and+selective+inhibitors+of+the+mammalian+target+of+rapamycin+%28mTOR%29+kinase"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=10.1021%2Fjm9012642&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm9012642%26sid%3Dliteratum%253Aachs%26aulast%3DNowak%26aufirst%3DP.%26aulast%3DCole%26aufirst%3DD.%2BC.%26aulast%3DBrooijmans%26aufirst%3DN.%26aulast%3DBursavich%26aufirst%3DM.%2BG.%26aulast%3DCurran%26aufirst%3DK.%2BJ.%26aulast%3DEllingboe%26aufirst%3DJ.%2BW.%26aulast%3DGibbons%26aufirst%3DJ.%2BJ.%26aulast%3DHollander%26aufirst%3DI.%26aulast%3DHu%26aufirst%3DY.%26aulast%3DKaplan%26aufirst%3DJ.%26aulast%3DMalwitz%26aufirst%3DD.%2BJ.%26aulast%3DToral-Barza%26aufirst%3DL.%26aulast%3DVerheijen%26aufirst%3DJ.%2BC.%26aulast%3DZask%26aufirst%3DA.%26aulast%3DZhang%26aufirst%3DW.-G.%26aulast%3DYu%26aufirst%3DK.%26atitle%3DDiscovery%2520of%2520potent%2520and%2520selective%2520inhibitors%2520of%2520the%2520mammalian%2520target%2520of%2520rapamycin%2520%2528mTOR%2529%2520kinase%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2009%26volume%3D52%26spage%3D7081%26epage%3D7089" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref23"><div class="reference"><strong class="refLabel"><a href="#ref23" class="rightTabRefNumLink">23</a></strong><div class="NLM_citation" id="rightTab-cit23"><span><span class="NLM_contrib-group">Malagu, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Duggan, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Menear, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hummersone, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gomez, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bailey, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Edwards, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Drzewiecki, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Leroux, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Quesada, M. J.</span><span> </span><span class="NLM_article-title">The discovery and optimization of pyrido[2,3-<i>d</i>]pyrimidine-2,4-diamines as potent and selective inhibitors of mTOR kinase</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">19</span><span class="NLM_x">, </span> <span class="NLM_fpage">5950</span><span class="NLM_x">–</span> <span class="NLM_lpage">5953</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2009&pages=5950-5953&author=K.+Malaguauthor=H.+Dugganauthor=K.+Menearauthor=M.+Hummersoneauthor=S.+Gomezauthor=C.+Baileyauthor=P.+Edwardsauthor=J.+Drzewieckiauthor=F.+Lerouxauthor=M.+J.+Quesada&title=The+discovery+and+optimization+of+pyrido%5B2%2C3-d%5Dpyrimidine-2%2C4-diamines+as+potent+and+selective+inhibitors+of+mTOR+kinase"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DMalagu%26aufirst%3DK.%26aulast%3DDuggan%26aufirst%3DH.%26aulast%3DMenear%26aufirst%3DK.%26aulast%3DHummersone%26aufirst%3DM.%26aulast%3DGomez%26aufirst%3DS.%26aulast%3DBailey%26aufirst%3DC.%26aulast%3DEdwards%26aufirst%3DP.%26aulast%3DDrzewiecki%26aufirst%3DJ.%26aulast%3DLeroux%26aufirst%3DF.%26aulast%3DQuesada%26aufirst%3DM.%2BJ.%26atitle%3DThe%2520discovery%2520and%2520optimization%2520of%2520pyrido%255B2%252C3-d%255Dpyrimidine-2%252C4-diamines%2520as%2520potent%2520and%2520selective%2520inhibitors%2520of%2520mTOR%2520kinase%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2009%26volume%3D19%26spage%3D5950%26epage%3D5953" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref24"><div class="reference"><strong class="refLabel"><a href="#ref24" class="rightTabRefNumLink">24</a></strong><div class="NLM_citation" id="rightTab-cit24"><span><span class="NLM_contrib-group">Menear, K. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gomez, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Malagu, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bailey, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Blackburn, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cockcroft, X.-L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ewen, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fundo, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gall, A. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hermann, G.</span><span> </span><span class="NLM_article-title">Identification and optimization of novel and selective small molecular weight kinase inhibitors of mTOR</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">19</span><span class="NLM_x">, </span> <span class="NLM_fpage">5898</span><span class="NLM_x">–</span> <span class="NLM_lpage">5901</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2009&pages=5898-5901&author=K.+A.+Menearauthor=S.+Gomezauthor=K.+Malaguauthor=C.+Baileyauthor=K.+Blackburnauthor=X.-L.+Cockcroftauthor=S.+Ewenauthor=A.+Fundoauthor=A.+L.+Gallauthor=G.+Hermann&title=Identification+and+optimization+of+novel+and+selective+small+molecular+weight+kinase+inhibitors+of+mTOR"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DMenear%26aufirst%3DK.%2BA.%26aulast%3DGomez%26aufirst%3DS.%26aulast%3DMalagu%26aufirst%3DK.%26aulast%3DBailey%26aufirst%3DC.%26aulast%3DBlackburn%26aufirst%3DK.%26aulast%3DCockcroft%26aufirst%3DX.-L.%26aulast%3DEwen%26aufirst%3DS.%26aulast%3DFundo%26aufirst%3DA.%26aulast%3DGall%26aufirst%3DA.%2BL.%26aulast%3DHermann%26aufirst%3DG.%26atitle%3DIdentification%2520and%2520optimization%2520of%2520novel%2520and%2520selective%2520small%2520molecular%2520weight%2520kinase%2520inhibitors%2520of%2520mTOR%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2009%26volume%3D19%26spage%3D5898%26epage%3D5901" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref25"><div class="reference"><strong class="refLabel"><a href="#ref25" class="rightTabRefNumLink">25</a></strong><div class="NLM_citation" id="rightTab-cit25"><span><span class="NLM_contrib-group">Zask, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Verheijen, J. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Curran, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kaplan, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Richard, D. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nowak, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Malwitz, D. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brooijmans, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bard, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Svenson, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lucas, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Toral-Barza, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, W.-G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hollander, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gibbons, J. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Abraham, R. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ayral-Kaloustian, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mansour, T. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yu, K.</span><span> </span><span class="NLM_article-title">ATP-competitive inhibitors of the mammalian target of rapamycin: Design and synthesis of highly potent and selective pyrazolopyrimidines</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">52</span><span class="NLM_x">, </span> <span class="NLM_fpage">5013</span><span class="NLM_x">–</span> <span class="NLM_lpage">5016</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm900851f" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=52&publication_year=2009&pages=5013-5016&author=A.+Zaskauthor=J.+C.+Verheijenauthor=K.+Curranauthor=J.+Kaplanauthor=D.+J.+Richardauthor=P.+Nowakauthor=D.+J.+Malwitzauthor=N.+Brooijmansauthor=J.+Bardauthor=K.+Svensonauthor=J.+Lucasauthor=L.+Toral-Barzaauthor=W.-G.+Zhangauthor=I.+Hollanderauthor=J.+J.+Gibbonsauthor=R.+T.+Abrahamauthor=S.+Ayral-Kaloustianauthor=T.+S.+Mansourauthor=K.+Yu&title=ATP-competitive+inhibitors+of+the+mammalian+target+of+rapamycin%3A+Design+and+synthesis+of+highly+potent+and+selective+pyrazolopyrimidines"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=10.1021%2Fjm900851f&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm900851f%26sid%3Dliteratum%253Aachs%26aulast%3DZask%26aufirst%3DA.%26aulast%3DVerheijen%26aufirst%3DJ.%2BC.%26aulast%3DCurran%26aufirst%3DK.%26aulast%3DKaplan%26aufirst%3DJ.%26aulast%3DRichard%26aufirst%3DD.%2BJ.%26aulast%3DNowak%26aufirst%3DP.%26aulast%3DMalwitz%26aufirst%3DD.%2BJ.%26aulast%3DBrooijmans%26aufirst%3DN.%26aulast%3DBard%26aufirst%3DJ.%26aulast%3DSvenson%26aufirst%3DK.%26aulast%3DLucas%26aufirst%3DJ.%26aulast%3DToral-Barza%26aufirst%3DL.%26aulast%3DZhang%26aufirst%3DW.-G.%26aulast%3DHollander%26aufirst%3DI.%26aulast%3DGibbons%26aufirst%3DJ.%2BJ.%26aulast%3DAbraham%26aufirst%3DR.%2BT.%26aulast%3DAyral-Kaloustian%26aufirst%3DS.%26aulast%3DMansour%26aufirst%3DT.%2BS.%26aulast%3DYu%26aufirst%3DK.%26atitle%3DATP-competitive%2520inhibitors%2520of%2520the%2520mammalian%2520target%2520of%2520rapamycin%253A%2520Design%2520and%2520synthesis%2520of%2520highly%2520potent%2520and%2520selective%2520pyrazolopyrimidines%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2009%26volume%3D52%26spage%3D5013%26epage%3D5016" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref26"><div class="reference"><strong class="refLabel"><a href="#ref26" class="rightTabRefNumLink">26</a></strong><div class="NLM_citation" id="rightTab-cit26"><span><span class="NLM_contrib-group">Yu, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Toral-Barza, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shi, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, W.-G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lucas, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shor, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Verheijen, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Curran, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Malwitz, D. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cole, D. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ellingboe, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ayral-Kaloustian, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mansour, T. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gibbons, J. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Abraham, R. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nowak, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zask, A.</span><span> </span><span class="NLM_article-title">Biochemical, cellular, and in vivo activity of novel ATP-competitive and selective inhibitors of the mammalian target of rapamycin</span> <span class="citation_source-journal">Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">69</span><span class="NLM_x">, </span> <span class="NLM_fpage">6232</span><span class="NLM_x">–</span> <span class="NLM_lpage">6240</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=69&publication_year=2009&pages=6232-6240&author=K.+Yuauthor=L.+Toral-Barzaauthor=C.+Shiauthor=W.-G.+Zhangauthor=J.+Lucasauthor=B.+Shorauthor=J.+Kimauthor=J.+Verheijenauthor=K.+Curranauthor=D.+J.+Malwitzauthor=D.+C.+Coleauthor=J.+Ellingboeauthor=S.+Ayral-Kaloustianauthor=T.+S.+Mansourauthor=J.+J.+Gibbonsauthor=R.+T.+Abrahamauthor=P.+Nowakauthor=A.+Zask&title=Biochemical%2C+cellular%2C+and+in+vivo+activity+of+novel+ATP-competitive+and+selective+inhibitors+of+the+mammalian+target+of+rapamycin"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DYu%26aufirst%3DK.%26aulast%3DToral-Barza%26aufirst%3DL.%26aulast%3DShi%26aufirst%3DC.%26aulast%3DZhang%26aufirst%3DW.-G.%26aulast%3DLucas%26aufirst%3DJ.%26aulast%3DShor%26aufirst%3DB.%26aulast%3DKim%26aufirst%3DJ.%26aulast%3DVerheijen%26aufirst%3DJ.%26aulast%3DCurran%26aufirst%3DK.%26aulast%3DMalwitz%26aufirst%3DD.%2BJ.%26aulast%3DCole%26aufirst%3DD.%2BC.%26aulast%3DEllingboe%26aufirst%3DJ.%26aulast%3DAyral-Kaloustian%26aufirst%3DS.%26aulast%3DMansour%26aufirst%3DT.%2BS.%26aulast%3DGibbons%26aufirst%3DJ.%2BJ.%26aulast%3DAbraham%26aufirst%3DR.%2BT.%26aulast%3DNowak%26aufirst%3DP.%26aulast%3DZask%26aufirst%3DA.%26atitle%3DBiochemical%252C%2520cellular%252C%2520and%2520in%2520vivo%2520activity%2520of%2520novel%2520ATP-competitive%2520and%2520selective%2520inhibitors%2520of%2520the%2520mammalian%2520target%2520of%2520rapamycin%26jtitle%3DCancer%2520Res.%26date%3D2009%26volume%3D69%26spage%3D6232%26epage%3D6240" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref27"><div class="reference"><strong class="refLabel"><a href="#ref27" class="rightTabRefNumLink">27</a></strong><div class="NLM_citation" id="rightTab-cit27"><span><span class="NLM_contrib-group">García Martínez, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Moran, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Clarke, R. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gray, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cosulich, S. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chresta, C. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Alessi, D. R.</span><span> </span><span class="NLM_article-title">Ku-0063794 is a specific inhibitor of the mammalian target of rapamycin (mTOR)</span> <span class="citation_source-journal">Biochem. J.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">421</span><span class="NLM_x">, </span> <span class="NLM_fpage">29</span><span class="NLM_x">–</span> <span class="NLM_lpage">42</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=421&publication_year=2009&pages=29-42&author=J.+M.+Garc%C3%ADa+Mart%C3%ADnezauthor=J.+Moranauthor=R.+G.+Clarkeauthor=A.+Grayauthor=S.+C.+Cosulichauthor=C.+M.+Chrestaauthor=D.+R.+Alessi&title=Ku-0063794+is+a+specific+inhibitor+of+the+mammalian+target+of+rapamycin+%28mTOR%29"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DGarc%25C3%25ADa%2BMart%25C3%25ADnez%26aufirst%3DJ.%2BM.%26aulast%3DMoran%26aufirst%3DJ.%26aulast%3DClarke%26aufirst%3DR.%2BG.%26aulast%3DGray%26aufirst%3DA.%26aulast%3DCosulich%26aufirst%3DS.%2BC.%26aulast%3DChresta%26aufirst%3DC.%2BM.%26aulast%3DAlessi%26aufirst%3DD.%2BR.%26atitle%3DKu-0063794%2520is%2520a%2520specific%2520inhibitor%2520of%2520the%2520mammalian%2520target%2520of%2520rapamycin%2520%2528mTOR%2529%26jtitle%3DBiochem.%2520J.%26date%3D2009%26volume%3D421%26spage%3D29%26epage%3D42" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref28"><div class="reference"><strong class="refLabel"><a href="#ref28" class="rightTabRefNumLink">28</a></strong><div class="NLM_citation" id="rightTab-cit28"><span><span class="NLM_contrib-group">Feldman, M. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Apsel, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Uotila, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Loewith, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Knight, Z. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ruggero, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shokat, K. M.</span><span> </span><span class="NLM_article-title">Active-site inhibitors of mTOR target rapamycin-resistant outputs of mTORC1 and mTORC2</span> <span class="citation_source-journal">Plos Biol</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">7</span><span class="NLM_x">, </span> <span class="NLM_fpage">e38</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2009&pages=e38&author=M.+E.+Feldmanauthor=B.+Apselauthor=A.+Uotilaauthor=R.+Loewithauthor=Z.+A.+Knightauthor=D.+Ruggeroauthor=K.+M.+Shokat&title=Active-site+inhibitors+of+mTOR+target+rapamycin-resistant+outputs+of+mTORC1+and+mTORC2"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DFeldman%26aufirst%3DM.%2BE.%26aulast%3DApsel%26aufirst%3DB.%26aulast%3DUotila%26aufirst%3DA.%26aulast%3DLoewith%26aufirst%3DR.%26aulast%3DKnight%26aufirst%3DZ.%2BA.%26aulast%3DRuggero%26aufirst%3DD.%26aulast%3DShokat%26aufirst%3DK.%2BM.%26atitle%3DActive-site%2520inhibitors%2520of%2520mTOR%2520target%2520rapamycin-resistant%2520outputs%2520of%2520mTORC1%2520and%2520mTORC2%26jtitle%3DPlos%2520Biol%26date%3D2009%26volume%3D7%26spage%3De38" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref29"><div class="reference"><strong class="refLabel"><a href="#ref29" class="rightTabRefNumLink">29</a></strong><div class="NLM_citation" id="rightTab-cit29"><span><span class="NLM_contrib-group">Folkes, A. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ahmadi, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Alderton, W. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Alix, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Baker, S. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Box, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chuckowree, I. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Clarke, P. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Depledge, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Eccles, S. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Friedman, L. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hayes, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hancox, T. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kugendradas, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lensun, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Moore, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Olivero, A. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pang, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Patel, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pergl-Wilson, G. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Raynaud, F. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Robson, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Saghir, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Salphati, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sohal, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ultsch, M. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Valenti, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wallweber, H. J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wan, N. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wiesmann, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Workman, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhyvoloup, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zvelebil, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shuttleworth, S. J.</span><span> </span><span class="NLM_article-title">The identification of 2-(1<i>H</i>-indazol-4-yl)-6-(4-methanesulfonyl-piperazin-1-ylmethyl)-4-morpholin-4-yl-thieno[3,2-<i>d</i>]pyrimidine (GDC-0941) as a potent, selective, orally bioavailable inhibitor of class I PI3 kinase for the treatment of cancer</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">51</span><span class="NLM_x">, </span> <span class="NLM_fpage">5522</span><span class="NLM_x">–</span> <span class="NLM_lpage">5532</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm800295d" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=32&amp;doi=10.1021%2Fjm301389h&amp;key=1%3ACAS%3A528%3ADC%252BD1cXhtVCmsr7E" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=51&publication_year=2008&pages=5522-5532&author=A.+J.+Folkesauthor=K.+Ahmadiauthor=W.+K.+Aldertonauthor=S.+Alixauthor=S.+J.+Bakerauthor=G.+Boxauthor=I.+S.+Chuckowreeauthor=P.+A.+Clarkeauthor=P.+Depledgeauthor=S.+A.+Ecclesauthor=L.+S.+Friedmanauthor=A.+Hayesauthor=T.+C.+Hancoxauthor=A.+Kugendradasauthor=L.+Lensunauthor=P.+Mooreauthor=A.+G.+Oliveroauthor=J.+Pangauthor=S.+Patelauthor=G.+H.+Pergl-Wilsonauthor=F.+I.+Raynaudauthor=A.+Robsonauthor=N.+Saghirauthor=L.+Salphatiauthor=S.+Sohalauthor=M.+H.+Ultschauthor=M.+Valentiauthor=H.+J.+A.+Wallweberauthor=N.+C.+Wanauthor=C.+Wiesmannauthor=P.+Workmanauthor=A.+Zhyvoloupauthor=M.+J.+Zvelebilauthor=S.+J.+Shuttleworth&title=The+identification+of+2-%281H-indazol-4-yl%29-6-%284-methanesulfonyl-piperazin-1-ylmethyl%29-4-morpholin-4-yl-thieno%5B3%2C2-d%5Dpyrimidine+%28GDC-0941%29+as+a+potent%2C+selective%2C+orally+bioavailable+inhibitor+of+class+I+PI3+kinase+for+the+treatment+of+cancer"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit29R"><div class="casContent"><span class="casTitleNuber">29</span><div class="casTitle"><span class="NLM_cas:atitle">The identification of 2-(1H-indazol-4-yl)-6-(4-methanesulfonyl-piperazin-1-ylmethyl)-4-morpholin-4-yl-thieno[3,2-d]pyrimidine (GDC-0941) as a potent, selective, orally bioavailable inhibitor of class I PI3 kinase for the treatment of cancer</span></div><div class="casAuthors">Folkes, Adrian J.; Ahmadi, Khatereh; Alderton, Wendy K.; Alix, Sonia; Baker, Stewart J.; Box, Gary; Chuckowree, Irina S.; Clarke, Paul A.; Depledge, Paul; Eccles, Suzanne A.; Friedman, Lori S.; Hayes, Angela; Hancox, Timothy C.; Kugendradas, Arumugam; Lensun, Letitia; Moore, Pauline; Olivero, Alan G.; Pang, Jodie; Patel, Sonal; Pergl-Wilson, Giles H.; Raynaud, Florence I.; Robson, Anthony; Saghir, Nahid; Salphati, Laurent; Sohal, Sukhjit; Ultsch, Mark H.; Valenti, Melanie; Wallweber, Heidi J. A.; Wan, Nan Chi; Wiesmann, Christian; Workman, Paul; Zhyvoloup, Alexander; Zvelebil, Marketa J.; Shuttleworth, Stephen J.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">51</span>
        (<span class="NLM_cas:issue">18</span>),
    <span class="NLM_cas:pages">5522-5532</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Phosphatidylinositol-3-kinase (PI3K) is an important target in cancer due to the deregulation of the PI3K/Akt signaling pathway in a wide variety of tumors.  A series of thieno[3,2-d]pyrimidine derivs. were prepd. and evaluated as inhibitors of PI3 kinase p110α.  The synthesis, biol. activity, and further profiling of these compds. are described.  This work resulted in the discovery of GDC-0941 (I) which is a potent, selective, orally bioavailable inhibitor of PI3K and is currently being evaluated in human clin. trials for the treatment of cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGojkFv29FXqO7Vg90H21EOLACvtfcHk0lhuKsylJWfXeg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXhtVCmsr7E&md5=742084954685353ceaf18660ab3a0703</span></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=10.1021%2Fjm800295d&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm800295d%26sid%3Dliteratum%253Aachs%26aulast%3DFolkes%26aufirst%3DA.%2BJ.%26aulast%3DAhmadi%26aufirst%3DK.%26aulast%3DAlderton%26aufirst%3DW.%2BK.%26aulast%3DAlix%26aufirst%3DS.%26aulast%3DBaker%26aufirst%3DS.%2BJ.%26aulast%3DBox%26aufirst%3DG.%26aulast%3DChuckowree%26aufirst%3DI.%2BS.%26aulast%3DClarke%26aufirst%3DP.%2BA.%26aulast%3DDepledge%26aufirst%3DP.%26aulast%3DEccles%26aufirst%3DS.%2BA.%26aulast%3DFriedman%26aufirst%3DL.%2BS.%26aulast%3DHayes%26aufirst%3DA.%26aulast%3DHancox%26aufirst%3DT.%2BC.%26aulast%3DKugendradas%26aufirst%3DA.%26aulast%3DLensun%26aufirst%3DL.%26aulast%3DMoore%26aufirst%3DP.%26aulast%3DOlivero%26aufirst%3DA.%2BG.%26aulast%3DPang%26aufirst%3DJ.%26aulast%3DPatel%26aufirst%3DS.%26aulast%3DPergl-Wilson%26aufirst%3DG.%2BH.%26aulast%3DRaynaud%26aufirst%3DF.%2BI.%26aulast%3DRobson%26aufirst%3DA.%26aulast%3DSaghir%26aufirst%3DN.%26aulast%3DSalphati%26aufirst%3DL.%26aulast%3DSohal%26aufirst%3DS.%26aulast%3DUltsch%26aufirst%3DM.%2BH.%26aulast%3DValenti%26aufirst%3DM.%26aulast%3DWallweber%26aufirst%3DH.%2BJ.%2BA.%26aulast%3DWan%26aufirst%3DN.%2BC.%26aulast%3DWiesmann%26aufirst%3DC.%26aulast%3DWorkman%26aufirst%3DP.%26aulast%3DZhyvoloup%26aufirst%3DA.%26aulast%3DZvelebil%26aufirst%3DM.%2BJ.%26aulast%3DShuttleworth%26aufirst%3DS.%2BJ.%26atitle%3DThe%2520identification%2520of%25202-%25281H-indazol-4-yl%2529-6-%25284-methanesulfonyl-piperazin-1-ylmethyl%2529-4-morpholin-4-yl-thieno%255B3%252C2-d%255Dpyrimidine%2520%2528GDC-0941%2529%2520as%2520a%2520potent%252C%2520selective%252C%2520orally%2520bioavailable%2520inhibitor%2520of%2520class%2520I%2520PI3%2520kinase%2520for%2520the%2520treatment%2520of%2520cancer%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2008%26volume%3D51%26spage%3D5522%26epage%3D5532" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref30"><div class="reference"><strong class="refLabel"><a href="#ref30" class="rightTabRefNumLink">30</a></strong><div class="NLM_citation" id="rightTab-cit30"><span><span class="NLM_contrib-group">Sutherlin, D. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bao, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Berry, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Castanedo, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chuckowree, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dotson, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Folks, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Friedman, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Goldsmith, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gunzner, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Heffron, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lesnick, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lewis, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mathieu, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Murray, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nonomiya, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pang, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pegg, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Prior, W. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rouge, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Salphati, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sampath, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tian, Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tsui, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wan, N. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wei, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wiesmann, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wu, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhu, B.-Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Olivero, A.</span><span> </span><span class="NLM_article-title">Discovery of a potent, selective, and orally available class I phosphatidylinositol 3-kinase (PI3K)/mammalian target of rapamycin (mTOR) kinase inhibitor (GDC-0980) for the treatment of cancer</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">54</span><span class="NLM_x">, </span> <span class="NLM_fpage">7579</span><span class="NLM_x">–</span> <span class="NLM_lpage">7587</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm2009327" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=32&amp;doi=10.1021%2Fjm301389h&amp;key=1%3ACAS%3A528%3ADC%252BC3MXht1Ort7%252FJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=54&publication_year=2011&pages=7579-7587&author=D.+P.+Sutherlinauthor=L.+Baoauthor=M.+Berryauthor=G.+Castanedoauthor=I.+Chuckowreeauthor=J.+Dotsonauthor=A.+Folksauthor=L.+Friedmanauthor=R.+Goldsmithauthor=J.+Gunznerauthor=T.+Heffronauthor=J.+Lesnickauthor=C.+Lewisauthor=S.+Mathieuauthor=J.+Murrayauthor=J.+Nonomiyaauthor=J.+Pangauthor=N.+Peggauthor=W.+W.+Priorauthor=L.+Rougeauthor=L.+Salphatiauthor=D.+Sampathauthor=Q.+Tianauthor=V.+Tsuiauthor=N.+C.+Wanauthor=S.+Wangauthor=B.+Weiauthor=C.+Wiesmannauthor=P.+Wuauthor=B.-Y.+Zhuauthor=A.+Olivero&title=Discovery+of+a+potent%2C+selective%2C+and+orally+available+class+I+phosphatidylinositol+3-kinase+%28PI3K%29%2Fmammalian+target+of+rapamycin+%28mTOR%29+kinase+inhibitor+%28GDC-0980%29+for+the+treatment+of+cancer"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit30R"><div class="casContent"><span class="casTitleNuber">30</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of a Potent, Selective, and Orally Available Class I Phosphatidylinositol 3-Kinase (PI3K)/Mammalian Target of Rapamycin (mTOR) Kinase Inhibitor (GDC-0980) for the Treatment of Cancer</span></div><div class="casAuthors">Sutherlin, Daniel P.; Bao, Linda; Berry, Megan; Castanedo, Georgette; Chuckowree, Irina; Dotson, Jenna; Folks, Adrian; Friedman, Lori; Goldsmith, Richard; Gunzner, Janet; Heffron, Timothy; Lesnick, John; Lewis, Cristina; Mathieu, Simon; Murray, Jeremy; Nonomiya, Jim; Pang, Jodie; Pegg, Niel; Prior, Wei Wei; Rouge, Lionel; Salphati, Laurent; Sampath, Deepak; Tian, Qingping; Tsui, Vickie; Wan, Nan Chi; Wang, Shumei; Wei, Bin Qing; Wiesmann, Christian; Wu, Ping; Zhu, Bing-Yan; Olivero, Alan</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">54</span>
        (<span class="NLM_cas:issue">21</span>),
    <span class="NLM_cas:pages">7579-7587</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The discovery of 2 (GDC-0980, I), a class I PI3K and mTOR kinase inhibitor for oncol. indications, is described. mTOR inhibition was added to the class I PI3K inhibitor 1 (GDC-0941) scaffold primarily through the substitution of the indazole in 1 for a 2-aminopyrimidine.  This substitution also increased the microsomal stability and the free fraction of compds. as evidenced through a pairwise comparison of mols. that were otherwise identical.  Highlighted in detail are analogs of an advanced compd. 4 that were designed to improve soly., resulting in 2.  This compd., is potent across PI3K class I isoforms with IC50s of 5, 27, 7, and 14 nM for PI3Kα, β, δ, and γ, resp., inhibits mTOR with a Ki of 17 nM yet is highly selective vs. a large panel of kinases including others in the PIKK family.  On the basis of the cell potency, low clearance in mouse, and high free fraction, 2 demonstrated significant efficacy in mouse xenografts when dosed as low as 1 mg/kg orally and is currently in phase I clin. trials for cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp-3-5KDI509bVg90H21EOLACvtfcHk0lhuKsylJWfXeg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXht1Ort7%252FJ&md5=ba7ede710885b51fffa63977fc64d3f5</span></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=10.1021%2Fjm2009327&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm2009327%26sid%3Dliteratum%253Aachs%26aulast%3DSutherlin%26aufirst%3DD.%2BP.%26aulast%3DBao%26aufirst%3DL.%26aulast%3DBerry%26aufirst%3DM.%26aulast%3DCastanedo%26aufirst%3DG.%26aulast%3DChuckowree%26aufirst%3DI.%26aulast%3DDotson%26aufirst%3DJ.%26aulast%3DFolks%26aufirst%3DA.%26aulast%3DFriedman%26aufirst%3DL.%26aulast%3DGoldsmith%26aufirst%3DR.%26aulast%3DGunzner%26aufirst%3DJ.%26aulast%3DHeffron%26aufirst%3DT.%26aulast%3DLesnick%26aufirst%3DJ.%26aulast%3DLewis%26aufirst%3DC.%26aulast%3DMathieu%26aufirst%3DS.%26aulast%3DMurray%26aufirst%3DJ.%26aulast%3DNonomiya%26aufirst%3DJ.%26aulast%3DPang%26aufirst%3DJ.%26aulast%3DPegg%26aufirst%3DN.%26aulast%3DPrior%26aufirst%3DW.%2BW.%26aulast%3DRouge%26aufirst%3DL.%26aulast%3DSalphati%26aufirst%3DL.%26aulast%3DSampath%26aufirst%3DD.%26aulast%3DTian%26aufirst%3DQ.%26aulast%3DTsui%26aufirst%3DV.%26aulast%3DWan%26aufirst%3DN.%2BC.%26aulast%3DWang%26aufirst%3DS.%26aulast%3DWei%26aufirst%3DB.%26aulast%3DWiesmann%26aufirst%3DC.%26aulast%3DWu%26aufirst%3DP.%26aulast%3DZhu%26aufirst%3DB.-Y.%26aulast%3DOlivero%26aufirst%3DA.%26atitle%3DDiscovery%2520of%2520a%2520potent%252C%2520selective%252C%2520and%2520orally%2520available%2520class%2520I%2520phosphatidylinositol%25203-kinase%2520%2528PI3K%2529%252Fmammalian%2520target%2520of%2520rapamycin%2520%2528mTOR%2529%2520kinase%2520inhibitor%2520%2528GDC-0980%2529%2520for%2520the%2520treatment%2520of%2520cancer%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2011%26volume%3D54%26spage%3D7579%26epage%3D7587" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref31"><div class="reference"><strong class="refLabel"><a href="#ref31" class="rightTabRefNumLink">31</a></strong><div class="NLM_citation" id="rightTab-cit31"><span><span class="NLM_contrib-group">Sutherlin, D. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sampath, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Berry, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Castanedo, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chang, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chuckowree, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dotson, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Folkes, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Friedman, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Goldsmith, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Heffron, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lesnick, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lewis, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mathieu, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nonomiya, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Olivero, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pang, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Prior, W. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Salphati, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sideris, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tian, Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tsui, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wan, N. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wiesmann, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wong, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhu, B.-Y.</span><span> </span><span class="NLM_article-title">Discovery of (thienopyrimidin-2-yl)aminopyrimidines as potent, selective, and orally available pan-PI3-kinase and dual pan-PI3-kinase/mTOR inhibitors for the treatment of cancer</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">53</span><span class="NLM_x">, </span> <span class="NLM_fpage">1086</span><span class="NLM_x">–</span> <span class="NLM_lpage">1097</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm901284w" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=53&publication_year=2010&pages=1086-1097&author=D.+P.+Sutherlinauthor=D.+Sampathauthor=M.+Berryauthor=G.+Castanedoauthor=Z.+Changauthor=I.+Chuckowreeauthor=J.+Dotsonauthor=A.+Folkesauthor=L.+Friedmanauthor=R.+Goldsmithauthor=T.+Heffronauthor=L.+Leeauthor=J.+Lesnickauthor=C.+Lewisauthor=S.+Mathieuauthor=J.+Nonomiyaauthor=A.+Oliveroauthor=J.+Pangauthor=W.+W.+Priorauthor=L.+Salphatiauthor=S.+Siderisauthor=Q.+Tianauthor=V.+Tsuiauthor=N.+C.+Wanauthor=S.+Wangauthor=C.+Wiesmannauthor=S.+Wongauthor=B.-Y.+Zhu&title=Discovery+of+%28thienopyrimidin-2-yl%29aminopyrimidines+as+potent%2C+selective%2C+and+orally+available+pan-PI3-kinase+and+dual+pan-PI3-kinase%2FmTOR+inhibitors+for+the+treatment+of+cancer"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=10.1021%2Fjm901284w&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm901284w%26sid%3Dliteratum%253Aachs%26aulast%3DSutherlin%26aufirst%3DD.%2BP.%26aulast%3DSampath%26aufirst%3DD.%26aulast%3DBerry%26aufirst%3DM.%26aulast%3DCastanedo%26aufirst%3DG.%26aulast%3DChang%26aufirst%3DZ.%26aulast%3DChuckowree%26aufirst%3DI.%26aulast%3DDotson%26aufirst%3DJ.%26aulast%3DFolkes%26aufirst%3DA.%26aulast%3DFriedman%26aufirst%3DL.%26aulast%3DGoldsmith%26aufirst%3DR.%26aulast%3DHeffron%26aufirst%3DT.%26aulast%3DLee%26aufirst%3DL.%26aulast%3DLesnick%26aufirst%3DJ.%26aulast%3DLewis%26aufirst%3DC.%26aulast%3DMathieu%26aufirst%3DS.%26aulast%3DNonomiya%26aufirst%3DJ.%26aulast%3DOlivero%26aufirst%3DA.%26aulast%3DPang%26aufirst%3DJ.%26aulast%3DPrior%26aufirst%3DW.%2BW.%26aulast%3DSalphati%26aufirst%3DL.%26aulast%3DSideris%26aufirst%3DS.%26aulast%3DTian%26aufirst%3DQ.%26aulast%3DTsui%26aufirst%3DV.%26aulast%3DWan%26aufirst%3DN.%2BC.%26aulast%3DWang%26aufirst%3DS.%26aulast%3DWiesmann%26aufirst%3DC.%26aulast%3DWong%26aufirst%3DS.%26aulast%3DZhu%26aufirst%3DB.-Y.%26atitle%3DDiscovery%2520of%2520%2528thienopyrimidin-2-yl%2529aminopyrimidines%2520as%2520potent%252C%2520selective%252C%2520and%2520orally%2520available%2520pan-PI3-kinase%2520and%2520dual%2520pan-PI3-kinase%252FmTOR%2520inhibitors%2520for%2520the%2520treatment%2520of%2520cancer%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2010%26volume%3D53%26spage%3D1086%26epage%3D1097" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref32"><div class="reference"><strong class="refLabel"><a href="#ref32" class="rightTabRefNumLink">32</a></strong><div class="NLM_citation" id="rightTab-cit32"><span><span class="NLM_contrib-group">Yang, B. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">O’Rourke, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, J.</span><span> </span><span class="NLM_article-title">Mild and selective debenzylation of tertiary amines using α-chloroethyl chloroformate</span> <span class="citation_source-journal">Synlett</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1993</span><span class="NLM_x">, </span> <span class="NLM_volume">1993</span><span class="NLM_x">, </span> <span class="NLM_fpage">195</span><span class="NLM_x">–</span> <span class="NLM_lpage">196</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=16&amp;doi=10.1021%2Fjm301389h&amp;key=10.1055%2Fs-1993-22398" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1993&publication_year=1993&pages=195-196&author=B.+V.+Yangauthor=D.+O%E2%80%99Rourkeauthor=J.+Li&title=Mild+and+selective+debenzylation+of+tertiary+amines+using+%CE%B1-chloroethyl+chloroformate"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit32&amp;dbid=16384&amp;doi=10.1055%2Fs-1993-22398&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1055%252Fs-1993-22398%26sid%3Dliteratum%253Aachs%26aulast%3DYang%26aufirst%3DB.%2BV.%26aulast%3DO%25E2%2580%2599Rourke%26aufirst%3DD.%26aulast%3DLi%26aufirst%3DJ.%26atitle%3DMild%2520and%2520selective%2520debenzylation%2520of%2520tertiary%2520amines%2520using%2520%25CE%25B1-chloroethyl%2520chloroformate%26jtitle%3DSynlett%26date%3D1993%26volume%3D1993%26spage%3D195%26epage%3D196" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref33"><div class="reference"><strong class="refLabel"><a href="#ref33" class="rightTabRefNumLink">33</a></strong><div class="NLM_citation" id="rightTab-cit33"><span><span class="NLM_contrib-group">Leach, A. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jones, H. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cosgrove, D. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kenny, P. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ruston, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">MacFaul, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wood, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Colclough, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Law, B.</span><span> </span><span class="NLM_article-title">Matched molecular pairs as a guide in the optimization of pharmaceutical properties; a study of aqueous solubility, plasma protein binding and oral exposure</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">49</span><span class="NLM_x">, </span> <span class="NLM_fpage">6672</span><span class="NLM_x">–</span> <span class="NLM_lpage">6682</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm0605233" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=32&amp;doi=10.1021%2Fjm301389h&amp;key=1%3ACAS%3A528%3ADC%252BD28XhtV2gtLnO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=49&publication_year=2006&pages=6672-6682&author=A.+G.+Leachauthor=H.+D.+Jonesauthor=D.+A.+Cosgroveauthor=P.+W.+Kennyauthor=L.+Rustonauthor=P.+MacFaulauthor=J.+M.+Woodauthor=N.+Colcloughauthor=B.+Law&title=Matched+molecular+pairs+as+a+guide+in+the+optimization+of+pharmaceutical+properties%3B+a+study+of+aqueous+solubility%2C+plasma+protein+binding+and+oral+exposure"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit33R"><div class="casContent"><span class="casTitleNuber">33</span><div class="casTitle"><span class="NLM_cas:atitle">Matched Molecular Pairs as a Guide in the Optimization of Pharmaceutical Properties; a Study of Aqueous Solubility, Plasma Protein Binding and Oral Exposure</span></div><div class="casAuthors">Leach, Andrew G.; Jones, Huw D.; Cosgrove, David A.; Kenny, Peter W.; Ruston, Linette; MacFaul, Philip; Wood, J. Matthew; Colclough, Nicola; Law, Brian</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">49</span>
        (<span class="NLM_cas:issue">23</span>),
    <span class="NLM_cas:pages">6672-6682</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">By identifying every pair of mols. that differ only by a particular, well-defined, structural transformation in a database of measured properties and computing the corresponding change in property, we obtain an overview of the effect that structural change has upon the property and set an expectation for what will happen when that transformation is applied elsewhere.  The mean change indicates the expected magnitude of the change in the property and the no. of cases in which the property increases give the probability that the structural transformation will cause the property to increase.  Outliers indicate potential ways of avoiding the general trend.  Comparing to changes in lipophilicity highlights structural transformations that have unusual effects, some of which can be explained by conformational changes.  In this paper, we focus upon the effects on aq. soly., plasma protein binding and oral exposure of adding substituents to arom. rings and methylating heteroatoms.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpcyrloR79Oq7Vg90H21EOLACvtfcHk0lgP9qCD-HqtpQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XhtV2gtLnO&md5=2c143b424aee3ddb6c34616aff699ee0</span></div><a href="/servlet/linkout?suffix=cit33&amp;dbid=16384&amp;doi=10.1021%2Fjm0605233&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm0605233%26sid%3Dliteratum%253Aachs%26aulast%3DLeach%26aufirst%3DA.%2BG.%26aulast%3DJones%26aufirst%3DH.%2BD.%26aulast%3DCosgrove%26aufirst%3DD.%2BA.%26aulast%3DKenny%26aufirst%3DP.%2BW.%26aulast%3DRuston%26aufirst%3DL.%26aulast%3DMacFaul%26aufirst%3DP.%26aulast%3DWood%26aufirst%3DJ.%2BM.%26aulast%3DColclough%26aufirst%3DN.%26aulast%3DLaw%26aufirst%3DB.%26atitle%3DMatched%2520molecular%2520pairs%2520as%2520a%2520guide%2520in%2520the%2520optimization%2520of%2520pharmaceutical%2520properties%253B%2520a%2520study%2520of%2520aqueous%2520solubility%252C%2520plasma%2520protein%2520binding%2520and%2520oral%2520exposure%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2006%26volume%3D49%26spage%3D6672%26epage%3D6682" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref34"><div class="reference"><strong class="refLabel"><a href="#ref34" class="rightTabRefNumLink">34</a></strong><div class="NLM_citation" id="rightTab-cit34"><span><span class="NLM_contrib-group">Grünwald, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">DeGraffenried, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Russel, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Friedrichs, W. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ray, R. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hidalgo, M.</span><span> </span><span class="NLM_article-title">Inhibitors of mTOR reverse doxorubicin resistance conferred by PTEN status in prostate cancer cells</span> <span class="citation_source-journal">Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2002</span><span class="NLM_x">, </span> <span class="NLM_volume">62</span><span class="NLM_x">, </span> <span class="NLM_fpage">6141</span><span class="NLM_x">–</span> <span class="NLM_lpage">6145</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=62&publication_year=2002&pages=6141-6145&author=V.+Gr%C3%BCnwaldauthor=L.+DeGraffenriedauthor=D.+Russelauthor=W.+E.+Friedrichsauthor=R.+B.+Rayauthor=M.+Hidalgo&title=Inhibitors+of+mTOR+reverse+doxorubicin+resistance+conferred+by+PTEN+status+in+prostate+cancer+cells"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit34&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DGr%25C3%25BCnwald%26aufirst%3DV.%26aulast%3DDeGraffenried%26aufirst%3DL.%26aulast%3DRussel%26aufirst%3DD.%26aulast%3DFriedrichs%26aufirst%3DW.%2BE.%26aulast%3DRay%26aufirst%3DR.%2BB.%26aulast%3DHidalgo%26aufirst%3DM.%26atitle%3DInhibitors%2520of%2520mTOR%2520reverse%2520doxorubicin%2520resistance%2520conferred%2520by%2520PTEN%2520status%2520in%2520prostate%2520cancer%2520cells%26jtitle%3DCancer%2520Res.%26date%3D2002%26volume%3D62%26spage%3D6141%26epage%3D6145" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref35"><div class="reference"><strong class="refLabel"><a href="#ref35" class="rightTabRefNumLink">35</a></strong><div class="NLM_citation" id="rightTab-cit35"><span><span class="NLM_contrib-group">Halladay, J. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Delarosa, E. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tran, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wong, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Khojasteh, S. C.</span><span> </span><span class="NLM_article-title">High-throughput, 384-well, LC–MS/MS CYP inhibition assay using automation, cassette-analysis technique, and streamlined data analysis</span> <span class="citation_source-journal">Drug Metab. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">5</span><span class="NLM_x">, </span> <span class="NLM_fpage">220</span><span class="NLM_x">–</span> <span class="NLM_lpage">230</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=16&amp;doi=10.1021%2Fjm301389h&amp;key=10.2174%2F187231211796905017" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=8&amp;doi=10.1021%2Fjm301389h&amp;key=21867481" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=32&amp;doi=10.1021%2Fjm301389h&amp;key=1%3ACAS%3A528%3ADC%252BC3MXht1Cit7bL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2011&pages=220-230&author=J.+S.+Halladayauthor=E.+M.+Delarosaauthor=D.+Tranauthor=L.+Wangauthor=S.+Wongauthor=S.+C.+Khojasteh&title=High-throughput%2C+384-well%2C+LC%E2%80%93MS%2FMS+CYP+inhibition+assay+using+automation%2C+cassette-analysis+technique%2C+and+streamlined+data+analysis"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit35R"><div class="casContent"><span class="casTitleNuber">35</span><div class="casTitle"><span class="NLM_cas:atitle">High-throughput, 384-well, LC-MS/MS CYP inhibition assay using automation, cassette-analysis technique and streamlined data analysis</span></div><div class="casAuthors">Halladay, Jason S.; Delarosa, Erlie Marie; Tran, Daniel; Wang, Leslie; Wong, Susan; Khojasteh, S. Cyrus</div><div class="citationInfo"><span class="NLM_cas:title">Drug Metabolism Letters</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">220-230</span>CODEN:
                <span class="NLM_cas:coden">DMLRBM</span>;
        ISSN:<span class="NLM_cas:issn">1872-3128</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">Here we describe a high capacity and high-throughput, automated, 384-well CYP inhibition assay using well-known HLM-based MS probes.  We provide consistently robust IC50 values at the lead optimization stage of the drug discovery process.  Our method uses the Agilent Technologies/Velocity11 BioCel 1200 system, timesaving techniques for sample anal., and streamlined data processing steps.  For each expt., we generate IC50 values for up to 344 compds. and pos. controls for five major CYP isoforms (probe substrate): CYP1A2 (phenacetin), CYP2C9 [(S)-warfarin], CYP2C19 [(S)-mephenytoin], CYP2D6 (dextromethorphan), and CYP3A4/5 (testosterone and midazolam).  Each compd. is incubated sep. at four concns. with each CYP probe substrate under the optimized incubation condition.  Each incubation is quenched with acetonitrile contg. the deuterated internal std. of the resp. metabolite for each probe substrate.  To minimize the no. of samples to be analyzed by LC-MS/MS and reduce the amt. of valuable MS runtime, we utilize timesaving techniques of cassette anal. (pooling the incubation samples at the end of each CYP probe incubation into one) and column switching (reducing the amt. of MS runtime).  Here we also report on the comparison of IC50 results for five major CYP isoforms using our method compared to values reported in the literature.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr6LFWUX9244rVg90H21EOLACvtfcHk0lgP9qCD-HqtpQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXht1Cit7bL&md5=87db89d19026e12386ba06d594eeb727</span></div><a href="/servlet/linkout?suffix=cit35&amp;dbid=16384&amp;doi=10.2174%2F187231211796905017&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F187231211796905017%26sid%3Dliteratum%253Aachs%26aulast%3DHalladay%26aufirst%3DJ.%2BS.%26aulast%3DDelarosa%26aufirst%3DE.%2BM.%26aulast%3DTran%26aufirst%3DD.%26aulast%3DWang%26aufirst%3DL.%26aulast%3DWong%26aufirst%3DS.%26aulast%3DKhojasteh%26aufirst%3DS.%2BC.%26atitle%3DHigh-throughput%252C%2520384-well%252C%2520LC%25E2%2580%2593MS%252FMS%2520CYP%2520inhibition%2520assay%2520using%2520automation%252C%2520cassette-analysis%2520technique%252C%2520and%2520streamlined%2520data%2520analysis%26jtitle%3DDrug%2520Metab.%2520Lett.%26date%3D2011%26volume%3D5%26spage%3D220%26epage%3D230" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref36"><div class="reference"><strong class="refLabel"><a href="#ref36" class="rightTabRefNumLink">36</a></strong><div class="NLM_citation" id="rightTab-cit36"><span><span class="NLM_contrib-group">Wallin, J. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Edgar, K. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Guan, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Berry, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Prior, W. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lesnick, J. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lewis, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nonomiya, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pang, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Salphati, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Olivero, A. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sutherlin, D. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">O’Brien, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Spoerke, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Patel, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lensun, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kassees, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ross, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lackner, M. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sampath, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Belvin, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Friedman, L. S.</span><span> </span><span class="NLM_article-title">GDC-0980 is a novel class I PI3K/mTOR kinase inhibitor with robust activity in cancer models driven by the PI3K pathway</span> <span class="citation_source-journal">Mol. Cancer Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">10</span><span class="NLM_x">, </span> <span class="NLM_fpage">2426</span><span class="NLM_x">–</span> <span class="NLM_lpage">2436</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=16&amp;doi=10.1021%2Fjm301389h&amp;key=10.1158%2F1535-7163.MCT-11-0446" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=8&amp;doi=10.1021%2Fjm301389h&amp;key=21998291" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=32&amp;doi=10.1021%2Fjm301389h&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhsFylurfJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2011&pages=2426-2436&author=J.+J.+Wallinauthor=K.+A.+Edgarauthor=J.+Guanauthor=M.+Berryauthor=W.+W.+Priorauthor=L.+Leeauthor=J.+D.+Lesnickauthor=C.+Lewisauthor=J.+Nonomiyaauthor=J.+Pangauthor=L.+Salphatiauthor=A.+G.+Oliveroauthor=D.+P.+Sutherlinauthor=C.+O%E2%80%99Brienauthor=J.+M.+Spoerkeauthor=S.+Patelauthor=L.+Lensunauthor=R.+Kasseesauthor=L.+Rossauthor=M.+R.+Lacknerauthor=D.+Sampathauthor=M.+Belvinauthor=L.+S.+Friedman&title=GDC-0980+is+a+novel+class+I+PI3K%2FmTOR+kinase+inhibitor+with+robust+activity+in+cancer+models+driven+by+the+PI3K+pathway"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit36R"><div class="casContent"><span class="casTitleNuber">36</span><div class="casTitle"><span class="NLM_cas:atitle">GDC-0980 Is a Novel Class I PI3K/mTOR Kinase Inhibitor with Robust Activity in Cancer Models Driven by the PI3K Pathway</span></div><div class="casAuthors">Wallin, Jeffrey J.; Edgar, Kyle A.; Guan, Jane; Berry, Megan; Prior, Wei Wei; Lee, Leslie; Lesnick, John D.; Lewis, Cristina; Nonomiya, Jim; Pang, Jodie; Salphati, Laurent; Olivero, Alan G.; Sutherlin, Daniel P.; O'Brien, Carol; Spoerke, Jill M.; Patel, Sonal; Lensun, Letitia; Kassees, Robert; Ross, Leanne; Lackner, Mark R.; Sampath, Deepak; Belvin, Marcia; Friedman, Lori S.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer Therapeutics</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">2426-2436</span>CODEN:
                <span class="NLM_cas:coden">MCTOCF</span>;
        ISSN:<span class="NLM_cas:issn">1535-7163</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Alterations of the phosphoinositide-3 kinase (PI3K)/Akt signaling pathway occur broadly in cancer via multiple mechanisms including mutation of the PIK3CA gene, loss or mutation of phosphatase and tensin homolog (PTEN), and deregulation of mammalian target of rapamycin (mTOR) complexes.  The dysregulation of this pathway has been implicated in tumor initiation, cell growth and survival, invasion and angiogenesis, thus, PI3K and mTOR are promising therapeutic targets for cancer.  We discovered GDC-0980, a selective, potent, orally bioavailable inhibitor of Class I PI3 kinase and mTOR kinase (TORC1/2) with excellent pharmacokinetic and pharmaceutical properties.  GDC-0980 potently inhibits signal transduction downstream of both PI3K and mTOR, as measured by pharmacodynamic (PD) biomarkers, thereby acting upon two key pathway nodes to produce the strongest attainable inhibition of signaling in the pathway.  Correspondingly, GDC-0980 was potent across a broad panel of cancer cell lines, with the greatest potency in breast, prostate, and lung cancers and less activity in melanoma and pancreatic cancers, consistent with KRAS and BRAF acting as resistance markers.  Treatment of cancer cell lines with GDC-0980 resulted in G1 cell-cycle arrest, and in contrast to mTOR inhibitors, GDC-0980 induced apoptosis in certain cancer cell lines, including those with direct pathway activation via PI3K and PTEN.  Low doses of GDC-0980 potently inhibited tumor growth in xenograft models including those with activated PI3K, loss of LKB1 or PTEN, and elicited an exposure-related decrease in PD biomarkers.  These preclin. data show that GDC-0980 is a potent and effective dual PI3K/mTOR inhibitor with promise for the clinic.  Mol Cancer Ther; 10(12); 2426-36.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp4yjwxW7TM3bVg90H21EOLACvtfcHk0lhlA80aUVOD0A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhsFylurfJ&md5=756410aaf86377284a63d8ee70ad36ec</span></div><a href="/servlet/linkout?suffix=cit36&amp;dbid=16384&amp;doi=10.1158%2F1535-7163.MCT-11-0446&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1535-7163.MCT-11-0446%26sid%3Dliteratum%253Aachs%26aulast%3DWallin%26aufirst%3DJ.%2BJ.%26aulast%3DEdgar%26aufirst%3DK.%2BA.%26aulast%3DGuan%26aufirst%3DJ.%26aulast%3DBerry%26aufirst%3DM.%26aulast%3DPrior%26aufirst%3DW.%2BW.%26aulast%3DLee%26aufirst%3DL.%26aulast%3DLesnick%26aufirst%3DJ.%2BD.%26aulast%3DLewis%26aufirst%3DC.%26aulast%3DNonomiya%26aufirst%3DJ.%26aulast%3DPang%26aufirst%3DJ.%26aulast%3DSalphati%26aufirst%3DL.%26aulast%3DOlivero%26aufirst%3DA.%2BG.%26aulast%3DSutherlin%26aufirst%3DD.%2BP.%26aulast%3DO%25E2%2580%2599Brien%26aufirst%3DC.%26aulast%3DSpoerke%26aufirst%3DJ.%2BM.%26aulast%3DPatel%26aufirst%3DS.%26aulast%3DLensun%26aufirst%3DL.%26aulast%3DKassees%26aufirst%3DR.%26aulast%3DRoss%26aufirst%3DL.%26aulast%3DLackner%26aufirst%3DM.%2BR.%26aulast%3DSampath%26aufirst%3DD.%26aulast%3DBelvin%26aufirst%3DM.%26aulast%3DFriedman%26aufirst%3DL.%2BS.%26atitle%3DGDC-0980%2520is%2520a%2520novel%2520class%2520I%2520PI3K%252FmTOR%2520kinase%2520inhibitor%2520with%2520robust%2520activity%2520in%2520cancer%2520models%2520driven%2520by%2520the%2520PI3K%2520pathway%26jtitle%3DMol.%2520Cancer%2520Ther.%26date%3D2011%26volume%3D10%26spage%3D2426%26epage%3D2436" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref37"><div class="reference"><strong class="refLabel"><a href="#ref37" class="rightTabRefNumLink">37</a></strong><div class="NLM_citation" id="rightTab-cit37"><span><span class="NLM_contrib-group">Hidalgo, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Buckner, J. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Erlichman, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pollack, M. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Boni, J. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dukart, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Marshall, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Speicher, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Moore, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rowinsky, E. K.</span><span> </span><span class="NLM_article-title">A phase I and pharmacokinetic study of temsirolimus (CCI-779) administered intravenously daily for 5 days every 2 weeks to patients with advanced cancer</span> <span class="citation_source-journal">Clin. Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">12</span><span class="NLM_x">, </span> <span class="NLM_fpage">5755</span><span class="NLM_x">–</span> <span class="NLM_lpage">5763</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=16&amp;doi=10.1021%2Fjm301389h&amp;key=10.1158%2F1078-0432.CCR-06-0118" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=8&amp;doi=10.1021%2Fjm301389h&amp;key=17020981" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=32&amp;doi=10.1021%2Fjm301389h&amp;key=1%3ACAS%3A528%3ADC%252BD28XhtVartbvK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2006&pages=5755-5763&author=M.+Hidalgoauthor=J.+C.+Bucknerauthor=C.+Erlichmanauthor=M.+S.+Pollackauthor=J.+P.+Boniauthor=G.+Dukartauthor=B.+Marshallauthor=L.+Speicherauthor=L.+Mooreauthor=E.+K.+Rowinsky&title=A+phase+I+and+pharmacokinetic+study+of+temsirolimus+%28CCI-779%29+administered+intravenously+daily+for+5+days+every+2+weeks+to+patients+with+advanced+cancer"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit37R"><div class="casContent"><span class="casTitleNuber">37</span><div class="casTitle"><span class="NLM_cas:atitle">A Phase I and Pharmacokinetic Study of Temsirolimus (CCI-779) Administered Intravenously Daily for 5 Days Every 2 Weeks to Patients with Advanced Cancer</span></div><div class="casAuthors">Hidalgo, Manuel; Buckner, Jan C.; Erlichman, Charles; Pollack, Marilyn S.; Boni, Joseph P.; Dukart, Gary; Marshall, Bonnie; Speicher, Lisa; Moore, Laurence; Rowinsky, Eric K.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">19</span>),
    <span class="NLM_cas:pages">5755-5763</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Purpose: Patients with advanced cancer received temsirolimus (Torisel, CCI-779), a novel inhibitor of mammalian target of rapamycin, i.v. once daily for 5 days every 2 wk to det. the max. tolerated dose, toxicity profile, pharmacokinetics, and preliminary antitumor efficacy.  Exptl. Design: Doses were escalated in successive cohorts of patients using a conventional phase I clin. trial design.  Samples of whole blood and plasma were collected to det. the pharmacokinetics of temsirolimus and sirolimus, its principal metabolite.  Results: Sixty-three patients were treated with temsirolimus (0.75-24 mg/m2/d).  The most common drug-related toxicities were asthenia, mucositis, nausea, and cutaneous toxicity.  The max. tolerated dose was 15 mg/m2/d for patients with extensive prior treatment because, in the 19 mg/m2/d cohort, two patients had dose-limiting toxicities (one with grade 3 vomiting, diarrhea, and asthenia and one with elevated transaminases) and three patients required dose redns.  For minimally pretreated patients, in the 24 mg/m2/d cohort, one patient developed a dose-limiting toxicity of grade 3 stomatitis and two patients required dose redns., establishing 19 mg/m2/d as the max. acceptable dose.  Immunol. studies did not show any consistent trend toward immunosuppression.  Temsirolimus exposure increased with dose in a less than proportional manner.  Terminal half-life was 13 to 25 h.  Sirolimus-to-temsirolimus exposure ratios were 0.6 to 1.8.  A patient with non-small cell lung cancer achieved a confirmed partial response, which lasted for 12.7 mo.  Three patients had unconfirmed partial responses; two patients had stable disease for ≥24 wk.  Conclusion: Temsirolimus was generally well tolerated on this intermittent schedule.  Encouraging preliminary antitumor activity was obsd.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq8PhKgWPGD_7Vg90H21EOLACvtfcHk0li-vUlBY_3h6A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XhtVartbvK&md5=00690373c9826dd9ad1f24d5f56b4962</span></div><a href="/servlet/linkout?suffix=cit37&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-06-0118&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-06-0118%26sid%3Dliteratum%253Aachs%26aulast%3DHidalgo%26aufirst%3DM.%26aulast%3DBuckner%26aufirst%3DJ.%2BC.%26aulast%3DErlichman%26aufirst%3DC.%26aulast%3DPollack%26aufirst%3DM.%2BS.%26aulast%3DBoni%26aufirst%3DJ.%2BP.%26aulast%3DDukart%26aufirst%3DG.%26aulast%3DMarshall%26aufirst%3DB.%26aulast%3DSpeicher%26aufirst%3DL.%26aulast%3DMoore%26aufirst%3DL.%26aulast%3DRowinsky%26aufirst%3DE.%2BK.%26atitle%3DA%2520phase%2520I%2520and%2520pharmacokinetic%2520study%2520of%2520temsirolimus%2520%2528CCI-779%2529%2520administered%2520intravenously%2520daily%2520for%25205%2520days%2520every%25202%2520weeks%2520to%2520patients%2520with%2520advanced%2520cancer%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2006%26volume%3D12%26spage%3D5755%26epage%3D5763" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref38"><div class="reference"><strong class="refLabel"><a href="#ref38" class="rightTabRefNumLink">38</a></strong><div class="NLM_citation" id="rightTab-cit38"><span><span class="NLM_contrib-group">Cloughesy, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yoshimoto, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nghiemphu, P.</span><span> </span><span class="NLM_article-title">Antitumor activity of rapamycin in a phase I trial for patients with recurrent PTEN-deficient glioblastoma</span> <span class="citation_source-journal">PLoS Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">5</span><span class="NLM_x">, </span> <span class="NLM_fpage">e8</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2008&pages=e8&author=T.+Cloughesyauthor=K.+Yoshimotoauthor=P.+Nghiemphu&title=Antitumor+activity+of+rapamycin+in+a+phase+I+trial+for+patients+with+recurrent+PTEN-deficient+glioblastoma"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit38&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DCloughesy%26aufirst%3DT.%26aulast%3DYoshimoto%26aufirst%3DK.%26aulast%3DNghiemphu%26aufirst%3DP.%26atitle%3DAntitumor%2520activity%2520of%2520rapamycin%2520in%2520a%2520phase%2520I%2520trial%2520for%2520patients%2520with%2520recurrent%2520PTEN-deficient%2520glioblastoma%26jtitle%3DPLoS%2520Med.%26date%3D2008%26volume%3D5%26spage%3De8" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref39"><div class="reference"><strong class="refLabel"><a href="#ref39" class="rightTabRefNumLink">39</a></strong><div class="NLM_citation" id="rightTab-cit39"><span><span class="NLM_contrib-group">Tabernero, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rojo, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Calvo, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Burris, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Judson, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hazell, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Martinelli, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cajal, S. R. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jones, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vidal, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shand, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Macarulla, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ramos, F. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dimitrijevic, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zoellner, U.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tang, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stumm, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lane, H. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lebwohl, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Baselga, J.</span><span> </span><span class="NLM_article-title">Dose- and schedule-dependent inhibition of the mammalian target of rapamycin pathway with everolimus: A phase I tumor pharmacodynamic study in patients with advanced solid tumors</span> <span class="citation_source-journal">J. Clin. Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">26</span><span class="NLM_x">, </span> <span class="NLM_fpage">1603</span><span class="NLM_x">–</span> <span class="NLM_lpage">1610</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=16&amp;doi=10.1021%2Fjm301389h&amp;key=10.1200%2FJCO.2007.14.5482" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=8&amp;doi=10.1021%2Fjm301389h&amp;key=18332469" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=32&amp;doi=10.1021%2Fjm301389h&amp;key=1%3ACAS%3A528%3ADC%252BD1cXltlWiu7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=2008&pages=1603-1610&author=J.+Taberneroauthor=F.+Rojoauthor=E.+Calvoauthor=H.+Burrisauthor=I.+Judsonauthor=K.+Hazellauthor=E.+Martinelliauthor=S.+R.+Y.+Cajalauthor=S.+Jonesauthor=L.+Vidalauthor=N.+Shandauthor=T.+Macarullaauthor=F.+J.+Ramosauthor=S.+Dimitrijevicauthor=U.+Zoellnerauthor=P.+Tangauthor=M.+Stummauthor=H.+A.+Laneauthor=D.+Lebwohlauthor=J.+Baselga&title=Dose-+and+schedule-dependent+inhibition+of+the+mammalian+target+of+rapamycin+pathway+with+everolimus%3A+A+phase+I+tumor+pharmacodynamic+study+in+patients+with+advanced+solid+tumors"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit39R"><div class="casContent"><span class="casTitleNuber">39</span><div class="casTitle"><span class="NLM_cas:atitle">Dose- and schedule-dependent inhibition of the mammalian target of rapamycin pathway with everolimus: a phase I tumor pharmacodynamic study in patients with advanced solid tumors</span></div><div class="casAuthors">Tabernero, Josep; Rojo, Federico; Calvo, Emiliano; Burris, Howard; Judson, Ian; Hazell, Katharine; Martinelli, Erika; Ramon y Cajal, Santiago; Jones, Suzanne; Vidal, Laura; Shand, Nicholas; Macarulla, Teresa; Ramos, Francisco Javier; Dimitrijevic, Sasa; Zoellner, Ulrike; Tang, Pui; Stumm, Michael; Lane, Heidi A.; Lebwohl, David; Baselga, Jose</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Clinical Oncology</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">26</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">1603-1610</span>CODEN:
                <span class="NLM_cas:coden">JCONDN</span>;
        ISSN:<span class="NLM_cas:issn">0732-183X</span>.
    
            (<span class="NLM_cas:orgname">American Society of Clinical Oncology</span>)
        </div><div class="casAbstract">Purpose: Everolimus is a selective mammalian target of rapamycin (mTOR) inhibitor with promising anticancer activity.  In order to identify a rationally based dose and schedule for cancer treatment, we have conducted a tumor pharmacodynamic phase I study in patients with advanced solid tumors.  Patients and Methods: Fifty-five patients were treated with everolimus in cohorts of 20, 50, and 70 mg weekly or 5 and 10 mg daily.  Dose escalation depended on dose limiting toxicity (DLT) rate during the first 4-wk period.  Pre- and on-treatment steady-state tumor and skin biopsies were evaluated for total and phosphorylated (p) protein S6 kinase 1, eukaryotic initiation factor 4E (eIF-4E) binding protein 1 (4E-BP1), eukaryotic initiation factor 4G (eIF-4G), AKT, and Ki-67 expression.  Plasma trough levels of everolimus were detd. on a weekly basis before dosing during the first 4 wk.  Results: We obsd. a dose- and schedule-dependent inhibition of the mTOR pathway with a near complete inhibition of pS6 and pelF-4G at 10 mg/d and ≥ 50 mg/wk.  In addn., pAKT was upregulated in 50% of the treated tumors.  In the daily schedule, there was a correlation between everolimus plasma trough concns. and inhibition of peIF4G and p4E-BP1.  There was good concordance of mTOR pathway inhibition between skin and tumor.  Clin. benefit was obsd. in four patients including one patient with advanced colorectal cancer achieving a partial response.  DLTs occurred in five patients: one patient at 10 mg/d (grade 3 stomatitis) and four patients at 70 mg/wk (two with grade 3 stomatitis, one with grade 3 neutropenia, and one with grade 3 hyperglycemia).  Conclusion: Everolimus achieved mTOR signaling inhibition at doses below the DLT.  A dosage of 10 mg/d or 50 mg/wk is recommended for further development.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpFaBqnJ0l_47Vg90H21EOLACvtfcHk0li-vUlBY_3h6A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXltlWiu7c%253D&md5=663073a6224755c94c42575a00989bbf</span></div><a href="/servlet/linkout?suffix=cit39&amp;dbid=16384&amp;doi=10.1200%2FJCO.2007.14.5482&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1200%252FJCO.2007.14.5482%26sid%3Dliteratum%253Aachs%26aulast%3DTabernero%26aufirst%3DJ.%26aulast%3DRojo%26aufirst%3DF.%26aulast%3DCalvo%26aufirst%3DE.%26aulast%3DBurris%26aufirst%3DH.%26aulast%3DJudson%26aufirst%3DI.%26aulast%3DHazell%26aufirst%3DK.%26aulast%3DMartinelli%26aufirst%3DE.%26aulast%3DCajal%26aufirst%3DS.%2BR.%2BY.%26aulast%3DJones%26aufirst%3DS.%26aulast%3DVidal%26aufirst%3DL.%26aulast%3DShand%26aufirst%3DN.%26aulast%3DMacarulla%26aufirst%3DT.%26aulast%3DRamos%26aufirst%3DF.%2BJ.%26aulast%3DDimitrijevic%26aufirst%3DS.%26aulast%3DZoellner%26aufirst%3DU.%26aulast%3DTang%26aufirst%3DP.%26aulast%3DStumm%26aufirst%3DM.%26aulast%3DLane%26aufirst%3DH.%2BA.%26aulast%3DLebwohl%26aufirst%3DD.%26aulast%3DBaselga%26aufirst%3DJ.%26atitle%3DDose-%2520and%2520schedule-dependent%2520inhibition%2520of%2520the%2520mammalian%2520target%2520of%2520rapamycin%2520pathway%2520with%2520everolimus%253A%2520A%2520phase%2520I%2520tumor%2520pharmacodynamic%2520study%2520in%2520patients%2520with%2520advanced%2520solid%2520tumors%26jtitle%3DJ.%2520Clin.%2520Oncol.%26date%3D2008%26volume%3D26%26spage%3D1603%26epage%3D1610" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></li><li id="pane-m3" aria-labelledby="pane-m3" class="tab__pane tab__pane-suppInfo empty"><div class="accessionCode mb-5"><div class="toolbar-section accession-codes"><ul><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=3IBE" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=3IBE','PDB','3IBE'); return false;">PDB: 3IBE</a></li></ul></div></div></li></ul><div class="recommendedDropzone7" data-pb-dropzone="recommendedDropzone7"><div data-ajaxurl="/pb/widgets/ux3/ux3-showRecommend?widgetId=b272b1fe-ab4e-454f-940c-a3deaf223d23&amp;doi=10.1021%2Fjm301389h&amp;pbContext=%3BrequestedJournal%3Ajournal%3Ajmcmar%3Bjournal%3Ajournal%3Ajmcmar%3Bpage%3Astring%3AArticle%2FChapter+View%3Bctype%3Astring%3AJournal+Content%3Bissue%3Aissue%3A10.1021%2Fjmcmar.2012.55.issue-24%3Bwgroup%3Astring%3AACHS+website+Group%3Barticle%3Aarticle%3A10.1021%2Fjm301389h%3Bwebsite%3Awebsite%3Aacspubs%3BpageGroup%3Astring%3APublication+Pages%3BsubPage%3Astring%3AFull+Text" class="show-recommended-placeholder"></div>




        
        <script>
$(document).ready(function() {
  setTimeout(function() {
    var myLink = $(".show-recommended").find("a").not("[href='http://acsmediakit.org']").not("[href='javascript:void(0);']");
    myLink.attr("href", function(i, href) {
        return href + '?ref=recommended';
    });
  }, 5000);
});
</script></div></div></div></div></div></div></div><div class="col-xs-12.clearfix"><div class="article_qv-xs-container"><div class="article_qv-xs"><ul><li><a href="#" title="In This Article"><span>In This Article</span></a></li><li><a href="#" title="Figures" data-slide-target=".tab__pane-figures" class="w-slide__btn slide-active"><i class="icon-image"></i><span>Figures</span></a></li><li><a href="#" title="References" data-slide-target=".tab__pane-references" class="w-slide__btn slide-active"><i class="icon-link"></i><span>References</span></a></li><li><a href="#" title="Supporting Information" data-slide-target=".tab__pane-suppInfo" class="w-slide__btn slide-active"><i class="icon-supporting-info"></i><span>Supporting Information</span></a></li><li><a href="#" title="Recommended Articles" data-slide-target=".recommendedDropzone7" class="show-recommended-qv w-slide__btn slide-active" target="_self"><i class="icon-newspaper-o"></i><span>Recommended Articles</span></a></li></ul><a title="PDF" href="/doi/pdf/10.1021/jm301389h" class="button_primary"><i class="icon-file-pdf-o"></i>PDF  <span class="filesize">[
                4MB]
            </span></a></div></div></div></div></div></div></article></main>




        
        <footer class="footer">



        
        <div class="footer_first-row" id="partners">
	<div class="container">
		<div class="row">
			<div class="col-xs-12">
				<div class="footer_first-row_title">
					<h2>
						Partners
					</h2>
				</div>
				<div class="footer_first-row_logos">
					<div>
						<a href="http://www.atypon.com/">
							<img src="/pb-assets/images/footer_logos/logo-atypon-1525376610217.png" alt="Atypon">
						</a>
					</div>
					<div>
						<a href="http://www.chorusaccess.org/">
							<img src="/pb-assets/images/footer_logos/logo-chorus-1525375622947.png" alt="Chorus">
						</a>
					</div>
					<div>
						<a href="http://publicationethics.org/">
							<img src="/pb-assets/images/footer_logos/logo-cope-1525375622977.png" alt="Cope publication ethics">
						</a>
					</div>
					<div>
						<a href="http://www.projectcounter.org/">
							<img src="/pb-assets/images/footer_logos/logo-counter-1523044519173.jpg" alt="Project Counter">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/">
							<img src="/pb-assets/images/footer_logos/logo-crossref-1525377362093.png" alt="Crossref">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/crosscheck/index.html">
							<img src="/pb-assets/images/footer_logos/logo-crosscheck-1525375623000.png" alt="Crossref similarity check">
						</a>
					</div>
					<div>
						<a href="http://www.orcid.org/">
							<img src="/pb-assets/images/footer_logos/logo-orcid-1525375623187.png" alt="Orcid Connecting Research and Researchers">
						</a>
					</div>
					<div>
						<a href="http://www.portico.org/">
							<img src="/pb-assets/images/footer_logos/logo-portico-1525375623203.png" alt="Portico digital preservation service">
						</a>
					</div>
				</div>
			</div>
		</div>
	</div>
</div>





        
        <div class="footer_second-row col-xs-12 gutterless ">









        <div data-widget-def="ux3-layout-widget" data-widget-id="f963f9aa-5ade-4a09-8515-e6cd8e6364cf" class="row container">
        



        
        <div class="col-xs-12">



        
        <div class="footer_second-row_left col-md-2 gutterless ">



        
        <a href="/"><img src="/pb-assets/images/pubslogo-small-1444685090580.png" alt="ACS Publications"></a>
<div class="footer_menu">
	<ul>
		<li class="footer_menu_address">
			<span>
				1155 Sixteenth Street N.W.
			</span>
		</li>
		<li class="footer_menu_address">
			<span>
				Washington, DC 20036
			</span>
		</li>

		<li class="footer_menu_copyright">
			<a href="http://www.acs.org/content/acs/en/copyright.html">
				Copyright © 2021<br>
				American Chemical Society
			</a>
		</li>
	</ul>
</div>
</div><div class="footer_second-row_middle col-md-2 gutterless "></div><div class="footer_second-row_right col-md-8 gutterless ">



        
        <div class="footer_second-row_about col-xs-4">



        
        <h2>About</h2>
<ul>
    <li><a href="/page/about-us.html">About ACS Publications</a></li>
    <li><a href="http://acsopenscience.org">ACS & Open Access</a></li>
    <li><a href="https://www.acs.org/content/acs/en/membership/member-benefits/publications-discounts.html">ACS Membership</a></li>
</ul>
</div><div class="footer_second-row_resources col-xs-5">



        
        <h2>Resources and Information</h2>
<ul>
	<li><a href="/action/showPublications?pubType=journal">Journals A-Z</a></li>
	<li><a href="/action/showPublications?pubType=book">Books and Reference</a></li>
    <li><a href="http://acsmediakit.org/digital/acs-pubs/?utm_source=Footer&amp;utm_medium=Pubs&amp;utm_campaign=CEN">Advertising Media Kit</a></li>
    <li><a href="https://solutions.acs.org">Institutional Sales</a></li>
    <li><a href="https://publish.acs.org/publish/">ACS Publishing Center</a></li>
    <li><a href="http://www.acs.org/content/acs/en/privacy.html">Privacy Policy</a></li>
    <li><a href="https://www.acs.org/content/acs/en/terms.html">Terms of Use</a></li>
</ul>
</div><div class="footer_second-row_support col-xs-3">



        
        <h2>Support & Contact</h2>
<ul>
    <li><a href="https://acs.service-now.com/acs">Help</a></li>
    <li><a href="#" onclick="SnapEngage.startLink();return false;" class="help help-chat">Live Chat</a></li>
    <li><a href="https://acs.service-now.com/acs">FAQ</a></li>
</ul>
</div>
</div>




        
        <div class="footer_social_section col-xs-12">



        
        <div class="footer_social_header">
	<h2>Connect with ACS Publications</h2>
</div>
<div class="footer_social">
	<ul>
		<li>
			<a href="https://preferences.acspubs.org/journals" class="icon-envelope-o" aria-label="email">
			</a>
		</li>
		<li>
			<a href="https://www.facebook.com/ACSPublications/" class="icon-facebook" aria-label="facebook" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://twitter.com/ACSPublications" class="icon-twitter" aria-label="twitter" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://www.youtube.com/user/AmerChemSoc" class="icon-youtube-play" aria-label="youtube" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="/page/follow.html?widget=follow-pane-rss" class="icon-rss" aria-label="rss feed">
			</a>
		</li>
	</ul>
</div>

</div>
</div>

        </div>
    
</div>
</footer>




        
        <script>
(function(){
	
	/*Event Tracking for RIS menu dropdown - Article pages*/

	$('.cit-download-dropdown_button').on('click',function(e)
	{	
		e.preventDefault();
	    ga('send', 'event', 'Citation', 'Export', 'Main');
	});


	$('.cit-download-dropdown_content ul li').on('click',function(e)
	{	
	//	e.preventDefault();
	    var idx = $(this).index();
	    
	    var label = '';
	    if (idx === 0 ) {
	    	label = 'Citation';
	    } else if (idx === 1 ) {
	    	label = 'Abstract';
	    } else if (idx === 2 ) {
	    	label = 'Reference';
	    } else if (idx === 3 ) {
	    	label = 'More Options';
	    }
	   ga('send', 'event', 'Citation', 'Export', label);
	});

	$('.header_contnav-next a').on('click', function(e){
        e.preventDefault();
        ga('send', 'event', 'Article', 'Top', 'Right Arrow');
	}); 

 	$('.header_contnav-pre a').on('click', function(e){
	    e.preventDefault();
	     ga('send', 'event', 'Article', 'Top', 'Left Arrow');
	}); 

	$('.share_button').on('click', function(e){
		e.preventDefault();
		ga('send', 'event', 'Article', 'Top', 'Share');
	});

	$("#pane-m1con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Figures');
	});

	$("#pane-m2con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'References');
	});

	$("#pane-m3con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Supporting Info');
	});

	$('.tab__close').on('click', function(){
		ga('send', 'event', 'Article', 'Sidebar', 'Close');
	}); 



})();

</script>






        
        <div aria-live="polite" aria-atomic="true" class="achs-mendeley"><input type="hidden" name="tokenEndpoint" value="https://sso.acs.org/mendeley/token" class="tokenEndpoint"/></input><input type="hidden" name="appID" value="literatum" class="appID"/></input><input type="hidden" name="reopen-mendeley-modal-after-reload" class="reopen-mendeley-modal-after-reload"/></input><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><div class="achs-mendeley_table"><div class="achs-mendeley_row"><div class="achs-mendeley_cell loop-trap"><div class="achs-mendeley_container"><a title="Close" aria-label="close" tabindex="0" class="achs-mendeley_close"><i aria-hidden="true" class="icon-close"></i></a><div class="achs-mendeley_dropzone1"><div class="achs-mendeley_dropzone1_state1">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state2">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state3">



        
        <p style="font-weight: bold;">You’ve supercharged your research process with ACS and Mendeley!</p>
</div></div><div class="achs-mendeley_continue-header"><button class="achs-mendeley_continue-btn"><span class="achs-mendeley_buttonText">Continue</span></button></div><div class="achs-mendeley_steps"><div class="achs-mendeley_steps_row"><div class="achs-mendeley_steps_cell achs-mendeley_acsLogin"><h6>STEP 1:</h6><button class="button_primary achs-mendeley_acsLogin_button"><span class="achs-mendeley_buttonText">Login with ACS ID</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><span class="achs-mendeley_acsLogin_label">Click to create an ACS ID</span><i class="icon-if-arrow-right"></i></div><div class="achs-mendeley_steps_cell achs-mendeley_login"><h6>STEP 2:</h6><button class="button_primary achs-mendeley_login_button"><i class="icon-mendeley"></i><span class="achs-mendeley_buttonText">Login with Mendeley</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><a href="https://id.elsevier.com/as/authorization.oauth2?state=c33c27125763433d4d32a15accaacc18&amp;prompt=login&amp;scope=openid%20email%20profile%20els_auth_info&amp;authType=SINGLE_SIGN_IN&amp;response_type=code&amp;platSite=MDY%2Fmendeley&amp;redirect_uri=https%3A%2F%2Fwww.mendeley.com%2Fcallback%2F&amp;client_id=MENDELEY" title="Create a Mendeley account">Create a Mendeley account</a></div></div></div><div class="achs-mendeley_dropzone2"><div class="achs-mendeley_dropzone2_state1">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state2">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state3">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div></div></div></div></div></div></div><div class="achs-mendeley_alert"><div class="achs-mendeley_alert_table"><div class="achs-mendeley_alert_row"><div class="achs-mendeley_alert_cell"><div class="achs-mendeley_alert_container"><a title="Close" aria-label="close" class="achs-mendeley_alert_close"><i aria-hidden="true" class="icon-close"></i></a><div role="alert" aria-live="polite" aria-atomic="true" class="achs-mendeley_alert_dropzone">



        
        <p>Please login with your ACS ID before connecting to your Mendeley account.</p><button class="button_tertiary achs-mendeley_acsLogin_button mendeley-acs-custom-login-btn" onclick="loginToAcsSso(event); return false;">Login with ACS ID</button>

<script>
 function loginToAcsSso(event){
 event.preventDefault();
 $('.achs-mendeley_acsLogin .achs-mendeley_acsLogin_button').trigger('click');
 }
</script>
</div><div class="achs-mendeley_alert_error-msg"></div></div></div></div></div><div class="pairing-expired-dialog-container"><div class="pairing-expired-dialog"><div class="pairing-expired-dialog_top-btns"><span class="pairing-expired-dialog_heading">MENDELEY PAIRING EXPIRED</span><button onClick="UX.achsMendeley.reconnectOnClickHandler();" class="pairing-expired-dialog_reconnect">Reconnect</button></div><div class="pairing-expired-dialog_content"><span>Your Mendeley pairing has expired. Please reconnect</span></div></div></div></div>




        
        <style type="text/css">
#gdpr-message-modal {
    display: none;
    /* Hidden by default */
    position: fixed;
    /* Stay in place */
    z-index: 2;
    /* Sit on top */
    /*padding-top: 100px;*/
    /* Location of the box */
    left: 0;
    bottom: 0;
    width: 100%;
    /* Full width */
    /*height: 100%;*/
    /* Full height */
    overflow: auto;
    /* Enable scroll if needed */
    /*background-color: rgb(0,0,0);*/
    /* Fallback color */
    /*background-color: rgba(0,0,0,0.4);*/
    /* Black w/ opacity */
}
#gdpr-message-content {
    font-family: Arial;
    background-color: #005083;
    color: #fff;
    margin: auto;
    padding: 5px 0 10px 0;
    /*border: 1px solid #888;*/
    box-shadow: 0 -1px 3px #666;
    width: 100%;
    display: block;
    bottom: 0;
}
#gdpr-message-container {
    /*width: 1130px;*/
    margin: 0 auto;
}
.gdpr-innerwrap {
    display: block;
    /*width: 1100px;*/
    margin: 0 auto;
    text-align: center;
}
#gdpr-message-content h1 {
    color: #0629b5;
    font-size: 26px;
    margin: 0.5em 0 0 0;
    border-bottom: solid 2px #4c7fb9;
    display: inline;
    padding-bottom: 10px;
}
#gdpr-message-content h4 {
    display: inline-block;
    margin-left: 0;
    margin-right: 14px;
    margin-top: 13px;
    /*width: 980px;*/
    font-size: 14px;
    font-weight: normal;
}
#gdpr-message-content p {
    font-size: 14px;
    margin: 2em 2em 0.5em 0em;
    text-align: left;
    font-weight: bold;
}
#gdpr-message-content a,
#gdpr-message-content a:hover {
    color: #9bcfff;
}
.gdpr-listwrap {
    display: block;
    margin-bottom: 10px;
    min-height: 100px;
    min-width: 200px;
}
#gdpr-message-content ul {
    margin-top: 20px;
    font-size: 13px;
}
#gdpr-ul1 {
    display: inline-block;
    float: left;
}
#gdpr-ul2 {
    display: inline-block;
    margin-left: 10px;
}
#gdpr-message-content ul li {
    margin-top: 4px;
}
a#gdpr-con-btn,
a#gdpr-con-btn:hover {
    width: 110px;
    height: 35px;
    background: #fec82a;
    background-image: none;
    background-image: -webkit-gradient(linear, 50% 0%, 50% 100%, color-stop(0%, #fec82a), color-stop(100%, #daa301));
    background-image: -webkit-linear-gradient(top, #fec82a, #daa301);
    background-image: -moz-linear-gradient(top, #fec82a, #daa301);
    background-image: -o-linear-gradient(top, #fec82a, #daa301);
    background-image: linear-gradient(top, #fec82a, #daa301);
    border-radius: 4px;
    color: #004a7b;
    display: inline-block;
    text-decoration: none;
    line-height: 35px;
    text-align: center;
    margin-top: 5px;
    /*margin-right: 14px;*/
    /*float: right;*/
    font-weight: bold;
}
#gdpr-message-btn {
    width: 60px;
    height: 38px;
    background: #4b8fc2;
    border-radius: 4px;
    color: white;
    display: inline-block;
    margin-top: -4px;
    font-size: 12px;
}
a#closebtn {
    float: right;
    color: #d4e5ef;
}
#gdpr-input {
    width: 200px;
    height: 30px;
    border-radius: 3px;
    border-width: 1px;
    box-shadow: none;
    margin-right: 10px;
    font-size: 14px;
    outline: none;
    padding-left: 2px;
    display: inline-block;
    float: left;
}
#gdpr-message-content p.gdpr_err {
    font-size: 15px;
    margin-top: 10px;
}
#gdpr-message-modal.mobile, #gdpr-message-modal.mobile .gdpr-message-content {
    height: 160px;
}
@media only screen and (min-width: 1026px) and (max-width: 1368px) {
	#gdpr-message-content h4 {
		width: 80%;
		text-align: left;
	}
}
</style>

<div id="gdpr-message-modal">
    <div id="gdpr-message-content">
        
	        <div class="gdpr-innerwrap container">
	            <h4>This website uses cookies to improve your user experience. By continuing to use the site, you are accepting our use of cookies. <a href="http://www.acs.org/content/acs/en/privacy.html">Read the ACS privacy policy</a>.</h4>
	            <a href="#" id="gdpr-con-btn">CONTINUE</a>
	        </div>
        
    </div>
</div>

<script type="text/javascript">
"use strict"
//Script checks gdpr cookie and submits form
	/* 
	Create an in-page pop-up message, only for the InfoCentral homepage, that will gather email registrants for the library marketing list.
	 
	Needs the end point
	*/

var infoCentralCapture = (function() {

    //Detect mobile device
    window.mobilecheck = function() {
        var check = false;
        (function(a){if(/(android|bb\d+|meego).+mobile|avantgo|bada\/|blackberry|blazer|compal|elaine|fennec|hiptop|iemobile|ip(hone|od)|iris|kindle|lge |maemo|midp|mmp|mobile.+firefox|netfront|opera m(ob|in)i|palm( os)?|phone|p(ixi|re)\/|plucker|pocket|psp|series(4|6)0|symbian|treo|up\.(browser|link)|vodafone|wap|windows ce|xda|xiino/i.test(a)||/1207|6310|6590|3gso|4thp|50[1-6]i|770s|802s|a wa|abac|ac(er|oo|s\-)|ai(ko|rn)|al(av|ca|co)|amoi|an(ex|ny|yw)|aptu|ar(ch|go)|as(te|us)|attw|au(di|\-m|r |s )|avan|be(ck|ll|nq)|bi(lb|rd)|bl(ac|az)|br(e|v)w|bumb|bw\-(n|u)|c55\/|capi|ccwa|cdm\-|cell|chtm|cldc|cmd\-|co(mp|nd)|craw|da(it|ll|ng)|dbte|dc\-s|devi|dica|dmob|do(c|p)o|ds(12|\-d)|el(49|ai)|em(l2|ul)|er(ic|k0)|esl8|ez([4-7]0|os|wa|ze)|fetc|fly(\-|_)|g1 u|g560|gene|gf\-5|g\-mo|go(\.w|od)|gr(ad|un)|haie|hcit|hd\-(m|p|t)|hei\-|hi(pt|ta)|hp( i|ip)|hs\-c|ht(c(\-| |_|a|g|p|s|t)|tp)|hu(aw|tc)|i\-(20|go|ma)|i230|iac( |\-|\/)|ibro|idea|ig01|ikom|im1k|inno|ipaq|iris|ja(t|v)a|jbro|jemu|jigs|kddi|keji|kgt( |\/)|klon|kpt |kwc\-|kyo(c|k)|le(no|xi)|lg( g|\/(k|l|u)|50|54|\-[a-w])|libw|lynx|m1\-w|m3ga|m50\/|ma(te|ui|xo)|mc(01|21|ca)|m\-cr|me(rc|ri)|mi(o8|oa|ts)|mmef|mo(01|02|bi|de|do|t(\-| |o|v)|zz)|mt(50|p1|v )|mwbp|mywa|n10[0-2]|n20[2-3]|n30(0|2)|n50(0|2|5)|n7(0(0|1)|10)|ne((c|m)\-|on|tf|wf|wg|wt)|nok(6|i)|nzph|o2im|op(ti|wv)|oran|owg1|p800|pan(a|d|t)|pdxg|pg(13|\-([1-8]|c))|phil|pire|pl(ay|uc)|pn\-2|po(ck|rt|se)|prox|psio|pt\-g|qa\-a|qc(07|12|21|32|60|\-[2-7]|i\-)|qtek|r380|r600|raks|rim9|ro(ve|zo)|s55\/|sa(ge|ma|mm|ms|ny|va)|sc(01|h\-|oo|p\-)|sdk\/|se(c(\-|0|1)|47|mc|nd|ri)|sgh\-|shar|sie(\-|m)|sk\-0|sl(45|id)|sm(al|ar|b3|it|t5)|so(ft|ny)|sp(01|h\-|v\-|v )|sy(01|mb)|t2(18|50)|t6(00|10|18)|ta(gt|lk)|tcl\-|tdg\-|tel(i|m)|tim\-|t\-mo|to(pl|sh)|ts(70|m\-|m3|m5)|tx\-9|up(\.b|g1|si)|utst|v400|v750|veri|vi(rg|te)|vk(40|5[0-3]|\-v)|vm40|voda|vulc|vx(52|53|60|61|70|80|81|83|85|98)|w3c(\-| )|webc|whit|wi(g |nc|nw)|wmlb|wonu|x700|yas\-|your|zeto|zte\-/i.test(a.substr(0,4))) check = true;})(navigator.userAgent||navigator.vendor||window.opera);
              return check;
        };

    var _isMobile = window.mobilecheck();
    if (_isMobile) {
        $('#gdpr-message-modal').addClass('mobile');
    }

    var emailValid = "",
        time = 3000,
        btnStatus = true,
        errorStatus = false,
        errormessage = "<p class='gdpr_err'><b>Please Enter a valid email address<b><p>";

    function init() {
        setTimeout(function() {
            var cookieExist = getCookie("gdpr");
            if (cookieExist) {
                //console.log("gdpr cookie exist");
                return false;
            } else {
                //console.log("gdpr cookie does not exist")
                gdprMessage();
            }
            //Events
            $('#closebtn').on("click", hideForm);

            //Handle submit
            $('#gdpr-message-btn').on("click", function(event) {
                handleClick();
            });

            // //Hide if clicked outside div - TO DO stop handling click after submit
            // $(document).click(function(event) {
            // 	event.stopPropagation();
            //   console.log(event.target);
            //   if (!$(event.target).closest("#gdpr-message-content").length) {
            //     $("body").find("#gdpr-message-modal").hide();
            //     $(this).off();
            //   }
            // });
            $('#gdpr-con-btn').click(function() {
                setCookie("gdpr", "true");
                hideForm();
            });
        }, time);
    }

    //Show the message
    function gdprMessage() {
        //console.log("Show GDPR Message");
        var tMessage, emailInput, messageButton, ewrap;

        $('#gdpr-message-modal').show();
    }

    function handleClick() {
        //console.log($("#gdpr-input").val());
        emailValid = validateEmail($("#gdpr-input").val());
        if (emailValid) {
            //Submit the form
            //Hide form
            if ($('.gdpr_err')) {
                $('.gdpr_err').hide();
            }

            $("#gdpr-message-content")
                //If successful then...
            setCookie("gdpr", "true");
            //console.log("emailValid " + emailValid + " submiting form");
        } else {
            //Show error message
            gdprErrorMessage();
            //console.log("emailValid " + emailValid);
        }
    }

    function gdprErrorMessage() {
        if (errorStatus) {
            return false;
        } else {
            errorStatus = true;
            $("#gdpr-message-content").append(errormessage);
        }
    }

    function validateEmail(email) {
        var re = /^(([^<>()\[\]\\.,;:\s@"]+(\.[^<>()\[\]\\.,;:\s@"]+)*)|(".+"))@((\[[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\])|(([a-zA-Z\-0-9]+\.)+[a-zA-Z]{2,}))$/;
        return re.test(String(email).toLowerCase());
    }

    function setCookie(name, value) {
        var expires = "";
        expires = "; expires=Fri, 31 Dec 9999 23:59:59 GMT";
        document.cookie = name + "=" + (value || "") + expires + "; path=/";
    }

    function getCookie(name) {
        var match = document.cookie.match(new RegExp(name + '=([^;]+)'));
        if (match) return match[1];
    }

    function hideForm() { //And set cookie
        $('#gdpr-message-modal').hide();
        setCookie("gdpr", "false");
        ga('send', 'event', 'Pubs GDPR', 'GDPR Modal', 'GDPR Dismissal');
    }

    return {
        init: init
    }
})();

$(document).ready(infoCentralCapture.init);
</script>





        
        <script>
    //Top nav tracking

    (function(){
        $('.header_my-activity a:first').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Activity')
            ga('send', 'event', 'Top Nav', 'Button', 'Activity');
        })


        $('.pubModal_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Publications')
            ga('send', 'event', 'Top Nav', 'Button', 'Publications');
        }) 

        $('.header_burger-menu_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Hamburger');
            ga('send', 'event', 'Top Nav', 'Button', 'Hamburger');
        }) 

        // $('.header_burger-menu_content ul li').on('click', function(e){
        //     // e.preventDefault();
        //     var idx = $(this).index();
        //     console.log('Menu item' + idx)
        // })
    })();
    
    
</script>




        
        
<script type="text/javascript">
    adroll_adv_id = "3LBZJ4KXKBF2PJ46QCMT3X";
    adroll_pix_id = "6EITYRDI4FFGJPSZQ62UJJ";

    (function () {
        var _onload = function(){
            if (document.readyState && !/loaded|complete/.test(document.readyState)){setTimeout(_onload, 10);return}
            if (!window.__adroll_loaded){__adroll_loaded=true;setTimeout(_onload, 50);return}
            var scr = document.createElement("script");
            var host = (("https:" == document.location.protocol) ? "https://s.adroll.com" : "http://a.adroll.com");
            scr.setAttribute('async', 'true');
            scr.type = "text/javascript";
            scr.src = host + "/j/roundtrip.js";
            ((document.getElementsByTagName('head') || [null])[0] ||
                document.getElementsByTagName('script')[0].parentNode).appendChild(scr);
        };
        if (window.addEventListener) {window.addEventListener('load', _onload, false);}
        else {window.attachEvent('onload', _onload)}
    }());
</script>










        
        <div class="activity-container hidden-lg hidden-md"><div class="recentlyViewed" style="right: -100%;"><div class="activity_title_container"><span class="activity_title">Recently Viewed</span><a href="javascript:void(0)" class="activity_back"><i class="icon-angle-left"></i></a></div></div></div>




        
        <script>
$(document).ready(function(){
    var cookie = "";
    var uri = "/doi/full/10.1021/html_original_uri?id=123";
    console.log("ACSPubs2 start");
    $.getJSON('https://extreme-ip-lookup.com/json/', function(data, status) {
            if ( status == 'success' ) {
                $.each(data, function(i, field){
                    cookie=cookie.concat(i+' = '+field+" - ");
                });
                
            } else {
                    cookie=status;
            }

            cookie1 = cookie;
            cookie = cookie1 + "; path=/; domain=.acs.org";
            //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
            $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
            //TODO send cookie val to the controller for logging
            console.log("ACSPubs2 success");
    })
    .fail(function(xx, status, err){
        cookie="error: 127.0.0.1";
        //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
        $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
        console.log("ACSPubs2 failed");
        //TODO send cookie val to the controller for logging
    });
});    
</script>





        
        



        
    

        </div>
    </div>





	

    <script>if (typeof define !== 'undefined')
    if (define.amd)
        define.amd = false</script><script src="/products/achs/releasedAssets/js/build.lazyload.bundle-191cb5c7d88ed9894acd.js"></script><script src="/products/achs/releasedAssets/js/main.bundle-524acd43b3dccf6df3df.js"></script>

<script type="text/javascript" src="/wro/kfa7~product.js"></script>































    












<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"67995def2c983ce2","token":"d4e766cffbf14806ad37e095398b9c5f","version":"2021.7.0","si":10}'></script>
</body>
</html>
